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Transcriptional regulation of the Ccn2 gene 
 
Stephanie Frost 
 
Abstract  
 
Cellular Communication Network Factor 2 (CCN2) is a matricellular protein which 
functions in many tissues, and is most notably expressed by chondrocytes, with 
knockout of the Ccn2 gene expression causing severe chondrodysplasia in mice. 
Regulation at the prerequisite stage of transcription by non-coding genomic 
elements is fundamental in the expression of every gene. Until now, the capacity 
for cis-acting regulatory modules to control the expression of Ccn2 has been 
obscure. The current project sought to delineate the capacity for cis-acting 
enhancer regions to regulate Ccn2 transcription within highly specific 
temporospatial contexts.  
 
A 300 kilobase intergenic genomic region upstream of Ccn2 was examined in silico 
in order to identify putative enhancer regions based on chromatin characteristics of 
enhancers; histone modification, DNase I hypersensitivity and interspecies 
evolutionary conservation of DNA sequence. Transgenic mice were created using 
constructs consisting of each putative enhancer region driving the expression of a 
LacZ reporter gene in conjunction with a silent Hsp68 minimal promoter. 
Expression of the protein product of LacZ, β-galactosidase was assayed at several 
developmental time-points in order to determine whether candidate enhancers 
were able to control gene transcription. Five enhancer regions of murine Ccn2 
expression, located -230kb, -198kb, -148kb, -137kb and -102kb upstream of the 
gene each drove LacZ expression in a tissue-specific manner at embryonic day 
E15.5. -230kb drove transgene activity within osteoblasts, whereas -198kb, -148kb 
and -137kb all exhibited function within chondrocytes. The -102kb enhancer was 
active within the superficial vasculature. More comprehensive examination of the -
148kb enhancer revealed function in adulthood, and that a truncated region of this 
sequence is also capable of enhancing gene transcriptional output. Enhancer 
sequences were also examined in vitro using Electrophoretic Mobility Shift Assay 
in order to test the capacity of transcription factors of interest to bind to enhancers 
and modulate function. Master regulator of chondrocyte physiology, the 
transcription factor SOX9 was found to bind to sequences within the -137kb, -148kb 
and -230kb enhancers.  
 
The findings described herein are the first to characterise the role of cis-acting 
enhancer regions in the transcription of Ccn2 within the murine genome. 
Understanding the mechanisms that underpin temporospatial control of Ccn2 
expression will inform both the characterisation and amelioration of profound 
pathological conditions that result from loss of CCN2 transcriptional regulation such 
as osteoarthritis, fibrosis and cancer in humans.   
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. Introduction  
 
1.1 Skeletal development and articulation is dependent on 
cartilage  
 
1.1.1 Cartilage and the chondrocyte 
 
Cartilage is a connective tissue which functions in the establishment and 
articulation of the skeleton, it is avascular and aneural, with chondrocytes as the 
only type of cell resident in the tissue. Cartilage is formed from an extracellular 
matrix (ECM) secreted by chondrocytes that is enriched for polysaccharides, 
proteoglycans and fibrous proteins, such as aggrecan, hyaluronan, cartilage 
oligomeric matrix protein (COMP) and cellular communication network factor 2 
(CCN2), in addition to collagen types II, IX, X, XI, VI, XII, and XIV (Heinegård 2009; 
Luo et al. 2017). The proportion of these components confers the properties of the 
three classes of cartilage; hyaline, fibrocartilage and elastic cartilage. Hyaline 
cartilage is marked by abundance of collagen type II and can be found in a 
temporary form in the anlage of the vertebrate skeleton, and permanently in the 
trachea and articular cartilage of synovial joints. This is in contrast to the 
fibrocartilage found in tendon and ligament attachment sites in addition to 
intervertebral discs (IVD), which contains a greater proportion of collagen type I 
lending this tissue greater rigidity. Finally, elastic cartilage contains elastic fibres 
that enable flexibility of the pinna and epiglottis (Hall 2015). In each type of cartilage 
chondrocyte behaviour must be tightly controlled in order to ensure physiological 
development and homeostasis. 
 
Chondrocytes are of the mesenchymal cell lineage, and during embryonic 
development develop through the condensation of somitic mesoderm and lateral 
plate mesoderm progenitor cells (Maes and Kronenberg 2016). As with every other 
cell and tissue type, stringent regulation of gene expression underlies cartilage and 
chondrocyte identity and function. Transcription factor (TF) proteins are integral in 
this; controlling target gene expression through interaction with genomic regulatory 
sequences. SOX9 (Sex Determining Region Y- Box 9) has a major role in 
chondrogenesis and is viewed as the ‘master’ regulator of chondrocyte behaviour 
and function (Karsenty 2008). This transcription factor regulates the expression of 
many genes that are vital in chondrocyte behaviour and cartilage homeostasis. 
Chondrocytes at the terminal stage of differentiation- hypertrophy, are the only sub-
population of chondrocyte to not express SOX9, with absence of messenger 
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ribonucleic acid (mRNA) in this cell type (Akiyama et al. 2002). SOX9 target genes 
include ECM components such as collagen types II (Col2a1), IX, X and collagen 
type XI (Bar Oz et al. 2016; Lefebvre and Dvir-Ginzberg 2017). Bernard et al. (2003) 
first described the capacity of SOX9 to dimerise in order to regulate the expression 
of cartilaginous collagens type IX (Col9a2) and type XI (Col11a2) through 
interaction with paired transcription factor binding sites (TFBS). Subsequently, 
many SOX9 target genes have been identified on the basis of TFBS within 
regulatory sequences (Oh et al. 2010). In addition, SOX9 is also capable of 
perpetuating further regulation of cartilage behaviour through control of genes 
encoding regulatory proteins; including SOX9 itself and binding partners such as 
SOX5 and SOX6 (Akiyama et al. 2002; Yao et al. 2015). SOX5 and SOX6 synergise 
with SOX9, forming the ‘chondrogenic Sox trio’ and are required for 
chondrogenesis (Lefebvre and Smits 2005). The binding of SOX9 to target 
sequences is improved through interaction with SOX5/6, and recognition sites for 
the three proteins are clustered in genomic regulatory elements (Han and Lefebvre 
2008; Liu and Lefebvre 2015). The profound importance of SOX9 in chondrocyte 
physiology is emphasised by the effect that loss of gene function has on cartilage. 
Bi et al. (2001) generated Sox9 haploinsufficient mice which exhibited a severe 
cartilage related phenotype resulting in the bending of many skeletal structures and 
perinatal mortality. In humans, aberration of SOX9 expression leads to chondrocyte 
and cartilage related pathologies including campomelic dysplasia and osteoarthritis 
(Yao et al. 2015). 
 
In a seminal study, Wright et al. (1995) were the first to directly prove that SOX9 
drives chondrogenesis, with Sox9 mRNA observed within mouse embryos at 
embryonic day 9 (E9), coinciding mesenchymal condensation. As chondrogenic 
differentiation ensues in mice, early chondrocytes are distinguishable by embryonic 
day 11.5 (E11.5) (Lefebvre and Smits 2005). Akiyama et al. (2002) demonstrated 
that removal of Sox9 expression prior to the induction of mesenchymal 
condensation prevents formation of cartilage and bone. In the same study, 
knockout of Sox9 after mesenchymal cell condensation repressed chondrocyte 
proliferation and differentiation. SOX9 has been well established as promoting 
chondrocyte proliferation in addition to the secretion of key ECM components such 
as aggrecan and collagen type II, thereby establishing cartilaginous tissue identity 
(Chimal-Monroy et al. 2003). Dy et al. (2012) used conditional knockout of Sox9 in 
pre-hypertrophic chondrocytes in the context of collagen type II expression to 
demonstrate that SOX9 reinforces lineage specificity in these cells, as removal of 
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Sox9 expression led to premature acquisition of osteoblastic phenotype. SOX9 is 
therefore capable of repressing the expression of genes non-specific to 
chondrocytes. This reinforces the findings of Oh et al. (2010) who found SOX9 
binding sites in regulatory sequences for bone related genes osterix (Osx) and runt-
related transcription factor 2 (Runx2), the expression of which are repressed in 
chondrocytes not undergoing differentiation. SOX9 is also required in cartilaginous 
tissue in the postnatal period, in order to ensure cartilage homeostasis. Henry et al. 
(2012) induced knockout of Sox9 expression in an aggrecan expression linked and 
therefore cartilage specific manner in adulthood, observing aberration of articular, 
growth plate and intervertebral disc cartilage.  
 
Sox9 function can be modulated through signalling of the Transforming Growth 
Factor β (TGF-β) superfamily of proteins, which also regulate cartilage and 
skeletogenesis (Wang et al. 2014). For example, TGF-β signalling stabilises and 
phosphorylates SOX9 thereby enhancing its function (Coricor et al. 2016). The 
TGF-β superfamily contains factors such as TGF-β, bone morphogenic proteins 
(BMPs) growth differentiation factors (GDFs) and Smads. Over the past 30 years 
TGF-β has been well established as a regulator of chondrogenesis, with early 
studies demonstrating that application of exogenous TGF-β to chick limb 
mesenchyme led to enhanced chondrogenesis and cartilage deposition (Kulyk et 
al. 1989; Leonard et al. 1991). TGF-β initiates further cascades of cellular signalling 
such as mitogen-activated protein kinases (MAPK) and extracellular signal-
regulated kinases (ERK), which regulate the expression of proteins such as N-
cadherin and fibronectin involved in mesenchymal condensation and adhesion in 
early chondrogenesis, (Song et al. 2007; Tuli et al. 2003). TGF-β also reinforces 
chondrocyte phenotype through Smad2/3 signal transduction which prevents 
premature hypertrophy and therefore terminal differentiation whilst cartilaginous 
tissue is being established (van der Kraan et al. 2009). BMPs are also important 
regulators of skeletogenesis (Minina et al. 2001). For example, Yi et al. (2000) 
created BMP receptor I B knockout mice which exhibited skeletal defects, primarily 
in digit development. The impairment of BMP signalling led to reduced chondrocyte 
proliferation and chondrogenesis in the phalanges, demonstrating that whilst this 
signalling was not crucial in the establishment of the skeleton on a gross scale, 
BMP signalling through this receptor is required in order to refine skeletal structure.  
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1.1.2 Skeletogenesis depends on tightly regulated ossification processes 
 
The skeleton is a highly dynamic structure which is stringently regulated in order to 
ensure proficient development and maintenance in every vertebrate organism. 
Skeletal tissue originates from primitive mesenchymal tissue that undergoes 
differentiation to form chondro-osseous tissues during embryonic development and 
beyond (Ono et al. 2014). Efficient skeletogenesis depends on the coordination of 
vastly complex cellular signalling and regulatory interactions that mediate 
patterning of the axial and appendicular skeletal structures in a highly specific 
temporospatial manner (Liu et al. 2017). All skeletal tissue is formed through the 
processes of endochondral ossification and intramembranous ossification (Maes 
and Kronenberg 2016). The use of murine models has been an imperative tool in 
the elucidation of the molecular processes that underpin skeletal biology. For 
example, the key steps in chondrogenesis and endochondral ossification typically 
occur between embryonic days 11.5 to 15.5 (E11.5-E15.5) during mouse 
development (Kaufman 2003). However, much is still unknown about the intricate 
mechanisms that facilitate dynamism in the skeleton during development and 
beyond. 
 
1.1.2.1 Endochondral ossification 
 
The appendicular skeleton and several components of the axial skeleton such as 
the ribs and vertebrae are formed through the process of endochondral ossification, 
whereby a cartilaginous anlage develops before being replaced with osseous tissue 
(Mackie et al. 2008). As aforementioned, chondrocytes arise from mesenchymal 
progenitor cells and form the cartilaginous template from which endochondral bone 
is created. In mice, this structure is well stratified by E15.5 on the basis of 
chondrocyte differentiation state, which further reinforces regulation of skeletal 
development (Long and Ornitz 2013). Primary endochondral ossification ensues as 
chondrocytes move along this growth plate differentiation gradient through five 
major zones; resting, proliferating, pre-hypertrophic, hypertrophic and ossification 
centre (as illustrated in Figure 1.1) (Mackie et al. 2008). This process is repeated 
in the postnatal period with secondary ossification that allows further interstitial 
growth of endochondral bones. Sox5, Sox6 and Sox9 are all highly expressed 
throughout the majority of endochondral tissue, with the exception of the 
hypertrophic zone (Chimal-Monroy et al. 2003). This expression profile reinforces 
chondrocyte function, therefore ensuring that sufficient cartilage template is created 
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for efficient endochondral bone growth during development. For example, loss of 
the expression of SOX9 target Col2a1 prevents endochondral ossification within 
long bones and leads to growth plate disorganisation (Li et al. 1995). This highlights 
the importance of efficient cartilage matrix deposition in endochondral bone 
formation.  
 
Resting and proliferative chondrocytes 
 
The resting zone is located at the ends of the endochondral bone anlage, the future 
epiphysis, and contains chondrocytes with round morphology that secrete typical 
cartilage ECM components such as aggrecan and collagen type II (Karsenty 2008). 
This hyaline cartilage is maintained to form articular cartilage upon completion of 
differentiation (Goldring 2012). The proliferative zone is found next to the resting 
region. Chondrocytes proliferate rapidly within this area and are found in clusters 
with flattened morphology (Mackie et al. 2008). These cells secrete ECM rich in 
collagen type VI and matrilin 1 (Goldring 2012). 
 
Pre-hypertrophic chondrocytes 
 
Moving along the growth plate and with more advanced cellular differentiation state, 
pre-hypertrophic chondrocytes are located next to proliferative chondrocytes and 
distinguished by columnar organisation and attenuation of cellular proliferation (Liu 
et al. 2017). These cells are observed by E13.5 in mice (St-Jacques et al. 1999). 
Parathyroid hormone-related peptide (PTHrP) and Indian hedgehog (Ihh) signalling 
are critical regulators of pre-hypertrophic chondrocyte behaviour (Mackie et al. 
2008). St-Jacques et al. (1999) created Ihh-/- mice, which exhibited abnormality in 
endochondral ossification. Mutants were similar to wild-type (WT) controls at E12.5; 
before the onset of pre-hypertrophic chondrocyte signalling, yet demonstrated 
significantly shorter limbs as endochondral ossification proceeded. Mutant 
chondrocytes were not organised in the pre-hypertrophic zone and chondrocyte 
proliferation was impaired. Mineral deposition had occurred in a similar fashion to 
WT controls, therefore disruption in hypertrophy was the cause of decreased bone 
length (St-Jacques et al. 1999). Ihh controls PTHrP signalling through the 
regulation of PTHrP expression (Vortkamp et al. 1996). PTHrP ligand is produced 
by chondrocytes of the proliferative zone and perichondrium, but signalling is 
transduced in pre-hypertrophic chondrocytes which express the PTHrP receptor 
(Long and Ornitz 2013; Mackie et al. 2008). PTHrP prevents chondrocyte 
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hypertrophy (Kobayashi et al. 2002). Huang et al. (2001) demonstrated that PTHrP 
signalling leads to phosphorylation of SOX9 in pre-hypertrophic chondrocytes. This 
promotes the retention of chondrocyte cellular phenotype and represses premature 
differentiation (Huang et al. 2001). This is exemplified by the observation that 
PTHrP-/- mice exhibit increased formation of endochondral bone, with larger zones 
of hypertrophic chondrocytes (Serra et al. 1999). PTHrP in turn limits Ihh 
prevalence through limiting the proportion of cells transitioning into hypertrophy, 
this negative feedback loop allows stringent regulation of chondrocyte 
differentiation (Mackie et al. 2008). 
 
Chondrocyte hypertrophy and primary ossification 
 
By embryonic day 15.5, pre-hypertrophic cells transition into terminal differentiation 
in the hypertrophic zone, which provides a front with the primary ossification centre 
where trabecular bone is formed (as illustrated in Figure 1.1) (Long and Ornitz 
2013). Hypertrophic chondrocytes are distinguished with larger cellular volume and 
elongated morphology compared to pre-hypertrophic chondrocytes (Lefebvre and 
Smits 2005). This transformation of cellular phenotype is accompanied by a marked 
change in gene expression profile, the composition of the cartilage ECM secreted 
by the chondrocytes is modified due to repression of the expression of typical 
cartilaginous markers such as Col2a1 and a change to collagen type X (Col10a1) 
production (Lefebvre and Smits 2005). The cartilage matrix becomes mineralised, 
or is resorbed as blood vessels, osteoclasts and osteoblasts invade from the 
periosteal bone collar (Mackie et al. 2008). Matrix remodelling occurs with invading 
osteoclasts degrading the cartilage matrix, which is subsequently replaced with 
trabecular bone matrix secreted by osteoblasts which is enriched for collagen type 
I (Col1a1), and mineralised through further deposition of hydroxyapatite (Mackie et 
al. 2008; Maes et al. 2010).  
 
Loss of Sox9 expression is a notable hallmark of hypertrophic chondrocytes. Hattori 
et al. (2010) generated mice harbouring knock-in of Sox9 expression in the context 
of Col10a1 thereby leading to aberrant Sox9 expression within hypertrophic 
chondrocytes. This caused repression of bone marrow formation, reduced 
vascularisation of cartilage and inhibition of the commitment to terminal state; 
therefore preventing ossification. However, Dy et al. (2012) showed that SOX9 
protein does prevail in wild-type hypertrophic chondrocytes, and is in fact necessary 
for the induction of hypertrophy. He et al. (2016) built on this with the discovery that 
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SOX9 acts in conjunction with activator protein-1 (AP-1) proteins to drive the 
expression of hypertrophy associated genes such as Col10a1, with repressive 
transcription factor function in the absence of AP-1. Vascular endothelial growth 
factor (VEGF) expression is repressed by SOX9 in immature chondrocytes, 
ensuring that expression is specific to hypertrophic chondrocytes (Hattori et al. 
2010). This protein mediates growth plate angiogenesis and therefore the blood 
vessel invasion within the avascular cartilage that is required for osteogenesis 
(Mackie et al. 2008).  
 
RUNX2 and RUNX3 are major regulators of hypertrophic chondrocyte and 
osteoblast cellular behaviour and function (Yoshida et al. 2004). Komori et al. 
(1997) used a Runx2-/- murine model to demonstrate that RUNX2 function is of 
paramount importance in ossification. These mice died shortly after birth and 
exhibited gross impairment of ossification. RUNX2 activity increases the expression 
of genes associated with chondrocyte terminal differentiation and 
osteoblastogenesis including Col10a1, VEGF and matrix metalloproteinases-9 and 
13 (MMP9 and MMP13); thereby promoting the transition from cartilage anlage to 
bone (Lefebvre and Smits 2005; Ortega et al. 2004). MMP9 and MMP13 degrade 
cartilaginous ECM components such as collagen type II and aggrecan which 
enables blood vessel and osseous cell invasion (Mackie et al. 2008).  
 
Secondary ossification  
 
Secondary ossification occurs during postnatal development and allows further 
endochondral bone growth (Long and Ornitz 2013). Within the long bones, 
secondary ossification centres are found in the epiphyseal ends, as demonstrated 
in Figure 1.1. Chondrocytes within these regions undergo cell cycle arrest and 
hypertrophy, in a similar manner as aforementioned, with invasion of blood vessels 
and osteoblasts leading to the conversion of the cartilaginous anlage into osseous 
tissue (Wang et al. 2014). A band of chondrocytes is retained after the resolution 
of the primary and secondary ossification centres (Mackie et al. 2008). This 
metaphyseal growth plate provides a reservoir of chondrocytes that undergo 
hypertrophy in an ordered fashion; facilitating further interstitial growth of the bone 
until the cessation of skeletal development in adulthood (Kronenberg 2003). The 
processes of primary and secondary ossification are illustrated in Figure 1.1.  
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Figure 1.1: Schematic representation of endochondral ossification of a long bone. The growth plate is stratified on the basis of cellular differentiation state. 
During primary ossification (A), chondrocytes in the resting zone are in a primitive state of differentiation. This is also true of proliferative chondrocytes which 
have a flattened morphology and replicate rapidly. Proliferative chondrocytes become organised as they transition into the pre-hypertrophic zone, forming 
columns of cells that are subject to PTHrP-Ihh signalling axis, which ensures adequate preliminary interstitial growth of the future bone. Cellular proliferation 
ceases as pre-hypertrophic cells move into the hypertrophic zone, and lose expression of SOX9, accompanying a change in matrix composition with expression 
of Col10a1. Hypertrophic chondrocytes undergo apoptosis or transdifferentiate into osseous cells in the primary ossification centre. This region is surrounded 
by the bone collar, from where blood vessels and osteoblasts invade. This results in matrix remodelling and mineralisation in the diaphysis of the future bone. 
This process is repeated in the secondary ossification centre which forms in the future epiphysis of the bone (B). The metaphyseal growth plate is retained 
during postnatal interstitial growth. 
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Hypertrophic chondrocyte cell lineage fate 
 
Hypertrophic chondrocytes have classically been viewed as undergoing apoptosis, 
making way for osteoblastic cells to populate the endochondral framework and form 
trabecular bone (Kronenberg 2003). In vivo lineage tracing methodology has been 
an important approach in attempts to understand the cellular differentiation 
processes that underpin endochondral ossification. A long held consensus view 
was that osteoblasts originate from the perichondrium (Long and Ornitz 2013). For 
example, Maes et al. (2010) labelled osteoblast cells based on regulation of 
reporter gene in the context of osteoblast markers Col1a1 and Osx. Labelled cells 
were initially observed within the periosteum at E14.5, yet by E16.5 were found 
within the osseous tissue. However, there were discrete differences in cellular 
localisation based on the two contexts of reporter gene expression. Osx targeted 
reporter expression occurred predominantly within trabecular bone, whereas 
reporter gene expression in the context of Col1a1 was mainly found in cortical 
bone. Findings from this study support the notion that the vast majority of primary 
ossification centre osteoblasts originate from the perichondrium. The rigidity in this 
process was rather controversially brought into question by Ono et al. (2014) who 
also used a lineage tracing approach in the examination of osteoblastogenesis 
during endochondral ossification. The Cre recombinases used in this study were 
expressed within cartilaginous (Col2a1) and osseous (Col1a1) contexts leading to 
the expression of reporter gene where these promoters were utilised initially, in 
addition to subsequent daughter cells. Reporter genes were concurrently 
expressed within pre-osteoblast cells within the perichondrium, with RUNX2 as a 
driver of osteoblastic differentiation. Therefore chondrocyte cells within the 
perichondrium were the progenitors of these osteoblastic cells (Ono et al. 2014).  
 
Further in vivo studies have demonstrated that hypertrophic chondrocytes are able 
to transdifferentiate into osteoblasts. Both Zhou et al. (2014) and Yang et al. (2014) 
used lineage tracing methodology specific to hypertrophic chondrocytes. The Cre-
recombinase transgene created in both of these studies was under the control of 
the Col10a1 promoter. This approach demonstrated that hypertrophic cells are 
progenitors for osseous cells within the primary ossification centre. Reporter protein 
was perpetuated within osseous cells of the primary ossification centre; if 
hypertrophic chondrocytes underwent apoptosis with no transdifferentiation this 
expression would have been lost. The concept of plasticity in skeletal cell 
differentiation was also explored by Mizuhashi et al. (2018) who examined the 
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prospect of cell lineage switching in the growth plate in further detail. This study 
used PTHrP based lineage tracing to demonstrate that chondrocytes within the 
resting zone of the growth plate go on to form columnar chondrocytes within the 
growth plate, eventually undergoing hypertrophy and terminal differentiation. 
Moreover, these cells gave rise to osteoblasts and bone marrow stromal cells rather 
than undergoing apoptosis. These precursor cells expressed stem cell markers 
therefore lending credence to the notion that these cells are progenitors of skeletal 
lineage cells (Mizuhashi et al. 2018). These studies highlight the intricacies involved 
in chondro-osseous cell lineage specification, in addition to the need for further 
examination of the protein function and molecular mechanisms that govern 
endochondral ossification. 
 
1.1.2.2 Intramembranous ossification 
 
Intramembranous ossification facilitates formation of the majority of the cranial and 
facial bones in addition to the clavicle during embryonic development (Maes and 
Kronenberg 2016). This process is simpler than endochondral ossification as 
osteoblast cells develop directly from mesenchymal progenitors, with no 
cartilaginous intermediate (Long and Ornitz 2013). The mesenchymal precursor 
cells condense and give rise to osteoblast cells which secrete osteoid matrix that 
becomes mineralised (Wu et al. 2016). RUNX2 is a major regulator of 
intramembranous ossification, promoting osteoblast differentiation from 
mesenchymal progenitors (Maes et al. 2010). Runx2-/- mice display a lack of 
intramembranous skeletal elements (Komori et al. 1997). These mice also do not 
express the aforementioned bone marker Osx; another transcription factor which 
induces osteoblast differentiation (Karsenty 2008). Through knockout of Osx in 
mice Nakashima et al. (2002) demonstrated that Osx functions downstream of 
RUNX2. There was no bone formation in Osx null mice, yet Runx2 was still 
expressed. In addition, osteoblasts of these mice expressed chondrocyte markers 
such as Sox9 and Col2a1. This therefore demonstrated that osterix is a negative 
regulator of chondrocyte cell specification and promotes osteogenesis. 
 
1.1.3 Articular cartilage  
 
Articulation of the vertebrate skeleton hinges on the function of synovial joints which 
form junctions between bones. The composition of synovial joints such as the knee 
allow efficient loading of weight, with the distribution of force across the articular 
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surface and joint cavity (Decker et al. 2014). Synovial joints are formed by several 
extracellular matrix rich tissues and cell types (Decker et al. 2015), as 
demonstrated in Figure 1.2. Briefly, the structure is enclosed by a joint capsule 
which is composed of fibrous tissue and forms a continuum of the periosteum. The 
cavity of the joint is lined with a synovial membrane and filled with synovial fluid 
(Rhee et al. 2005). Synovial fluid contains an array of molecules, including, growth 
factors, and lubricating factors such as hyaluronan and lubricin (Hui et al. 2012). 
This fluid sustains the avascular cartilage and tissues of the joint, provides 
lubrication and aids in the mechanical function of the joint. Within the knee, 
ligaments stabilise the structure and fibrocartilage forms the menisci which aid in 
the dispersal of mechanical loading across the joint (Lories and Luyten 2011; Salva 
and Merrill 2017). The bones that meet to form the joint are covered by hyaline 
articular cartilage, which is of critical importance in ensuring joint physiology 
(Goldring 2012).  
 
1.1.3.1 Articular cartilage structure  
 
Articular cartilage is split into three distinct zones in accordance with distance from 
the articular surface and properties of the chondrocytes that reside within; 
superficial, intermediate and deep (Heinegård and Saxne 2011). Superficial zone 
chondrocytes have flattened morphology and secrete matricellular proteins such as 
lubricin, that aid in the mechanics of the joint through reducing friction at the 
articular surface (Goldring 2012; Rhee et al. 2005). The intermediate and deep 
zone chondrocytes have rounder morphology and produce typical cartilage 
extracellular matrix components such as collagen type II (Decker et al. 2015). The 
extracellular matrix of articular cartilage is also highly organised, with composition 
dependent on localisation with respect to the chondrocyte cell, as demonstrated in 
Figure 1.2. The cell surface membrane of a chondrocyte contains many types of 
receptor that facilitate communication between the cell and ECM. Receptors for 
factors such as TGF-b and BMPs, as previously mentioned, allow transduction of 
signalling pathways that are key in chondrocyte behaviour (Kobayashi et al. 2005; 
van der Kraan and van den Berg 2012). The pericellular matrix is in the immediate 
vicinity to chondrocytes. This matrix contains proteins such as CCN2, perlecan and 
collagen type VI; but not collagen type II, and mediates cartilage biochemical and 
biomechanical structure in addition to signalling between the extracellular matrix 
and chondrocyte (Tang et al. 2018; Wilusz et al. 2014). Furthermore, the 
composition of this portion of the ECM prevents erroneous activation of 
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chondrocyte cell surface receptors. For example, the interaction between 
chondrocyte surface receptor discoidin domain receptor 2 (DDR2) and its ligand 
collagen type II is blocked by the pericellular matrix (Goldring 2012). Activation of 
DDR2 leads to MMP13 activity and therefore degradation of the cartilage matrix 
(Mackie et al. 2008). The territorial matrix surrounds the pericellular matrix and 
contains structural elements such as collagen type VI and aggrecan. The latter 
protein is also found in the inter-territorial matrix which is located most distally from 
the chondrocyte and forms a network with structural proteins such as collagen type 
II, IX and XI (Heinegård and Saxne 2011). This region is also marked by abundance 
of COMP (Zaucke et al. 2001). The organisation of the chondrocyte cell surfaces, 
extracellular matrix; and articular cartilage as a whole, enables efficient 
compression upon weight bearing and gliding movement with articulation.  
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Figure 1.2: Schematic representation of a synovial joint and ECM secreted by articular chondrocytes. The epiphysis of two bones meet to form the joint 
which is enclosed by a fibrous joint capsule. The synovial joint cavity prevents direct contact between the two bones. The cavity is lined by a synovial membrane 
and filled with synovial fluid which lubricates the joint. Synovial fluid also prevents friction between the articular cartilage surfaces which line the bone epiphysis. 
This structure allows mechanical force to be distributed effectively across the joint. The metaphyseal growth plate is found below the subchondral bone and 
allows interstitial growth of the bone in the postnatal developmental period. The box shows organisation of cartilage extracellular matrix in greater detail. The 
pericellular matrix is enriched for cellular signalling molecules allowing efficient interaction with receptors on the surface of chondrocyte cells. The territorial 
matrix contains collagen type VI and aggrecan. This region is surrounded by the interterritorial matrix which is enriched for structural proteins such as collagen 
type II.  
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1.1.3.2 Articular cartilage development  
 
Articular joints develop during embryogenesis from a mesenchymal interzone that 
forms between cartilaginous anlage at the site of the future joint (Decker et al. 2014; 
Koyama et al. 2008). Thus, chondrocytes within the interzone lose expression of 
chondrocyte markers including Col2a1, and instead express genes such as growth 
and differentiation factor 5 (GDF5), Wnt9a and Noggin (Koyama et al. 2008; 
Shwartz et al. 2016). In addition, this process is perpetuated through loss of Sox9 
expression in the interzone which is caused by Wnt signalling through β-catenin 
that promotes joint formation (Guo et al. 2004). GDF5 expression marks synovial 
joint progenitor cells from E11.5 (Storm and Kingsley 1996). Segmentation of 
cartilage and formation of the synovial cavity is achieved through cells in the centre 
of the interzone undergoing apoptosis (Guo et al. 2004; Rhee et al. 2005). Cellular 
differentiation processes allow the assembly of joint tissues such as the synovial 
membrane and other structural features such as ligaments, and secretion of 
synovial fluid, therefore allowing joint function (Decker et al. 2014). Interzone cells 
have typically been viewed as progenitors for the synovial joint. For example, 
Koyama et al. (2008) used GDF5 expression linked reporter gene based assay to 
demonstrate that interzone cells remained in the vicinity of the developing joint with 
localisation that was concomitant with that of articular chondrocytes upon joint 
formation. Therefore, articular chondrocytes were derived from interzone 
progenitors. (Koyama et al. 2008) The homogeneity of interzone cells in 
subsequent articular cartilage has, however recently been questioned. Shwartz et 
al. (2016) used a GDF5 lineage-tracing model, observing that articular joints 
surfaces were not exclusively populated with GDF5 positive cells. Therefore, not 
all of the joint-forming cells were derived from the interzone; indicating recruitment 
of cells from outside of the interzone. Moreover, this study also demonstrated that 
cells are continually recruited in order to form the joint. Recent work from Roelofs 
et al. (2017) has demonstrated that GDF5 expressing cells originating from the 
interzone are found in adult mouse synovium. Each of these studies highlight the 
complexity in the processes that determine cellular differentiation and stratification 
in tissue type during articular joint development. 
 
1.1.3.3 Osteoarthritis  
 
Postnatal regulation of articular chondrocyte behaviour is of integral importance in 
maintaining synovial joint physiology. Osteoarthritis (OA) is a profound and 
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currently incurable pathology caused by loss of synovial joint homeostasis (Chen 
et al. 2017). Changes in articular cartilage underpins aetiology, however the entire 
joint is affected in the disease (Goldring 2012). This progressive disease self-
perpetuates with unpreventable and gradual destruction of the joint, which can 
cause severe pain as a result of friction within the joint. Several factors have been 
implicated in triggering OA, such as ageing, genetic susceptibility, injury and 
obesity (Mobasheri et al. 2017). Articular cartilage, menisci and ligaments 
degenerate and aberrant bone formation occurs with subchondral bone sclerosis 
and the appearance of osteophytes (Heinegård and Saxne 2011; Liu et al. 2018b). 
Chondrocytes within normal cartilage are quiescent, and the ECM that they secrete 
undergoes little turnover (Goldring 2012), thereby preserving cartilage homeostasis 
in addition to allowing efficient response to mechanical and molecular signalling 
events. This is exemplified by the fact that many of the ECM proteins within 
cartilage have extremely long half-lives in the order of decades (Mobasheri et al. 
2017). This contrasts OA chondrocytes which exhibit increased proliferation with a 
greater rate of ECM component production (Lories and Luyten 2011). This triggers 
an increase in the expression and secretion of catabolic factors such as MMPs and 
a disintegrin and metalloproteinase with a thrombospondin motif (ADAMTS) which 
degrade the structural proteins of the ECM (Chen et al. 2017). For example, 
MMP13 degrades collagen type II; which is the most abundant form of collagen 
within articular cartilage (Goldring 2012). In a murine model with MMP13 
expression knockout, mice are protected from cartilage degradation after surgical 
induction of OA (Little et al. 2009). In addition, Echtermeyer et al. (2009) 
demonstrated that the syndecan 4 membrane receptor on the surface of 
chondrocytes is involved in osteoarthritis through enhanced ADAMTS-5 activity. 
Ultimately, loss of homeostasis within the joint favours catabolic activity. 
Inflammatory factors are expressed by several cell types within an OA joint 
including chondrocytes and synoviocytes (Goldring 2012). This therefore 
perpetuates the expression of catabolic enzymes and further cartilage degradation. 
Further change in articular chondrocytes is signified by switch to hypertrophic 
phenotype and expression of terminal differentiation markers including Runx2 , in 
addition to ECM calcification (Lories and Luyten 2011). Changes in TGF-β 
signalling also contribute to OA, with switch from signalling through Smad2/3 which 
is chondroprotective, to Smad1/5/8 which promotes chondrocyte hypertrophy (van 
den Bosch et al. 2014). 
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1.2 CCN2 is an imperative protein within the matricellular environment  
 
1.2.1 CCN2 is a member of the CCN family of proteins 
 
The cellular communication network factor ((CCN) (Cyr61 (cysteine-rich protein 
61), CTGF (connective tissue growth factor), NOV (nephroblastoma overexpressed 
gene)) family of proteins consists of six members (CCN1-6) (Perbal et al. 2018). 
These proteins function in extracellular signalling through interaction with 
matricellular signalling molecules and cell membrane receptors (Leask and 
Abraham 2006). CCN family members function in many biological processes such 
as cellular differentiation, migration, adhesion and proliferation within many tissues 
(Perbal 2004). The effects of the CCN family members may complement one 
another, or be antagonistic (Yeger and Perbal 2007). For example, CCN1 and 
CCN2 are pro-angiogenic, whereas CCN6 is anti-angiogenic (Perbal 2004). The 
family are cysteine rich and share protein structure which consists of four domains 
(modules I-IV) (Leask and Abraham 2006), as illustrated in Figure 1.3.  
 
 
Figure 1.3: Modular structure of CCN family proteins underpins matricellular function 
Each CCN family member is composed of a modular structure containing domains (I-IV) 
that are capable of interacting with many signalling factors. The hinge region between 
modules II and III is sensitive to proteolysis (Krupska et al. 2015).  
 
Each domain confers interaction with other proteins localised at cellular 
membranes and within the extracellular matrix (Leask and Abraham 2006). Module 
I consists of an insulin-like growth factor protein binding domain (IGFB), module II 
is a von Willebrand factor type C (vWC) binding domain which is linked to module 
III; a thrombospondin (TSP) domain, by a hinge region, and module IV is a C-
terminal domain that contains a cysteine knot motif (Bork 1993). The peptide 
sequence of this region is variable between CCN family members (Holbourn et al. 
2008). CCN5 does not contain the CT domain module IV (Perbal 2004). Many 
signalling factors interact with each domain, giving rise to the broad variety of 
processes in which CCN family members are involved. Moreover, CCN function 
may reflect simultaneous interactions of several signalling molecules across the 
domains of the CCN protein (Holbourn et al. 2008). This therefore allows the 
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integration of complex signalling pathways in a highly coordinated and specific 
manner (Jun and Lau 2011).  
 
CCN2, systematically named as Cellular Communication Network Factor 2; also 
known as CTGF, hypertrophic chondrocyte-specific gene product-24 (HCS-24), 
Insulin-Like Growth Factor-Binding Protein 8 (IGFBP-8), FISP-12 or ecogenin is a 
fundamental mediator of matricellular signalling (Eguchi et al. 2008). The CCN2 
protein is encoded by Ccn2 (archaically annotated as Ctgf). Within the murine 
genome, Ccn2 is located within the q arm of chromosome 10, within cytogenetic 
band A4 (10qA4). The gene is composed of five exons with four intervening introns; 
exon one codes for the N-terminal signal of the protein and the subsequent exons 
each encode the modules (I-IV) of the protein. First described by Bradham et al. 
(1991), within human umbilical vein endothelial cells, the 38kDa protein functions 
in many tissue types during development and beyond, including cartilage, skeletal, 
vascular, endocrine and neuronal tissues (Hall-Glenn and Lyons 2011). The 
modular structure of CCN2 mediates its activity. This was demonstrated by 
Grotendorst and Duncan (2005) who found that the C-terminal of the protein 
functions in the differentiation of myofibroblasts, whereas the N-terminal of the 
protein promotes fibroblast proliferation. Further studies have also shown that 
individual modules of the CCN2 protein mediate interaction with specific signalling 
factors and cellular proteins. Module IV of the CCN2 protein binds to heparin in 
adhesion of fibroblasts, myofibroblasts, endothelial and epithelial cells (Ball et al. 
2003). CCN2 can directly bind to BMP4 and TGF-β through module II; inhibiting 
and enhancing the effect of these signalling pathways respectively (Abreu et al. 
2002). 
 
Friedrichsen et al. (2003) used in situ hybridisation methodology in order to 
examine the localisation of the mRNA product of Ccn2 during embryonic 
development. Ccn2 was strongly expressed within the vascular endothelium, 
perichondrium and neural tissue. This procedure was repeated by the same group 
in order to assess Ccn2 transcription in adulthood (Friedrichsen et al. 2005). Ccn2 
was found to be expressed within mesenchymal tissue across several organs 
including the heart and kidney. However, aside from skeletal muscle, there is no 
mention of musculoskeletal system based Ccn2 expression in adulthood, which is 
a major oversight given the expression of Ccn2 in primitive forms of these tissues 
during embryonic development (Friedrichsen et al. 2003; Ivkovic et al. 2003). Given 
the extracellular nature of CCN2 protein function it is unsurprising that there may 
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be discrepancies between the localisation of its mRNA and protein product. For 
example, Nishida et al. (2003) found Ccn2 mRNA product was localised within 
hypertrophic chondrocytes, yet CCN2 protein was found from the proliferative zone 
into the hypertrophic zone.  
 
Aberrant expression of CCN2 and Ccn2 genes has been associated with several 
pathologies including fibrosis, cancer and osteoarthritis (Hall-Glenn and Lyons 
2011). CCN2 has been well established as a mediator of fibrosis in many organs 
(Leask et al. 2009). Transgenic mice with fibroblast based overexpression of Ccn2 
display fibrosis in the skin, lung and kidney with enhanced proliferation of 
fibroblasts, differentiation into myofibroblasts and increased secretion of ECM 
factors such as fibronectin and tissue inhibitor of metalloproteinases 1 and 3 (TIMP-
1 and 3) (Sonnylal et al. 2010). In a murine model of skin fibrosis, Mori et al. (1999) 
found that exogenous application of TGF-β and CCN2 potentiated fibrosis 
compared to treatment with only one of the factors. This synergistic interaction has 
subsequently been well documented in the perpetuation of fibrosis (Jun and Lau 
2011). Ectopic expression of CCN2 has also been found in several cancers. 
Rachfal and Luquette (2004) found that CCN2 is expressed by several cell types 
within desmoplastic small round cell tumours, leading to the postulation that 
autocrine and paracrine CCN2 function further perpetuates tumorigenesis through 
enhanced angiogenesis and matrix deposition. The severity of breast cancer has 
been linked to the extent of CCN2 production within tumours (Xie et al. 2001). 
Furthermore, in an in vivo model of breast cancer metastasis, the capacity for 
metastatic progression was hampered through neutralisation of CCN2 function with 
an antibody (Shimo et al. 2006). This antibody against CCN2 was also used by 
Aikawa et al. (2006) in the attenuation of pancreatic cancer with decreased tumour 
growth, angiogenesis and cancer cell proliferation. Each of these studies therefore 
highlight the importance of stringent regulation of CCN2 expression and function.  
 
1.2.2 CCN2 is fundamental in cartilage physiology  
 
Each CCN family member is involved in skeletal development (Holbourn et al. 
2008). CCN2 has been well documented as a major regulator of chondrocyte and 
cartilage physiology. The pivotal work of Ivkovic et al. (2003) revealed that global 
knockout of CCN2 profoundly affects cartilaginous tissue. In this study, Ccn2-/- mice 
exhibited gross chondrodysplasia with dysmorphism in the chondrocranium, 
sternum and vertebrae, with kinked appearance of the ribs and long bones. 
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Aberration of rib development ultimately caused respiratory failure and perinatal 
mortality. Further scrutiny revealed that defects in stratification of the growth plate 
and resultant endochondral ossification were the cause of this severe phenotype. 
Firstly, expression of Ccn2 in WT embryos was detected in the perichondrium at 
E12.5, with expression in hypertrophic chondrocytes increasing with the onset and 
progression of endochondral ossification. The role of CCN2 in the transition into 
hypertrophy was highlighted in the knockout mice as this is the zone where the long 
bones were misshapen, which suggests abnormality in the deposition of cells 
during the shift in differentiation state (Ivkovic et al. 2003). This in turn was shown 
to be due to reduced chondrocyte proliferation, consolidating a previous study by 
Nakanishi et al. (2000) who found that in vitro, CCN2 overexpression in 
chondrosarcoma cells led to increased cellular proliferation. These findings are 
reiterated by those of Lambi et al. (2012) who described the proliferative zone being 
smaller, with enlarged hypertrophic zone in Ccn2 null mice compared to WT control 
mice. Disruption of cartilage caused by the removal of Ccn2 expression is further 
perpetuated by a loss of vital ECM components such as aggrecan (Ivkovic et al. 
2003). CCN2 may also promote hypertrophy, with Maeda et al. (2009) describing 
interaction between BMP2 and CCN2 as leading to increased chondrocyte 
hypertrophy, reduction in cellular proliferation and increase in the expression of 
mature differentiation markers.  
 
Hall-Glenn et al. (2013) also utilised Ccn2-/- mice in order to explore stress response 
in chondrocytes. Chondrocyte cell death was observed within the growth plate. In 
addition, cellular morphology, and more specifically the endoplasmic reticulum and 
nucleus, were altered compared to WT control. This was attributed to lack of 
interaction between the C-terminal of CCN2 and integrin α5β1 which endogenously 
aids in resistance to stress. CCN2 null mice were also used by Maeda-Uematsu et 
al. (2014) who described the role of CCN2 in chondrocyte metabolism. 
Chondrocytes cultured ex vivo from knockout mice had decreased cellular 
adenosine triphosphate (ATP) level compared to wild-type control. The addition of 
recombinant CCN2 (rCCN2) to Ccn2-/- chondrocytes partially restored ATP 
concentration to that of the control. Furthermore, the expression of genes 
associated with energy metabolism and ATP production were reduced in knockout 
cells compared with control. Murase et al. (2016) built on this with the finding that 
amino acid and protein metabolism in Ccn2-/- mice was perturbed with a deficiency 
in amino acids. This led to the postulation that CCN2 interacts with and regulates 
free amino acids in cartilage ECM. Whilst chondrocytes are the primary cell type 
37 
affected in Ccn2-/- mice, Ivkovic et al. (2003) found that angiogenesis within the 
growth plate is also affected by loss of Ccn2 expression. This aberration in 
angiogenesis reinforced abnormality in endochondral ossification, because 
vascular and osteoblast invasion, and therefore replacement of cartilage with bone 
was curtailed. However, on a global scale the vasculature was not perturbed by 
knockout of Ccn2 (Ivkovic et al. 2003). 
 
The overexpression of Ccn2 also has ramifications in skeletal development. This 
has been explored in several mouse models harnessing conditional knock-in of 
CCN2 expression in the context of other cartilage markers. Firstly, Nakanishi et al. 
(2001) generated transgenic mice overexpressing Ccn2 in the context of collagen 
type XI, which as aforementioned, is a constituent of cartilage (Lefebvre and Smits 
2005). In these transgenic mice, embryonic development of the skeleton occurred 
as in the wild-type control. This was surprising given that CCN2 is seen as 
promoting endochondral ossification, it would be expected that the transition to 
hypertrophy would occur prematurely, or chondrocytes would proliferate more 
rapidly prior to transition into hypertrophy, affecting interstitial growth embryonic 
limb length. However, in postnatal development mutant mice did display dwarfism 
and reduced mineralisation of bone compared to control. This was rationalised with 
the notion that premature angiogenesis and subsequent ossification caused by 
overexpression of Ccn2 prevented growth in postnatal development rather than 
during embryonic development (Nakanishi et al. 2001). 
 
The importance of considering the context of transgenic overexpression is 
highlighted by Tomita et al. (2013), who also used an approach of Ccn2 
overexpression within a cartilaginous context. This group used Col2a1 linked 
overexpression, which led to transgenic mice with longer limbs at birth compared 
to wild-type. The effect of Ccn2 overexpression within this context was therefore 
mediated during embryonic endochondral ossification, albeit no gross differences 
in skeletal structure were observed at E15.5. Nevertheless, later in embryonic 
development proliferation of chondrocytes was observed across the growth plate 
of transgenic embryos with increased bone length; whereas in wild-type controls 
proliferation was confined to the proliferative zone. By eight weeks of age, the 
femurs of transgenic mice were longer with greater mineralisation and cortical bone 
thickness than wild-type controls (Tomita et al. 2013). Mirroring the aforementioned 
work of Ivkovic et al. (2003), this study also found enhanced production of cartilage 
ECM components such as aggrecan and collagen type II in Ccn2 overexpressing 
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mice. Moreover, chondrocyte proliferation was increased in these mice. Ultimately, 
the phenotype observed in these transgenic mice was attributed to increased rate 
of chondrogenesis and endochondral ossification (Tomita et al. 2013).  
 
This transgenic mouse line with Col2a1 based Ccn2 overexpression was also used 
by Itoh et al. (2013) who examined the role of CCN2 in cartilage degeneration 
during adulthood. Overexpression of Ccn2 in cartilage had a chondroprotective 
effect, limiting cartilage degradation associated with increasing age through a 
reduction in OA-like changes within the knee joints of transgenic mice compared 
with wild-type controls. Ccn2 overexpression led to increased chondrocyte 
proliferation and cartilage ECM production, with repression of catabolic factors such 
as MMP13. Whilst this study suggests that CCN2 is important in maintaining 
cartilage physiology, the role of CCN2 in osteoarthritis is convoluted and unclear. 
Omoto et al. (2004) examined the expression of CCN2 in cartilage from OA 
patients, finding CCN2 was more abundant within OA cartilage and osteophyte 
tissue compared with unaffected control. This was postulated to be a contributory 
factor in the acquisition of a fibrotic phenotype in chondrocytes which perturbs 
cartilage homeostasis and leads to the reactionary instigation of catabolic factors 
that cause degradation and perpetuation of osteoarthritis. Nishida et al. (2004) 
induced OA in a rat model before addition of rCCN2 within a hydrogel matrix into 
the affected joint cavity. Ccn2 expression was greater in cartilage in which OA had 
been induced. This therefore supported the consensus that CCN2 expression is 
induced in order to limit cartilage degradation. Recombinant CCN2 was observed 
to ameliorate cartilage defects triggered by OA, with rescue of normal chondrocytes 
residing in cartilage ECM; CCN2 therefore had a chondroprotective role (Nishida 
et al. 2004). 
 
Abd El Kader et al. (2014) treated surgically induced cartilage injury with the module 
III TSP domain of CCN2 alone, observing that induction of cartilage repair was 
similar; if not better than the application of the complete CCN2 protein. This 
supports the principle that CCN2 is a positive influence in cartilage integrity and 
maintenance of physiology. Moreover, this study demonstrates how the modular 
structure of CCN2 mediates its function in cartilage. Nishida et al. (2003) applied 
rCCN2 protein to immortalised human chondrosarcoma (HCS) -2/8 cells, finding 
that the proteoglycan perlecan was co-localised with rCCN2. Furthermore, this 
interaction increased cellular proliferation. Aoyama et al. (2009) found that CCN2 
is capable of direct interaction with aggrecan. More specifically, this was mediated 
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by modules I and II of CCN2. Module IV of CCN2 binds to fibronectin via integrin 
α5β1, promoting chondrocyte adhesion (Hoshijima et al. 2006). Interaction between 
CCN2 and fibronectin has also been implicated in mesenchymal condensation 
during chondrogenesis (Song et al. 2007). Khattab et al. (2015) found that rCCN2 
interacts with other cartilaginous ECM molecules including GDF5, VEGF and TGF-
β, but not PTHrP. However, this study did not determine the points within the CCN2 
protein that facilitate these interactions. Further work is required in order to 
understand the intricacies of these interactions and their effect in cartilage. 
 
The relationship between CCN2 and TGF-β has been well-documented, and this 
interaction also occurs in chondrogenesis and cartilaginous tissue. For example, 
Song et al. (2007) used an in vitro approach to demonstrate that CCN2 functions 
during the condensation of mesenchymal cells, and therefore in the early stages of 
chondrogenesis and endochondral ossification. This group utilised a well-
established model of preliminary chondrogenesis consisting of application of TGF-
β to immortalised C3H10T1/2 mesenchymal cells. In this study CCN2 expression 
and function was induced by TGF-β and contributed to the process of 
chondrogenesis (Song et al. 2007). The importance of this is unclear as Ivkovic et 
al. (2003) did not find aberration in initial chondrogenesis in the CCN2-/- mice. A 
recent study by Tang et al. (2018) found that knockout of Ccn2 in cartilage in a 
post-natal manner led to reduced susceptibility to OA, with thicker cartilage; 
contradicting the consensus of CCN2 as being chondroprotective. This study also 
suggested that CCN2 controls the function of TGF-β in cartilage through direct 
interaction between the proteins that control the release of TGF-β. This is a 
controversial result as it suggests that CCN2 functions in the latent complex of 
proteins that sequesters TGF-β and regulates function (Tang et al. 2018). 
Furthermore, in this study low-density lipoprotein receptor-related protein 1 (LRP1) 
did not interact with CCN2 in regulating function; contradicting previous work that 
has characterised interaction between the two proteins in chondrocytes (Segarini 
et al. 2001). LRP1 is bound by many factors; both at the extracellular surface and 
within the intracellular space, thereby mediating cellular signalling, lipid metabolism 
and endocytosis (Herz and Strickland 2001). Kawata et al. (2006) described LRP1 
as a receptor for CCN2 in chondrocytes, with LRP1 aiding the endocytosis of 
CCN2. The same group examined this interaction further, finding that LRP1 
facilitates transcytosis of CCN2 in chondrocytes. Moreover, transcytosis has been 
posited as a method of distributing CCN2 protein across zones of the growth plate 
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from cells expressing Ccn2 such as pre-hypertrophic chondrocytes (Kawata et al. 
2006).  
 
1.2.3 CCN2 function within osseous tissue  
 
Whilst the function of CCN2 in chondrocytes and cartilage has been widely 
explored, CCN2 also has key functions in bone. Safadi et al. (2003) demonstrated 
that CCN2 mRNA and protein product are expressed in rat bone at two weeks of 
age, with Ccn2 mRNA predominantly found in the osteoblasts lining the trabeculae. 
In this study, and others CCN2 protein has been found in active osteoblasts and in 
some osteocytes (Kawaki et al. 2011; Safadi et al. 2003). Further results from the 
work of Safadi et al. (2003) suggest that CCN2 functions in osteoblast proliferation 
and differentiation, in addition to matrix production and mineralisation. CCN2 has 
also been shown to function in osteoclastogenesis, potentiating the differentiation 
of osteoclasts from haemopoietic precursors (Nishida et al. 2011).  
 
Several studies have gone on to further characterise the role of CCN2 within bone 
using transgenic murine models. In Ccn2-/- mice, mineralisation of the femora was 
decreased, with reduced trabecular bone formation that was attributed to defective 
angiogenesis rather than osteoblastic cell function (Ivkovic et al. 2003). Kawaki et 
al. (2008) investigated intramembranous ossification in Ccn2-/- mice finding that 
osteoblast proliferation was reduced in null mice, with rescue of cellular proliferation 
in a dose dependent manner with rCCN2 treatment in osteoblast cultures. 
Expression of Col1a1 and Bone gamma-carboxyglutamate protein (BGLAP) were 
reduced in Ccn2 null calvarial osteoblasts and bone mineralisation was also 
reduced in knockout mice compared to wild-type control (Kawaki et al. 2008). Lambi 
et al. (2012) further characterised the skeletal impact of the removal of Ccn2 
expression and demonstrated that bone formation and the expression of Runx2, 
alkaline phosphatase (ALP), and BGLAP were increased in the kinked diaphysis of 
Ccn2 null mice. However, this trend was reversed in the parietal bone. In addition, 
the trabecular bone of the femoral metaphysis of knockout mice was reduced 
(Lambi et al. 2012). This discrepancy in bone formation could be accounted for by 
the different regulatory signalling interactions that control endochondral and 
intramembranous ossification, and their effect on Ccn2 expression. Yamaai et al. 
(2005) found that knockout of Runx2 led to decrease in CCN2 abundance within 
skeletal elements during embryonic development and at postnatal day 0 (P0). 
Overexpression of Ccn2 within an osseous context also causes defective 
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skeletogenesis. Smerdel-Ramoya et al. (2008) generated transgenic mice over-
expressing Ccn2 within the context of BGLAP expression. This study found that 
overexpression of Ccn2 led to decreased bone mineral density and apposition, with 
decreased rate of bone formation and trabecular bone volume compared to WT 
control (Smerdel-Ramoya et al. 2008).  
 
These studies therefore highlight the importance of tight regulation of Ccn2 within 
osseous tissue in order to ensure physiological bone volume and density. 
Moreover, these studies suggest that CCN2 may function in feedback loops within 
osseous tissue in a spatially specific manner. Luo et al. (2004) used an in vitro 
model of osteogenesis to demonstrate that CCN2 acts downstream of Wnt3A and 
BMP9 during the early differentiation period. This study also showed that the effect 
of Wnt3A was dependent on canonical Wnt signalling, and that the ultimate effect 
of BMP9 signalling was dependent on CCN2 expression, yet overexpression of 
CCN2 repressed BMP9 and Wnt3A function. Treatment of osteoblasts with BMP2 
has also been found to increase the expression of Ccn2 (Parisi et al. 2006). In 
addition, Arnott et al. (2007) stimulated osteoblasts with TGF-β and found an 
increase in the production of CCN2 mRNA and protein. Canonical notch signalling 
also regulates CCN2 expression in osteoblasts (Canalis et al. 2014). CCN2 function 
within bone is therefore governed by complex cellular signalling mechanisms and 
regulatory interactions; much of which remains unknown.  
 
1.3 Enhancers mediate temporospatial specificity in gene expression  
 
1.3.1 Gene transcription underpins every biological process  
 
The central dogma of molecular biology dictates that deoxyribonucleic acid (DNA) 
sequence is firstly read and transcribed into a ribonucleic acid (RNA) intermediate 
before translation into amino acid sequence and assembly into functional protein 
(Crick 1970). Whilst a vast proportion of the genome is transcribed, protein coding 
genes only reflect a small fraction of transcriptional template (Djebali et al. 2012; 
The ENCODE Project Consortium 2012). The production of each transcript must 
be stringently regulated in order to prevent aberrant expression that would 
ultimately lead to pathology. The holoenzyme RNA polymerase II (Pol II) forms the 
basis of the protein machinery required for the interpretation of DNA sequence and 
catalysis of complementary RNA (Sayre et al. 1992). Transcription occurs in bursts 
with cycling of key stages; initiation, pausing, elongation and termination (Bartman 
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et al. 2016). The rate at which Pol II is recruited to the promoter and moves along 
the DNA template catalysing RNA production, in addition to the number of 
transcripts produced per burst are important factors in the efficiency of transcription 
(Fukaya et al. 2016). Transcription begins, and is primarily regulated at the non-
coding regulatory DNA sequence upstream of a gene; its promoter region. The core 
promoter is the segment of this locus most proximal to the transcription start site 
(TSS) and typically spans -40 base pairs (bp) to +40bp of this site (Juven-Gershon 
and Kadonaga 2010). Core promoters are typically classed as being ‘focused’ or 
‘dispersed’ based on the positioning of TSS and transcription factor binding sites; 
which results in corresponding transcription initiation patterns. Focused 
transcription is directed from specific TSS and frequently occurs for genes that are 
expressed in a highly cell-specific manner (Haberle and Stark 2018). This contrasts 
with dispersed core promoters from which transcription is initiated from several 
TSS, which is favoured in the expression of many housekeeping genes (Juven-
Gershon and Kadonaga 2010). Regardless of the shape of a core promoter, it 
contains TFBS for the protein machinery and accessory proteins that are required 
for gene transcription (Levine et al. 2014). General transcription factors (GTF); 
transcription factors II A, B, D, E, F and H, along with TATA binding protein (TBP) 
interact with this region using motifs such as the TATA box, TFIIB recognition 
element (BRE), initiator (Inr) and downstream promoter element (DPE) (Juven-
Gershon and Kadonaga 2010; Roy and Singer 2015). Interactions with these 
factors in addition to co-activator proteins and chromatin remodelling proteins, in 
conjunction with the recruitment of Pol II allows formation of the classical pre-
initiation complex (PIC), although the proteins involved in this are highly variable 
(Levine et al. 2014) (illustrated in Figure 1.4). 
  
43 
 
Figure 1.4: Assembly of the transcription pre-initiation complex at the core promoter. 
General transcription factors bind to consensus recognition binding motifs within the core 
promoter upstream of the gene (5’ direction). RNA polymerase II is recruited to the core 
promoter and the pre-initiation complex is formed with general transcription factors II A, B, 
D, E, F and H. Phosphorylation of the C-terminal domain (CTD) of Pol II enables release 
from the promoter and movement along the coding sequence and therefore transcription in 
the 3’ direction from the transcription start site (TSS).  
 
The proximal promoter is the regulatory locus that resides further upstream of the 
TSS than the core promoter. This region contains binding sites for cell lineage-
specific transcription factors that contribute to basal rates of gene expression 
(Harmston and Lenhard 2013).Transcription is initiated by phosphorylation of the 
serine residues within the C-terminal domain of Pol II, which allows release of the 
enzyme from the TSS. Pol II subsequently moves along the coding sequence 
catalysing the production of complementary mRNA. The progress of transcription 
is halted as Pol II stalls approximately 50bp downstream of the TSS (Core et al. 
2012; Muse et al. 2007). This pausing confers an essential regulatory step in 
transcription (Gilchrist et al. 2010; Haberle and Stark 2018; Meng and Bartholomew 
2018). Pausing is mediated by interaction between Pol II and negative elongation 
factor complex (NELF), with release of Pol II and the elongation phase of 
transcription triggered by interaction with positive elongation factor b (P-TEFb) 
(Core et al. 2014). Pol II accumulates at the promoter and is stabilised by the 
process of pausing, therefore allowing greater organisation and efficiency in the 
production of RNA transcript (Core et al. 2012; Henriques et al. 2018). Pausing has 
been posited as a facilitator of rapid transcription upon a regulatory cue that 
enables Pol II release, or through interaction between paused Pol II and other 
regulatory proteins that boost transcription rates (Lagha et al. 2012). Furthermore, 
promoters at which paused Pol II is observed ultimately exhibit greater 
transcriptional output (Core et al. 2008). The process of transcription is terminated 
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as RNA pol II reaches the end of the template sequence (terminator sequence) with 
change in protein affinity interaction with the template triggering detachment of the 
polymerase, in addition to the mRNA transcript detachment from Pol II (Proudfoot 
2016).  
 
Transcription typically occurs in a bidirectional manner (Meng and Bartholomew 
2018). Core et al. (2008) found that approximately 80% of active genes in IMR90 
human lung fibroblast cells demonstrated Pol II occupancy upstream of the TSS, 
resulting in RNA production upstream of the TSS. However, mRNA is only 
produced from downstream read-through of coding sequence. Scruggs et al. (2015) 
built on this model with the identification of multiple discrete TSS within a single 
promoter that facilitate bidirectional transcription, with the distance between these 
loci impacting on promoter structure leading to the postulation that this confers 
further regulation of gene transcription. Upstream antisense RNAs (uaRNAs) that 
result from divergent transcription are unstable and therefore rapidly degraded 
(Haberle and Stark 2018).  
 
1.3.2 Gene transcription is dependent on chromatin state 
 
The behaviour of any cell depends on the highly specific profile of cell lineage-
specific genes that it expresses at any given time (De Laat and Duboule 2013). 
Regulation of gene transcription is therefore of paramount importance in cellular 
identity and tissue homeostasis. A pivotal aspect of this control is modulation of the 
interactions between DNA sequences and corresponding regulatory elements 
(Stampfel et al. 2015). Within the nucleus DNA is packaged as chromatin, of which 
there are two forms; euchromatin and heterochromatin (Gibcus and Dekker 2013). 
Euchromatin has an open structure that allows interaction between DNA sequence 
and regulatory elements and therefore gene transcription. This contrasts 
heterochromatin which has a highly compacted structure that inhibits gene 
expression. Chromatin is spatially isolated within the nucleus on the basis of these 
two states (Gibcus and Dekker 2013). Therefore, chromatin is highly dynamic and 
state is dependent on cellular context, which in turn reinforces cell-specific patterns 
of gene transcription (Ernst et al. 2011; Gibcus and Dekker 2013). Consequently 
gene expression can modify chromatin state and therefore 3D organisation of the 
genome (Rowley et al. 2017).  
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Chromatin is highly ordered with hierarchical structure. Gross scale organisation 
occurs with the formation of chromosomes, which occupy specific areas; 
chromosome territories, within the nucleus (Petit et al. 2017). Within chromosomes, 
chromatin is further organised on the basis of activity with spatial separation into 
A/B compartments (Lieberman-Aiden et al. 2009). A compartments have an open 
structure, containing many genes which are transcribed, whereas B compartments 
are transcriptionally silent with a compacted structure (Fortin and Hansen 2015; 
Gibcus and Dekker 2013). Chromosomal compartments are then divided into 
topologically associated domains (TADs) as illustrated in Figure 1.5 (Bonev and 
Cavalli 2016). These regions encompass several genes and cognate regulatory 
sequences and are largely conserved between cell types and organisms (Dixon et 
al. 2012; Gong et al. 2018b). Using Hi-C chromatin conformation capture based 
methodology, Dixon et al. (2012) initially described TADs as having a typical span 
of approximately 880 kilobases (kb), however subsequent refinement of this 
technique has led to the consensus that TAD size may vary greatly, yet on average 
is approximately 185kb (Bonev and Cavalli 2016; Rao et al. 2014). TAD function 
hinges on 3D chromatin organisation which facilitates interaction between DNA 
sequences. Furthermore, intra-TAD interaction is a major aspect of cell-specific 
gene transcription, with dynamism in these interactions mediating regulation of 
transcription (Fukaya et al. 2016; Plank and Dean 2014). 
 
The boundaries of TADs are enriched for architectural protein motifs; namely 
CCCTC-binding factor (CTCF) and cohesin (Dixon et al. 2012). These proteins are 
frequently found in close proximity to one another (Tang et al. 2015). Whilst 
classically viewed as a repressor of transcription through insulator function, CTCF 
is increasingly being hailed as a facilitator of gene transcription (Ong and Corces 
2014). CTCF has a major role in organising chromatin topology and function, with 
Guo et al. (2015) demonstrating that genome editing based disruption of CTCF 
sites perturbs chromatin topology. This is reinforced by the work of Nora et al. 
(2017) who showed that deletion of CTCF affects the looping within a TAD between 
the boundaries and that CTCF therefore mediates TAD insulation. Cohesin has 
classically been associated with chromosome structure, but also functions in 
organisation of chromatin topology. This protein is pre-requisite in TAD formation 
and stabilises CTCF interactions (Nuebler et al. 2018; Ong and Corces 2014). 
Busslinger et al. (2017) demonstrated that cohesin is unable to interact at TAD 
boundaries when CTCF is removed. Whilst the studies of Schwarzer et al. (2017) 
and Rao et al. (2017) showed that depletion of cohesin and its capacity to interact 
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with chromatin causes loss of TAD arrangement and chromatin looping. These 
findings highlight the importance of interaction between CTCF and cohesin in the 
efficient organisation of chromatin and subsequent regulation of gene expression. 
TAD boundaries prevent non-specific inter-TAD interactions between regulatory 
elements and therefore reinforce fidelity in interactions between regulatory 
elements and cognate genes, thereby repressing aberrant gene transcription 
(Figure 1.5B). For example, Lupiáñez et al. (2015) used clustered regularly 
interspersed short palindromic repeats- Caspase 9 (CRISPR-Cas9) genome 
editing to manipulate the boundaries of a genomic locus in which structural variants 
are associated with pathological limb phenotypes in humans. Disruption of the TAD 
resulted in loss of specificity in regulatory element to cognate gene interactions, 
leading to aberrant gene expression and recapitulation of disease phenotype in 
murine models. The strength of isolation provided by TAD boundaries is variable, 
with greater binding of CTCF denoting a stronger boundary (Gong et al. 2018b). 
 
Figure 1.5: Chromatin is segregated into topologically associated domains (TADs).  
Chromosome compartments may contain several TADs (A). Chromatin is looped through 
the function of structural proteins CTCF (purple pentagon) and cohesin (yellow loop). This 
enables genes (blue rectangle, A) regulatory elements (green circles, A) and protein 
machinery required for transcription to be brought together. Within a TAD (B) there may be 
several genes (rectangles) and their cognate regulatory elements (circles). TAD boundaries 
are marked by cohesin and CTCF, enabling intra-TAD looping and preventing non-specific 
inter-TAD interaction.  
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The basic unit of chromatin is a nucleosome, which is composed of an octamer of 
histone proteins (two each of histone proteins H2A, H2B, H3 and H4), around which 
147bp of DNA is wound (Richmond and Davey 2003). Nucleosome positioning and 
occupancy varies across the genome and is a factor in DNA accessibility (Struhl 
and Segal 2013). Nucleosome depleted regions (NDR) occur in specific loci across 
the genome, such as in regulatory elements (Scruggs et al. 2015; Struhl and Segal 
2013). For example, nucleosomes are often absent at core promoters where 
transcription is occurring (Haberle and Stark 2018). Chromatin remodelling 
enzymes facilitate nucleosome sliding which causes shifts in nucleosome 
positioning and therefore DNA availability for interaction with regulatory proteins 
(Ho and Crabtree 2010). Post-translational modifications of histone proteins have 
a major role in chromatin state. A plethora of chromatin remodelling reader and 
writer enzymes are capable of recognising and catalysing variable modification of 
the histones such as methylation and acetylation, which impact on nucleosome 
compaction and DNA accessibility (Calo and Wysocka 2013; Heintzman et al. 
2007). For example, trimethylation of lysine 27 residue of histone 3 (H3K27me3) is 
associated with repressive chromatin state. This modification is deposited by 
Polycomb repressive complex 2 (PRC2), leading to increased chromatin 
compaction and therefore silencing of gene expression (Margueron and Reinberg 
2011). This contrasts acetylation modification of the same residue (H3K27ac) which 
characterises regulatory regions associated with active transcription (Kieffer-Kwon 
et al. 2013; Rada-Iglesias et al. 2011). Moreover, Stasevich et al. (2014) found that 
H3K27ac aids Pol II in the induction of the elongation step of transcription. 
Antagonism between H3K27ac and H3K27me3 is therefore important in regulation 
of chromatin state. In addition, this highlights the fact that regulatory element 
function within the genome can be identified on the basis of histone modification. 
 
1.3.3 Enhancers are fundamental regulators of gene transcription  
 
Whilst the promoter region for a gene orchestrates basal levels of gene 
transcription, further regulatory elements are required to refine the process of gene 
transcription (Zabidi and Stark 2016). Enhancers are an imperative class of cis-
regulatory module (CRM) that mediate transcription of a target gene in a highly 
specific temporospatial manner. Recent advances in high-throughput sequencing 
methodology has galvanised the study of enhancers, for example The 
Encyclopaedia of DNA Elements (ENCODE) Project Consortium (2012) identified 
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399,124 loci within the human genome that had enhancer-like characteristics. 
Given the latest estimate that the human genome contains approximately 21,000 
protein coding genes, the number of putative enhancers demonstrates the 
complicated regulatory mechanisms that allow the transcriptional regulation of each 
gene in every cell throughout life (Pertea et al. 2018). There may be several 
enhancers for a single gene, with each functioning in a specific cellular context 
(Kieffer-Kwon et al. 2013). Furthermore, many enhancers exhibit function that is 
specific to one cell type (Ernst et al. 2011). The importance of these elements is 
exemplified by the fact that the transcriptional output from a promoter alone is weak 
when compared with the combinatory action of a promoter and enhancer (Shlyueva 
et al. 2014). 
 
1.3.3.1 Enhancer function is dependent on interaction with promoter regions  
 
Interaction between an enhancer and the promoter region of its target gene 
underpins enhancer activity (Li et al. 2012). TAD organisation of chromatin is critical 
in facilitating this; highlighting a key characteristic of enhancers, the ability to 
interact with their target gene regardless of distance or orientation (Haberle and 
Stark 2018; Harmston and Lenhard 2013). There may be several genes and their 
cognate enhancers within a TAD, therefore interaction between an enhancer and 
target gene promoter must be highly specific in order to ensure efficient 
transcription (Zabidi and Stark 2016). TADs may be divided into ‘sub-TAD’ regions 
allowing the segregation of genes that are being actively transcribed and their 
cognate enhancers (Dowen et al. 2014). Enhancers are irregularly activated with 
expression of non-target genes upon disruption of CTCF and cohesin binding at 
sub-TAD boundaries (Hanssen et al. 2017). Dynamism in chromatin structure 
facilitates specificity in function, as interactions are dependent on cellular 
differentiation state (Rubin et al. 2017; Zhu et al. 2013a). For example, the work of 
Dowen et al. (2014) and later Hanssen et al. (2017) demonstrated that TAD and 
sub-TAD organisation enables regulatory elements to be activated or repressed 
through a common mechanism of insulation, in a cell-specific and tissue-specific 
manner. The extent of stringency in the interaction between an enhancer and 
corresponding promoter can vary with cell type, which correlates with gene 
function; for example there is less stringency in broad functioning housekeeping 
enhancer interactions compared with those of cell lineage-specific enhancers 
(Zabidi et al. 2015).  
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There are multiple models as to how the promoter and enhancer communicate, but 
the ‘looping model’ has strongest consensus as to how these two genomic regions 
are able to interact (Harmston and Lenhard 2013). This model dictates that the 
enhancer and promoter are brought together through a hierarchy of interactions 
that causes the intervening chromatin between the two regulatory loci to become 
looped (Harmston and Lenhard 2013; Meng and Bartholomew 2018). Enhancer-
promoter communication is dependent on an array of DNA-protein and protein-
protein interactions. Enhancers are formed of clusters of TFBS, which are utilised 
through interaction with cell lineage-specific combinations of transcription factors 
(Calo and Wysocka 2013; Reiter et al. 2017). The advent of Chromatin 
immunoprecipitation Sequencing (ChIP-Seq) methodology has enabled genome 
wide interrogation of TFBS; a useful tool in the identification of putative enhancer 
regions (Dogan et al. 2015; Visel et al. 2009a). The binding of ‘pioneer’ transcription 
factors to enhancer regions is a preliminary step in the commissioning of enhancer 
function (Spitz and Furlong 2012). Pioneer factors are transcription factors that are 
capable of interacting with inactive, closed chromatin (Iwafuchi-Doi and Zaret 
2014). Cell lineage specificity in the function of these TF reinforces temporospatial 
specificity in enhancer function (Donaghey et al. 2018). Pioneer factor interaction 
facilitates the recruitment of further transcription factors and chromatin remodelling 
proteins (CR) (Reiter et al. 2017). More specifically, the binding of pioneer factors 
causes nucleosome displacement and reorganisation that results in open 
chromatin structure that is capable of interaction with further regulatory proteins; 
therefore mediating enhancer function (Iwafuchi-Doi and Zaret 2014; Shlyueva et 
al. 2014). 
 
The spacing, orientation, order and number of TFBS within an enhancer dictate 
transcription factor interaction; a concept known as ‘enhancer grammar’ (Harmston 
and Lenhard 2013). There are several models of enhancer grammar and the 
mechanisms through which transcription factors assemble at enhancers. Firstly, 
the ‘enhanceosome’ model denotes enhancers that consist of strictly arranged 
TFBS, with enhancer output dependent on cooperative binding between highly 
ordered transcription factors positioned relative to one another (Spitz and Furlong 
2012). In addition, the function of enhancers displaying this grammar is more 
susceptible to mutations which may cause the loss of TFBS and therefore 
transcription factor interaction, halting enhancer activity (Dickel et al. 2013). This 
contrasts the flexibility exhibited in the ‘billboard’ model. First proposed by Kulkarni 
and Arnosti (2003), this model is based on enhancers composed of clusters of 
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TFBS positioned in a non-specific order, with enhancer activity reflecting the input 
of multiple TFs that may have antagonistic impact on enhancer function. 
Transcription factor binding occurs on an independent basis and enhancer function 
is not dependent on cooperative and sequential interaction of these proteins 
(Harmston and Lenhard 2013). Furthermore, in this form of organisation the type 
of transcription factor bound is more important than where it positioned (Long et al. 
2016). Given the stringency of the enhanceosome organisation, it is not surprising 
that is not observed as commonly as the more robust billboard model (Reiter et al. 
2017). A further model, the TF-collective model has been used to describe 
transcription factor binding at enhancers where TF interact indirectly with enhancer 
motifs through protein-protein interactions (Long et al. 2016; Spitz and Furlong 
2012). The complexity in transcription factor binding at enhancers is compounded 
by the fact that many enhancers exhibit characteristics of all models (Dickel et al. 
2013; Long et al. 2016). For example, a recent study by Grossman et al. (2018) 
demonstrated that the motifs for specific groups of TF lie within particular regions 
of the enhancer. This further reinforces the importance of TF binding organisation 
across an enhancer, yet emphasises the fact that the extent and fidelity of 
transcription factor binding interaction in driving enhancer function is still very much 
unknown. 
 
Further hierarchical interactions between transcription factors bound to the 
enhancer, structural proteins, transcriptional co-activators and chromatin 
remodelling factors such the histone acetyltransferases cAMP response element-
binding protein (CREB) binding protein (CBP) and p300, culminates in the 
enhancer-promoter interaction that underlies enhancer activity (Grossman et al. 
2018; Visel et al. 2009a). The Mediator complex is an important aspect of this and 
has classically been viewed as a ‘bridge’ between the two regulatory loci (Bonev 
and Cavalli 2016; Yin and Wang 2014). This complex is formed of approximately 
30 protein subunits which function in the coordination of signals between enhancer 
and promoter; an individual Mediator complex interacts with both enhancer and 
promoter (Petrenko et al. 2016; Soutourina 2017). The seminal work of Kagey et 
al. (2010) demonstrated that Mediator interacts in a cell-specific manner alongside 
cohesin in order to facilitate association between an enhancer and promoter. 
Moreover, Mediator can contribute to the release of Pol II in transcription initiation 
(Petrenko et al. 2016). As aforementioned, CTCF is a critical regulator of chromatin 
looping and is therefore an important aspect of enhancer-promoter communication, 
and can be bound to both elements (Ong and Corces 2014; Weintraub et al. 2017). 
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Ren et al. (2017) demonstrated that the binding of CTCF to motifs in close proximity 
to enhancers facilitates the proximity between interacting enhancers and 
promoters, in addition to stabilising the interaction between these two regions. Yin 
Yang 1 (YY1) is a further protein that has been associated with enhancer-promoter 
interaction, through binding at both elements (Weintraub et al. 2017).  
 
Enhancer-promoter interaction and therefore enhancer function positively 
influences transcriptional bursting, which results in increased gene transcription 
(Catarino and Stark 2018). For example, strong enhancers are associated with 
greater burst frequency (Fukaya et al. 2016). However, the extent of enhancer 
interaction throughout the entirety of a transcriptional burst is not yet known 
(Bartman et al. 2016). The strongest consensus on enhancer function is that 
enhancer-promoter interaction aids in the recruitment and stabilisation of the PIC 
at the promoter region and therefore boosts transcription initiation rate (Haberle 
and Stark 2018; Meng and Bartholomew 2018). A schematic representation of 
these interactions is outlined in Figure 1.6. 
 
Figure 1.6: Enhancer-promoter interaction facilitates recruitment of the pre-initiation 
complex (PIC) to the promoter and the initiation of gene transcription. Cell lineage-
specific pioneer factors and co-activator transcription factors (TF) interact with both the 
active enhancer and promoter regions. Subsequent interactions with chromatin remodelling 
proteins (CR), structural proteins including CTCF, cohesin and Mediator allow chromatin 
looping with the enhancer and promoter being brought into close proximity with one another. 
This culminates in the recruitment of the PIC to the gene promoter and the initiation of gene 
transcription. Inactive enhancers are spatially unable to interact with the target promoter 
through chromatin looping.  
 
Enhancers are also capable of influencing transcription at the elongation stage. 
Interaction between enhancers and regulatory proteins can aid in the recruitment 
of p-TEFb complex and the release of Pol II from the transcriptional pausing stage 
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(Haberle and Stark 2018). Liu et al. (2013) described ‘anti-pause enhancers’ as 
enhancers that regulate the release of Pol II from pausing stage and trigger 
transcriptional elongation. An influential study by Sawado et al. (2003) 
demonstrated that deletion of the locus control region enhancer for the β-globin 
gene caused a decrease in pre-initiation complex assembly, in addition to reduced 
phosphorylation of Pol II and transition into elongation phase; this enhancer 
therefore functioned in multiple stages of gene transcription.  
 
Whilst enhancers function as regulators, they must in turn be regulated in order to 
ensure stringent specificity in patterns of gene transcription (Visel et al. 2009b). 
Chromatin state is an integral factor in enhancer activity. As outlined previously, 
chromatin with closed and compacted structure is unable to interact with regulatory 
proteins, enhancers subject to this chromatin state are inactive (Heinz et al. 2015). 
As aforementioned, pioneer factors are able to overcome inactive chromatin state 
and activate enhancer activity, which is an integral stage in cellular reprogramming 
and differentiation (Iwafuchi-Doi and Zaret 2014). Enhancers often exhibit 
nucleosome depletion as a result of pioneer factor binding, with open chromatin 
state causing hypersensitivity to deoxyribonuclease I (DNase I), which is an 
attribute that is commonly used to predict enhancer regions (Heinz et al. 2015; 
Shlyueva et al. 2014; Thurman et al. 2012). Where nucleosomes are present in an 
enhancer, histones may be substituted with non-canonical histone variants such as 
H2A.Z and H3.3, the former of which is associated with strong enhancers (Calo and 
Wysocka 2013; Ernst et al. 2011; Meng and Bartholomew 2018). These histone 
variants cause greater instability in nucleosome structure, which allows them to be 
displaced from DNA more easily, enabling greater rates of TF-DNA interaction 
(Harmston and Lenhard 2013). DNA methylation state also influences the utilisation 
of enhancers; active enhancers are often hypomethylated (Kieffer-Kwon et al. 
2013). Sheaffer et al. (2014) found that depletion of the expression of DNA 
methyltransferase 1 (DNMT1); which maintains DNA methylation, led to aberrant 
activation of gene transcription through pathological enhancer-TF interaction which 
was repressed by DNA methylation in wild-type samples. (Aran and Hellman 2013). 
King et al. (2016) described DNMT1 based DNA methylation in the regulation of 
histone methylation which therefore reinforces regulation of enhancer activity. In 
addition, abnormal methylation of enhancer DNA has been associated with cancer 
(Fleischer et al. 2017). 
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1.3.3.2 Posttranslational modification of histones affects enhancer activity  
 
The post-translational modification of histones is an important factor in the 
identification of putative enhancer regions and can be used to predict the activity of 
an enhancer at a given time point (Calo and Wysocka 2013; Rada-Iglesias et al. 
2011; Zhu et al. 2013b). The work of Heintzman et al. (2007) demonstrated that 
enhancers can be distinguished from promoters due to the extent of methylation of 
the fourth lysine of histone protein three; promoters are marked with trimethylation 
of this residue (H3K4me3), whereas enhancers are associated with 
monomethylation of the residue (H3K4me1). Moreover, H3K4me1 is intrinsic at 
enhancer regions (Bonn et al. 2012). As previously mentioned, H3K27ac is another 
histone modification associated with regulatory function which can be useful in 
enhancer identification. Both Creyghton et al. (2010) and Rada-Iglesias et al. 
(2011) described enhancer regions with nucleosomes exhibiting both H3K27ac and 
H3K4me1 modifications as being active, with enhancers where H3K4me1 alone is 
present being denoted as being inactive and ‘poised’ for activation. The latter form 
of enhancer are also enriched for the aforementioned repressive H3K27me3 mark 
(Rada-Iglesias et al. 2011) as illustrated in Figure 1.7. Bonn et al. (2012) expanded 
on this with the finding that H3K27me3 may also be used to distinguish enhancers 
with repressed activity rather than poised, with enhancers displaying this mark in 
mesodermal cells inactive, yet functioning in other cell types. There are further 
histone modifications that have been associated with enhancers, such as 
trimethylation of lysine 79 of histone 3 (H3K79me3) (Bonn et al. 2012), acetylation 
of lysine 64 of histone 3 (H3K64ac) and acetylation of lysine 122 of histone 3 
(H3K122ac) (Pradeepa et al. 2016), however these have not been broadly adopted 
in the identification of putative enhancers. Yan et al. (2018) knocked out expression 
of the histone methyltransferase Myeloid/Lymphoid or Mixed-Lineage Leukaemia 
3/4 (MLL3/4), observing that this led to a decrease in H3K4me1 deposition at 
enhancers and reduction in chromatin interactions. In addition, loss of MLL3/4 also 
caused reduction in Mediator interaction, indicating that H3K4me1 acts in the 
recruitment of Mediator and therefore chromatin topological organisation (Yan et 
al. 2018). It would therefore be expected that this mechanism would result in 
developmental anomaly if perturbed. However, Rickels et al. (2017) knocked out 
expression of the Drosophila ortholog of MLL3/4, Trr, observing no profound effect 
on Drosophila development. Furthermore, in this study, the catalytic function of 
MLL3/4 was reduced in mouse embryonic stem cells (mESC), which caused a 
decrease in H3K4me1 deposition, but did not impair cellular proliferation. Each of 
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these studies emphasise the need for further elucidation of the extent and roles of 
histone modifications in enhancer function (Li et al. 2016). 
 
 
Figure 1.7: Chromatin state and interactions with regulatory proteins varies between 
active and poised enhancers. Active enhancers (A) display both H3K4me1 and H3K27ac 
histone modifications, with open chromatin structure that interacts with pioneer transcription 
factors (TF), chromatin remodelling proteins (CR) and coactivator TF. This is in contrast to 
poised enhancers which display H3K4me1 and the repressive H3K27me3 histone which is 
mediated by the Polycomb repressive complex (PRC2). This leads to chromatin structure 
that is able to interact with pioneer factors, yet the absence of cell-specific activator 
transcription factors prevents enhancer activity. 
 
The ability to categorise enhancers on the basis of activity has had important 
ramifications in the understandings of the mechanisms involved in enhancer 
function. It is widely accepted that poised enhancers enable rapid induction of gene 
expression through a reduction in the number of steps required in order to induce 
initiation of gene transcription. Pioneer factors are capable of binding to poised 
enhancers which ensures that enhancer activity is triggered faster and more 
efficiently when the abundance of protein cofactors changes as the context of a cell 
transitions to specific conditions required for enhancer function (Figure 1.7) (Lagha 
et al. 2012; Levine et al. 2014). Poised enhancers are activated through interaction 
with chromatin remodelling proteins such as p300/CBP, in addition to cell lineage-
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specific transcription factors, leading to a switch from H3K27me3 to H3K27ac with 
the loss of PRC2 repressive complex and the onset of chromatin looping, 
culminating in the enhancer and promoter being brought together; and the switch 
to active enhancer state (Plank and Dean 2014; Rada-Iglesias et al. 2011; Smith 
and Shilatifard 2014). Creyghton et al. (2010) suggest that enhancer poising is 
crucial in cell lineage determination, with Rada-Iglesias et al. (2011) and 
Bogdanović et al. (2012) reinforcing this with the notion that poised enhancers are 
marked at early stages of development in anticipation of activation in later stages 
of differentiation. However, many enhancers that are active do not transition from 
a poised to active state with changes in cellular differentiation state (Rada-Iglesias 
et al. 2011; Spitz and Furlong 2012).  
 
1.3.3.3 Temporospatial specificity of enhancer function  
 
As outlined previously, the most crucial feature of an enhancer is temporospatial 
specificity in function. The activity of most enhancers is delimited to a specific 
cellular lineage, which further reinforces cellular identity and the control of cell 
lineage (De Laat and Duboule 2013; Kieffer-Kwon et al. 2013). This attribute is 
particularly important, and utilised during development, with a significant 
consensus across the field that enhancers are critical determinants of cell lineage-
specific patterns of gene expression and cell behaviour (Heinz et al. 2015; Kieffer-
Kwon et al. 2013). This is exemplified by the work of Ernst et al. (2011) who found 
that enhancers are prevalent regulators of genes with developmental and tissue-
specific roles; but not housekeeping genes. Moreover, housekeeping genes 
typically have fewer enhancers Osterwalder et al. (2018). The concept of 
housekeeping function is also posited by Zabidi et al. (2015), with the notion that 
developmental enhancers function in a highly specific cell type, whereas 
housekeeping enhancers function in multiple cell types. High-throughput 
methodology has enabled enhancer activity to be compared between cellular 
differentiation states. For example, Nord et al. (2013) identified 90,000 putative 
enhancers and studied their activation during development through the profiling of 
H3K27ac modification. Lineage-determining transcription factors interact with 
enhancers, with the abundance of these factors changing with developmental state, 
therefore moderating gene transcriptional output in a cell-specific manner (Kieffer-
Kwon et al. 2013). Huang et al. (2016) demonstrated modified enhancer activity in 
erythropoietic stem cells as differentiation proceeded, and that differences in 
enhancer utilisation between cell stages was accounted for by combinatorial 
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interactions with coactivator proteins, rather than lineage-determining TF; the 
abundance of which was similar between lineages. 
 
The stability and timing of enhancer-promoter interaction is a factor in enabling 
temporospatial specificity of function. Jin et al. (2013) observed enhancer-promoter 
interaction that had been forged prior to the presence of signals required in order 
to induce enhancer function in response to external stimuli. This is supported by 
Ghavi-Helm et al. (2014) who described looping interactions between enhancers 
and promoters as occurring in a stable manner. Paused Pol II has also been shown 
to reside concurrently with these interactions; albeit not with the replete PIC 
machinery. This suggests that Pol II stabilises these interactions and acts as a final 
major step in the switch from inactive to active gene transcription (Core et al. 2012; 
Ghavi-Helm et al. 2014; Lagha et al. 2012). The work of Fukaya et al. (2016) 
contrasts this, with the suggestion that enhancer-promoter interactions occur in a 
dynamic manner with interaction that occurs in a more transient manner for rapid 
transcriptional bursting. Pre-assembly of enhancer-promoter interaction is more 
frequently associated with tissue-specific enhancers that are rapidly activated in 
response to signalling triggered by cell-signalling effectors, such as in response to 
environmental stimuli (De Laat and Duboule 2013). Ostuni et al. (2013) found that 
poised enhancers can become activated in response to extracellular events. In 
addition, they described a further class of latent enhancers that were 
indistinguishable from surrounding non-functional chromatin on the basis of 
H3K4me1 or TF binding in unstimulated cells, but were activated in the presence 
of cognate cytokines; with the acquisition of enhancer marks, pioneer factor 
binding, enhancer activity and consequential gene transcription (Ostuni et al. 2013). 
This suggests that latent enhancer activation is a compromise between specificity 
in response to cognate stimuli and the timing involved in this. These enhancers 
have an increased threshold for activation given the lack of enhancer attributes that 
contribute to priming enhancer function, however, resultant activity is specific to 
stimuli and not inappropriately induced as could occur with pre-existing enhancer-
promoter interaction. De novo enhancer-promoter interactions can be instigated by 
specific cellular context and are associated with more refined patterns of enhancer 
function; such as occurs with cell lineage-specific enhancers (De Laat and Duboule 
2013). Rubin et al. (2017) examined enhancer-promoter interaction in cellular 
differentiation, describing two classes of such interaction. ‘Stable’ interactions 
existed prior to the commencement of differentiation with presence of cohesin as a 
facilitator of the interaction and no change in H3K27ac. ‘Gained’ interactions 
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mirrored poised enhancers with lack of cohesin, increase in H3K27ac, and increase 
in interaction strength upon differentiation. It remains to be seen whether future 
research will perpetuate this classification, however each of the aforementioned 
studies highlights the importance of cellular context as a determinant of enhancer 
purpose and activity.  
 
Whilst temporospatial specificity is a fundamental feature that underpins enhancer 
function, there may be overlap in the activities of multiple enhancers for a cognate 
gene. Firstly, shadow enhancers are seemingly redundant cis-acting regulatory 
elements (Spitz and Furlong 2012). These forms of enhancer are located more 
distally from the target gene than other enhancers with highly similar identical 
patterns of TF binding and enhancer activity (Smith and Shilatifard 2014). However, 
shadow enhancers do not necessarily exhibit weaker function. Fukaya et al. (2016) 
observed greater induction of gene transcription facilitated by a shadow enhancer 
than a primary enhancer located proximal to the gene. This discrepancy in 
transcriptional output was due to increased bursting of transcription directed by the 
shadow enhancer. Cannavò et al. (2016) investigated the prevalence of shadow 
enhancers in Drosophila development, finding that shadow enhancers occur more 
commonly than previously envisaged and there may be multiple shadow enhancers 
for an enhancer, each of which are highly conserved. Redundancy in shadow 
enhancer function ensures robust gene expression (Lagha et al. 2012). For 
example, perturbation of the sequence and therefore function of one enhancer 
would be compensated for by the activity of a shadow enhancer being utilised in 
the same temporospatial context, preserving transcriptional output. The effects of 
this on topological organisation are unclear (Spitz and Furlong 2012). Redundancy 
between enhancers may be limited and only occur in a specific temporospatial 
window if enhancers display greater activity in divergent cell types (Cannavò et al. 
2016). Osterwalder et al. (2018) used CRISPR-Cas9 based genome editing 
techniques in order to delete ten enhancers that have been proven to drive robust 
expression of genes involved in limb development. Knockout of these genes in mice 
causes limb malformation, and it was therefore expected that enhancer knockout 
would recapitulate these phenotypes. However, this loss-of-function approach did 
not cause limb associated phenotype for any enhancer that was deleted, thereby 
suggesting that redundancy between multiple enhancers for a gene.  
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1.3.3.4 Enhancers may be arranged within super-enhancers  
 
Grouping of enhancer activity can also occur within super-enhancers. Whyte et al. 
(2013) first described super-enhancers as regions encompassing multiple 
enhancers and associated epigenetic modifications, with binding of cell lineage-
determining transcription factors and enriched interaction with the Mediator protein 
complex. The function of multiple enhancers is therefore assimilated into stronger 
transcriptional output than from a typical single enhancer (Heinz et al. 2015; Huang 
et al. 2016). Nevertheless, the concept of super-enhancers is controversial. Hay et 
al. (2016) investigated the α-globin putative super-enhancer, with examination of 
multiple enhancer elements. They found that that there was variable function 
between enhancer elements within this region and that this resulted in additive 
function of individual elements as opposed to collaborative function. Organisation 
of sub-TADs is a further confusing aspect of this, as the organisation of a gene and 
its cognate enhancers into a sub-TAD grouping may confer super-enhancer 
identity. The recent work of Gong et al. (2018) illustrated that super-enhancers are 
insulated by strong TAD boundaries. This suggests that super-enhancers are 
closely regulated in order to ensure fidelity in function and that the potent 
transcription that arises from their function remains specific to the target gene. 
Further research is required in order to understand the veracity of super-enhancers 
and their function.  
 
1.3.3.5 Enhancers may themselves be transcribed  
 
The complexity in enhancer function is compounded by the fact that they may be 
transcribed when active. The seminal studies of de Santa et al. (2010) and Kim et 
al. (2010) described the occupation, and activity of Pol II at enhancer regions, 
catalysing the transcription of non-coding RNAs; which the latter group denoted as 
being enhancer RNA (eRNA). Bidirectional transcription of eRNA is more common 
than unidirectional transcription and whilst resultant transcripts can be 
polyadenylated, they typically have a short half-life and exhibit nascent nuclear 
localisation (Natoli and Andrau 2012; Rahman et al. 2016). A pertinent question in 
the field is whether eRNA is simply a consequence of Pol II presence at an 
enhancer, or an intrinsic aspect of enhancer mediated regulation of gene 
transcription. There is a growing consensus that eRNA function is important in 
transcriptional regulation, with several mechanisms as to how this is mediated, 
however this has not been extensively elucidated (Mikhaylichenko et al. 2018). 
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Enhancers are not transcribed in the absence of interaction with the target gene 
promoter, eRNA production is therefore a consequence of the interaction between 
enhancer and promoter (Kim et al. 2010; Zhu et al. 2013b). In addition, enhancer 
activity has been correlated with enhancer transcription (Mikhaylichenko et al. 
2018). Arner et al. (2015) used cap analysis of gene expression (CAGE) 
methodology in order to examine the timing of transcription from promoters and 
enhancers, observing that active enhancers are transcribed before transcription of 
the cognate target gene. Mousavi et al. (2013) demonstrated that depletion of 
eRNA through short interfering RNA (siRNA) based silencing reduced chromatin 
accessibility and the loading of Pol II at cognate promoter region. This is echoed by 
Lam et al. (2013) who demonstrated that transcription of eRNA can be repressed 
by regulatory protein, leading to down-regulation of gene expression. This therefore 
suggests that eRNA have a role in the assembly of the PIC at the promoter and 
subsequent initiation of transcription. The effect of eRNA on histone modification 
was also echoed by the work of Kaikkonen et al. (2013) who described transcription 
from latent enhancers as leading to methylation of the histones of the enhancer. 
This group suggest that histone modification provides a form of epigenetic memory 
with the marking of enhancers for further activity. Enhancer RNAs have also been 
demonstrated to function in enhancer-promoter looping interaction. Li et al. (2013) 
observed that eRNA are capable of interaction with cohesin, and function in 
stabilising interaction between enhancer and promoter. These findings are 
contradicted by Schaukowitch et al. (2014) and Rahman et al. (2016) who found 
that eRNA are not required for enhancer-promoter interaction, with the former study 
demonstrating that reduction of eRNA abundance did not negatively impact on 
enhancer-promoter looping interaction. A further confounding factor in 
understanding eRNA is that function may occur during the transcriptional bursting 
process. Schaukowitch et al. (2014) described eRNA interaction with transcriptional 
pausing mediator NELF, which facilitated the release of Pol II and the 
commencement of the elongation phase of transcription. Each of these studies 
highlight the need for further interrogation of the role of eRNA in enhancer function. 
Moreover, recent work by Mikhaylichenko et al. (2018) has demonstrated the 
capacity for enhancers to act as promoters, and vice versa; further reiterating the 
complexity involved in attempting to understand enhancer function.  
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1.3.3.6 Enhancers are evolutionarily conserved 
 
A further major trait associated with enhancers is a high degree of sequence 
conservation between evolutionary disparate species (Pennacchio et al. 2006). 
Genetic sequences with function, such as enhancers, are observed to be 
maintained in the genome through generations as a result of selective pressure, 
whilst non-functional regions are subject to genetic drift (Visel et al. 2007a). The 
conservation of TFBS is a critical aspect of enhancer conservation, ensuring that 
regulatory interactions can be maintained; and therefore an enhancer may still elicit 
function over evolutionary time (Taher et al. 2011). Loss of enhancer function may 
also contribute to evolution. Kvon et al. (2016) demonstrated that the process of 
loss of limbs in snake evolution could have been facilitated through inactivating 
mutations within the ZRS enhancer of limb development-related gene sonic 
hedgehog (SHH). CRISPR-Cas9 based replacement of murine enhancer genomic 
sequence with corresponding snake genomic sequence led to limb truncation in 
homozygous transgenic mice. This phenotype was rescued with the introduction of 
17bp of evolutionarily conserved sequence present in the lizard but not the snake 
genome into the snake ZRS sequence in transgenic mice (Kvon et al. 2016). Dickel 
et al. (2018) illustrated that ‘ultraconservation’ over hundreds of base pairs is 
required for the function of some developmental enhancers, with developmental 
abnormality resulting from sequence aberration.  
 
The disruption of DNA regions, such as TADs can have pathological consequences 
as mentioned previously (Lupiáñez et al. 2015). This is also true with aberration of 
enhancer DNA sequences and resultant function, which has been implicated in 
many diseases (Murakawa et al. 2016). Pathology may result from loss of 
enhancer-regulatory protein interaction if the regulatory protein has been mutated 
in a manner that diminishes capacity to recognise target DNA sequences or co-
activator proteins (Smith and Shilatifard 2014). Much of the study of the role of 
enhancers in disease has however focused on changes in the DNA sequences of 
enhancers. For example, Maurano et al. (2012) examined the prevalence of 
disease associated single nucleotide polymorphisms (SNP) within putative 
regulatory elements predicted through the identification of DNase I hypersensitive 
regions. This study demonstrated that SNP within enhancers may be linked to 
phenotypes observed due to pathological changes in target gene expression. 
Subsequent improvements in whole genome methodology has enabled 
characterisation of the roles of many more enhancer mutations in pathology 
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(Murakawa et al. 2016). The manipulation of enhancer sequences and restoration 
of function through genome editing therefore represents a powerful future potential 
therapeutic approach in the amelioration of profound diseases. Moreover, greater 
elucidation of enhancer regions within the genome will facilitate a much greater 
understanding of many pathologies and the mechanisms that underpin them. 
 
1.4 Transcriptional regulation of Ccn2/CCN2 
 
Given that CCN2 is expressed in many tissues concurrently, the transcription of 
CCN2 must be tightly controlled in order to ensure cell and tissue specificity in 
function. Many of the aforementioned studies that found changes in Ccn2 
expression after treatment with cellular signalling factors did not explore the 
mechanisms underlying this regulation. Characterisation of the Ccn2/CCN2 
promoter region has been an essential aspect of understanding regulation of 
transcription and therefore protein production. Many studies have used reporter 
assays in order to examine the ability of cellular signalling factors to regulate the 
transcriptional output from the human CCN2 promoter (Eguchi et al. 2017).  
 
Several transcription factors and cellular signalling mechanisms have been 
described as modulating Ccn2/CCN2 expression via the promoter region, and are 
outlined in Figure 1.8. For example, the transcription factor specificity factor 1 (Sp1) 
binds to the CCN2 promoter close to the coding sequence, within a region between 
-86b and +17bp relative to the TSS (Holmes et al. 2003). Furthermore, increased 
expression of CCN2 was mediated by Sp1 in fibroblasts derived from scleroderma 
patients. The first study to scrutinise TFBS within the CCN2 promoter was that of 
Grotendorst et al. (1996). This group used a fragment spanning -823bp to +74bp 
of the human CCN2 promoter sequence to drive the expression of luciferase 
reporter gene. Treatment with TGF-β led to approximately 30 times greater reporter 
expression compared to untreated control in NIH3T3 fibroblast immortalised cell 
line. This study identified a TGF-β response element (Tβ-RE) located 
approximately 150bp upstream of the CCN2 TSS. Response from this element was 
also found in HCS-2/8 cells (Eguchi et al. 2001). This region was later 
demonstrated to be required for basal CCN2 promoter activity and became known 
as the basal control element (BCE) (Holmes et al. 2001). Endothelin-1 (ET-1) based 
regulation of CCN2 expression is also dependent on utilisation of BCE-1, in addition 
to Mitogen-associated protein kinase kinase (MEK)/extracellular signal-regulated 
kinases (ERK) signalling (Shi-Wen et al. 2004).  
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Subsequent studies have discovered further regulatory motifs that mediate TGF-β 
control of CCN2 expression. Abraham et al. (2000) found that TGF-β and tumour 
necrosis factor-α (TNFα) regulate CCN2 transcription though motifs between -
244bp and -166bp upstream of the CCN2 TSS. (Figure 1.8) These proteins had 
antagonistic effects, with TGF-β stimulating transcription whereas TNF-α ablated 
this. Moreover, this TGF-β response element was further upstream of the 
previously described Tβ-RE/BCE (Figure 1.8). This work was further refined by 
Holmes et al. (2001) who showed that it was a Smad binding motif that mediated 
TGF-β response in this region. Smad transcription factors function downstream of 
TGF-β and BMP, all of which are members of the TGF-β superfamily of proteins 
(Massagué et al. 2005). Activation of TGF-β in turn leads to receptor triggered 
phosphorylation of Smad2 and Smad3, which form complexes with Smad4 and 
translocate to the nucleus where they can interact with co-activator proteins such 
as p300 and ultimately TFBS in coordinating gene transcription (Morikawa et al. 
2013). Holmes et al. (2001) found that Smad 3 and 4 synergistically increase CCN2 
transcriptional output. Furthermore, in this study, TGF-β response was dependent 
on the function of Smad3. Smad 2 and 3 are also involved in TGF-β response in 
osteoblasts (Arnott et al. 2008). TGF-β regulation of CCN2 expression in fibroblasts 
is also mediated through protein kinase C and Ras/MEK/ERK, and repressed by c-
Jun N-terminal kinase (JNK) signalling (Leask et al. 2003). ERK functions 
downstream of both SRC and actin filament-associated protein (AFAP1) in TGF-β 
based CCN2 promoter response in osteoblasts (Arnott et al. 2008; Cho et al. 2015). 
Leask et al. (2003) also described a transcription enhancer factor (TEF/TEAD) 
binding motif that was required for TGF-β regulation within the CCN2 promoter in 
fibroblastic cells, thereby implicating interaction with the Hippo signalling pathway. 
However, further work by van Beek et al. (2006) revealed that Ets-1 is involved in 
TGF-β based CCN2 promoter regulation and interacts at the TEF/TEAD motif. In 
addition, Ets-1 was found to function in the presence of Smad3 and was required 
in TGF-β response. A further transcription factor, friend leukaemia integration-1 
(Fli-1) was also shown to interact alongside Ets-1. Ets-1 has also been shown to 
mediate TGF-β based CCN2 promoter regulation in osteoblasts (Geisinger et al. 
2012). 
 
Utilisation of consensus sequences within the CCN2 promoter is dependent on cell 
type. For example in the study from Grotendorst et al. (1996), TGF-β response 
occurred in fibroblastic and smooth muscle cells, but not epithelial cells. This is 
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supported by Eguchi et al. (2001) who compared basal CCN2 promoter activity 
between HCS-2/8 chondrocytic cell line and HeLa cell line, finding that a 110 
fragment located from -202bp to -88bp upstream of the CCN2 TSS was more active 
in the chondrocyte derived cells. These studies therefore demonstrate that 
promoter activity is dependent on cellular context, and that chondrocyte specific 
response elements reside in this region. This work was expanded on with the 
discovery of the ‘transcription enhancer dominant in chondrocytes’ (TRENDIC) 
element located -202bp to -180bp upstream of the CCN2 TSS (Eguchi et al. 2002). 
Utilisation of this element was found to be HCS-2/8 chondrocyte cell line-specific, 
further reinforcing the concept of CCN2 transcriptional regulation in a cell type 
specific manner. Further study of TRENDIC demonstrated that it is bound by MMP3 
which results in increased transcriptional output directed from the CCN2 promoter 
(Eguchi et al. 2008).  
 
Further chondrocyte specific regulation of CCN2 transcription is mediated through 
a SOX9 TFBS. Firstly, Huang et al. (2010) described SOX9 and T-cell factor- 
lymphoid enhancer binding factor (TCF-LEF) consensus sites in the regulatory 
region surrounding Ccn2 in the murine genome, and their utilisation in an in vitro 
model of endochondral ossification with regulatory sequence function linked to 
luciferase reporter gene expression. SOX9 and TCF-LEF recognise consensus site 
(A/T)(A/T) ACAA(A/T)G and inverted repeat sequence respectively, thereby 
facilitating antagonism between the two signalling mechanisms (Huang et al. 2010; 
Oh et al. 2010). Huang et al. (2010) found TCF-LEF sites at -443bp, -542bp, -
1963bp and -3941bp upstream of the Ccn2 TSS (Figure 1.8). In this study, β-
catenin signalling mediated by TCF-LEF increased CCN2 promoter activity and the 
expression of CCN2 through the -443bp motif. SOX9 was observed to bind to this 
motif in a monomeric form that repressed gene expression. It was therefore 
postulated that TCF-LEF and SOX9 compete in order to bind to this motif and 
control Ccn2 transcription. In this study, SOX9 was predicted to repress the 
expression of Ccn2 in the primitive stages of mesenchymal condensation and 
chondrogenesis, with CCN2 activation by TCF-LEF in latter stages of endochondral 
ossification as TCF-LEF expression and function becomes dominant over SOX9. 
The concept of antagonism between SOX9 and β-catenin is logical given the 
differences in the points at which they function in skeletogenesis and this has been 
previously proven (Akiyama et al. 2004). A puzzling aspect of the results obtained 
in this study is that a sequence from approximately -4kb to the TSS drove β-
galactosidase (LacZ) reporter gene in vivo in intervertebral disc (IVD) chondrocytes 
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but not growth plate cartilage during embryonic development. This confounds 
previous work and their own study that found Ccn2 expression in several 
populations of growth plate chondrocytes (Aoyama et al. 2009; Ivkovic et al. 2003; 
Kubota and Takigawa 2011).  
 
Oh et al. (2016) also interrogated the capacity of SOX9 to regulate CCN2 
expression, however their data suggests that SOX9 promotes Ccn2 transcription. 
This group used an ex vivo model with conditional knockout of Sox9 expression in 
costal chondrocytes, finding that removal of Sox9 function led to a decrease in 
CCN2 expression. ChIP methodology revealed that SOX9 binds near to the CCN2 
TSS in the rat genome. A reductionist approach was subsequently used with 
luciferase reporter plasmids with different sized Ccn2 promoter constructs in order 
to find the sequence that responds to SOX9. Mutation of a SOX9 motif -70bp to -
64bp upstream of the TSS in the rat genome led to a decrease in reporter gene 
expression, moreover this site was bound by SOX9. This contradicted the findings 
of Huang et al. (2010) by firstly not discovering the previously described motif, and 
secondly with the observation monomeric SOX9 motif was utilised in increasing 
CCN2 expression. Furthermore, Oh et al. (2016) also found that Ccn2 expression 
within the growth plate of Sox9 conditional knockout mice was reduced compared 
to control mice. The discrepancies between these studies highlight the importance 
of chondrocyte differentiation state in the context of Ccn2 gene transcription. 
 
Hiyama et al. (2018) also found that Wnt/β-catenin signalling can regulate the 
expression of CCN2 in rat IVD chondrocytes. This study utilised a CCN2 promoter 
reporter construct, with an increase in β-catenin function leading to decreased 
reporter expression. However, it is unclear how large a fragment of the CCN2 
promoter was used to drive reporter expression and there were no attempts to 
further refine the sequence within the construct that mediates the regulatory 
mechanism. 
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Figure 1.8: Basic schematic representation of transcription factor binding sites 
within the promoter region for Ccn2/CCN2 in both mouse and human sequences. 
Many signalling mechanisms regulate the expression of CCN2. TGF-β is a potent regulator 
of CCN2 with control mediated through the Smad, BCE and Sp1 elements. Binding site 
utilisation is dependent on transcription factor abundance, and therefore cell type-specific.  
 
Further studies have examined broader regulatory region encompassing kilobases 
of sequence upstream of CCN2. (Chiou et al. (2006) used a zebrafish model with 
green fluorescent (GFP) reporter gene expression under the control of a region 
spanning approximately 3kb upstream of CCN2. Treatment with growth hormone 
(GH) in addition to insulin-like growth factor 1 and 2 (IGF-1 and 2 respectively) 
caused an increase in promoter activity. Higgins et al. (2004) found hypoxia 
inducible factor-1 (HIF-1) binding motifs at approximately -3740bp and -1550bp 
upstream of Ccn2 within the murine genome. These motifs were utilised in hypoxia 
response leading to an increase in Ccn2 expression. This contrasts the findings of 
Tran et al. (2013) who assessed hypoxia response in nucleolus pulposus cells, 
finding that hypoxia caused a decrease in Ccn2 expression and that HIF-1 reduced 
Ccn2 expression, but this effect was not mediated by the HIF-1 response element 
motifs. 
 
The 3’ untranslated region (3’UTR) of CCN2 also has regulatory function. This was 
first discovered by Kubota et al. (1999) who found that a segment of the 3’UTR 
repressed the expression of a luciferase reporter gene, and later named it as cis-
acting element of structure-anchored repression (CAESAR) (Kubota et al. 2000). 
This therefore demonstrated that production of CCN2 is also regulated at the 
posttranscriptional level. Kondo et al. (2006) expanded on this by demonstrating 
hypoxic conditions in the culture of HCS-2/8 led to interaction between the 
CAESAR element in CCN2 mRNA and protein that caused greater stability of the 
mRNA and therefore increased translational output of CCN2. 
 
As part of a project exploring genes expressed in the brain, Gong et al. (2003) 
created a transgenic mouse (Tg(Ctgf-EGFP)FX156Gsat) containing a bacterial 
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artificial chromosome (BAC) construct containing a GFP gene in the location of the 
endogenous translation initiation codon for Ccn2. Therefore, GFP reporter gene 
expression would be a surrogate for endogenous Ccn2 expression driven by the 
surrounding regulatory sequence. This construct (RP24-96J1) is approximately 
160kb in size and constitutes the region from chr10:24,258,010-24,418,466 in the 
mm9 mouse genome, which corresponds to approximately 60kb upstream of the 
TSS to approximately 100kb downstream of Ccn2. The resultant transgenic mouse 
was characterised at one month of age by Hall-Glenn and Lyons (2011) who 
described reporter gene expression within the cartilage of the intervertebral disc, 
costal cartilage, femoral growth plate and articular cartilage in addition to the cranial 
sutures and vasculature within the lungs, coronary arteries, and kidneys. Further 
examination of the function of this transgenic construct within the vasculature 
revealed reporter expression within arterial endothelium (Hall-Glenn et al. 2012). 
However reporter gene expression from the BAC construct does not completely 
recapitulate the endogenous expression of Ccn2 within multiple tissues, suggesting 
that further regulatory elements outside that region are responsible for the complete 
expression profile of the gene. Moreover, the broad region that this BAC 
encompasses has not been further examined in attempts to refine understanding 
of Ccn2 transcriptional regulation. Fundamentally, as of yet no enhancer related 
cis-regulatory module element has been described as a regulator of Ccn2 
expression. This is surprising given the range of cell types that the gene is 
expressed in, and the differential expression of the gene during development and 
beyond. 
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1.5 Aims 
 
The lack of understanding on the capacity of cis-acting regulatory modules to 
regulate transcription of the Ccn2 gene paved the way for the current study. The 
hypothesis of the current project was that enhancer regions would be present in the 
intergenic region upstream of murine Ccn2, and that combinatorial function of these 
cis-acting regions would drive temporospatial gene expression accounting for the 
endogenous pattern of Ccn2 expression. Given the significance of Ccn2 expression 
during cartilage and skeletogenesis, examination of enhancers governing Ccn2 
within skeletal tissues was given priority over other tissues.  
 
Therefore the aims of the project were to: 
 
1. Identify putative enhancer regions of Ccn2 in an in silico approach 
utilising publicly available datasets concerning enhancer associated 
chromatin characteristics in embryonic limb tissue.  
 
2. Assess the capacity of enhancers to drive reporter gene expression in 
vivo, primarily during embryonic development, in addition to in vitro in cell 
lines  
 
3. Determine transcription factor binding motifs that mediate and 
regulate enhancer activity, through the identification of TFBS in silico and 
validation of TF-DNA interaction in vitro using Electrophoretic Mobility Shift 
Assay 
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. Materials and Methods  
 
2.1 In silico prediction of enhancer regions  
 
The Ccn2/CCN2 gene is still systematically known as Ctgf/CTGF in all in silico 
resources used.  
 
The University of California Santa Cruz (UCSC) Genome Browser 
(https://genome.ucsc.edu) (Kent et al. 2002) available as part of the Encyclopaedia 
of DNA Elements (ENCODE) was used to visualise genomic loci of interest within 
the murine (Mus musculus) genome. The Genome Browser predominantly serves 
as a map of genomic sequence with capacity to integrate many annotations and 
datasets, these ‘tracks’, include gene function and structure, phylogenetic 
conservation and epigenetic modification of sequence within samples from a variety 
of tissues and cells at many time-points. 
 
The mm9 (National Center for Biotechnology Information (NCBI) 37/mm9) 
assembly of the Genome Browser was primarily used. This genome build contains 
more annotations and a greater variety of datasets, than the newer murine mm10 
(GRCm38/mm10) build, however tracks from mm10 and human hg18 
(NCBI36/hg18) and human hg19 (GRCh37/hg19) assemblies were also used. The 
Genome Browser has a ‘lift-over’ tool which enables sequence coordinates to be 
converted between genome assemblies, therefore enabling equivalent sequences 
to be used regardless of source assembly build. The ‘view DNA’ function within the 
browser was used to gather genomic sequences for regions of interest in FASTA 
format.  
 
A key aspect of the Genome Browser is the ability to add user generated custom 
tracks to the Browser, enabling tailored annotation of areas of interest. Custom 
tracks containing genomic coordinates for regions of interest were created through 
the conversion of basic text files (.txt) to browser extensible data (BED) (.bed) file 
format in order for upload onto the Genome Browser. For example, a custom track; 
‘regions of interest’ with description ‘CTGF/CCN2 enhancers’ was created with 
each of the potential enhancer region assigned a colour, as demonstrated in Figure 
2.1. 
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Figure 2.1: Creation of UCSC Genome Brower custom tracks. Basic text files are firstly 
created with entry of track name and description, region of interest coordinates, name, and 
orientation along with colour assignment for track points. These files are converted to BED 
format to enable upload onto UCSC Genome Browser.  
 
The Genome Browser encompasses many datasets available from the ENCODE 
project that can be assimilated into the Browser. Firstly, sequence conservation 
information was obtained from the 30-Way Multiz Alignment resource (Blanchette 
et al. 2004). This track set enables comparative analysis of vertebrate DNA 
sequence with alignment of genomic sequence between species. Sequences from 
varying vertebrate clades were used, predominantly; mouse, rat, human, opossum, 
platypus, chicken, lizard and fugu. Tracks regarding DNase I hypersensitivity within 
forelimb bud, hind limb bud and mesodermal tissue at E11.5, in addition to lung 
fibroblast cells and NIH3T3 immortalised fibroblastic cells were used from 
ENCODE/University of Washington. ChIP-Seq tracks examining histone protein 
modification linked to transcriptional regulatory function were also incorporated into 
the Genome Browser session. Datasets from E14.5 limb tissue for the promoter 
specific H3K4me3, in addition to enhancer associated H3K4me1 and H3K27ac 
modifications were procured from ENCODE/Ludwig Institute for Cancer Research 
(LICR).  
 
Further publicly available ChIP-Seq datasets regarding specific cell lineage related 
transcription factors were obtained from the NCBI’s Gene Expression Omnibus 
(GEO) DataSets repository (https://www.ncbi.nlm.nih.gov/gds) (Barrett et al. 2012). 
Datasets were uploaded onto the UCSC Genome Browser in the BigWig or BED 
formats and incorporated into custom browser sessions. The aforementioned lift-
over tool was used to convert datasets between genome builds. Datasets used can 
be found in Appendices Chapter 5.1.  
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2.2 Commonly used reagents and protocols 
 
2.2.1 Nucleic acid manipulation 
 
Mouse genomic sequences only were used for all experiments.  
 
Invitrogen™ UltraPure™ diethyl pyrocarbonate (DEPC) -Treated Water 
(ThermoFisher Scientific, Waltham, Massachusetts, 750024) was used as the 
default nuclease free water in molecular techniques and in the suspension and 
dilution of nucleic acids.  
 
All polymerase chain reaction (PCR) primer oligonucleotides were procured from 
Eurofins Genomics (Ebersberg, Germany). These oligonucleotides were 
unmodified with salt free purification. Lyophilised oligonucleotides were re-
suspended to 100μM concentration as standard.  
 
Deoxyribonucletotide triphosphates (dNTPs) (Bioline, London, United Kingdom, 
BIO-39025) were used in PCR methodology. Stock solutions were created 
containing 10μM each of deoxyadenosine triphosphate (dATP), deoxycytidine 
triphosphate (dCTP), deoxyguanosine triphosphate (dGTP), deoxythymidine 
triphosphate (dTTP) diluted with nuclease free water.  
 
2.2.1.1 Primer design  
 
The online tool ‘Primer Basic Local Alignment Search Tool (Primer-BLAST)’, 
available from NCBI at https://www.ncbi.nlm.nih.gov/tools/primer-blast/ was used 
to find primers suitable for generation of amplicons from genomic sequences. This 
tool was also used to find any potential non-specific amplicon that could be 
generated during PCR using the ‘Primer Pair Specificity Checking Parameters’ 
based on the Mus musculus genome. Alternately, primers were manually selected 
at the ends of regions of interest. Sequences of approximately 20bp were selected 
with guanosine/cytosine (GC) content of 40 to 60%, melting temperature (Tm) of 
approximately 60°C with G or C at the 3’ end of the primer in order to promote 
specific binding. The Tm for primers in a pair were no more than 5°C different from 
one another. Primers designed manually were also examined in the Primer-BLAST 
tool in order to assess suitability.  
 
71 
Where restriction enzyme recognition sites were added to the 5’ of primers, 
additional nucleotides required for restriction endonuclease recognition were added 
in line with the New England BioLabs ‘cleavage close to the end’ resource, 
available at: https://international.neb.com/tools-and-resources/usage-
guidelines/cleavage-close-to-the-end-of-dna-fragments.  
 
2.2.1.2 PCR 
 
Purified mouse genomic DNA (Promega, Madison, Wisconsin, United States, 
G3091) was used as template in all non-genotyping PCR reactions. All PCR 
reactions were incubated in T100™ PCR Thermal Cycler (Bio-Rad, Hercules, 
California, United States) or SimpliAmp™ Thermal Cycler (ThermoFisher). 
 
Where reaction efficiency was low with weak product formation, or where multiple 
products had formed, gradient PCR runs were conducted whereby replicate 
reactions were annealed at a range of temperatures in order to find optimum 
annealing temperature. Touchdown PCR was also used for difficult amplicons, this 
typically consisted of using an initial annealing temperature 5°C higher than the Tm 
of the primers before being reduced by 1°C per cycle for the first 10 cycles of the 
reaction before further cycling with annealing temperature predicted to be optimum 
for primer pair. Where optimum annealing temperature for a primer pair was within 
1°C of the polymerase extension temperature, two step cycling approach was used 
whereby the annealing step was integrated into a longer extension step. 
 
GoTaq® G2 Flexi DNA Polymerase 
 
For the amplification of DNA amplicons of 2kb or less, GoTaq® G2 Flexi DNA 
Polymerase (Promega, M7805) was used as standard DNA polymerase unless 
otherwise stated.  
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Typical 25μL reaction set up consisted of: 
 
Component  Volume Final concentration 
5X Colourless GoTaq® Flexi Buffer 1 5μL 1X 
MgCl2 solution (25mM) 2μL 2mM 
dNTP mix (10μM each dNTP) 0.5μL 200μM 
Forward primer (10μM) 0.5μL 200μM 
Reverse primer (10μM) 0.5μL 200μM 
DNA template (100ng) X2 4ng/μL 
GoTaq® Flexi polymerase (5u/μL) 0.125μL 0.025U/μL 
Nuclease free water to 25μL  
 
Standard cycling parameters consisted of: 
 
Stage Temperature Duration 
Initial denaturation 94°C  3 minutes 
30 cycles:   
Denaturation 94°C 30 seconds 
Annealing Y3 30 seconds 
Extension 72°C 1 minute per kb product 
Final extension  72°C 5 minutes 
Hold  4°C indefinite 
 
Phire™ Hot Start II DNA Polymerase  
 
For amplicons greater than 2kb in length, the Phire Hot Start II DNA Polymerase 
(ThermoFisher, F122S) was used, unless stated otherwise. 
 
  
                                               
1 For end-point PCR the 5X Green GoTaq® Flexi Buffer was used in place of the 5X 
Colourless GoTaq® Flexi Buffer. 
X2 Volume of DNA template was dependent on concentration of DNA and adjusted 
accordingly for a total of 100ng per reaction. 
Y3 Standard annealing temperature for each amplicon was typically 5°C lower than the 
lowest Tm in each primer pair. 
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Typical 20μL reaction set up consisted of:  
 
Component  Volume Final concentration 
5X Phire Reaction Buffer  4μL 1X  
dNTP mix (10μM each dNTP) 0.4μL 200μM 
Forward primer (10μM) 1μL 500nM 
Reverse primer (10μM) 1μL 500nM 
DNA template X4 5ng/μL 
Phire™ Hot Start II DNA polymerase 0.4μL Y5 
Nuclease free water  to 20μL  
 
Standard cycling parameters consisted of:  
 
Stage Temperature Duration 
Initial denaturation 98°C 30 seconds 
30 cycles:   
 Denaturation 98°C 5 seconds 
 Annealing Z6 5 seconds 
 Extension 72°C 15 seconds per kb product  
Final Extension 72°C 1 minute 
Hold  4°C indefinite 
 
Platinum™ Pfx Polymerase  
 
Platinum™ Pfx Polymerase (ThermoFisher Scientific, 11708) was also used in the 
generation of longer PCR amplicon.  
  
                                               
X4 Volume of DNA template was dependent on concentration of DNA and adjusted 
accordingly for a total of 100ng per reaction. 
Y5 No details from the supplier regarding the concentration of the enzyme. 
Z6 Annealing temperatures used were typically 3°C higher than the lower primer Tm of a pair  
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Typical 25µL reaction consisted of:  
Component Volume Final concentration 
10x Pfx amplification buffer 5 μL 2x 
dNTP(10μM) 0.75 μL 0.3μM 
MgSO4 (50mM) 0.5μL 1mM 
Forward primer (10µM) 0.75μL 0.3μM 
Reverse primer (10µM) 0.75μL 0.3μM 
DNA template (100ng) μL 4ng/μL 
Pfx polymerase (1.25U/μL) 0.2μL 0.5U 
Nuclease free water to 25μL  
 
Standard cycling parameters consisted of:  
 
Stage Temperature Duration 
Initial denaturation 94°C 3 minutes 
30 cycles:   
 Denaturation 94°C 15 seconds 
 Annealing X7 30 seconds 
 Extension 68°C 1 minute per kb product  
Final Extension 68°C 1 minute 
Hold  4°C indefinite 
 
2.2.2 Agarose gel electrophoresis  
 
Molecular grade agarose powder was procured from Sigma-Aldrich (St Louis, 
Missouri, United States, A9539) and Bioline (BIO-41025). Tris-acetic acid- 
ethylenediaminetetraacetic acid (EDTA) (TAE) buffer system was used for all gels. 
50x stock buffer was prepared using the following recipe: 242g Tris base (Merck 
Millipore, Burlington, Massachusetts, United States, 648310), 57.1mL glacial acetic 
acid (Sigma Aldrich, A6283), 18.6g EDTA disodium salt dehydrate (VWR, Radnor, 
Pennsylvania, United States, 20296.291) with distilled water to total volume of one 
litre. This was diluted to 1X working solution using distilled water. Gels were 
typically cast using 1% w/v agarose in 1X TAE buffer. Gels were stained using 
                                               
X7 Annealing temperature was typically 5°C lower than that of the lowest primer Tm of a pair 
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Ethidium Bromide (EtBr) solution (Promega, H5041) at final concentration of 
100pg/μL, or SYBR Safe DNA Gel Stain (ThermoFisher Scientific, S33102). The 
latter is supplied as a 10,000X concentrate, which was used at 1 in 25,000 dilution. 
Sub-Cell® and Mini-Sub® cell agarose gel electrophoresis systems (Bio-Rad) were 
used for all gels. 6x Purple Gel Loading Dye (New England BioLabs, B7024S) was 
used to prepare samples for electrophoresis at a final concentration of 1X. This was 
omitted where samples already contained gel loading dye as a PCR buffer 
constituent. Quick-Load® Purple 2-Log DNA ladder (1 kb Plus DNA ladder), Quick-
Load Purple 1kb Plus DNA Ladder and λ-HindIII Digest (New England BioLabs, 
Ipswich, Massachusetts, United States, N3200S, N0550S and N3012S) were 
typically loaded at 500ng per well and used for determination of fragment size and 
concentration. Gels were run at voltage of 10V/cm. 
 
Gels were visualised using Gel Doc XR system (Bio-Rad) or Genegenius system 
(Syngene, Bangalore, India).  
 
2.2.3 Gel extraction  
 
Gels were visualised using a UV transluminator. In order to avoid mutagenesis, 
gels were left in the casting tray and the wavelength of the transluminator was set 
at 365nm with 80% emittance rate. Fragments of interest were excised quickly 
using a clean scalpel. 
 
The QIAquick Gel Extraction Kit (Qiagen, Hilden, Germany, 28706) was used to 
purify DNA from gel fragments, in accordance with the manufacturer’s instructions. 
All centrifugation steps were carried out at room temperature and consisted of one 
minute spins at 16,000g. Briefly, fragments were weighed before addition of Buffer 
QG of volume 3x that of the gel fragment mass, after which samples were incubated 
at 55°C in a waterbath. Samples were removed at two minute intervals and 
vortexed in order to aid gel disintegration. When no visible trace of gel was 
observed, molecular grade isopropanol (Sigma Aldrich, I9516) was added to the 
sample at a volume equal to that of the gel fragment mass. Samples were then 
applied to QIAquick column before centrifugation, after which flow-through was 
discarded. 750μL Buffer PE was then added to the column before centrifugation. 
Flow through was discarded and column was centrifuged again in order to remove 
residual buffer. Columns were transferred to clean microcentrifuge tubes before 
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30μL nuclease free water was added to the centre of each column with incubation 
at room temperature for five minutes prior to centrifugation.  
 
For fragments greater than 2kb, nuclease free water was heated to 55°C prior to 
addition to the column. Where replicate samples were purified, the product of one 
column was used to elute the DNA from the second column with two stages of 
incubation prior to centrifugation.  
 
Yield of gel extraction product DNA was assessed using agarose gel 
electrophoresis with comparison of sample band intensity to ladder fragments of 
known mass (Chapter 2.2.2) 
 
2.2.4 Column PCR product purification  
 
PCR products were purified using the Monarch® PCR and DNA Cleanup Kit (New 
England BioLabs, T1030S), in accordance with the manufacturer’s guidelines. PCR 
product was diluted in Binding Buffer at ratio of 2:1 buffer to DNA for fragments 
larger than 2kb and 5:1 buffer to DNA for amplicon smaller than 2kb. Centrifugation 
steps consisted of one minute spins at 16,000g. Diluted samples were applied to a 
Monarch column prior to centrifugation, after which flow-through was discarded. 
200μL Wash buffer was then added to the column before centrifugation. Flow-
through was discarded before wash step was repeated. Columns were then 
transferred to clean microcentrifuge tubes prior to addition of 30μL nuclease free 
water to the centre of each column and incubation at room temperature for five 
minutes. As with the gel extraction protocol, multiple reactions were pooled at the 
elution stage.  
 
Concentration of purified products was assessed through spectrophotometry using 
Nanodrop™ 2000 (ThermoFisher Scientific).  
 
2.2.5 Restriction digests  
 
Where multiple restriction enzymes were used within a reaction the ‘NEBcloner 
Digestion: Restriction Enzyme Selection’; available at 
https://nebcloner.neb.com/#!/redigest, was used to find the most efficient 
incubation temperature and buffer conditions for digestion.  
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DNA restriction digests were typically double digests and consisted of 4μg DNA, 
1μL restriction enzyme one (typically ten units), 1 μL restriction enzyme two 
(typically ten units), 2.5μL of 10X buffer (NEBuffer 1.1, 2.1, 3.1 or Cutsmart® Buffer 
(New England Biolabs, B7200S)).  
 
Reactions were incubated at 37°C, with the exception of those containing ApaI. 
This restriction enzyme was used at room temperature as its optimal temperature 
is 25°C. Where ApaI was used in double digests, reactions were incubated at room 
temperature overnight with ApaI before addition of second enzyme and increase in 
temperature to 37°C for further digestion for two hours.  
 
2.2.6 Bacterial culture  
 
Lennox L (LB) broth and agar (Invitrogen®, 12780-052 and 22700-025 
respectively) were prepared in accordance with manufacturer’s instructions and 
used as standard media for the propagation of E. coli bacteria.  
 
2.3 Cloning and plasmid DNA extraction  
 
2.3.1 Vectors  
 
‘Serial Cloner’ (Serial Basics) freeware software was used to visualise and 
manipulate plasmid sequences and sites of interest in silico for each vector 
generated. Cloning was carried out prior to the adoption of Ccn2 as the official gene 
symbol, therefore CTGF is used to denote the gene. 
 
2.3.1.1 pCR™8/GW/TOPO®TA 
 
Each full enhancer region, aside from -230kb and -255kb, was cloned into the 
pCR™8/GW/TOPO®TA vector by Dr Ian Li (ThermoFisher Scientific, K2500). This 
is a basic plasmid used in the maintenance and propagation of sequences of 
interest. The plasmid contains the prerequisite sequences required for 
maintenance in bacteria and is used to create insert containing entry vectors for the 
Gateway™ (GW) cloning system (Invitrogen, ThermoFisher Scientific, Hartley et al. 
(2000)), with map of sequences outlined in Figure 2.2. 
 
78 
 
Figure 2.2: pCR™8/GW/TOPO®TA. This is an entry vector for gateway cloning. Insert is 
placed in vector using TA cloning. The insert is cloned into the vector using the TA sites. 
The vector contains a spectinomycin resistance gene for bacterial selection, in addition to 
a pUC origin for plasmid replication within bacteria.  
 
2.3.1.2 β-galactosidase reporter vectors 
 
Each enhancer region was cloned into reporter plasmids based on the Heat shock 
protein 68- β galactosidase (Hsp68-lacZ) vector, which was a gift from Dr Nadav 
Ahituv (Pennacchio et al. 2006). Based on the work of Kothary et al. (1989), this 
plasmid contains lacZ derived from E. coli which encodes the β-galactosidase 
metabolic enzyme and is commonly used as a reporter in transgenic animal 
models. Expression of the gene is mediated by an Hsp68 promoter region which is 
incapable of directing tissue specific expression. Therefore, an enhancer sequence 
placed upstream of both the promoter and lacZ regulates reporter gene expression. 
Two strategies were used for this; either the use of TOPO entry vectors combined 
with the Hsp68-LacZ-GW destination vector, or sticky end cloning of inserts into an 
Hsp68-LacZ vector which has been modified to remove the GW sites.  
 
The Hsp68-lacZ-Gateway plasmid is a destination vector in the Invitrogen™ 
Gateway™ system which is based on sites of recombination within entry and 
destination vectors (Figure 2.3). The -4kb, -102kb, -137kb, -148kb, -198kb and -
255kb Hsp68LacZGW vectors were created by Dr Ian Li, with plasmid maps in the 
Appendices (Chapter 5.2.1)  
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Figure 2.3:Hsp68LacZGW basic plasmid map. This gateway destination vector contains 
recombination sites (att) enabling sequence of interest to be inserted upstream of the Hsp68 
minimal promoter and LacZ coding sequence (dark blue). The vector also contains 
ampicillin resistance gene for bacterial selection (map courtesy of Dr Ian Li)  
 
A modified version of this vector was used for the creation of the  
-137kbshortHsp68LacZ and -230Hsp68LacZ vectors (Figure 2.4) with plasmid 
maps detailed in Appendices Chapter 5.2.2. This plasmid does not have the sites 
required for Gateway® recombination, therefore inserts were sub-cloned into the 
vector using sticky-end restriction cloning.  
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Figure 2.4: Hsp68-LacZ plasmid map. This vectors contains the Hsp68 minimal promoter 
region and LacZ, but does not contain sites required for Gateway® recombination. Inserts 
are cloned into the vector upstream of the Hsp68 minimal promoter, therefore enabling an 
enhancer to regulate the expression of LacZ. Selection in bacteria is based on ampicillin 
resistance.  
 
Inserts were cloned into the plasmid using sites within the multiple cloning site 
upstream of the Hsp68 promoter. Primers were designed for inserts with a 
restriction enzyme recognition site and required additional base pairs for efficient 
cutting. 
 
2.3.1.3 Luciferase reporter vectors  
 
The pGL4.10 plasmid (Promega, E6651) was used as the basis for enhancer 
containing luciferase expression vectors (Figure 2.5). This plasmid contains firefly 
(Photinus pyralis) luc2 reporter gene which is codon optimised for mammalian 
expression, in addition to a synthetic β-lactamase gene for ampicillin resistance 
based bacterial selection. The basic plasmid has no promoter region, but contains 
a multiple cloning site (MCS) for fragment insertion.  
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Figure 2.5: pGL4.10 luciferase reporter basic plasmid map. This reporter plasmid does 
not have an enhancer or promoter region, enabling the introduction of custom regulatory 
elements within the multiple cloning site (MCS) which are used to regulate the expression 
of a firefly luciferase gene (luc2). 
 
The Ccn2 promoter region spanning from -353bp to +17bp of the Ccn2 coding 
sequence was used to drive the expression of luc2. This promoter sequence was 
selected based on consensus from literature that has demonstrated that this region 
drives gene expression (Leask et al. 2003). This region was inserted upstream of 
luc2 using KpnI restriction site at the 5’ of the insert and HindIII site at the 3’ end 
(Figure 2.5). The resultant plasmid became known as pSLF01 (plasmid map 
detailed in Appendices, Chapter 5.2.3). Each enhancer region of interest was 
inserted upstream of the promoter region using KpnI site at the 5’ end of the insert, 
with either SacI or NheI site at 3’ end of the insert. The -255kb enhancer was 
inserted using an XhoI site at the 3’. This allowed luc2 expression to be regulated 
by the enhancer sequence via the Ccn2 promoter. Each of the enhancer containing 
variants of pSLF01 is detailed in Appendices Chapter 5.2.3  
 
2.3.2 Vector assembly  
 
2.3.2.1 pCR™8/GW/TOPO®/TA 
 
Creation of pCR™8/GW/TOPO enhancer vectors was carried out by Dr Ian Li 
(Frost et al. 2018). Insert DNA was amplified using PCR with the REDExtract-N-
Amp polymerase (Sigma Aldrich, E3004). This polymerase has leaves 3’ A 
overhangs which are required for integration of product into pCR™8/GW/TOPO® 
TA. Primers used are listed in Table 2.1   
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Table 2.1: Primers for amplification of basic enhancer region sequences. These primers were used for the amplification of the full enhancer region 
sequences. Resultant amplicon were placed in pCR™8/GW/TOPO®/TA vector using TA cloning. These primers were also used for general amplification of the 
enhancers  
Enhancer Coordinates (mm9) Primer name Sequence 5’ to 3’ Tm (°C) Product length (bp) 
-4kb 
chr10: 24311246-24311268 -4 CTGF Fw CTCTACCCCAGACTACAGGTTCA 64.2 
1295 
chr10: 24312517-24312541 -4 CTGF Rv TGAAAGGGTGAAGACAGAAGACTAC 61.3 
-102kb 
chr10:24212606-24212628 -102 CTGF Fw ACCAGATCAGACACCGAGCAATA 60.6 
2282 
chr10:24214866-24214888 -102 CTGF Rv TGGTTAATGGCTCACGTGGATTC 60.6 
-137kb 
chr10:24177497-24177520 -137 CTGF Fw GAAGCGCAAGAAGGAAGACCAAAG 62.7 
2575 
chr10:24180046-24180069 -137 CTGF Rv CAGCTCCTTTGCCTTTGCACTGTA 62.7 
-148kb 
chr10:24166687-24166708 -148 CTGF Fw TTCTTGCAGATGTGCTGAGGTG 60.3 
2574 
chr10:24115344-24115366 -148 CTGF RV GAAAGATGGAGGGTTAGAGACAAG 61.0 
-198kb 
chr10:24115344-24115366 -198 CTGF Fw GGTCTTAGGCAAGCAAATCTCTG 60.6 
2395 
chr10:24117717-24117739 -198 CTGF Rv CATTGAAGAGTCCAAGAAGCAGG 60.6 
-255kb 
chr10:24059327-24059350 CTGF -255 F CAGAATGCCTGAGTGAGATAGAAG 61.0 
2050 
chr10:24061349-24061377 CTGF -255 R TGTTTGTGAATTATCTAGCAAGGGAAAAG 61.0 
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Typical PCR reaction set up consisted of: 
 
Component Volume Final concentration 
2x REDExtract-N-Amp PCR reaction 
mix 
10μL 1x 
Forward primer (10μM) 0.8μL 0.4μM 
Reverse primer (10µM) 0.8μL  0.4μM 
DNA template (100ng) X 8 5ng/μL 
Nuclease free water to 20μL  
 
Typical cycling parameters:  
 
Stage Temperature Duration 
Initial denaturation 94°C 3 minutes 
30 cycles:   
Denaturation 94°C 30 seconds 
Annealing  Y9 30 seconds 
Extension 72°C 1 minute per kb product 
Final extension 72°C 10 minutes 
Hold 4°C indefinite 
 
Specificity of PCR products was assessed using agarose gel electrophoresis.  
 
TOPO® cloning reactions were set up using manufacturer’s guidelines as follows: 
2µL PCR product, 1µL salt solution, 2µL RNase/DNase free water and 1µL TOPO® 
vector. These reactions were incubated at 25°C for five minutes before being 
placed on ice prior to bacterial transformation. 2µL of these reactions was then 
added to a vial of One Shot™ TOP10 chemically competent E. coli before being 
incubated on ice for 30 minutes. Transformation reactions were then placed at 42°C 
for 30 seconds prior to incubation on ice for two minutes. 250µL super optimal broth 
with catabolite repression (SOC) media (Invitrogen, 15544-034) was then added to 
reactions before shaking incubation at 37°C for one hour. Reactions were then 
plated on LB agar plates containing 50µg/mL spectinomycin (Sigma Aldrich, 
S4014) before overnight incubation at 37°C. 
                                               
X8 Template volume varied depending on concentration of stock solution 
Y9 Annealing temperature of 5°C lower than the lowest primer Tm was used as standard.  
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2.3.2.2 Gateway™ recombination  
 
For each of the regions listed in Table 2.1 lacZ reporter destination vectors were 
created using the Invitrogen™ Gateway Recombination™ Technology. Plasmid 
inserts were generated using the aforementioned pCR8/TOPO entry vector 
(Chapter 2.3.2.1). Each enhancer insert was therefore flanked by attL sites within 
the pCR8/TOPO vector. The Hsp68-lacZ-GW vector contains attR sites upstream 
of the Hsp68 promoter region. The LR Clonase™ II system (ThermoFisher) 
facilitates recombination between these sites, and therefore the incorporation of the 
enhancer insert upstream of the promoter region and lacZ reporter gene. 
 
Briefly, 5µL of enhancer containing pCR8/TOPO entry vector DNA was mixed with 
1µL Hsp68-lacZ-GW vector DNA, 2µL Tris-EDTA (TE) buffer (pH 8.0), 2µL LR 
Clonase™ II enzyme mix and incubated at 25°C for one hour. 1µL proteinase K 
solution was added to each reaction before incubation of samples at 37°C for ten 
minutes. One Shot™ chemically competent E. coli were then transformed as 
before, with 100µg/mL ampicillin (Sigma Aldrich, A9518) based selection rather 
than spectinomycin. 
 
2.3.2.3 Sticky-end cloning  
 
Insert generation  
 
For -137kbshortCTGFHsp68LacZ, -230kbCTGFHsp68lacZ and all luciferase 
based reporter vectors, enhancer regions were amplified using primers with 
restriction enzyme sites incorporated into the 5’ end as detailed in Table 2.2.  
  
The Ccn2 promoter was first cloned into the pGL4.10 vector, with the resultant 
pSLF01 vector being used as a backbone for subsequent cloning of enhancer 
regions. For cloning into luciferase vectors, inserts were amplified with pre-existing 
pCR8/TOPO enhancer plasmids as template where available, using primers 
flanking the inserts. Primers amplifying from within vector backbone sequence with 
restriction enzyme sites added at the 5’ end which were designed by Dr Ian Li. PCR 
product specificity was verified using agarose gel electrophoresis. DNA fragments 
were purified using either the QIAquick gel extraction kit or Monarch® PCR and 
DNA Cleanup Kit; as outlined in sections 2.2.3 and 2.2.4 respectively. 
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Table 2.2: Primers for sticky-end cloning of enhancer reporter vectors. Primers contained restriction enzyme recognition site and required extra bases on 
5’ end for sticky-end cloning into reporter gene plasmids. The prIL primers were designed by Dr Ian Li, with complementary sequence in the TOPO sequence 
flanking inserts. This enabled them to be suitable to amplify any insert that had been cloned into the pCR8/TOPO vector backbone  
  
Region of interest Destination vector Primer name Sequence 5’ to 3’ Tm (°C) Product length (bp) 
-137kb short enhancer Hsp68-LacZ 
137s+ApaI_F GAgggcccGCATTTCCAAAGGGGAGACCTGGA 74.6 
1299 
137s+XhoI_R GTACctcgagGTGAGCCCAGTGAATGTCCTTG 72.0 
-230kb enhancer Hsp68-LacZ 
-230+ApaI_F GAgggcccGGGCAATTTTAACAAGGCTGAGTA 70.8 
1441 
-230+HindIII_R GCCaagcttTCTCAGGTTCTCAGTCAGTTCTTT 68.2 
Ccn2 promoter pSLF01 
CTGFPRXho_F GCATCTCGAGGGCCCATGGTATTTGCCTCTTGAG 73.1 
388 
CTGFPRHind_R CGTAAGCTTCCGGCTCGCCAAAGAACTGA 69.5 
-137kb short enhancer pSLF01 
137Kpn_F GTGGTACCGCATTTCCAAAGGGGAGACCTGGA 72.0 
1298 
137Nhe_R GACGCTAGCGTGAGCCCAGTGAATGTCCTTG 72.1 
-230kb enhancer pSLF01 
SF_CTGF230 kpnI F GTGGTACCGGGCAATTTTAACAAGGCTGAGTA 68.2 
1444 
SF_CTGF230 NheI_R GACGCTAGCTCTCAGGTTCTCAGTCAGTTCTTT 69.5 
-255kb enhancer pSLF01 
SF_-255+NheIF CTGGCTAGCCAGAATGCCTGAGTGAGATA 68.1 
2047 
SF_-255+XhoIR CGTGCTCGAGGTTTGTGAATTATCTAGCAAGG 68.2 
-4kb, 
-137kb full, 
-148kb, 
-198kb enhancers 
pSLF01 
prIL16KpnI TGATGGTACCAGCTCGGGCCCCAAATAATG 69.5 1572, 2849, 
2851, 2672 prIL17NheI TGACGCTAGCGGGATATCAGCTGGATGGCAAAT 70.9 
-102kb enhancer pSLF01 
prIL16KpnI TGATGGTACCAGCTCGGGCCCCAAATAATG 69.5 
2559 
prIL17SacI CATGGAGCTCGGGATATCAGCTGGATGGCAAAT 70.7 
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Ligation  
 
Inserts were restriction digested before purification through agarose gel 
electrophoresis and gel extraction (Chapter 2.2).  
 
Vector backbone and insert fragments were ligated using T4 DNA ligase (New 
England BioLabs, M0202). The molar ratio for ligation was calculated using the 
following equation: 
 
insert size (bp)
vector size (bp) x vector amount (ng)=insert amount (1:1) 
  
Reactions were set up using the manufacturer’s guidelines. A ratio of 4:1 insert: 
vector was typically used. For example, in the ligation of pSLF01_137kbshort: 
vector backbone (pSLF01) size 4576bp, insert (-137kb short) size 1298bp, where 
vector amount is 50ng 
 
1298
4576 x 50=14.18 
 
14.18ng of insert required for 1:1 ratio; 56.72ng for 4:1 insert to vector. Therefore, 
ligation reaction set up consisted of: 2µLT4 DNA Ligase Buffer, 50ng pSLF01 
vector, 56.72ng -137kb short insert, 1µL T4 DNA Ligase and RNase/DNase free 
water to a total of 20µL. Reaction components were gently aspirated before brief 
centrifugation and incubation at 16°C for 16 hours. Reactions were heat inactivated 
with incubation at 65°C for ten minutes.  
 
Transformation 
 
DH5α (ThermoFisher Scientific, 18265017) and JM109 (Promega, L2001) strains 
of chemically competent E. coli were transformed with ligation products. 50µL 
aliquots of cells were allowed to thaw on ice before addition of 10ng ligation product 
with gentle agitation to mix. Samples were incubated on ice for 30 minutes. Heat-
shock was carried out with incubation in a waterbath at 42°C for 20 seconds for 
DH5α and 50 seconds for JM109, after which tubes were returned to ice for two 
minutes. 450μL SOC media was then added to each reaction before shaking 
incubation at 225rpm and 37°C for one hour. Reactions were then plated at varying 
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densities, with 20μL, 50μL and 100μL spread on LB agar plates containing 
100μg/mL ampicillin before plates were incubated at 37°C overnight. 
 
Control transformation reactions were carried out using the pUC19 (ThermoFisher 
Scientific, SD0061) in order to ensure transformation efficiency, with 250pg of 
plasmid used to transform cells as above.  
 
2.3.3 Colony PCR  
 
Single colonies were sampled from bacterial transformation plates using pipette tip 
which was then placed in a microcentrifuge tube containing 100µL nuclease free 
water. This inoculum was vortexed before 1µL was used as template in PCR. Insert 
primers were used to generate amplicon with reaction parameters as used for insert 
preparation. PCR products were ran on agarose gels to confirm insert presence. 
 
Insert positive colonies were propagated for plasmid DNA extraction (Chapter 
2.3.4) 
 
2.3.4 Plasmid DNA extraction  
 
For propagation from glycerol stock, bacteria were firstly streaked across an LB 
agar plate containing suitable selection antibiotic before being incubated at 37°C 
overnight. Single colonies were isolated from agar plates from glycerol stock 
propagation and transformation plates using a pipette tip before addition to 3mL LB 
broth containing suitable selection antibiotic at appropriate concentration. Tubes 
were briefly vortexed before shaking (225rpm) incubation at 37°C overnight.  
 
After this incubation period, cultures were briefly vortexed. 1.5mL of overnight 
culture was then added to a microcentrifuge tube before bacteria were pelleted 
through centrifugation at 9600g for three minutes. The supernatant was removed 
before the addition of a further 1.5mL of culture and repetition of centrifugation step 
and removal of supernatant. 
 
2.3.4.1 PureYield™ Plasmid Miniprep System  
 
Mini-preparation of plasmid DNA was conducted using PureYield™ Plasmid 
Miniprep System (Promega, A1223) in accordance with the manufacturer’s 
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guidelines. All centrifugation steps were carried out at 16,200g at room 
temperature.  
 
Overnight culture bacterial pellets were re-suspended in 600μL nuclease free water 
before addition of 100μL Cell Lysis Buffer and inversion of tubes six times. 350μL 
of cold Neutralisation Solution (4°C) was then added before tube was inverted six 
times. Samples were then centrifuged for three minutes. Supernatant was 
transferred to PureYield™ Minicolumn prior to centrifugation at for 15 seconds. 
Flow-through was discarded before 200μL Endotoxin Removal Wash was added 
to the column before centrifugation for 15 seconds. Flow-through was discarded 
before addition of 400μL Column Wash Buffer to column. Samples were then 
centrifuged for 30 seconds. Columns were then transferred to a clean 
microcentrifuge tube after which 30μL nuclease free water or TE buffer was added 
to centre of the column before incubation at room temperature for five minutes. 
Plasmid DNA was eluted with final centrifugation step of 15 seconds before storage 
at -20°C. 
 
2.3.4.2 Crude mini-preparation of plasmid DNA 
 
The protocol for crude mini-preps of plasmid DNA is based on that of the Qiagen 
Plasmid kit protocols, utilising buffers P1, P2 and P3.  
 
Overnight bacterial culture pellet was re-suspended in 100μL buffer P1 (50mM Tris 
Cl pH 8.0, 10mM EDTA, 10µg/mL Ribonuclease (RNase) A, LyseBlue) (Qiagen), 
ensuring that no visible clumps of bacteria remained. 100µL buffer P2 (200mM 
sodium hydroxide (NaOH), 1% sodium dodecyl sulfate (SDS) (w/v)) (Qiagen) was 
then added before gentle inversion six times, ensuring suspension was 
homogenous and incubation for five minutes at room temperature. 100µL buffer P3 
(3M potassium acetate pH 5.5) was then added before gentle inversion six times 
or until there was no visible LyseBlue blue dye in suspension. Samples were then 
incubated on ice for five minutes before centrifugation at 16,200g for ten minutes. 
750µL of cold molecular grade absolute ethanol (Sigma Aldrich, 51976) (kept at -
20°C) was then added to the resultant supernatant before gentle inversion twice, 
after which samples were placed at -20°C for ten minutes. After this period, 
samples were inverted twice before centrifugation at 16,200g for ten minutes. The 
supernatant was discarded before 1mL 70% molecular grade ethanol was added 
to sample and subsequently removed in order to wash plasmid DNA pellet. Pellets 
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were left to air dry at room temperature for approximately ten minutes and then re-
suspended in 30µL TE buffer (10mM Tris Cl pH 8.0, 1mM EDTA) and left to 
reconstitute at room temperature for one hour or at 4°C overnight. Plasmid DNA 
was stored at -20°C.  
 
2.3.4.3 Maxi-preparation of plasmid DNA 
 
Larger scale plasmid DNA extraction was carried out using the Plasmid Maxi Kit 
(Qiagen, 12162). All centrifugation steps were carried out at 4°C.  
 
Bacterial starter cultures were created from glycerol stocks as aforementioned, 
however these cultures were incubated for eight hours rather than overnight. 200μL 
of this starter culture was then transferred to 100mL LB broth containing 
appropriate selection antibiotic and incubated at 37°C overnight with shaking at 
225rpm.  
 
Bacterial cells were pelleted through centrifugation at 6000g for 15 minutes before 
re-suspension in 10mL Buffer P1. 10mL Buffer P2 was then added before inversion 
six times; ensuring homogenous suspension, and incubation at room temperature 
for five minutes. 10mL of cold (4°C) Buffer P3 was the added before further 
inversion six times and incubation on ice for 20 minutes. Samples were inverted 
once and then centrifuged at 20,000g for 30 minutes. The supernatant was 
removed prior to further centrifugation at 20,00g for 15 minutes. Resultant 
supernatant was then applied to QIAGEN-tip 500 which had been pre-equilibrated 
through application of 10mL Buffer QBT (750mM sodium chloride (NaCl) 50mM 
MOPS pH 7.0, 15% isopropanol (v/v), 0.15% Triton® X-100 (v/v)). Samples were 
allowed to pass through the column before washing with 30mL Buffer QC (1M NaCl, 
50mM MOPS pH 7.0, 15% isopropanol (v/v)). This wash step was repeated before 
application of 15mL Buffer QF (1.25M NaCl, 50mM Tris-HCl pH 8.5, 15% 
isopropanol (v/v)). Eluate from this step was collected before addition of 10.5mL 
molecular grade isopropanol and gentle inversion. Samples were then centrifuged 
for 30 minutes before supernatant was discarded. 5mL 70% ethanol was then 
added to pellet before centrifugation at 15,000g for ten minutes. Supernatant was 
discarded and plasmid DNA pellets were left to air-dry for approximately ten 
minutes. Pellets were re-suspended in 500μL nuclease free water before being left 
at 4°C overnight.  
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2.3.5 Glycerol stocking  
 
After verification of vector insert sequence presence and orientation using colony 
PCR and restriction digests, 500µL overnight bacterial culture was added to 500µL 
50% glycerol (v/v with distilled water) (Sigma Aldrich, G5516). The resultant 
solution was gently inverted to ensure homogenous mixture before being snap-
frozen on dry ice and stored at -80°C. 
 
2.4 CRISPR-Cas9 based genome editing  
 
CRISPR-Cas9 (Clustered Regularly Interspaced Short Palindromic Repeats- 
Caspase 9) technology has galvanised the field of molecular biology in allowing 
targeted manipulation of specific genomic sequences. There are many emerging 
variants of CRISPR-Cas9 technology, however for the current project an approach 
of inducing double strand breaks (DSB) in the DNA sequence with wild-type 
Streptococcus pyrogenes Cas9 (SpCas9) was used. In this variant of the 
methodology, CRISPR-Cas9 function hinges on the association of guide RNA 
(gRNA) that recognises target sequences, and Cas9 protein that induces double 
strand breaks in genomic sequence. Single guide RNA (sgRNA) contain a 
protospacer sequence which is complementary to target genomic DNA sequence 
(Cong et al. 2013). This DNA sequence is found next to a protospacer adjacent 
motif (PAM) that is recognised by the complexed Cas9 (Nowak et al. 2016). The 
PAM for SpCas9 is -NGG. A trans-activating CRISPR RNA (tracrRNA) interacts 
with the sgRNA and facilitates Cas9 interaction and therefore formation of the 
gRNA-Cas9 complex required for the recognition and cleavage of target DNA 
(Jinek et al. 2012). Cas9 contains two endonuclease domains RuvC and HNH 
which cleave target DNA sequence to produce a DSB. For the purpose of this 
project, target loci were chosen in the proximity of the 5’ and 3’ boundary of 
enhancer regions. The enhancer sequences would therefore be excised and 
because there was no replacement of enhancer DNA with a donor sequence, DSB 
would be recognised and repaired using non-homologous end joining (NHEJ) 
mechanism. This would therefore lead to the loss of the enhancer region and joining 
of the sequence in the vicinity of the 5’ boundary, to sequence in proximity of the 3’ 
boundary of the enhancer.  
 
The methodology used in the current project is based on that of Professor David 
Young at Newcastle University. Initially target loci and suitable gRNA were 
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identified in silico. Guide RNA and TRACR RNA were transcribed from a DNA 
template which was prepared through PCR from a vector template. The forward 
primer was specific for each gRNA used and mismatch in annealing between the 
primer and template allowed amplification of primer sequence and therefore gRNA 
template DNA. The transcript generated was referred to as gRNA and purified 
before in vitro validation of the ability of gRNA-TRACR-Cas9 to induce DSB in PCR 
product substrate. Finally, gRNA-TRACR and SpCas9 were microinjected into 
mouse embryos with the ambition of deleting Ccn2 enhancers in vivo.  
 
2.4.1 In silico design of guide RNA  
 
The CHOPCHOP online tool (Labun et al. 2016; Montague et al. 2014), available 
at http://chopchop.cbu.uib.no/ was used to find suitable guide RNAs. This software 
utilises the mm10 build of the murine genome therefore loci of interest were 
converted from mm9 to mm10 using the lift-over function within the UCSC Genome 
Browser as detailed in Chapter 2.1.  
 
Guides were selected to target loci within the vicinity of the 5’ and 3’ boundary of 
each enhancer (as illustrated in Figure 2.6). Two guides were chosen for each 
enhancer boundary loci. Coordinates based on the enhancer boundary +/-100bp 
were initially used to search for suitable guide RNA target sequences. Where this 
yielded guides with poor predicted efficiency the search region was expanded to 
+/-200bp from the enhancer boundary. 
Figure 2.6: Schematic representation of strategy in selecting guide RNA for enhancer 
excision. Guides were chosen within 200bp (red dashed box) of the 5’ and 3’ boundary of 
each enhancer region of interest (black box). 
 
Search parameters utilised consisted of: CRISPR/Cas9, with sgRNA length without 
PAM of 20 nucleotides (nt), 3’ NGG as a PAM and off-targets were determined with 
up to three mismatches in the protospacer region (Hsu et al. 2013). Searches with 
efficiency scores based on the algorithms of (Xu et al. 2015) and (Moreno-Mateos 
et al. 2015) were used. The CHOPCHOP tool automatically ranks potential guides 
based on predicted off-targets and efficiency scoring. The highest ranked guides; 
enhancer
5’ boundary 3’ boundary
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and therefore those predicted to have greatest efficiency, were chosen for each 
enhancer boundary. 
 
For the excision of both the -148kb and -137kb enhancers simultaneously, guides 
were selected within loci more distal from the enhancer boundary. A region 
spanning 15kb and encompassing both of these enhancers was used in order to 
find a single guide upstream of the -148kb 5’ boundary, with a second guide 
selected downstream of the -137kb 3’ boundary.  
 
For example, for the -148kb 5’ boundary (chr10:24,446,883) a targeting region +/-
200bp (chr10: 24,446,683-24,447,083) was used as region of interest. This 
generated 24 potential sgRNA sequences of which the two best ranked were 
chosen (highlighted with blue circles Figures 2.7 and 2.8) (Appendices Chapter 
5.3).  
  
93 
 
 
Figure 2.7: Screenshot of CHOPCHOP guide selection. This tool finds and ranks potential guide sequences within genomic regions of interest based on 
GC%, self-complementarity, and possible off-targets. Guides are ranked based on the efficiency with which they are predicted to mediate the cutting of the 
target sequence. The highest ranking sequences were used for guide synthesis (highlighted with blue circle)  
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The CHOPCHOP tool also allows assimilation of guide sequences into the UCSC 
Genome Browser in the form of a custom track (Figure 2.8). This therefore allows 
more accurate assessment of the proximity between potential guides and enhancer 
regions.  
 
 
Figure 2.8: Incorporation of CHOPCHOP guides into custom UCSC Genome Browser 
session. CHOPCHOP predicted guides can be imported as a custom track into UCSC 
Genome Browser sessions, therefore allowing visualisation of guide position with respect 
to each enhancer region of interest.  
 
2.4.2 Guide RNA synthesis and purification  
 
The Tra2bgl in CRISPRV2 plasmid (a gift from Professor David Young, Newcastle 
University) was used as template in the generation of DNA precursor for guide 
RNA. This plasmid is a modified version of pX330-U6-Chimeric_BB-CBh-hSpCas9 
(Hsu et al. 2013) containing a guide RNA sequence that has been cloned in 
upstream of a TRACR sequence. The basic pX330 plasmid is illustrated in Figure 
2.9.  
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Figure 2.9: pX330 CRISPR guide Cas9 expression plasmid This plasmid contains a 
TRACR sequence that is required for CRISPR gRNA function (Hsu et al. 2013). In PCR 
amplification of guide template, the 3’ end of the forward primer used (highlighted pale blue) 
and the reverse primer (green) both amplify the TRACR sequence. Whilst the plasmid 
contains sequence encoding Cas9, this was not used in the current approach. 
 
2.4.2.1 Synthesis and purification of DNA template for guide RNA transcription  
 
Guide sequences found from CHOPCHOP were incorporated into a long forward 
primer (Figure 2.10) specific for each guide which contained a T7 promoter for in 
vitro transcription, the guide sequence without the PAM and the 5’ extremity of the 
TRACR motif sequence required for the secondary structure of the RNA  
 
 
Figure 2.10: Schematic representation of a long forward primer used for amplification 
of gRNA template DNA. A T7 promoter was upstream of the guide sequence specific for 
each target site in addition to the 5’ end of the TRACR sequence. The guide sequence of 
the primer would mismatch with the vector template DNA in PCR annealing, leading to 
amplification of the guide-specific sequence rather than vector DNA.  
 
Each guide specific forward primer (listed in Table 2.3) was used in conjunction 
with a reverse primer that had sequence complementary to the 3’ end of the TRACR 
sequence (highlighted green in Figure 2.9) with sequence: 5’-
AAAAGCACCGACTCGGTGCC. The amplicon for each guide template was 
approximately 120bp long. GoTaq® Flexi G2 DNA polymerase was used for PCR, 
as outlined in Chapter 2.2.1.2. In brief, 20ng of plasmid DNA was used as template 
in a 50μL reaction. Touchdown PCR was used in order to reduce the effect of large 
primer Tm discrepancy on reaction efficiency.   
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Table 2.3: Forward primers used for the generation of gRNA DNA template. Each primer contained the T7 promoter (italic and bold), specific targeting 
sequence and 5’ segment of the TRACR sequence.  
Enhancer region  Guide name  Sequence  
-137kb 
-137_5'_1 atgcatTTAATACGACTCACTATAgGGCTGGTATCCACAATGAGGTTGTTTTAGAGCTAGAAAT 
-137_5'_2 atgcatTTAATACGACTCACTATAgGGTGGTATCCACAATGAGGTTCGTTTTAGAGCTAGAAAT 
-137_3'_1 atgcatTTAATACGACTCACTATAgGGTATGGAGTTTTGCTGAACTGGTTTTAGAGCTAGAAAT 
-137_3'_2 atgcatTTAATACGACTCACTATAGGGTTGACTCTAAACTATTATGGTTTTAGAGCTAGAAAT 
-148kb 
-148_5'_1 atgcatTTAATACGACTCACTATAgGGATGTCCCTAACCCTTGCTTAGTTTTAGAGCTAGAAAT 
-148_5'_2 atgcatTTAATACGACTCACTATAgGGTATGCCATAAGCAAGGGTTAGTTTTAGAGCTAGAAAT 
-148_3'_1 atgcatTTAATACGACTCACTATAgGGCTCAGGACTACAATTGCATCGTTTTAGAGCTAGAAAT 
-148_3'_2 atgcatTTAATACGACTCACTATAgGGCCGTCTTACAAAACATATAAGTTTTAGAGCTAGAAAT 
-148kb/-137kb 
-148/137_5 atgcatTTAATACGACTCACTATAgGGTTGATAGTGGCCACAAGAGAGTTTTAGAGCTAGAAAT 
-148/137_3 atgcatTTAATACGACTCACTATAGGGTGAATCCCAAATTGTGACTGTTTTAGAGCTAGAAAT 
-230kb 
-230_5'_1 atgcatTTAATACGACTCACTATAgGGAGTTACCATAAGCCCACCAGGTTTTAGAGCTAGAAAT 
-230_5'_2 atgcatTTAATACGACTCACTATAgGGTAAGGCTTTACATTAGCGAAGTTTTAGAGCTAGAAAT 
-230_3'_1 atgcatTTAATACGACTCACTATAgGGAGCACAGATGATGTCGTTTGGTTTTAGAGCTAGAAAT 
-230_3'_2 atgcatTTAATACGACTCACTATAgGGAAGAGCAATGATGTGCTATAGTTTTAGAGCTAGAAAT 
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Assessment of PCR efficiency and specificity was made using agarose gel 
electrophoresis (Chapter 2.2.2). 5µL of PCR product for each guide was ran on a 
2% agarose gel in order to assess reaction specificity and efficiency. PCR product 
was purified using the Monarch® PCR and DNA Cleanup Kit (Chapter 2.2.4). 
Resultant product was used as template in the transcription of the guide RNA.  
 
2.4.2.2 In vitro transcription and guide RNA purification  
 
An RNase free environment was used throughout the preparation of gRNA.  
 
Guide RNA was produced using the MEGAshortscript™ T7 Transcription Kit 
(ThermoFisher Scientific, AM1354) which utilises a T7 polymerase, in accordance 
with the manufacturer’s guidelines. 150nM column purified PCR product was used 
as template for each reaction. Transcription reactions were prepared at room 
temperature as follows: 2µL T7 10x Reaction Buffer, 2µL 75mM T7 adenosine 
trisphosphate (ATP) solution, 2µL 75mM T7 cytidine triphosphate (CTP) solution, 
2µL 75mM T7 guanosine triphosphate (GTP) solution, 2µL 75mM T7 uridine 
triphosphate (UTP) solution, 2µL T7 Enzyme Mix, with template DNA and nuclease 
free water to a final volume of 20µL. Reactions were incubated in a thermal cycler 
at 37°C for 4 hours, after which 1µL of Turbo DNase was added to each reaction 
before further incubation at 37°C for 15 minutes.  
 
Resultant RNA was immediately purified or stored at -80°C prior to purification.  
 
The pTRI-RNA 18s template supplied in the MEGAshortscript™ T7 Transcription 
Kit was used as a positive control in accordance with the manufacturer’s guidelines.  
 
Guide RNA was purified using the MEGAclear™ Transcription Clean-Up Kit 
(ThermoFisher Scientific, AM1908) in accordance with the manufacturer’s 
guidelines. 80µL Elution solution was added to each transcription reaction product, 
after which samples were gently mixed before addition of 350µL Binding Solution 
Concentrate was added and samples were aspirated gently. 200µL absolute 
molecular grade ethanol was then added and samples were gently aspirated to mix. 
Samples were applied to the filter cartridge and centrifuged at 9600g for one 
minute. Flow-through was discarded before 500µL Wash solution was added to 
each column with centrifugation at 9600g for one minute. This step was repeated 
after flow-through was discarded. Columns were then centrifuged at 9600g for 30 
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seconds in order to remove any residual Wash Solution. 50µL embryo water (Sigma 
Aldrich, W1503) was then added to each column which were incubated at 70°C for 
ten minutes prior to final elution centrifugation step of 9600g for one minute. RNA 
concentration and purity was assessed using Nanodrop. 
 
2.4.3 CRISPR cutting assay substrate preparation  
 
2.4.3.1 Substrate primer design  
 
In addition to guide prediction, the CHOPCHOP tool also enables the selection of 
primer pairs for in vitro assessment of sgRNA-Cas9 cutting efficacy. Search 
parameters can be changed to customise product length, primer length, primer Tm 
and minimum distance between primer and guide target site. Search parameters 
used were: 300bp to 1000bp product length, primer size of 18nt to 25nt with 
optimum of 22nt, primer Tm of 55°C to 70°C with an optimum of 65°C and minimum 
distance between guide cutting site and primer of 50bp. Primers were selected so 
that cutting of substrate fragment would not lead to fragments of around 100bp in 
length that could be confused with any gRNA band on gel. Potential primer pairs 
were entered into the Primer-Blast tool as outlined in Chapter 2.2, in order to 
confirm product specificity and predict primer self-complementarity.  
 
A primer pair was selected for each enhancer boundary region. Where the guides 
for a boundary were too far from one another to be examined efficiently within one 
amplicon, such as with the attempt to simultaneously delete both -148kb to -137kb 
enhancer simultaneously, primer pairs were generated for individual guide cutting 
sites (as detailed in Table 2.4). Two strategies were used for the in vitro cutting 
assay with either one guide RNA per reaction, or a combination of a 5’ and 3’ guide 
RNA for a region. This enabled testing of whether guides could be used in 
conjunction with one another in order to excise a whole enhancer region in vitro. 
Where multiple guide RNA were used within a reaction, primer pairs were combined 
with the use of the forward primer from the 5’ cutting substrate amplicon and 
reverse primer from the 3’ cutting substrate amplicon.  
 
Where guides were predicted to cut within enhancer regions, primers used for the 
general manipulation of the enhancer, such as those used for cloning (Chapter 2.3) 
were used.  
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Table 2.4: Primers for the generation of substrate for in vitro CRISR cutting assay. Primers were designed to amplify products spanning CRISPR guide 
recognition sites 
  
Enhancer Primer name Sequence 5’ to 3’ Tm (°C) Product length (bp) 
-137kb 5’ 
137_5’C_F GACCATATGAAGCGCAAGAAGG 59.8 
529 
137_5’C_R AATGGCCACTCCTCCTACTGA 60.3 
-137kb 3’ 
137_3’/2_C_F AGCAAGGACATTCACTGGGCTC 62.1 
978 
137_3’/2_C_R GGAGGCGAAAACTGACTCCTGA 62.1 
-148kb 3’ 
148_3'/1_C_F AAGCCTTGGGTTCCATCTGTGA 60.3 
752 
148_3'/1_C_R CCCAGAGAATGAGGAGCCAGAA 62.1 
-148kb/-137kb 5’ 
148-137_5'_C_F CTACCCGTGTCTCCTTCTCCCA 64.0 
884 
148-137_5'_C_R GGACTGGTGAACCCTCATGGAC 64.0 
-148kb/-137kb 3’ 
148-137_3'_C_F CAGTAGCCCAGACTAGCCCCAA 64.0 
942 
148-137_3'_C_R TCAGGTATCCAAAGAGCCTCGG 62.11 
-230kb 5’ 
230_5'_C_F TTATTTATTTGCACGTTTTGCG 52.8 
869 
230_5'_C_R CCCACCAGAGGACAGTTAAAAG 60.3 
-230kb 3’ 
230_3'_C_F CGCGCACATATCTATTGTTCAT 56.5 
648 
230_3'_C_R TAGCCCAGAGATTGGATGAAGT 58.4 
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2.4.3.2 Substrate amplification and purification  
 
Cutting assay substrate was generated using PCR. For amplicon shorter than 2kb 
in length GoTaq® G2 Flexi DNA Polymerase reaction protocol was used (Chapter 
2.2.1.2). For amplicon greater than 2kb in length, Phire Hot Start II DNA 
Polymerase was used (Chapter 2.2.1.2). For all reactions 200ng of purified DNA 
template was used in a 50μL reaction. 
 
PCR product specificity was assessed using agarose gel electrophoresis prior to 
purification using the Monarch® PCR and DNA Cleanup Kit (Chapter 2.2). 
 
 
2.4.4 In vitro cutting assay  
 
Incubation of Cas9 protein, guide RNA and DNA substrate enabled the capacity of 
the guide RNA to recruit Cas9 to target sites and therefore capacity to cut substrate 
to be assessed in vitro.  
 
Streptococcus pyrogenes recombinant Cas9 protein containing a nuclear 
localisation signal (NLS) (Labomics/Toolgen, Cas9-TOO-50) was reconstituted in 
embryo water to concentration of 5µg/µL. For initial cutting assays, reaction 
conditions recommended by the Cas9 manufacturer were used and consisted of: 
500ng Cas9 protein, 350ng of purified gRNA, 150ng of purified substrate, 1µL 
NEBuffer 3 (New England Biolabs), 1µL 10xBSA (New England Biolabs) and 
nuclease free water to a total volume of 10µL. 175ng of each guide RNA was used 
in duplex assays.  
 
This reaction set up was altered to a molar ratio of 10:10:1 Cas9 protein: gRNA: 
substrate in optimised conditions (Gong et al. 2018a; Kouranova et al. 2016). 
Based on 500ng of Cas9 protein (molecular weight 160kDa) having molarity of 
3.12µM, subsequent reactions were used with 3.12µM Cas9, 3.12µM gRNA and 
312nM substrate DNA. 
 
Molarity was determined on the basis that one base pair of nucleic acid has a molar 
mass of 660g/mol, with one nucleotide having a molar mass of 330g/mol  
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For example for 312nM of substrate with length of 1kb:  
 
1000 base pairs of 660g/mol per base pair = 1000x660 = 6.6x105 
 
312nM = 3.12x10-13 mols/µL 
 
 6.6x105 x 3.12x10-13 = 2.06x10-7 g = 206ng substrate DNA 
 
Reactions were incubated at 37°C for one hour prior to agarose gel electrophoresis. 
Control reactions were used for each substrate, with nuclease free water in place 
of guide RNA. This enabled the effect of gRNA on substrate to be more accurately 
assessed, and the extent to which presence of Cas9 protein slowed DNA fragment 
progression through agarose gel to be assessed.  
 
2.5 Generation of transgenic mice  
 
All animal work was conducted in accordance with the Animals (Scientific 
Procedures) Act (APSA) (1986) and was subject to local ethical committee review. 
This work was carried out under Professor George Bou-Gharios’ project licence, 
PPL number 70/9047.  
 
Mice were housed at the University of Liverpool’s Biomedical Services Unit under 
specific pathogen free (SPF) environmental conditions. The mice were housed with 
maintained at 22±2 ˚C and a cycle of 12 hours of light, 12 hours of darkness.  
 
All purchased wild-type mice were procured from Charles River (Wilmington, 
Massachusetts, United States). Transgenic mice lines were generated using 
B6CBAF1 as a background strain. These mice are generated as F1 cross of pairing 
female C57BL/6J and male CBA/CaCrl.  
 
Aside from preparation of DNA constructs and guide RNA, each stage of this 
protocol was carried out by Dr Ke Liu (University of Liverpool). Microinjection of cell 
cell-stage embryos was carried out in accordance with Ittner and Götz (2007).  
 
2.5.1 Reporter construct DNA preparation  
 
Plasmids containing enhancer regions driving reporter gene via a promoter region 
(as detailed in Chapters 2.3 and 5.2) were cut in order to produce constructs for 
examination of in vivo reporter gene expression, as schematically represented in 
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Figure 2.11. Each transgenic line was named in accordance with the plasmid the 
construct originated from.  
 
 
Figure 2.11: Schematic representation of DNA constructs used in the creation of 
transgenic mice. Constructs consisted of enhancer regions (white) placed upstream of a 
promoter (grey) and reporter gene (black), with the enhancer therefore regulating the 
transcription of the reporter gene. 
 
LacZ containing plasmids were cut using restriction enzymes recognising 
sequences upstream of the 5’ enhancer sequence boundary and downstream of 
the 3’ polyA tail of the lacZ gene. This ensured the removal of sequences necessary 
for bacterial maintenance that are not required in mammalian in vivo system. 
Plasmid DNA was prepared as outlined in Chapter 2.3. Restriction digests were 
carried with agarose gel electrophoresis and cutting of the gel in order to isolate 
DNA fragments of interest (outlined in Chapter 2.2 and illustrated in Chapter 5.2).  
 
In order to create the -148kb_short Hsp68LacZ transgenic mice, the -
148kbCTGFHsp68LacZGW plasmid was cut using ScaI, which cuts 1044bp 
downstream of the 5’ enhancer boundary, leading to a 1531bp sub-region of the 
enhancer driving reporter gene expression.  
 
Construct DNA fragments were purified using the gel extraction protocol as outlined 
in Chapter 2.2.3. However, after the initial centrifugation step following addition of 
sample to the column, 500μL buffer QG was added to the column before 
centrifugation for one minute and continuation of standard protocol. Purified DNA 
was pooled through elution from multiple QIAquick columns to a total of 30µL in 
embryo water. Constructs were further purified by being placed on an Ultrafree®-
MC column (Merck Millipore, UFC30GV25) which was subsequently centrifuged for 
two minutes at 12,000g.  
 
Concentration of construct DNA was determined using gel electrophoresis with 
0.8% agarose gel containing 0.5µg/µL Ethidium Bromide, with sample dilutions ran 
alongside 0.5µg and 1.0µg each of λ-HindIII digest and 2 log ladders. Concentration 
of construct DNA was estimated based on the known mass of ladder bands. 
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2.5.2 Preparation of embryos  
 
Female B6CBAF1 mice aged five to six weeks were treated to induce 
superovulation through intraperitoneal injection (IP) of 5U follicle stimulating 
hormone (FSH) on day one, followed by IP injection of 5U luteinising hormone (LH) 
on day three. These mice were paired with stud male B6CBAF1 overnight. The 
following morning embryos were isolated (0.5 days post-coitum (dpc)) from females 
where copulation plugs were present. 300µg/mL hyaluronidase was then used to 
remove cumulus cells before zygotes were transferred to M16 media (Merck 
Millipore, MR-016-D). This procedure was carried out by Dr Ke Liu.  
 
2.5.3 Microinjection  
 
For reporter gene constructs, DNA was diluted to 2ng/µL in embryo water before 
injection into the pro-nuclei of viable embryos.  
 
For the generation of mice harbouring CRISPR-Cas9 based genomic alterations, 
guide RNA was incubated with Cas9 protein at an equimolar ratio (either 0.5µM or 
1.5µM) for 10 minutes at room temperature prior to the commencement of injection 
to allow protein-gRNA complex formation (Jinek et al. 2012). Recombinant Cas9 
protein was prepared as in Chapter 2.4.3. Complexes were injected into the 
cytoplasm of embryos as the Cas9 protein used has a nuclear localisation signal 
(NLS) (Horii et al. 2014). Injected embryos were incubated in M16 media until 
transfer. This procedure was carried out by Dr Ke Liu. 
 
2.5.4 Embryo transfer  
 
Female CD1 mice were paired with vasectomised male CD1 mice overnight. Where 
copulation plug had formed, resultant pseudo-pregnant females were used as 
surrogate mothers for embryo transfer. Female mice were anaesthetised before 
10-15 viable embryos at the one cell stage that had survived microinjection were 
transferred to the ampulla of uterine tube, approximately 30 embryos per female 
mouse. This procedure was carried out by Dr Ke Liu. 
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2.5.5 Genotyping  
 
2.5.5.1 DNA extraction  
 
Ear notch samples were taken from mice upon weaning at approximately three 
weeks of age. Samples for genotyping were also taken from the distal portion of 
tails, or ears of mice collected for tissue, in addition to placental tissue from 
embryos.  
 
Samples were suspended in 100µL lysis buffer (50mM Tris-HCl, pH 8.0; 0.1M NaCl; 
1% w/v SDS; 20mM EDTA) before the addition of 10µL 10mg/mL Proteinase K 
(Sigma Aldrich, P2308 or Bioline, BIO-37037) (stored in 50% glycerol solution). 
Samples were then vortexed briefly before incubation overnight at 55°C.  
 
Following incubation overnight, samples were allowed to cool to room temperature 
before being briefly vortexed. Samples were examined to ensure that tissue had 
been broken down in the digestion step. Samples were then centrifuged at 16200g 
for three minutes. Resultant supernatant was transferred to clean 1.5mL 
microcentrifuge tube before the addition of an equal amount of molecular grade 
absolute isopropanol. Samples were gently inverted twice before centrifugation 
using aforementioned conditions. Supernatant was discarded before samples were 
centrifuged at 16200g for a further 30 seconds, after which supernatant was 
removed with a pipette. Pellets were left to air-dry at room temperature for 
approximately ten minutes. 25µL TE buffer was subsequently used to reconstitute 
pellets, samples were gently flicked in order to aid this before incubation at room 
temperature for one hour with gentle flicking of sample every 15 minutes in order 
to aid reconstitution. 
 
This protocol was later adapted with an ethanol pellet wash step in order to reduce 
isopropanol contamination and therefore improve ratio for 260/230nm absorbance 
measurement for DNA samples. Prior to the pellet drying step, 500µL 70% (v/v) 
molecular grade ethanol in nuclease free water was added to each sample before 
being discarded and pellet left to dry prior to standard reconstitution method.  
 
For adult tail samples and embryonic placental material, double volumes of each 
reagent were used at each stage.  
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Concentration and quality of resultant DNA was assessed using Nanodrop as 
aforementioned. 
 
2.5.5.2 Genotyping PCR  
 
An internal control PCR reaction was used for each DNA sample to ensure DNA 
purity and integrity was sufficient for PCR and to allow determination of false-
negatives in amplicon of interest PCR reactions. The internal forward primer 
sequence was 5’- TGG ACA GGA CTG GAC CTC TGC TTT CCT AGA and the 
internal control reverse primer had sequence of 5’- TAG AGC TTT GCC ACA TCA 
CAG GTC ATT CAG. The internal control reaction amplicon is a 194bp product 
which spans exon 1 of the Fabp2 gene (chr3:122,598,282-122,598,475). For the 
CRISPR genome edited transgenic mice, this locus was not predicted to be 
affected by off-target effects of any of the guide RNAs. Therefore, this reaction 
would still be suitable as a control in the genotyping of CRISPR transgenic mice. 
 
GoTaq® G2 Flexi DNA polymerase (as outlined in Chapter 2.2.1.2) was used to 
amplify products of interest with 100ng of template DNA in each reaction with 
primers listed in Table 2.5.  
 
Construct specific primers were designed which spanned from the enhancer region 
into the promoter region. Preliminary PCR using purified genomic DNA as a 
template was used to check primer specificity and optimise amplification conditions 
for each primer pair used prior to usage with DNA samples extracted for 
genotyping.  
 
Where primer Tm similarity allowed, duplex reactions were used whereby the 
internal control and amplicon for genomic alteration of interest were amplified within 
one reaction. PCR reaction set-up was modified for this approach as follows: 5µL 
5x reaction buffer, 2µL 25mM MgCl2, 0.75µL 10mM dNTP, 0.5µL 10µM forward 
internal reaction primer, 0.5µL 10µM reverse internal reaction primer, 0.5µL 10µM 
forward amplicon of interest primer, 0.5µL 10µM reverse amplicon of interest 
primer, 100ng template, 0.15µL GoTaq® G2 Flexi DNA polymerase with water to a 
total of 25µL per reaction. 
 
Where copy number was trying to be assessed or DNA impurity hampered the 
efficiency of reactions, template amount was reduced to 50ng or 25ng per reaction.  
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Table 2.5: Primers used to genotype LacZ reporter transgenic mice. For construct specific genotyping, PCR amplicon were selected spanning from the 
enhancer region into the promoter region. Further primers were also used that amplified within the LacZ gene  
 
  
Amplicon Primer name Sequence 5’ to 3’ Tm (°C) Product length (bp) 
LacZ reporter gene 
LacZ 008 GTTGCAGTGCACGGCAGATACACTTGCTGA 69.5 
389 
LacZ 009 GCCACTGGTGTGGGCCATAATTCAATTCGC 69.5 
CTGF-4 (-4kbCTGFHsp68LacZ) 
-4CTGFGWgeno_F CAAAAAGGTTGGGCTAGGGC 59.4 
550 
148CTGFgeno2_R GTCCGGTGACGTGATCCTCT 61.3 
CTGF137s (-
137kbshortCTGFHsp68LacZ 
-137sGWgeno_F GACTGCTGAAGACGTCGCTACAT 62.4 
608 
148CTGFgeno2_R GTCCGGTGACGTGATCCTCT 61.3 
CTGF148Hsp68lacZ (CTGF148 and -
148kb_short) 
148CTGFgeno2_F GCACTCTTCCCAATATTTATGTATGC 58.7 
749 
148CTGFgeno2_R GTCCGGTGACGTGATCCTCT 61.3 
CTGF230 
230GWgeno_ F GAGTCGCATAAATACCTTGTGAGC 61.0 
789 
148CTGFgeno2_R GTCCGGTGACGTGATCCTCT 61.3 
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The 148CTGFgeno2_R primer was used as reverse primer for all construct specific 
reactions for lacZ reporter lines as this primer sits within the Hsp68 promoter region.  
For the CRIPSR-Cas9 transgenic mice lines, primers used for generating substrate 
for the in vitro cutting assay were used to genotype using the reaction set up and 
conditions outlined in appendices Chapter 5.3. Amplification of these regions would 
not be possible if the enhancer regions were excised. 
 
PCR products were ran on 1% agarose gels before visualisation for confirmation of 
genotype. 
 
2.6 X-gal (5-Bromo-4-chloro-3-indolyl-β-D-galactopyranoside) staining 
 
2.6.1 X-gal staining 
 
Expression of lacZ reporter gene expression was qualitatively assessed using X-
gal staining.  
 
All mice taken for tissue were culled in accordance with Home Office protocol and 
housed as aforementioned in Chapter 2.5.  
 
For embryonic time points, mice were paired for two evenings with presence of 
copulation plug in the morning assumed to be E0.5. Embryos were taken at E11.5, 
E12.5, E13.5, E15.5 and E17.5 dpc. Embryos were placed in cold phosphate 
buffered saline (PBS) before removal of placenta and yolk sac. For E17.5 embryos, 
skin was dissected in addition to a sagittal abdominal incision to allow penetration 
of solutions. For the -4kb, -102kb, -137kb and preliminary work for -148kb 
transgenic assay at E15.5, Christoph Zimmer or Dr Ian Li carried out this procedure.  
 
Adult tissue samples were also placed in cold PBS once dissected. Skeletal 
samples taken consisted of the cranium, thoracic vertebrae, lumbar vertebrae, ribs 
and hind limbs. Soft tissue samples were taken from the brain, eye, heart, lung, 
kidney and liver. For knee tissue samples, incisions were made within the menisci 
region and dorsal aspect of knee in order to destabilise the joint and allow solution 
penetration into the medial regions of the joint.  
 
All samples were rinsed through placing them in fresh cold PBS, prior to transfer to 
cold X-gal fix solution (0.2% glutaraldehyde solution (v/v), 0.1 M sodium phosphate 
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buffer pH 7.3, 5mM Ethylene glycol-bis(2-aminoethylether)-N,N,N′,N′-tetraacetic 
acid (EGTA) pH 8.0, 2mM MgCl2, 2% neutral buffered formalin) on ice. Samples 
were then fixed at room temperature whilst rotating for a duration of time dependent 
on developmental stage (Table 2.6)  
 
Developmental stage Fixation duration 
E11.5 20 minutes 
E13.5 35 minutes 
E15.5 45 minutes 
E17.5 60 minutes 
adult 120 minutes 
 
Table 2.6: X-gal staining tissue fixation durations. Fixation duration depended on 
developmental time-point  
 
After fixation, fix solution was decanted and replaced with rinse solution (0.1M 
sodium phosphate buffer, 2mM MgCl2, 0.1% sodium deoxycholate (w/v), 0.2% NP-
40 substitute (v/v). Samples were rinsed initially whilst rotating at room temperature 
for 30 minutes before rinse solution was discarded. This process was repeated a 
further two times. X-gal stain solution, composed of: 1mg/mL X-gal substrate 
(VWR, 437132J), 5mM potassium ferricyanide (Sigma Aldrich, P-3667), 4mM 
potassium ferrocyanide (Sigma Aldrich, P-9387) dissolved in rinse solution was 
then added to samples which were then shielded from light before rotating 
incubation overnight at room temperature. Progression of staining was observed at 
regular intervals, typically hourly for the first four hours. After staining period, stain 
solution was discarded before addition of rinse solution and three stages of rinsing 
as carried out previously.  
 
Whole mount imaging was conducted using an Olympus SZX12 microscope with 
QCapture camera and software (Q Imaging, Surrey, British Columbia, Canada).  
 
2.6.2 Soft tissue clearing of X-gal stained tissue 
 
The soft tissue was cleared from X-gal stained embryos and adult skeletons in 
preparation for further whole mount imaging, based on the protocol of Rigueur and 
Lyons (2014). This was carried out after post staining-fix in 10% neutral buffered 
formalin solution for 24 hours at 4°C. Embryos were firstly transferred to a 1% (w/v) 
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potassium hydroxide (KOH) solution before being left at room temperature 
overnight. This solution was replaced daily with repetition of incubation process for 
three days. After this point, the solution was changed to 0.8%KOH/20% glycerol 
(Sigma Aldrich, G5516), after which samples were left at room temperature for 
seven days. This incubation process was repeated firstly with 0.6%KOH/40% 
glycerol and subsequently 0.2%KOH/80% glycerol. Whole mount images were 
taken before embryos were stored in 100% glycerol. 
 
For adult skeletal samples, as much soft tissue such as muscle was removed 
through dissection, with ligamentous tissue left intact in order to maintain 
articulation of the skeleton. Samples were transferred to 2% KOH solution for a 
total of seven days at room temperature, with total solution change daily. After this 
period, solution was changed to 1% KOH with replacement every 48 hours or when 
solution became discoloured. As with the embryos, the ratio of KOH in clearing 
solution was gradually reduced, with increasing proportion of glycerol. Samples 
were imaged and stored in 100% glycerol.  
 
The background was removed from images using Gnu Image Manipulation 
freeware software. 
 
2.7 Histology  
 
Tissue samples were fixed at 4°C for a period of 24 hours using 10% neutral 
buffered formalin solution. Samples were then placed in 70% ethanol solution until 
tissue processing. Skeletal tissue samples were decalcified through being placed 
in 10% EDTA (w/v) pH 7.4 solution on a rocking platform at room temperature for 
2 weeks prior to processing.  
 
2.7.1 Soft tissue clearing  
 
All tissue samples were processed using Leica ASP300 tissue processor.  
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For soft tissue samples and embryos, the following parameters were used:  
 
Solution Duration Temperature 
Ethanol (70%) 30 minutes Room temperature 
Ethanol (90%)  30 minutes Room temperature 
Ethanol (absolute) 5 minutes Room temperature 
 10 minutes Room temperature 
 10 minutes Room temperature 
 20 minutes Room temperature 
Xylene  10 minutes Room temperature 
 20 minutes Room temperature 
 30 minutes  40°C 
Wax 30 minutes 62°C 
 60 minutes 62°C 
 150 minutes 62°C 
 
For hard tissue; decalcified skeletal samples, the following parameters were used:  
 
Solution Duration Temperature 
Ethanol (70%) 15 minutes Room temperature 
Ethanol (90%) 60 minutes Room temperature 
Ethanol (absolute) 20 minutes Room temperature 
 40 minutes Room temperature 
 60 minutes Room temperature 
 120 minutes Room temperature 
Xylene  20 minutes Room temperature 
 40 minutes Room temperature 
 60 minutes 40°C 
Wax 30 minutes 62°C 
 60 minutes 62°C 
 150 minutes 62°C 
 
After processing, samples were embedded within Surgiplast Paraplast (Leica, 
39601006) using Leica EG1150 C embedding station.  
 
Sections of samples were cut to a thickness of six micrometres (µm) using a Leica 
2135 manual microtome. All embryos were sectioned in the sagittal plane. 
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Postnatal tissue samples were sectioned in the coronal plane aside from the paw 
which was sectioned in the transverse plane. Sections were transferred to slides 
which were incubated at 37°C overnight.  
 
2.7.2 Eosin counterstaining and imaging  
 
Samples stained for β-galactosidase activity were counterstained using eosin. 
Briefly, slides were dewaxed through two stages of being placed in Histo-Clear 
(National Diagnostics, HS-200) for two minutes. Slides were then transferred to 
100% ethanol for two minutes, then 90% ethanol solution for two minutes, then 70% 
ethanol solution for two minutes. Slides were then dipped in running tap water 
before being transferred to eosin Y (alcoholic eosin, Leica, 3801600BBE) for two 
minutes. Slides were then dipped in running tap water before dehydration through 
being placed in 70% ethanol for 30 seconds, 90% ethanol for 30 seconds and 100% 
ethanol for 30 seconds. Slides were then transferred to Histo-Clear. Specimens 
were mounted and coverlipped using Pertex® (Histolab, 00811) or DPX (BDH, 
360294H) as mounting media.  
 
Specimens were imaged using an Olympus BX60 light microscope in conjunction 
with a Zeiss Axiocam camera system using ZEN blue edition software. The Atlas 
of Mouse Development (Kaufman 2003) and eHistology Atlas 
(http://www.emouseatlas.org/emap/eHistology) (Graham et al. 2015) were used to 
identify histological tissues.  
 
2.8 In vitro modelling of enhancer function  
 
2.8.1 pRL-TK 
 
Immortalised cell lines were used to model enhancer function. Cells were 
transfected with firefly luciferase reporter plasmid DNA; the creation and 
preparation of which is outlined in Chapter 2.3.  
 
The pRL-TK plasmid (Promega, E2241) was used as an internal control in 
luciferase assays. This vector encodes a Renilla luciferase gene, the expression of 
which is driven by a thymidine kinase (TK) promoter region taken from Herpes 
Simplex Virus for consistent basal expression of Renilla luciferase, as illustrated in 
Figure 2.12.  
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Figure 2.12: Map of pRL-TK expression plasmid. This expression plasmid contains a 
renilla luciferase gene (Rluc), the expression of which driven by a thymidine kinase (TK) 
promoter to give low to moderate levels of gene expression. 
 
Co-transfection of Firefly luciferase and Renilla luciferase vectors in conjunction 
with use of the Dual-Luciferase® Reporter Assay System (Promega, E1910) 
enables signal stemming from Firefly luciferase driven by enhancer regions to be 
distinguished from Renilla luciferase from pRL-TK. This therefore enables 
discrepancies in cell number or transfection efficiency to be overcome in assessing 
enhancer function.  
 
2.8.2 Cell culture  
 
All cells were maintained in incubators with 5% CO2 at 37ºC. Cells were regularly 
passaged when confluence reached 70%-90% at constant split ratio; typically 1:3. 
All cells were grown in media supplemented with 10% heat inactivated Foetal 
Bovine Serum (FBS) (ThermoFisher Scientific, 10500064) unless otherwise stated. 
During passage and seeding, cells were detached from culture plastic using 
TypLE™ Express Enzyme (ThermoFisher Scientific, 12604). 
 
HTB-94 human chondrosarcoma cells (also known as SW-1353), Human 
Embryonic Kidney cells (HEK293-A) and NIH3T3 murine embryonic fibroblast cells 
were maintained in high glucose Dulbecco’s Modified Eagle Medium 
(ThermoFisher Scientific, 41965039). TC28-i2 human rib derived chondrocyte cells 
were maintained using DMEM/Ham’s F-12 (ThermoFisher Scientific, 11320). 
Murine calvarial MC3T3-E1 were cultured using α- Modified Eagle Medium (MEM) 
(no nucleosides, no ascorbic acid; ThermoFisher, A1049001).  
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2.8.3 Transfection of cells 
 
Transfections were carried out in 48 well plate format. Cells were seeded 24 hours 
prior to transfection, with a density of 1.75x104 cells per well for each cell line.  
 
Triplicate reactions were carried out for each reporter plasmid of interest in each 
transfection. Lipofectamine® 2000 (ThermoFisher Scientific, 11668019) was used 
as transfection reagent. For each well transfected, 500ng of firefly reporter plasmid, 
30ng of renilla plasmid and 1µL Lipofectamine 2000® was used. Mastermixes were 
created for each pSLF01 vector variant of interest. Firstly, firefly and renilla plasmid 
DNA was diluted in Opti-MEM™ with gentle aspiration to mix (ThermoFisher 
Scientific, 31985070). Lipofectamine® was also diluted in Opti-MEM™ before 
resultant solution was gently flicked to mix and incubated at room temperature for 
five minutes. Opti-MEM dilution solutions were then combined in 1:1 ratio before 
being gently flicked to mix and incubation at room temperature for 20 minutes. 
Resultant transfection complexes were added dropwise to the centre of seeded cell 
wells, before plates were returned to 37°C incubator. After four hours of incubation 
standard media was added to each transfected well.  
 
Control procedure were also carried out whereby lipofectamine and Opti-MEM™ 
mixture was added to the cells in the same manner as DNA transfection complexes.  
 
2.8.4 Luciferase assay 
 
2.8.4.1 Cell lysis  
 
For each stage of the luciferase assay, reagents from the Dual-Luciferase® kit were 
used in accordance with the manufacturer’s instructions.  
 
24 hours after transfection, the media was removed from cell culture plate wells 
and cells were washed with PBS. This wash solution was removed before cells 
were lysed using Passive Lysis Buffer that had been diluted to 1x working solution 
using distilled water. 65µL of Passive Lysis Buffer was added to each well, after 
which plates were left a rocking platform for 15 minutes at room temperature. 
Resultant lysed cell solution was transferred to a clean microcentrifuge tube.  
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2.8.4.2 Luminescence reading  
 
Luminescence was assessed using Glomax® Multi-Detection System (Promega). 
50µL of Luciferase Assay Reagent II (LARII) was added to triplicate wells within a 
white walled plate (Sigma Aldrich, M4811) for each pSLF01 variant sample. 
Luminescence in the plate was then read with two second integration period per 
well using the luminescence program and recorded as a Microsoft Excel file. This 
therefore allowed the identification of any background luciferase activity in the plate 
or reagent. 10µL of cell lysate was then added to each well, with the contents being 
gently aspirated four times in order to ensure samples were thoroughly mixed but 
no bubbles were present. Luminescence was then measured again, in the same 
manner as before with generation of another spreadsheet containing raw data. 
50µL Stop and Glo® reagent was then added to each well, before gentle aspiration 
and reading of luminescence and collection of excel data file as before.  
 
2.8.4.3 Data interpretation  
 
The luminescent signal produced by the firefly luciferase protein and therefore 
pSLF01 plasmid variant function was the signal detected after the addition of LAR 
II. The data point from each well was divided by that of the reading from the same 
well after the addition of Stop and Glo® (renilla luciferase signal). This allowed 
normalisation of luciferase signal and accounted for any discrepancies in cell 
number between wells. Means were taken for the normalised data for each pSLF01 
variant.  
 
Fold differences in luciferase expression were calculated and normalised to the 
basic promoter along pSLF01 plasmid. Data was assumed to be normally 
distributed and unpaired Student’s t-tests were carried out using Microsoft Excel to 
compare responses between enhancer regions.  
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2.9 Identification and in vitro validation of transcription factor binding 
sites  
 
2.9.1 Putative transcription factor binding motif prediction  
 
2.9.1.1 Motif prediction  
 
The Transcription Factor Affinity Prediction (TRAP) web tool, available at: 
http://trap.molgen.mpg.de/cgi-bin/home.cgi was used to identify putative TFBS. 
The results generated from this tool are based on affinity between transcription 
factor and DNA sequence. TF are ranked based on the probability scores (p-value) 
for affinity to the sequence compared with distribution within the background model. 
p-values of <0.05 correspond to predicted transcription factor-sequence of interest 
affinity which exceeds that of the transcription factor-random sequence within the 
background model. Therefore a p value <0.05 dictates significant TF-sequence of 
interest interaction (Manke et al. 2008).  
 
The TRAP single sequence function was used (Manke et al. 2008; Roider et al. 
2007). Sequences for regions of interest were entered in FASTA format, with 
testing against the TRANSFAC database of TFBS (‘transfac_2010.1’ vertebrate 
matrix file), mouse promoters as the background model and Benjamini-Hochberg 
multiple test correction (Figure 2.13).  
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Figure 2.13: Screenshot of entry of DNA sequences into the TRAP tool. Sequences 
were entered in FASTA format, with results generated using the transfac_2010.1 vertebrate 
matrix file and mouse promoter as background model. Benjamini-Hochberg was selected 
for multiple test correction  
 
TRAP results are obtained as a ranked list of transcription factors, with p-value, 
matrix number and matrix name (Figure 2.14 and Chapter 5.4). The matrix number 
is a unique to each transcription factor. There may be multiple matrices per TF, 
therefore each matrix number reflects a specific consensus binding motif. The 
positioning of binding sites can also be visualised in the results using the Binding 
Sites ‘sites’ function. 
 
 
 
 
 
 
 
 
 
 
117 
 
Figure 2.14: Selection of transcription factor binding matrices generated by TRAP. 
Transcription factor matrices are ranked based on the probability of interaction (P-value). 
Results can be interpreted through the affinity plot and binding site functions which allow 
visualisation of TFBS within sequence of interest.  
 
A specific matrix ID is selected and the DNA sequence of the region is visualised 
with highlighting of the sequences predicted to be bound by the transcription factor. 
The distribution of sites for a matrix across a region of interest can also be 
visualised using the Affinity Plot ‘graph’ function.  
 
MotifMap (http://motifmap.ics.uci.edu) (Daily et al. 2011) and SwissRegulon Portal 
(http://swissregulon.unibas.ch/sr/) (Pachkov et al. 2013) are both online databases 
of transcription factor binding motifs. These resources were used as to find 
documented consensus motifs related to the TFBS within sequences of interest.  
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2.9.1.2 Examination of TFBS sequence conservation 
 
The conservation of putative TFBSs were assessed using the aforementioned 
Multiz function within the UCSC Genome Browser (Chapter 2.1), in addition to 
Clustal Omega. Firstly sequences of interest were identified within the UCSC 
Genome Browser, ‘show details for feature’ was then used to examine aligned 
sequences from organisms including; mouse, rat, human, opossum, platypus, 
chicken, lizard and fugu (Figure 2.15) 
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Figure 2.15: UCSC ENCODE Genome Browser based identification of conserved sequences. Alignment of sequences from multiple organisms was 
visualised with the Multiz alignment tracks. Sequences similar between species are represented by black bars. By clicking on conserved sequences within the 
Genome Browser, alignment at nucleotide level can be accessed.  
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This enabled the base-wise conservation of sites of interest between organisms to 
be visualised, as demonstrated in Figure 2.16.  
 
 
Figure 2.16: Visualisation of Multiz alignment of conservation of DNA sequences. 
Nucleotides are organised into blocks which are aligned based on sequence conservation 
across species of interest. 
 
DNA sequences were then taken from Multiz for mouse, human and the most 
evolutionarily distant, yet conserved organism and aligned using Clustal Omega 
(Sievers et al. 2011), available at https://www.ebi.ac.uk/Tools/msa/clustalo/. 
Sequences were inputted in FASTA format, with output format of ClustalW with 
character counts as shown in Figure 2.17. Reverse complement function was used 
to ensure that DNA for organisms; for example humans, where sequence running 
along negative strand was efficiently aligned against that of the mouse.  
 
  
121 
 
Figure 2.17: Input of DNA sequence from various organisms into the ClustalOmega 
interface. Sequences from each organism of interest gathered from Multiz (Figure 2.16) 
were entered in FASTA format and aligned using the ClustalW function.  
 
Results are a percentage of conserved bases between the aligned sequences, in 
addition conservation of aligned between sequences can be visualised with asterisk 
denoting aligned nucleotides between all species under investigation.  
 
2.9.2 Electrophoretic mobility shift assay (EMSA) 
 
EMSA methodology employed herein was adapted from that of Dr Louise Reynard 
at Newcastle University.  
 
2.9.2.1Oligonucleotide probe and competitor design  
 
Oligonucleotides were designed to span putative TFBS identified with additional 
flanking sequence to a total of approximately 30 nucleotides in length. 
Oligonucleotide sequences were inputted into TRAP in order to ascertain specificity 
of probe to transcription factor of interest and verify predicted consensus motif 
positioning within probe. For mutant oligonucleotides, nucleotides within the 
consensus binding motif were substituted in order to limit recognition and 
interaction with the cognate transcription factor. Mutant oligonucleotide sequence 
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TF affinity was compared to that of the WT oligonucleotide using the single 
sequence TRAP interface as aforementioned.  
 
2.9.2.2 Oligonucleotide preparation 
 
Forward and reverse complement oligonucleotides were custom synthesised and 
purchased for each TFBS of interest, incorporating a 5’ dye at each end with high 
performance liquid chromatography (HPLC) grade purification. Oligonucleotides 
purchased from Integrated DNA Technologies had ‘IRDye™700’ as the 5’ 
modification, whereas oligonucleotides procured from Eurofins Genomics had a 5’ 
‘DY682’ modification. Both modifications were compatible with the Li-Cor 
Odyssey® imaging system (Li-Cor, Lincoln, Nebraska, United States) Light 
exposure was minimised at all times in order to prevent bleaching of probes.  
 
For RUNX2 optimisation a positive control probe was used based on validated 
RUNX2 binding site within the osteocalcin gene promoter sequence (Lamour et al. 
2007). The probe contained DY682 modification at the 5’ end. Forward probe 
sequence: 5’- GCTGCAGTCACCAACCACAGCATCCTTTGG and reverse probe 
sequence 5’- CCAAAGGATGCTGTGGTTGGTGACTGCAGC.  
 
Sequences for probes and competitors are detailed in Tables 2.7 to Table 2.9.  
 
Lyophilised probes were reconstituted to 100μM master stock solution using 
nuclease free water and stored at -80°C. Probes were annealed as follows; 10μL 
each of forward and reverse 100μM stock were added to 10μL annealing buffer 
(100mM Tris HCl, 500mM NaCl, 10mM EDTA) along with 70μL nuclease free 
water, before incubation at 95°C for five minutes in a heat block, which was allowed 
to cool to room temperature before removal of resultant 20μM annealed probe 
stocks. Probes were further diluted to 100nM stock using nuclease free water, and 
stored at -20°C. 
 
Competitor oligonucleotides were purchased for each probe of interest (Eurofins 
Genomics) and reconstituted to 100μM with nuclease free water. These 
oligonucleotides were annealed in the same manner as for the probes.  
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Table 2.7: Oligonucleotide sequences for EMSA testing of SOX9 interaction within -137kb enhancer. Oligonucleotides containing SOX9 consensus motif 
and flanking sequence were used to create probes labelled at the 5’with near-infrared dye, and with unlabelled oligonucleotides as competitors in EMSA. SOX9 
consensus motif was mutated through substitution of CAA core motif nucleotides. Forward and reverse oligonucleotides were annealed for each sequence of 
interest 
Probe/ 
competitor  Sequence name label Sequence 5’ to 3’ 
Probe 137sox9WT_F IRD700 GGCACTGAACAATGGGGGCCTGTTCTCTCCTGT 
Probe 137sox9WT_R IRD700 ACAGGAGAGAACAGGCCCCCATTGTTCAGTGCC 
Probe 137sox9MUT_F IRD700 GGCACTGCCCGGTGGGGGCCTGTTCTCTCCTGT 
Probe 137sox9MUT_R IRD700 ACAGGAGAGAACAGGCCCCCACCGGGCAGTGCC 
Competitor 137SOX9CTRL_F none CTAGGGCACTGAACAATGGGGGCCTGTTCTCTCCTGT 
Competitor 137SOX9CTRL_R none CTAGACAGGAGAGAACAGGCCCCCATTGTTCAGTGCC 
Competitor 137SOX9MUT1_F none CTAGGGCACTGCTCAATGGGGGCCTGTTCTCTCCTGT 
Competitor 137SOX9MUT1_R none CTAGACAGGAGAGAACAGGCCCCCATTGAGCAGTGCC 
Competitor 137SOX9MUT2_F none CTAGGGCACTGAACCCTGGGGGCCTGTTCTCTCCTGT 
Competitor 137SOX9MUT2_R none CTAGACAGGAGAGAACAGGCCCCCAGGGTTCAGTGCC 
Competitor 137SOX9MUT3_F none CTAGGGCACTGCTCCCTGGGGGCCTGTTCTCTCCTGT 
Competitor 137SOX9MUT3_R none CTAGACAGGAGAGAACAGGCCCCCAGGGAGCAGTGCC 
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Probe/ 
competitor  Sequence name label Sequence 5’ to 3’ 
Probe 148sox9-WtP_F DY682 CCATCTGTCAACAGAGGCTCTCAGCTGCTT 
Probe 148sox9-WtP_R DY682 AAGCAGCTGAGAGCCTCTGTTGACAGATGG 
Competitor 148sox9-1WTcomp1_F None CCATCTGTCAACAGAGGCTCTCAGCTGCTT 
Competitor 148sox9-1WTcomp_R None AAGCAGCTGAGAGCCTCTGTTGACAGATGG 
Competitor 148sox9-1MutComp_F None CCATCTGTCCCCCGAGGCTCTCAGCTGCTT 
Competitor 148sox9-1MutComp_R None AAGCAGCTGAGAGCCTCGGGGGACAGATGG 
Probe 148sox9-2-WtP_F DY682 GCCACATCTAATGTTTATGACCTAACGCCT 
Probe 148sox-2-WtP_R DY682 AGGCGTTAGGTCATAAACATTAGATGTGGC 
Competitor 148sox9-2-WtC_F None GCCACATCTAATGTTTATGACCTAACGCCT 
Competitor 148sox9-2-WtC_R None AGGCGTTAGGTCATAAACATTAGATGTGGC 
Competitor 148sox9-2-MutC_F None GCCACATCTAATAGGTATGACCTAACGCCT 
Competitor 148sox9-2-MutC_R None AGGCGTTAGGTCATACCTATTAGATGTGGC 
 
Table 2.8: Oligonucleotide sequences for EMSA testing of SOX9 interaction within -148kb enhancer. Oligonucleotides containing SOX9 consensus motif 
and flanking sequence were used to create probes labelled at the 5’with near-infrared dye, and with unlabelled oligonucleotides as competitors in EMSA. SOX9 
consensus motif was mutated through substitution of CAA core motif nucleotides. Forward and reverse oligonucleotides were annealed for each sequence of 
interest 
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Probe/ 
competitor  Sequence name label Sequence 5’ to 3’ 
Probe -230soxIR_F IRD700 CAGGGACAAAGTACCTTTGTCAACG 
Probe -230soxIR_R IRD700 CGTTGACAAAGGTACTTTGTCCCTG 
Probe 230soxIRMUT_F IRD700 CAGGGGCGGGGTACCGGGGGCAAC 
Probe 230soxIRMUT_R IRD700 GTTGCCCCCGGTACCCCGCCCCTG 
Competitor 230sox_WTC_F none CAGGGACAAAGTACCTTTGTCAACG 
Competitor 230soxWTC_R none CGTTGACAAAGGTACTTTGTCCCTG 
Competitor 230sox_MUTC1_F none CAGGGACGGGGTACCTTTGTCAACG 
Competitor 230sox_MUT1C_R none CGTTGACAAAGGTACCCCGTCCCTG 
Competitor 230sox_MUTC2_F none CAGGGACAAAGTACCGGGGTCAACG 
Competitor 230sox_MUTC2_R none CGTTGACCCCGGTACTTTGTCCCTG 
Competitor 230sox_MUTC3_F none CAGGGACGGGGTACCGGGGTCAACG 
Competitor 230sox_MUTC3_R none CGTTGACCCCGGTACCCCGTCCCTG 
 
Table 2.9: Oligonucleotide sequences for EMSA testing of SOX9 TFBS within -230kb enhancer. Oligonucleotides containing SOX9 consensus motif and 
flanking sequence were used to create probes labelled at the 5’with near-infrared dye, and with unlabelled oligonucleotides as competitors in EMSA. SOX9 
consensus motif was mutated through substitution of CAA core motif nucleotides. Forward and reverse oligonucleotides were annealed for each sequence of 
interest 
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2.9.2.3 In vitro protein production  
 
Proteins of interest were generated using an in vitro transcription and translation 
system with expression vectors containing protein of interest as template. The 
T7/SP6 TNT® Coupled Reticulocyte Lysate System (Promega, L5020) was used 
in accordance with the manufacturer’s guidelines.  
 
SOX9 protein was generated using SOX9-4xFLAG T7 plasmid as template, a gift 
from Veronique Lefebvre (Lefebvre et al. 1998). RUNX2 protein was generated 
using pcDNARunx2 expression vector.  
 
2.9.2.4 Gel preparation  
 
Native polyacrylamide gels were used with Tris-borate-EDTA (TBE) based buffer 
system. The Hoeffer SE400 electrophoresis system was used for gel running. Gel 
mixes were composed of 30.5mL distilled water, 4.25mL 5xTBE, 5.1mL 40% Bis-
acrylamide solution (Bio-Rad, 161-0144), 140.8µL 20% (w/v) ammonium persulfate 
(Sigma Aldrich, 09913) solution and 40µL N, N, N’, N’-Tetramethylethylenediamine 
(TEMED) (Sigma Aldrich, T928). Cast gels were left to set for one hour at room 
temperature before storage overnight at 4°C 
 
2.9.2.5 Protein-oligonucleotide binding reactions  
 
The Odyssey® EMSA Buffer kit (Li-Cor, 82907910) was used as the source for all 
reaction components and loading dye; aside from the protein, oligonucleotides and 
water. 
 
Basic reactions consisted of: 
 
Component  Volume  
10X Binding buffer 2 μL 
25mM Dithiothreitol (DTT)/ 2.5%Tween® 20 2μL 
1μg/μL Poly(dI-dC) 0.5μL 
100nM oligonucleotide probe 2μL 
Protein 2μL 
Nuclease free water to 20μL 
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Binding reaction optimisation experiments were carried out for each combination of 
oligonucleotide probe and protein. This involved replicate binding reactions with an 
additional microlitre of additives supplied in the Buffer kit: 50% glycerol, 1% NP-40, 
1M potassium chloride (KCl), 100mM (Magnesium chloride) MgCl2 and 200mM 
EDTA. Comparisons of the effects of the additives on binding reactions were drawn 
upon examination of gel image, with the additive that yielded clearest shift used for 
subsequent reactions. Where competitor oligonucleotides were used, they were 
used in excess of either 25x or 50x the concentration of the oligonucleotide probe.  
 
Once assembled, reactions were incubated in the dark for 20 minutes at room 
temperature prior to the addition of 2µL 10X Orange Loading Dye.  
 
2.9.2.6 Gel running  
 
Gels were pre-ran at 160V (10V/cm gel) for one hour at 4°C. After this period, 
samples were loaded and gels were run at 160V for three hours at 4°C in the dark. 
 
2.9.2.7 Gel imaging  
 
The Odyssey® CLx Infrared Imaging System in conjunction with Image Studio 
software (both Li-Cor) was used for gel visualisation. After gels had ran, the tank 
was quickly unassembled before the gel was shielded from light whilst still within 
glass plates. Gels remained in plates for imaging, which were wiped with 
isopropanol prior to imaging. Scans of gels were conducted using the following 
parameters; 700nm channel, focus offset of 4mm, 169µM resolution, intensity of 
eight and medium quality. Images were converted to black on white using the 
Image Studio Software.  
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. Results 
 
3.1 Prediction of Ccn2 enhancers and their positioning within a TAD 
 
3.1.1 Identification of putative Ccn2 enhancers 
 
The region upstream of Ccn2 was examined in silico in order to identify enhancers 
that may regulate transcription of the gene. Given the well-established role of Ccn2 
within cartilaginous tissue, datasets and annotation related to this tissue type was 
prioritised in the prediction of enhancers. Within the mm9 assembly of the Genome 
Browser, the sequence encoding Ccn2 resides on the q arm of chromosome 10 at 
position chr10:24,315,532-24,317,417. The entire transcript from Ccn2; including 
UTR spans from chr10:24,315,248-24,318,488. An area of 300kb encompassing 
from the nearest gene upstream of Ccn2; monooxygenase DBH-like 1 (Moxd1), 
until approximately 2kb downstream of the Ccn2 coding sequence was the focus 
of enhancer predictions (chr10:24,020,350-24,320,350), with a UCSC Genome 
Browser session created to examine this region, as illustrated in Figure 3.1.  
 
Potential enhancers were identified using epigenetic annotations associated with 
enhancer function as outlined in Chapter 1.3 and Chapter 2.1 (datasets detailed in 
Chapter 5 appendices Table 5.1). These datasets were primarily gathered from the 
ENCODE consortium. Data concerning coding genes (Figure 3.1 B), histone 
posttranslational modification (Figure 3.1 C), DNase I hypersensitivity (Figure 3.1 
D) and intra-species conservation (Figure 3.1 E) were compiled. The promoter 
region for Ccn2 was identified using H3K4me3 signal at E14.5; with a single sharp 
peak in close proximity to the Ccn2 gene (Figure 3.1 B and C). The promoter was 
also identified using lift-over of previously published human sequences examining 
this region (Leask et al. 2003). An E14.5 limb H3K4me1 signal track was used to 
identify potential enhancers, with several peaks across the region of interest (Figure 
3.1 C). Limb based H3K27ac signal at E14.5 was also used to identify cis-
regulatory elements, there was a sharp peak for this modification at the promoter 
region for Ccn2 and further peaks across the region of interest. The distribution of 
this modification in comparison with H3K4me1 enabled preliminary prediction of 
enhancer activity. Chromatin state was further interrogated using DNase I 
hypersensitivity tracks from limb and mesoderm samples at E11.5 in addition to 
adult lung fibroblast at eight weeks. Peaks in each of these tracks were distributed 
throughout the region of interest. Highly conserved stretches of sequence were also 
observed across the region of interest, indicating important regulatory function.   
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Figure 3.1: Identification of putative enhancer regions upstream of Ccn2 (Ctgf). The non-coding genomic region between Ccn2 (depicted as Ctgf) and 
nearest 5’ gene Moxd1 (B) served as the basic region in the identification of enhancers. Putative enhancers (A) and coloured loops) were identified on the 
basis of histone posttranslational modification, DNase I hypersensitivity (D) and evolutionary conservation of sequence (E). Enhancers were identified at -4kb, 
-102kb, -137kb,-148kb, -198kb, -230kb and -256kb from the Ccn2 transcription start site.
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Seven putative enhancers of Ccn2 transcription within limb tissue were identified 
where peaks for these characteristics overlapped (Figure 3.1 coloured blocks A and 
loops) and named according to the position of the putative enhancer in kb relative 
to the transcription start site for Ccn2 at position chr10:24,315,248 (Table 3.1). 
 
Putative Enhancer Genomic coordinates Size (bp) 
-4kb chr10:24311246-24312541 1295 
-102kb10 chr10:24212606-24214888 2282 
-137kb10 ch10:24177497-24180069 2572 
-148kb chr10:24166687-24169261 2574 
-198kb chr10:24115344-24117739 2395 
-230kb10 chr10:24084486-24085909 1423 
-255kb10 chr10:24059327-24061377 2050 
 
Table 3.1: Genomic coordinates of putative enhancer regions identified in ENCODE 
UCSC Browser. Enhancers were named according to distance from Ccn2 TSS.  
 
Unfortunately, there is not an H3K27me3 dataset available for the limb histone 
posttranslational modifications track used, so predictions of enhancer poising and 
inactivity are limited. However, basic predictions of activity can still be made on the 
basis of H3K4me1 and H3K27ac modification. For example, the peaks of H3K4me1 
vs H3K27ac within -4kb, -102kb, and -255kb are similar, and in the -137kb and -
230kb regions the H3K27ac peak is larger than H3K4me1. These observations 
suggest an active regulatory role for these regions in the limb at E14.5. This 
contrasts the -148kb region which has a greater peak for H3K4me1 than H3K27ac 
which indicates that this region may be in a poised state in this temporospatial 
context. 
 
3.1.2 Prediction of Ccn2 positioning within a TAD 
 
There must be higher order organisation of the locus surrounding Ccn2 in order to 
facilitate function of multiple enhancers in a cell type, or differential organisation of 
the enhancers in several tissue types. This therefore raises the question as to 
where Ccn2 is positioned within a topologically associated domain. On the basis of 
previous studies, it would be assumed Ccn2 lies within the same TAD as cognate 
                                               
10 Enhancers that have been reported in publication are also known by the distance from 
the 3’ enhancer boundary to Ccn2 TSS: -102kb is -100kb; -137kb is -135kb; -230kb is -
229kb and -255kb is -254kb (Frost et al. 2018). 
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cis-acting regulatory regions (De Laat and Duboule 2013). A TAD containing Ccn2 
has not been specifically examined in the literature, but publicly available datasets 
can be used to predict the positioning of Ccn2, and enhancer regions described 
herein within a TAD.  
 
Firstly, the aforementioned Hi-C data from Dixon et al. (2012) (Chapter 1.3) is 
available at as part of the ‘3D Genome Browser’ http://promoter.bx.psu.edu/hi-
c/view.php (Wang et al. 2018). Within mouse embryonic stem cells, within a 1.5 
megabase (mb) viewpoint there is an enrichment of interactions between 
sequences spanning from upstream of Ccn2 (CTGF) near neighbouring Moxd1 to 
downstream of CCN2, near Enpp1 (Figure 3.2). This region is annotated to be a 
TAD using this resource and dataset (Dixon et al. 2012; Wang et al. 2018) 
(highlighted blue box, Figure 3.2).  
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Figure 3.2: CCN2 
(CTGF) positioning 
within a TAD based on 
Hi-C interrogation of 
chromatin 
interactions. Ccn2 
(Ctgf) is predicted to lie 
within a TAD that 
predominantly flanks 
upstream of the gene. 
With enrichment 
interactions (red 
intensity) peaking in the 
middle of the putative 
TAD region (black 
arrow). The predicted 
TAD is highlighted with 
a blue box.  
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The 3D Genome Browser also contains Chromatin Interaction by Paired-End Tag 
Sequencing (ChIA-PET) datasets, which is a further technique used in the 
examination of chromatin interactions via protein, and ChIP-Seq datasets for CTCF 
and cohesin interactions (Wang et al. 2018). This is an important aspect of the 
prediction of TADs given that both of these proteins are involved in the looping and 
isolation of chromatin that constitutes TAD structure, as detailed in Chapter 1.3. 
(Dixon et al. 2016; Ong and Corces 2014; Rao et al. 2017). Data pertaining to these 
interactions within both human and mouse tissues can be examined, which was 
carried out for sequence in the vicinity of CCN2 and Ccn2 (Chapter 5.5). The 
regions of genomic sequence predicted to be looped through CTCF and cohesin 
can be compiled into a track on the UCSC Genome Browser with the 1.5mb 
viewpoint used in the Hi-C dataset (Figures 3.3 and Figure 3.2 respectively), 
alongside GEO-DataSet ChIP-Seq data for CTCF and cohesin (GSE55045 and 
GSM2169995 respectively, Figure 3.3 E and D respectively) (Barutcu et al. 2014; 
Kim et al. 2018). An ENCODE/LICR track for limb CTCF ChIP-Seq can also be 
compiled into the UCSC Genome Browser (Figure 3.3 E). There is enrichment for 
CTCF and cohesin interaction with the sequences in close vicinity to the ends of 
the Hi-C predicted TAD. Further datasets from the 3D-Genome Interaction Viewer 
and Database (Yang et al. 2018), available at http://kobic.kr/3div/ (Chapter 5.5), 
also allow visualisation of chromatin interactions and predictions of the localisation 
of Ccn2 and CCN2 within a TAD.  
 
All of this evidence suggests that Ccn2 sits within a TAD approximately 300kb long 
stretching 5’ from approximately 8kb upstream of the -255kb putative enhancer to 
3’ approximately 35kb downstream of Ccn2 (highlighted with red box in Figure 3.3). 
This therefore reinforces the findings of the current project, as enhancers are 
predominantly found within the same TAD as their target gene (Nuebler et al. 2018), 
and each of the enhancer regions described herein is predicted to be located in the 
same TAD as CCN2. Future work should seek to understand the higher order 
chromatin looping that constitutes this putative TAD and how this impacts on 
enhancer function. For example, further CTCF and cohesin sites may be utilised 
throughout the TAD in order to isolate enhancers that are not active and prevent 
interaction with the Ccn2 promoter region, thereby reinforcing specific 
temporospatial function of each of the enhancers (Ren et al. 2017).  
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Figure 3.3: In silico 
prediction of Ccn2 
positioning within a TAD in 
the UCSC Genome 
Browser. Import of datasets 
pertaining to CTCF and 
cohesin binding (Barutcu et 
al. 2014; Kim et al. 2018; 
Yang et al. 2018), (A, B, C, D 
and E) allow prediction of 
chromatin organisation and 
TAD structure within a 1.5mb 
viewpoint encompassing 
Ccn2 (Ctgf) and neighbouring 
genes (F). The putative TAD 
predicted in the Hi-C dataset 
and CTCF (A and B) and 
cohesin (C and D) 
interactions is highlighted 
with a red box. Conserved 
sequences (G) occur both 
within and between coding 
sequences.  
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Another interesting facet in the organisation of the enhancers is the prospect of 
super-enhancer function. As outlined in Chapter 1.3, super-enhancers are clusters 
of enhancers that function collaboratively under the control of cell lineage-specific 
TF leading to high levels of target gene transcription (Whyte et al. 2013). Overlap 
in the temporospatial activity of the enhancers described herein could therefore 
constitute super-enhancer function in ensuring robust expression of Ccn2 in 
chondrocytes during embryonic development. Ohba et al. (2015) tried to define 
super-enhancers in chondrocytes using the ethos of Whyte et al. (2013), with SOX9 
as the master transcription factor. On the basis of ChIP-Seq data validated SOX9 
TFBS, this study suggested that there is a super-enhancer spanning approximately 
8.2kb from upstream of the -4kb enhancer described herein, to approximately 1kb 
downstream of Ccn2. The genomic occupancy of Mediator within these regions 
would have to be determined in order to validate super-enhancer predictions, as 
this is a criteria upon which super-enhancer is judged (Pott and Lieb 2015). 
However, Ohba et al. (2015) also suggest that SOX9 binds to several cognate 
enhancer elements for genes involved in chondrocyte behaviour and function, 
without the super-enhancer annotation.  
 
3.2 Multiple enhancers are active during embryonic development 
 
Preliminary experiments were conducted in order to assess the capacity of the  
-4kb, -102kb, -137kb, -198kb, -230kb and -255kb putative enhancers to function as 
regulators of the expression of a LacZ reporter gene during embryonic development 
at E15.5 (Frost et al. 2018). Whilst the in silico datasets in Figure 3.1 concerned 
E14.5, the E15.5 time-point was used for in vivo experiments as cartilaginous tissue 
is more substantial at the latter time point, and endochondral ossification is more 
advanced (Kaufman 2003). X-gal staining, whole mount imaging and histological 
sectioning and staining of embryos at E15.5 was carried out by Dr Ian Li and 
Christoph Zimmer for each enhancer aside from -148kb short and -230kb region. 
More data was gathered for the function of the -148kb enhancer and so there are 
sub-chapters dedicated to this enhancer and a truncated version of it.  
 
3.2.1 -4kb and -255kb putative enhancers do not seem to function at E15.5  
 
For the -4kb enhancer, two attempts were made to establish transgenic lines that 
harboured the enhancer-Hsp68-LacZ construct by Dr Ian Li. Firstly, microinjection 
of construct (as outlined in Chapter 2.3 and 2.5) was carried out; from which a total 
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of 26 mice were born. Three of these were genotyped as being positive for the 
transgene. In pairings these founder (F0) together, or pairings of their progeny (F1) 
for E15.5 with wild-type mice, no X-gal positive staining was observed in any 
embryo at E15.5. For the second attempt, two mice were born, of which neither 
were genotyped to have either transgenic construct and so, enhancer function at 
E15.5 was not assessed. The capacity for the -255kb putative enhancer to drive 
LacZ expression was also examined at E15.5, there was negative staining for all 
transgenic E15.5 embryos generated. 
 
3.2.2 -102kb is active within the vasculature at E15.5  
 
A stable line of transgenic mice for examination of the enhancer located -102kb 
upstream of Ccn2 was not created, instead assessment of the capacity for the 
enhancer to function at E15.5 was carried out with F0 embryos by Dr Ian LI. 
Transgene activity was observed in six embryos, as detailed in Table 3.2.  
 
Founder Whole mount staining intensity Staining localisation 
Intensity of local 
staining 
1 ++ Superficial vasculature, superficial eye orbit +++ 
2 ++ Superficial vasculature +++ 
3 ++++ Superficial vasculature ++++ 
4 ++ Superficial vasculature +++ 
5 ++ Superficial vasculature +++ 
6 + Superficial vasculature + 
 
Table 3.2: Comparison of X-gal staining intensity and localisation across positive 
founder -102kbHsp68LacZ E15.5 embryos. Staining intensity (+ is negligible, ++ diffuse, 
+++ moderate, ++++strong, +++++intense) was recorded for a whole mount embryo, in 
addition to the specific location where staining was observed, enabling consistency of 
staining between F0 to be assessed.  
 
Staining occurred in close proximity to the superficial dermal layer each of these 
embryos, albeit to a varying degree. Three of the embryos exhibited staining in a 
highly similar manner as illustrated in Figure 3.4. 
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Figure 3.4: Representative whole mount images of X-gal stained E15.5 embryos 
containing the -102kbHsp68LacZGW reporter construct. Three of the embryos (A-C); 
corresponding to founders 2, 4 and 5 in Table 2, exhibited a highly similar pattern of 
punctate X-gal staining globally. Upon closer examination (C2), blue staining co-localised 
with microvasculature, however larger blood vessels were not stained.  
 
Histological sectioning of the embryos enabled more in-depth examination of the 
tissue in which the enhancer was functioning (Figure 3.5). Section images 
reinforced those from the whole mount imaging, with X-gal positive blue cells only 
observed within the superficial microvasculature. Tissue-specific staining was co-
localised with endothelial cells of the capillary vessels of the dermal 
microvasculature. Moreover, erythrocytes were observed within branched blue 
vessel structures, lending credence to the notion that the enhancer was active 
within endothelial cells (Figure 3.5 B). β-galactosidase activity was absent in other 
populations of endothelial cells, such as within larger blood vessels, or the blood 
vessels within the growth plates of long bones undergoing endochondral 
ossification (Figure 3.5 C). X-gal staining was not observed within any other tissue; 
including the musculoskeletal system, as demonstrated in the cartilage anlage of 
the humerus (Figure 3.5 C), ribs (Figure 3.5 E), or tail vertebrae.  
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Figure 3.5: Histological examination of X-gal stained E15.5 -102kbHsp68LacZGW 
embryos. Blue staining, and therefore transgene activity was observed within superficial 
microvasculature of the dermis globally (highlighted black arrows). More specifically, 
staining was observed within the branched structures of the capillary vessels such as within 
the cranium (A) neck (B) and dermis surrounding the proximal, distal forelimb and caudal 
vertebrae (C, D and F respectively). There was no transgene activity in other vascular 
structures or blood vessels such as within the endochondral growth plates of the radius and 
ulna (C) or ribs (E).  
 
3.2.3 -137kb functions within articular chondrocytes at E15.5 
 
The capacity of the -137kb putative enhancer was examined in F0 E15.5 embryos 
harbouring LacZ driven by the -137kb region (-137kbHsp68LacZ). Five founders 
were generated, with intensity and localisation of X-gal staining recorded in Table 
3.3.  
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Founder Whole mount staining intensity Staining localisation 
Intensity of local 
staining 
1 ++ Cranium, elbow, wrist, knee, ankle ++++ 
2 ++ Elbow, wrist, knee, ankle +++ 
3 ++ Elbow, wrist, knee, ankle +++ 
4 + Wrist, ankle ++ 
5 + Wrist, distal phalanx of paw + 
 
Table 3.3: X-gal staining localisation and intensity in E15.5 transgenic embryos 
containing the -137kbHsp68LacZ construct. Staining intensity (+ is negligible, ++ diffuse, 
+++ moderate, ++++strong, +++++intense). A highly similar pattern of staining was 
observed across 3 of the embryos with moderate staining of some joints.  
 
Reproducible X-gal staining was observed in the wrist in each of the five F0; albeit 
to varying extents. Tissue of the ankle was stained in four of the F0. Two of the 
founders exhibited highly similar intensity and localisation of staining; as shown in 
Figure 3.6.  
 
 
Figure 3.6: Representative whole mount imaging of β-galactosidase activity in E15.5 
embryos harbouring the -137kbHsp68LacZ transgenic construct. X-gal staining was 
reproducibly confined to the articular regions of the elbow, wrist, knee and ankle (A and B).  
 
Sub-populations of chondrocytes such as in the chondrocranium (Figure 3.7 A), rib 
(Figure 3.7 B) or within the broader endochondral skeleton precursor; such as 
within the diaphysis of the humerus, radius and ulna (Figure 3.7 C) did not exhibit 
X-gal staining. Where staining was observed in four of the founders it occurred in 
a lateral area of the articular joint, with a fifth founder demonstrating more diffuse 
staining across the joints Staining was not observed in the shoulder or hip (not 
shown) or intra-digit articular joints such as those in the manus (Figure 3.7 D). Upon 
histological sectioning, these observations were confirmed with positive staining 
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only occurring in the articular chondrocytes of the elbow (Figure 3.7 C), wrist (Figure 
3.7 D) and ankle (Figure 3.7 E). 
 
 
Figure 3.7: Representative histological sections of -137kbHsp68LacZ transgenic 
E15.5 embryos. Staining was not observed in chondrocranium primordium of the temporal 
bone (A), ribs (B), or precursor diaphysis region of the long bones such as the radius (C). 
Positive blue stained cells were most abundant within the vicinity of the articular surface of 
the radius (C), wrist (D) and ankle (E).  
 
Where X-gal staining was present, it was observed to be stronger at articular joint 
surfaces. This occurred most strikingly in the elbow (Figure 3.7 C), where darker 
blue staining was observed proximal to the articular space, with stratification of 
staining intensity in cells located more distally from the articular surface.  
 
An attempt was made to establish a line of -137kbshortHsp68LacZ transgenic mice, 
harbouring a conserved fragment of the -137kb enhancer (-137kb short). This 
shorter region was a truncated version of the -137kb enhancer containing 
approximately 1275bp of the middle of the sequence that was most highly 
conserved. The coordinates of this region are chr10:24,178,225-24,179,499 in the 
mm9 genome build. This region was also used in in vitro experiments. Three 
founders were genotyped as being positive for the transgenic construct but there 
was no transgene expression in E15.5 derived from any of these founders. 
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3.2.4 -198kb is active in multiple tissues at E15.5  
 
The -198kb region was examined at E15.5 in three F0 embryos by Dr Ian Li and 
Christoph Zimmer. Each founder that was positive in X-gal staining exhibited a 
different pattern of X-gal staining, as detailed in Table 3.4. Whole mount images 
were taken of each embryo, as shown in Figure 3.8.  
 
 
Table 3.4: X-gal staining and intensity in E15.5 transgenic embryos containing the -
198kbHsp68LacZ construct. Staining intensity (+ is negligible, ++ diffuse, +++ moderate, 
++++strong, +++++intense) Intensity of staining varied between each embryo. Staining 
intensity and localisation varied between each of the 3 founder embryos.  
 
One of the embryos stained very strongly globally (A, Table 3.4 and Figure 3.8 A). 
This contrasted the other positively stained embryos, in which blue staining was 
observed in a more diffuse manner.  
 
 
Figure 3.8: Whole mount imaging of X-gal stained -198kbHsp68LacZ embryos at 
E15.5. Three founder embryos exhibited blue staining of tissues. Transgene activity 
occurred in several tissues in each embryo. 
 
Histological sectioning revealed that the intense staining observed in A occurred 
throughout the sagittal plane of the embryo. Staining was observed in several 
tissues and cell types. Staining was observed in the mesenchymal tissue of 
craniofacial dermal layer (Figure 3.9 A and B), hypertrophic chondrocytes within 
the humerus (Figure 3.9 C), articular chondrocytes of the elbow (Figure 3.9 D), 
mesenchymal tissue of the dorsal dermal layer (Figure 3.9 E) and chondrocytes of 
the ribs (Figure 3.9 F), articular chondrocytes of the hip (Figure 3.9 G), hypertrophic 
Founder Whole mount staining intensity Staining localisation 
Intensity of local 
staining 
A ++++++ Subdermal globally, absent in distal phalanx +++++ 
B +++ Punctate superficial staining globally. Nares, +++ 
C ++ Nasal bone primordium, nares ++++ 
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chondrocytes within the hind limb (Figure 3.9 H) and fibroblastic tissue of the 
ligament/tendon attachment sites in the hind paw (Figure 3.9 I) 
 
 
Figure 3.9: Histological section images of X-gal stained-198Hsp68LacZ E15.5 founder 
A. Strong X-gal staining was observed in a variety of tissues and cell types. Intense staining 
was observed within the reticular layer of the dermis, as demonstrated in the craniofacial 
(A) and dorsal (E) regions. The tissue surrounding the vibrissae follicles (B) also stained 
within the cranium. Staining occurred in several chondrocyte subpopulations including the 
hypertrophic cells of the humerus (C), ribs (F) in addition to the tibia and fibula (H). Articular 
chondrocytes of the elbow (D) and hip (G) also exhibited blue staining. Fibroblastic activity 
was also observed within ligamentous tissue, such as within the hind paw (I). 
 
Strong X-gal staining was also observed within sub-populations of chondrocytes; 
however not all chondrocytes were X-gal stained. Staining within tissue undergoing 
endochondral ossification was stratified in line with the differentiation state of the 
chondrocytes. This was clearly illustrated within the humerus (Figure 3.9 C) and 
the tibia and fibula of the hind limb (Figure 3.9 F). Proliferative chondrocytes of the 
resting zone were negative for staining, whereas hypertrophic chondrocytes in 
proximity to the primary ossification centre exhibited strong X-gal staining. 
Osteoblastic cells within the ossification centre were not stained; therefore within 
endochondral tissue, lacZ expression was restricted to the hypertrophic 
hip 
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chondrocytes. Transgene expression was also observed within the articular 
chondrocytes of the elbow, hip and knee (Figures 3.9 D, G and H). Chondrocytes 
within the rib (Figure 3.9 E and F) also demonstrated strong X-gal staining. 
 
The staining pattern observed within embryo A was not observed in histological 
sections of embryo B (Figure 3.10 A-C) or embryo C (Figure 3.10 D-G). Neither of 
these embryos demonstrated clear chondrocyte based X-gal staining. There was 
negligible staining within endochondral tissue within embryo C with single blue 
chondrocytes in a field of view (black arrow, Figure 3.10 E). Neither embryo 
displayed clear staining of any given cell type or tissue on a global scale. 
 
 
Figure 3.10: Representative histological samples from X-gal stained-198Hsp68LacZ 
E15.5 B and C. Sparse positive X-gal staining was observed in embryo B (A-C) with 
representative sections from the cranium (A), rib (B) and distal forelimb (C). Weak staining 
was also observed within embryo C such as near the nasal cavity (D), scapula (E), cervical 
vertebrae (F) and caudal vertebrae (G).  
 
Within embryo B, the strongest X-gal staining occurred in line with ligamentous and 
tendinous tissue. The strongest staining in embryo C was observed within the nasal 
craniofacial region, whole mount staining suggested that this could have occurred 
in the primordial nasal cartilage, however sectioning revealed that the X-gal stained 
cells did not have chondrocyte morphology, with the chondrocytes of the primordial 
nasal septum negative for staining (Figure 3.10 D). Staining in this tissue was more 
closely allied with the localisation of the serous glands of nasal cavity.  
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3.2.5 -230kb functions in osseous tissue in development and adulthood 
 
The putative enhancer located -230kb upstream of Ccn2 was also examined using 
transgenic mice harbouring the enhancer driving expression of lacZ via an Hsp68 
promoter (-230Hsp68LacZ). Rather than transient assessment of function in F0, 
founders were left to develop to adulthood, with assessment of E15.5 transgene 
activity in F1 or F2. The activity of the -230Hsp68LacZ construct at E15.5 was 
assessed in lines of four founders which were genotyped as containing the 
transgene, as detailed in Table 3.5. Tissue samples were not available to assess 
enhancer function in adulthood for Founder A.  
 
Founder Whole mount staining intensity Staining localisation 
Intensity of local 
staining 
A +++++ 
Tissue subject to 
ossification- Frontal 
cranium, limbs; not as 
strongly in paws, 
vertebrate, ribs, tail 
+++++ 
B +++ 
Cranium; frontal bone 
region, nasal septum, 
inter-parietal and ex-
occipital region. Spine. 
Sparse staining within 
paws 
Cranium ++++ paws 
++ 
C - Negative for staining - 
D - Negative for staining - 
 
Table 3.5: X-gal staining localisation and intensity in E15.5 transgenic embryos 
containing the -230kbHsp68LacZ construct. Staining intensity (+ is negligible, ++ diffuse, 
+++ moderate, ++++strong, +++++intense). There was no staining in any E15.5 embryos 
from founders C and D. Cranial staining was observed in all X-gal positive embryos.  
 
Whole mount images of positively stained embryos are depicted in Figure 3.11.  
 
Figure 3.11: Whole mount imaging of X-gal stained -230kbHsp68LacZ E15.5 embryos. 
E15.5 originating from founder A (A) exhibited intense whole mount staining, soft tissue 
clearing (A2) revealed strong staining of skeletal elements such as the cranium, ribs and 
limb. The staining of E15.5 from founder B was strongest in the cranium (B).  
 
145 
From the whole mount imaging of embryos derived from founder A, it was assumed 
that stained had occurred throughout the tissues which were X-gal positive. This 
was disproved upon histological sectioning with the observation that staining of 
skeletal elements was confined to the periosteum in regions including the orbital 
plate of the frontal bone (Figure 3.12 A), rib (Figure 3.12 C), and tibia and fibula of 
the hind limb (Figure 3.12 F).  
 
Figure 3.12: Representative histological section images of X-gal stained E15.5 
progeny of -230kbHsp68LacZ founder A. Potent β-galactosidase activity was observed 
within osseous tissue. Periosteal tissue exhibited the greatest intensity of staining. Strong 
staining was observed in the frontal bone (A), mandible (B) and ribs (C). The costal cartilage 
(D) was devoid of staining, as was the endochondral cartilage of the digits (E). Further 
potent expression was observed within the periosteum of the tibia and fibula (F), contrasting 
sparse staining within the intervertebral disc (G).  
 
The costal cartilage was negative for staining, with blue positive staining confined 
to the portion of the rib that undergoes ossification. This was also illustrated in the 
mandible (Figure 3.12 B) with intense staining of osteoblastic cells, surrounding the 
Meckel’s cartilage which was negative for X-gal activity. LacZ activity was observed 
in primitive skeletal tissues undergoing both intramembranous and endochondral 
ossification processes. The chondrocytes of the endochondral anlage such as in 
heart 
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the tibia and fibula of the hind limb (Figure 3.12 F) were negative for X-gal activity 
further reinforcing the osteoblastic based expression of the transgene in this tissue. 
However, there was some limited staining of cartilaginous tissue such as within the 
intervertebral disc of the caudal vertebrae (Figure 3.12 G), in addition to sparse 
staining within the chondrocranium. Staining was also observed within fibroblastic 
cells of the reticular layer of the dermis (Figure 3.12 C) and at tendon and ligament 
attachment sites, such as in the paw (arrowhead, Figure 3.12 E). Soft tissue cleared 
embryo (Figure 3.11 A2) demonstrated staining of the umbilicus region, sectioning 
revealed that this originated from the lumen of the mid-gut loop (Figure 3.12 B).  
 
This expression pattern was not recapitulated in the E15.5 embryos stemming from 
founder B (Figure 3.13).  
 
 
Figure 3.13: Representative histological section images of X-gal stained E15.5 
progeny of 230Hsp68LacZ founder B. Few regions of blue X-gal stained cells were 
observed, predominantly occurring in the brain (A and B) in addition to the nervous tissue 
within the spine (C). Weak staining occurred within musculoskeletal tissues such as 
negligible chondrocytes staining (black arrow, D) and within the paw (E). There was no 
staining within osseous tissue. 
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Whilst the progeny from founder C did not exhibit transgene activity at E15.5, X-gal 
staining was observed postnatally. Firstly, at postnatal day seven (P7) β-
galactosidase activity occurred within skeletal tissue alone. This staining was not 
in an intense manner, and was present within discrete areas of osseous tissue. Soft 
tissue clearing enabled this to be visualised more efficiently whole mount (Figure 
3.14)  
 
 
Figure 3.14: Whole mount imaging of soft tissue cleared X-gal stained progeny of P7 
-230Hsp68lacZ founder C. X-gal staining only occurred in osseous tissues such as the 
cranium (A), sternebrae (B), thoracic vertebrae and dorsal portion of the ribs (C), forelimb 
(D) , in addition to the pelvis and hind limb (E). Within these tissues, staining was discrete 
yet with heterogeneous distribution, with strongest staining in the vicinity of the ends of the 
bones in a band-like pattern such as within the femur and tibia (arrows, E).  
 
Within the skull, punctate staining was observed in the temporal region, contrasting 
the more intense blue staining of the frontal, nasal, maxillary and mandible bones 
(Figure 3.14 A). Within other osseous tissues, staining occurred proximal to the 
epiphysis, with weaker staining towards the diaphysis where there was negligible 
LacZ activity, for example within the radius and ulna (arrow Figure 3.14 D). Staining 
was not observed within cartilaginous tissues such as the xiphoid, articular joint 
surfaces of the elbow (Fig. 3.14D), knee (Fig. 3.14E) or hip (Fig. 3.14E). The 
specificity of staining to osseous tissue as oppose to cartilaginous tissue was 
exemplified in ribs (B) where the costal cartilage was negative for staining, whereas 
osseous tissues of the sternebrae and dorsal portion of the ribs (Fig. 3.14C) were 
positive. Histological sectioning allowed further refinement of the cells and tissues 
in which the transgene was active (Figure 3.15).  
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Figure 3.15: Representative histological sectioning images from P7 progeny of 
founder C of the -230Hsp68LacZ transgenic line. There was no transgene activity in any 
cartilaginous tissues such as the costal cartilage (A), or articular cartilage of the hip (B) or 
tail (E). Chondrocytes of growth plates were also negative for staining such as within the 
distal tibia (C). However, blue X-gal positive cells were observed in metaphyseal osseous 
tissue in close proximity to endochondral ossification fronts (black arrows) globally such as 
within the sternebrae (A), lesser trochanter of the femur (B) and phalanx (D).  
 
Transgene activity in F1 of founder C was also detected at six weeks of age, as 
shown in whole mount imaging in Figure 3.16. Six weeks was used as a time point 
due to fiscal limitations due to the costs associated with propagating the line for 
longer. 
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Figure 3.16: Whole mount images of X-gal stained six week old progeny from founder 
C of the -230Hsp68LacZ transgenic mouse line. Positive blue staining was observed 
within many skeletal elements such as; the cranium (A), sternebrae and ribs (B), vertebrae 
(C), femoral trochanter (D), tibia (E) and tail (F). More specifically, staining occurred within 
the metaphyseal and epiphyseal regions of bones.  
 
As at P7, staining of tissue from mice aged six weeks occurred in osseous tissue 
and was observed in both whole mount staining and histological sectioning of 
tissues (Figure 3.16 and 3.17 respectively). This contrasted wild-type littermates 
that were negative for staining (data not shown). Within the cranium, staining was 
not observed globally with punctate staining within the nasal bone and maxillary 
(Figure 3.16 A). Cartilaginous elements such as the costal cartilage (Figure 3.16 B, 
Figure 3.17 C), intervertebral discs (Figure 3.16 C and F, Figure 3.17 B and D), and 
articular cartilage of the femoral head (Figure 3.16 D) and femoral condyles (Figure 
3.16 E) were negative for β-galactosidase activity. However, X-gal staining was 
observed in close proximity to the cartilage of the epiphyseal plates, for example at 
the greater trochanter of the femur (Figure 3.16 D) and tibial plateau (Figure 3.16 
F, Figure 3.17 C). The intensity of staining was reduced as proximity to the growth 
plate decreased; clearly demonstrated in the tibia (Figure 3.16 E, Figure 3.17 C), 
with dark blue staining observed at the metaphysis and loss of staining towards the 
diaphysis.  
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Figure 3.17: Histological section images of x-gal stained six week old offspring of 
founder C of the -230Hsp68LacZ transgenic mouse line. Chondrocytes were negative 
for any positive staining such as within the costal cartilage (A), thoracic vertebrae (B), 
articular cartilage of the knee (C) and intervertebral disc (IVD) (D). Transgene activity was 
observed within osteoblasts the primary spongiosa in close proximity to epiphyseal plates 
within the rib (A), proximal tibial growth plate (C) and tail (D).  
 
LacZ expression was assessed in F1 offspring of founder C at four months, and in 
founder C at six months of age. There was no X-gal staining of any tissue at these 
time points, as represented in whole mount images of founder C at six months 
(Figure 3.18). Regions that had stained at six weeks during postnatal bone growth 
in F1 progeny were negative for transgene activity at this later time point; such as 
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in the rib (Figure 3.18 A), thoracic vertebrae (Figure 3.18 B), or caudal vertebrae 
(Figure 3.18 E).  
 
 
Figure 3.18: Whole mount images of X-gal stained -230Hsp68lacZ founder C aged six 
months. Blue staining was not observed in any tissue including the musculoskeletal 
system, as demonstrated in the ribs (A), thoracic vertebrae (B), hip (C) knee (D) and tail 
(E).  
 
A Summary of the patterns in X-gal staining results for -230kb line variants is 
detailed in Table 3.6.  
 
Founder Time-point Staining localisation 
A E15.5 
Tissue subject to ossification- Frontal cranium, 
limbs; not as strongly in paws, vertebrate, ribs, 
tail 
B E15.5 
Cranium; frontal bone region, nasal septum, 
inter-parietal and ex-occipital region. Spine. 
Sparse staining within paws 
C 
E15.5  Negative for staining 
P7 Osseous tissue; epiphysis of tissue that develops through endochondral ossification 
Six weeks Osseous tissue; epiphysis of tissue that develops through endochondral ossification 
Four months Negative for staining 
D E15.5  Negative for staining 
 
Table 3.6: Table 3.6: summary of LacZ expression patterns driven by the -230kb 
enhancer across four variants of the -230Hsp68lacZ line. Expression within osseous 
tissue was common between founders A and C, albeit the prevalence of expression varied 
between the lines, with expression in A being strong at E15.5, whereas for the line derived 
from founder C, expression was greatest in the early postnatal period.  
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3.3 -148kb functions in founder embryos 
 
The putative enhancer located -148kb upstream of Ccn2 (Figure 3.1) exhibited 
strong function within chondrocytes and so function of this enhancer was 
scrutinised in greater detail than for the other enhancer regions. Assay of β-
galactosidase expression was carried out in both founder and stable line 
(CTGF148) mice at several time points. The findings for this enhancer are arranged 
in order of developmental chronology, but the E15.5 time-point was characterised 
first, which led to the decision to further scrutinise a wider range of time-points. 
Unfortunately this process could not be carried out for the other enhancers owing 
to fiscal and time constraints.  
 
3.3.1 -148kb functions at E11.5 in founders  
 
Assessment of the -148kb enhancer to drive the expression of lacZ at E11.5 was 
carried out using X-gal staining. E11.5 was chosen as it precedes chondrogenesis, 
and would therefore aid assessment of chondrocyte based enhancer function, and 
the timing involved in this. A total of seven embryos were positively X-gal stained. 
A total of nine embryos were found to have the construct within their genome upon 
genotyping of placental samples. Transgene activity varied in each positive 
embryo, as detailed in the whole mount images of Figure 3.19. Some of the 
embryos gathered in this process (Fig. 3.19B, E and G) exhibited developmental 
delay and resembled embryonic day 8.5-9.5 (E8.5-E9.5) time-point more closely 
than E11.5. This made histological sectioning and comparisons of tissue specificity 
in transgene activity more difficult. The strong transgene activity within embryo C 
was reaffirmed upon histological sectioning, with staining of somitic tissue (Figure 
3.20).  
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Figure 3.19: X-gal staining of E11.5 F0 -148kbHsp69LacZ transgenic mice. X-gal 
staining occurred in several tissues across several founders. Staining of caudal elements 
occurred in all embryos. There was a developmental delay in embryos B, E and G, which 
more closely resemble E9.5 embryos.  
 
 
 
Figure 3.20: Histological sectioning of positively stained founders C and E E11.5 
embryos harbouring the -148kbHsp68LacZ construct. Staining of the somites of embryo 
C was confirmed upon histological sectioning, with strong staining of the tissue throughout 
the sagittal plane of the embryo (A). The sectioning of Embryo E (B) was punctate across 
the embryo, the developmental delay made it difficult to compare the tissues in which 
transgene activity was observed.  
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3.3.2 -148kb functions at E15.5 in founders  
 
Founder embryos were also used to assay the ability of the -148kb enhancer to 
drive expression at E15.5. This work was carried out by Dr Ian Li. Three embryos 
exhibited positive X-gal staining and were imaged (Figure 3.21), with localisation of 
transgene activity recorded in Table 3.7 
 
 
Figure 3.21: Whole mount imaging of founder E15.5 harbouring the -148kbHsp68LacZ 
construct. Each positive embryo had a different pattern of staining. The ribs and maxillary 
region stained in all positive F0. Staining within the limb also occurred within all three 
founders albeit with differential intensity. 
 
 
Table 3.7: X-gal staining and localisation in -148kbHsp68LacZ transgenic founder 
E15.5. Staining intensity (+ is negligible, ++ diffuse, +++ moderate, ++++strong, 
+++++intense). Skeletal elements were commonly stained between each founder.  
 
Activity within chondrocytes was observed upon sectioning of all three embryos, 
albeit in slightly different sub-populations of chondrocytes. There was staining of 
pre-hypertrophic and hypertrophic chondrocytes in all three embryos, with this 
being most clearly observed in founder A. There was staining of the interzone of 
articular joints in Founders B and C such as the elbow of founder C and future joint 
between basioccipital and vertebral atlas and elbow (Figures 3.22 C and E 
respectively). Further mesenchymal transgene activity was observed in all three 
embryos such as surrounding the eye of founder C (Figure 3.22 F). Tissue of the 
dorsal root ganglion was also positive for transgene activity in Embryo B (Figures 
3.22 C and D).  
 
 
Founder Whole mount staining intensity Staining localisation 
Intensity of local 
staining 
A +++ Cranium, ribs, limbs ++++ 
B + Maxillary, ribs, limbs +++ 
C ++ Eye, mouth, ribs, wrist, ankle ++++ 
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Figure 3.22: Representative histological sections of -148kbHsp68LacZ transgenic 
founder E15.5. Staining of Embryo A (A and B) occurred most prominently within pre-
hypertrophic and hypertrophic chondrocytes, such as within the humerus (B). 
Perichondrium/periosteum also exhibited modest transgene activity in Embryo A, such as 
within the mandible (A). There was punctate chondrocyte staining within Embryo B (C-E) 
within structures such as the vertebrae (C), ribs (D) and tail (E). Pre-hypertrophic 
chondrocytes were also positively stained within Embryo C (F-I), including within the ribs 
(arrows, G), humerus (H) and femur (I). Further transgene activity was most notable within 
the mesenchyme surrounding the eye (F).  
 
The clearest demonstration of hypertrophic chondrocyte expression was observed 
within the limbs of founder A (Figure  3.22 B). There was an absence of transgene 
activity within the chondrocytes of the resting and proliferative zones, but strong 
elbow
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staining of pre-hypertrophic zones of the growth plate such as in the humerus 
(Figure  3.22 B). Osteoblasts within the primary ossification centre were not X-gal 
stained. Weak staining of the perichondrium and periosteum was also observed 
such as within the mandible and ribs (Figure 3.22 A and B).  
 
3.4 LacZ expression occurred at several time points in a stable -148kb 
transgenic mouse line 
 
After preliminary assessment of activity within founders, a stable transgenic line 
(CTGF148) was propagated from a male founder (F0 4.3), which was crossed with 
a wild-type B6CBAF1/J female. Because of the creation of this line, enhancer 
function was tested at more time-points than for the other enhancers. The 
expression of the LacZ reporter gene was observed using X-gal staining of tissues 
at several time points during embryonic development and beyond. 
 
3.4.1 -148kb functions at E11.5 in CTGF148  
 
Transgene expression within the CTGF148 line was firstly assayed at E11.5, as 
illustrated in whole mount images in Figure 3.23. After only two hours (2hr) of 
exposure to the X-gal substrate, staining was observed in a punctate and superficial 
manner across embryos, this pattern was much richer after overnight staining with 
deep blue colour in embryos (Figure 3.23) 
 
 
Figure 3.23: Representative whole mount imaging of an X-gal stained E11.5 embryo 
from the CTGF148 line. After two hours, staining occurred in a punctate, superficial 
manner globally, tallying with vascular localisation. Further staining was also visible in the 
heart. This staining pattern intensified after overnight incubation.  
 
Histological sectioning of these embryos reinforced the observation from whole 
mount imaging that positive X-gal staining most prominently occurred in the 
vasculature. Throughout each embryo, erythrocytes were observed within 
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branched blue stained blood vessels. This was well demonstrated in the superficial 
superior cranium (Figure 3.24 A). Potent transgene activity was observed 
throughout the sagittal plane of the heart, for example within the branchial arch and 
primordial tissues of both ventricles and atria (Figure 3.24 B).  
 
 
Figure 3.24: Representative histological sectioning of CTGF148 E11.5 embryos. 
Vascular localisation of staining was prominent, with erythrocytes visible within stained 
structures. This occurred within the superficial surface of the cranium (A) and trunk (C). 
Strong blue staining was observed within the heart, particularly within the branchial arch 
and lining of the atria (B).  
 
Further transgene activity was also observed within the distal edges of the limb 
buds (Figure 3.24 B). However, there was no staining within the primitive 
mesenchymal tissue within the limb bud Figure 3.24 B). The somites were negative 
for staining, but vasculature surrounding them was positive (Figure 3.24C). 
 
3.4.2 -148kb is active at E12.5 in CTGF148  
 
Transgene activity within the CTGF148 line was assessed as E12.5. After overnight 
X-gal staining, strong positive staining was observed across embryos in whole 
mount embryos, as demonstrated in Figure 3.25. Staining predominantly occurred 
in a superficial manner, with blue staining co-localising with blood vessel structures. 
Rich transgene activity was also observed in the limbs and tail, with dark blue 
staining of the distal surfaces of the primitive fore and hind paws.  
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Figure 3.25: Representative whole mount imaging of CTGF148 transgenic mice at 
E12.5 after overnight X-gal staining. Strong β-galactosidase activity was observed 
globally, mostly in a superficial manner, for example, staining was not clearly observed 
within the primitive skeletal anlage.  
 
The pattern of whole mount staining was similar to that observed at E11.5. This 
was also true upon histological sectioning. Blue staining was most prominent within 
the superficial vasculature, with rich blue pigmentation of blood vessel structures 
encasing erythrocytes such as in the tail (Fig. 3.26 B). Staining was also observed 
within the heart; however this was weaker compared to staining at E11.5 (Figure 
3.26), within the endocardial cushions and cells lining the ventricles exhibiting 
positive staining. (Fig. 3.26 B and C).  
 
Further staining was also observed within primitive cartilaginous tissue. Positively 
staining chondrocytes were most abundant in the parachordal cartilage of the 
chondrocranium (Fig. 3.26 A), in addition to the proximal forelimb (Fig. 3.26 D). 
Positively stained cells within these structures were distributed in a mosaic-like 
manner. This diffuse manner of staining was also observed in the primitive vertebral 
column, albeit to a much lesser extent.  
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Figure 3.26: Histological sectioning representative of X-gal stained E12.5 from the 
CTGF148 line. Staining occurred most prominently within superficial vascular structures 
including within the tail (B) and dorsal dermis (C). Further vascular-related transgene activity 
occurred within the heart (arrows, B and C). Blue positive cells were also observed within 
the primitive cartilaginous condensations of the chondrocranium (arrow, A) and scapula (D).  
 
3.4.3 -148kb functions at E13.5 in CTGF148  
 
Transgene expression within the CTFG148 line was also assayed at E13.5. Whole 
mount imaging was conducted after two hours of X-gal staining, in addition to 
overnight staining (as illustrated in Figure 3.27). The strongest β-galactosidase 
activity was detected in the cartilaginous anlage of the skeleton, occurring within 
the limbs after only two hours of staining.  
heart 
Future 
rib 
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Figure 3.27: Whole mount images of a typical X-gal stained CTGF148 E13.5 embryo 
at varying staining durations. After two hours of staining, prominent transgene activity 
was observed within the limbs, caudal vertebrae and nasal bone primordia tallying with the 
localisation of endochondral cartilage anlage.  
 
After overnight staining incubation, staining was observed in regions corresponding 
to cartilaginous tissue across each embryo. Additional albeit weak staining was 
observed in a more superficial manner at the distal edges of the primitive fore and 
hind paws. This contrasts the potent superficial staining that was seen at E11.5 
(Figure 3.23). These observations were reaffirmed upon histological sectioning of 
the embryos (Figure 3.28). 
 
Chondrocytes exhibited strong β-galactosidase activity in every cartilaginous 
element, such as within the Meckel’s cartilage (Fig. 3.28 A), ribs and vertebrae (Fig. 
3.26 B) and future long bones including the tibia and fibula (Fig. 3.28 D).  
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Figure 3.28: Representative histological sections of X-gal stained CTGF148 E13.5 
embryos. The most significant positive X-gal staining of cells occurred observed within 
cartilaginous tissues, including the Meckel’s cartilage (arrow, A) and chondrocranium (A), 
vertebrae and ribs (B) and limb such as in the primitive tibia and fibula (D). Faint staining 
was also observed within the atria of the heart (C). 
 
The strong X-gal staining observed within vascular elements at E11.5 and E12.5 
(Figures 3.24 and 3.26 respectively) was not repeated at E13.5. This was most 
notably observed in the heart (Figure 3.26 C), where staining was present in the 
atria. Superficial staining of the vasculature as seen at E11.5 was much decreased 
at E13.5. Additional staining was also observed within the brain (Figure 3.28 A) and 
lung (arrow, Figure 3.28 B). 
 
3.4.4 -148kb functions at E15.5 in CTGF148  
 
The capacity of -148kb to drive the expression of lacZ in CTGF148 was examined 
at E15.5. Strong expression of the transgene was observed in a cartilage specific 
manner, as demonstrated in Figures 3.27 and 3.28. Potent β-galactosidase activity 
was demonstrated after a short duration of X-gal staining (2 hr, Figure 3.29). Upon 
this initial stage of imaging, strong blue staining was observed within all limbs and 
each primordial skeletal element within. Further staining was also observed within 
the chondrocranium and ribs.  
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Figure 3.29: Whole mount imaging of X-gal stained E15.5 embryos from the CTGF148 
line at varying stain durations. Strong blue staining was observed within the limbs and 
tail after two hours of staining, with weaker staining observed within the chondrocranium 
and ribs. After overnight staining, cartilaginous tissue has stained intensely on a global 
scale. This was highlighted by soft tissue clearing of overnight stained embryos, which 
demonstrated intense staining of every cartilaginous structure. 
 
Embryos were re-imaged after overnight staining incubation (overnight, Figure 
3.29). The staining pattern occurred in the same locations as at two hours, however 
staining was much more intense than after two hours. Embryos were then cleared 
to remove soft tissue before further imaging (cleared, Figure 3.29). Every 
cartilaginous tissue within the embryos exhibited potent β-galactosidase activity. 
Osseous tissues that arise through intramembranous ossification such as the 
frontal and parietal bones of the cranium were negative for staining.  
 
Histological sectioning of embryos further reinforced the observation of intense 
cartilaginous staining, as illustrated in Figure 3.30. Moreover, staining was confined 
to chondrocyte cells within positive tissues. Soft tissue structures such as the eye 
(Figure 3.30 D) did not contain positively stained blue cells. There was no staining 
of cardiac tissue as seen at E11.5, E12.5 and E13.5, as shown in the heart (Figure 
3.30 H) in which there were no transgene positive cells.  
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Figure 3.30: Representative histological sections from CTGF148 E15.5 embryos. 
Staining occurred in chondrocyte cells throughout the sagittal plane of embryos. Hyaline 
cartilage anlage of the exoccipital bone (arrow, A), parietal (C), scapula (E), humerus, radius 
and ulna (F), ribs (G and H), hind paw (J) and tail (K) bones all exhibited strong transgene 
activity. Further cartilaginous β-galactosidase activity was observed within the Meckel’s 
cartilage (B) and intervertebral disc (K). Soft tissue elements such as the eye (D), heart (H) 
and mid-gut loop (I) were all negative for staining. 
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Sectioning revealed that not every chondrocyte demonstrated intense staining. For 
example, the frontal portion of the ribs (Fig. 3.30H) contained β-galactosidase 
positive cells, but this was not homogenous across each rib structure, with punctate 
staining pattern of cells within some ribs. This was echoed in the shoulder joint (Fig. 
3.30E), where more diffuse staining was observed in the resting zone of 
chondrocytes near to the shoulder joint, with greater proportion of positive cells in 
more mature chondrocytes, towards the future bone diaphysis of the humerus and 
centre of the scapula.  
 
3.4.5 -148kb is active at E17.5 in CTGF148  
 
Transgene expression driven by the -148kb enhancer within the CTGF148 line was 
also examined at E17.5. The most potent β-galactosidase activity occurred within 
tissue undergoing endochondral ossification, including the scapula (Figure 3.31 B), 
humerus (Figure 3.31 C), ribs (Figure 3.31 D) sternebrae (Figure 3.31F), femur, 
tibia and fibula of the hind limb (Figures 3.31 G and H) and phalanx (Figure 3.31I). 
Unlike the staining of cartilage that occurred at E15.5, there was heterogeneity in 
the extent of staining observed within endochondral tissue. Moreover, this occurred 
in line with the differentiation state of chondrocytes; blue X-gal staining intensity 
was depleted with increasing proximity to the primary ossification centre 
(ossification centres are marked with arrowheads across Figure 3.29). Further 
chondrocyte based transgene activity also occurred within the chondrocranium 
(Figure 3.31 A) and xiphoid (Figure 3.31 E).  
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Figure 3.31: Representative histological sections from E17.5 CTGF148 embryos. The 
most profound transgene activity was observed within the chondrocytes of cartilaginous 
tissue, such as within the chondrocranium (A), scapula (B), humerus (C), ribs (D), xiphoid 
(E), sternebrae (F), hind limb (G and H) and hind paw (I). However, the distribution of 
staining of chondrocytes occurred in a heterogeneous manner across cartilage, with richer 
transgene activity in distal location from ossification centres. This was most strikingly 
observed in the humerus (C) and femur and tibia (H). Ossification centres are highlighted 
with arrows.  
 
3.4.6 CTGF148 mice exhibit β-galactosidase activity in early adulthood  
 
Mice from the CTGF148 line were taken for tissue in early adulthood at nine weeks 
of age. Staining for β-galactosidase activity revealed strong transgene expression 
within cartilaginous structures, as demonstrated in whole mount imaging of soft 
tissue cleared skeletal structures (Figure 3.32).  
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Figure 3.32: Representative whole mount imaging of soft tissue cleared, X-gal 
stained nine week old CTGF148 mice. Cartilage structures demonstrated strong global 
staining (A). This included the trachea (B), costal cartilage (E) in addition to the articular 
surfaces of the hip (G) and knee (H) joints. Growth plate cartilage also exhibited strong 
staining within the wrist, thoracic vertebrae (D) femur and tibia (H) and caudal vertebrae (I). 
The fibrocartilage of the intervertebral disc also exhibited transgene expression. 
 
The chondrocyte-specific nature of β-galactosidase activity at this time-point was 
reinforced upon histological sectioning, which revealed staining predominantly 
within hyaline cartilage structures such as the costal cartilage (Figure 3.33 A), 
articular cartilage of the vertebral endplates (Figure 3.33 B), femoral head (Figure 
3.33 C) knee (Figure 3.33 D); in addition to the epiphyseal growth plate such as 
within the tibia (Figure 3.33 D). The transgene was also active in fibrocartilage 
structures including the annulus fibrosus of the intervertebral discs (Figure 3.33 B) 
and knee meniscus (arrow, Figure 3.33 D). There was an absence of staining within 
osseous structures on a global scale, with cartilaginous growth plates the only 
location within bones where positive X-gal staining occurred. 
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Figure 3.33: Histological sections of X-gal stained CTGF148 mouse at nine weeks of 
age Transgene activity exclusively occurred within chondrocytes. Hyaline cartilage of the 
costal cartilage (A), articular cartilage of the femoral head (C) and knee (D) and epiphyseal 
plates globally all exhibited positive staining. Further chondrocyte based transgene activity 
was observed within the fibrocartilage of the intervertebral disc such as within the annulus 
fibrosus of the thoracic vertebrae (B) and tail (E). 
 
meniscus 
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3.4.7 -148kb drives transgene activity during mature adulthood in CTGF148 
mice  
 
Transgene function within the CTFG148 line was also tested in mature adulthood 
at approximately five months of age. Whole mount imaging of X-gal stained tissue 
revealed cartilage specific staining (Figure 3.34). 
 
 
Figure 3.34: Whole mount imaging of X-gal stained CTGF148 mice at five months of 
age. Staining was observed within many structures composed of hyaline cartilage, such as 
the trachea (A), costal cartilage (C) and femoral head and knee articular cartilage (D and E 
respectively). Further cartilaginous transgene activity was observed within the intervertebral 
disc (B and F).  
 
Strong staining of hyaline cartilage occurred throughout the animal, within 
structures including the trachea (Figure 3.34 A and Figure 3.3 5A), costal cartilage 
(Figure 3.34 C) articular joint surfaces of the femoral head (Figure 3.34 D and 
Figure 3.35 B) knee (Figure 3.34 E and Figure 3.35 D and E), in addition to the 
vertebral endplate of the thoracic and tail vertebrae (Figures 3.34 B and F, Figure 
3.35 C). The staining observed both in whole mount and histological sectioning was 
weaker at this time-point than in early adulthood (Figure 3.32). For example, 
staining of the femoral head was more punctate in mature adulthood, with few blue 
articular chondrocytes in histological sections (Figure 3.35 B).  
 
 
 
169 
  
Figure 3.35: Histological sectioning of X-gal stained tissue from five month old 
CTGF148 mouse. Staining was observed in a chondrocyte specific manner. Punctate 
distribution of staining was observed within chondrocytes of hyaline cartilage within the 
trachea (A), in addition to growth plate and articular surfaces of the femoral head (B), femur 
(D) and tibia (E). The fibrocartilage structure of the nucleolus pulposus of the intervertebral 
disc (C) also exhibited transgene activity. 
 
3.5 A truncated version of -148kb functions in embryonic development 
and adulthood  
 
A reductionist approach was used in order examine the sequence required for -
148kb enhancer function. Upon visualisation of the enhancer in the UCSC Genome 
Browser (Figure 3.36), peaks for enhancer associated chromatin attributes (Figure 
3.36 C) and conservation of the sequence (Figure 3.36 D) are split into two sub-
regions. A ScaI restriction enzyme site between these two peak areas was used to 
cut the -148kbHsp68LacZ construct (red dashed line, Figure 3.36). This created 
the -148kb_short construct (Figure 3.36 A) which encompassed the 3’ 1529bp 
sequence of the enhancer. Transgenic mice were created as outlined previously, 
with the resultant line being named -148kb_short.   
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Figure 3.36: Visualisation of the sequences used to create the -148kb_short transgenic mouse line. The full -148kb sequence (B) of the -148kbHsp68LacZ 
construct was cut (red dashed line) on the basis of a split between peaks for enhancer associated chromatin attributes (C) and sequence conservation (D). This 
created the -148kb_short construct used to create the -148kb_short line.  
  
A 
B 
C 
D 
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Mice were genotyped upon weaning with a total of five founders positive for the 
transgenic construct. Staining for β-galactosidase activity was conducted on F0 and 
F1 mice originating from each founder. For the generation of F1, founders were 
crossed with wild-type littermates. Line variants originated from each founder A-E, 
and are denoted accordingly; i.e. -148kb_short A denotes tissue from founder A, or 
its progeny. 
 
3.5.1 -148kb_short drives transgene activity at E15.5  
 
The capacity of the -148kb_short construct to drive the expression of LacZ was first 
examined at E15.5 for each of the F0 variants of the transgenic mice. Whole mount 
examination of X-gal stained embryos was carried out, with results recorded in 
Table 3.8, with representative images in Figure 3.37.  
 
Table 3.8: Whole mount image staining intensity of -148kb_short E15.5 that were 
positive for X-gal staining. Staining intensity (+ is negligible, ++ diffuse, +++ moderate, 
++++strong, +++++intense). The embryos in two transgenic line variants exhibited intense 
global staining. 
 
Embryos from founders A and D (Figures 3.37 A and D respectively) exhibited 
intense blue X-gal staining across the whole of each positive embryo, aside for one 
embryo stemming from -148kb_short A, in which intense staining only occurred in 
the cranium (Figure 3.37 A2). The main difference between embryos from these two 
founders in whole mount imaging was that the eye was positively stained for -
148kb_short D, but not A. Positive X-gal staining for E15.5 descendants from 
founders B and C was more constrained. For example, staining occurred in the 
cranium for both, yet in E15.5 of founder B staining was diffuse throughout the 
cranium (Figure 3.37 B), whereas for -148kb_short C, staining overlapped with the 
location of the frontal and parietal bones (Figure 3.37 C).  
  
Founder Whole mount staining intensity Staining localisation 
Intensity of local 
staining 
A ++++++ and +++ A1; global staining A2: cranium ++++++ 
B +++ cranium +++ 
C ++++ Cranium , ribs, limbs +++++ 
D ++++++ Global ++++++ 
E - n/a - 
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Figure 3.37: Whole mount images of X-gal stained E15.5 from stemming from four 
founder -148kb_short transgenic mice. Two patterns were observed in the embryos from 
founder A (A1 and A2). E15.5 stemming from -148kb_short A (A1) and D (D) demonstrated 
very intense global staining. E15.5 from founder B demonstrated staining within the cranium 
and midsection. Embryos from founder C exhibited staining that tallied with the parietal 
bone in the skull, ribs and diaphysis of the long bones of the limbs. 
 
No transgene activity was observed whole mount in embryos derived from founder 
E. Hence, no further examination of transgene activity was carried out for this 
founder. Histological sectioning of tissues was carried out for -148kb short_ A to D, 
enabling greater understanding of the tissue and cellular localisation of transgene 
activity. 
 
3.5.1.1 Histological examination of β-galactosidase activity in -148kb_short A 
 
The intense blue staining of E15.5 -148kb_short A in whole mount was due to 
staining within sub-dermal mesenchyme. The epidermis was devoid of staining. 
However, fibroblastic cells of the reticular layer of the dermis were positive for 
transgene activity. This was clearly visible within the mouth (Figure 3.38 A) fore 
paw (Figure 3.38 F) and dorsal region (Figure 3.38 G).  
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Figure 3.38: Representative histological sections of X-gal stained E15.5 embryos 
from derived from founder A of the -148kb_short line. Profound subdermal localisation 
of β-galactosidase activity was observed on a global scale, as demonstrated in the 
craniofacial region (A), fore paw (F) and dorsal region (G). Primitive skeletal tissues were 
largely negative for staining, for example no staining was observed within the Meckel’s 
cartilage (B). There was however, some staining of chondrocytes within the phalanges (F) 
and within the bone collar region of the radius, in addition to discrete staining surrounding 
the ribs (G). Although there was no staining within the heart (C), there was some staining 
within blood vessels, which was readily distinguishable due to the presence of erythrocytes 
(white arrows, D). Further staining occurred in the lumen of the midgut loop (E).  
 
Soft tissue organs such as the heart (Figure 3.38 C) did not demonstrate β-
galactosidase activity, although the lumen of the midgut loop was strongly positive 
for X-gal staining (Figure 3.38 E). Staining was also observed within blood vessels, 
with blue cells and tissue surrounding erythrocytes (white arrows, Figure 3.38 D). 
Transgene activity was largely absent within the musculoskeletal system, for 
example the Meckel’s cartilage and surrounding osseous material of the mandible 
were negative for any X-gal staining. However, there was limited staining the bone 
collar of the radius (Figure 3.38 D), of chondrocytes  within the phalanx of the fore 
paw (Figure 3.38 F) with some staining and periosteal region of the ribs (Figure 
3.38 G).  
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3.5.1.2 Histological examination of β-galactosidase activity in -148kb_short B  
 
The strong transgene activity within the cranium of -148kb_short B at E15.5 in 
whole imaging was echoed in histological sectioning, with blue positive stained 
tissue predominantly occurring within the mouth and nose (Figure 3.39 A). There 
was no staining within chondro-osseous structures such as the ribs (Figure 3.39 B) 
or hind limb (Figure 3.39 C).  
 
 
Figure 3.39: Representative histological section images from X-gal stained E15.5 
descended from -148kb_short founder B. X-gal staining positive cells were localised 
predominantly within the soft tissue of the cranium (A). There was an absence of staining 
within soft tissues such as the heart (B), in addition to skeletal elements such as the ribs, 
humerus (both B) or hind limb and paw (C). 
 
3.5.1.3 Histological examination of β-galactosidase activity in -148kb_short C  
 
Histological sectioning of E15.5 -148kb_short C revealed highly specific β-
galactosidase activity. There was no staining of any soft tissue organ, including the 
heart (Figure 3.40 E). Staining did not occur in chondrocytes, with cartilaginous 
structures such as the Meckel’s cartilage (Figure 3.40 B) or hind paw (Figure 3.40 
F) containing no blue, positively X-gal stained cells. Transgene activity was 
confined to the periosteal regions of osseous anlage such as within the mandible 
(Figure 3.40 B), radius (Figure 3.40 C), ribs (Figure 3.40 D) and tibia (Figure 3.40 
G).  
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Figure 3.40: Histological analysis of X-gal stained E15.5 progeny of founder C of -
148kb_short. Staining was co-localised with primitive periosteal tissue such as within the 
maxillary (A), mandible (B), fore limb (C), ribs (D) and tibia (G). Soft tissues such as the 
heart (E) were negative for staining. Further weak staining was observed within the 
vertebrae of the tail (H). 
 
3.5.1.4 Histological examination of transgene activity in -148kb_short D 
 
Transgene activity occurred in tissue of mesenchymal origin. Positively X-gal 
stained chondrocytes were present in the cartilage anlage of several bones 
including the exoccipital and atlas (Figure 3.41 A) and femur and tibia (Figure 3.41 
F). The variability of staining intensity within cartilaginous tissues is highlighted in 
the femur (Figure 3.41 F) with the proportion of blue stained cells changing with 
proximity to the diaphysis of the future long bone. In addition, other cartilaginous 
structures such as the temporal bone anlage (Figure 3.41 A) and Meckel’s cartilage 
(Figure 3.41 B) were negative for β-galactosidase activity. Transgene activity was 
also observed within the mesenchymal tissue of the reticular layer of the dermis, 
tissue surrounding the follicles of the vibrissae (Figure 3.41 B) and midgut loop 
(Figure 3.41 G).  
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Figure 3.41: Representative images of histological analysis of X-gal stained E15.5 
stemming from founder D of -148kb_short. Limited X-gal staining was observed within 
chondrocytes of future osseous tissues such as in the exoccipital bone and atlas (A), in 
addition to ribs (E), femur and tibia (F). Other cartilaginous structures including the Meckel’s 
cartilage (B) were negative for transgene activity. Strong staining occurred in the dermis, in 
addition to mesenchymal tissues, including within the sub-dermal layer such as within the 
lips (B), the hind limb (F) in addition to the mesenchyme of the primitive vibrissae follicles 
(B) and midgut herniation (G). The heart (D) and lung (E) were negative for transgene 
activity. 
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3.5.2 -148kb_short founder B exhibited negligible transgene expression in 
adulthood  
 
LacZ transgene activity was assessed in mature adulthood, at approximately five 
months for -148kb_short founder B. The only location in which transgene activity 
was observed was the heart, as demonstrated by whole mount and histological 
sectioning of the heart imaging (Figure 3.42).  
 
Figure 3.42: Whole mount images of X-gal stained tissue from -148kb_short founder 
B aged five months. Staining was observed across the surface of the heart in a 
heterogeneous manner in whole mount imaging (A) and sectioning C). 
 
3.5.3 Potent LacZ activity was observed in -148kb_short founder C in 
adulthood 
 
Staining for β-galactosidase activity was carried out on the tissue of -148kb_short 
founder C in mature adulthood at approximately six months of age. Intense staining 
was observed in several tissues, as demonstrated in Figure 3.43. Muscular tissue 
demonstrated potent transgene activity for example the intercostal (Figures 3.43 D 
and E) and gastrocnemius (Figure 3.43 G). This was not true of cardiac 
musculature, with rich X-gal staining of the atria (arrow, Figure 3.43 B), yet 
superficial staining across the heart was not in a uniform manner (Figure 3.43 C). 
Further soft tissue based transgene activity was observed in the kidney with 
punctate superficial staining. There was no clear staining of osseous or 
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cartilaginous tissue, with no blue staining of the articular surfaces of the hip or knee 
(Figures 3.43 F and G respectively).  
 
 
Figure 3.43: Whole mount images of X-gal stained tissue of founder C from -
148kb_short line at six months of age. Intense staining was observed within the 
musculature surrounding the skeletal tissue of the cranium (A), ribs (D) spine (E), hip (F), 
knee (G) and tail (I). Staining also occurred in the heart, with strong staining of the atria 
(arrow, B), further staining in patched pattern occurred across the heart (B and C). Punctate 
staining of the kidney was also observed (H).  
 
The pattern of transgene expression was reaffirmed upon histological sectioning 
(Figure 3.44).  
 
 
179 
 
Figure 3.44: Histological sectioning of X-gal stained tissue of founder C of -
148kb_short at six months of age. The most potent positive X-gal staining occurred within 
myocardium of the heart atria (A). Further cardiac staining was observed on the superficial 
surface of the heart (B), There was no staining of any cartilaginous or osseous structure 
such as within the vertebrae (C), ribs (D) the knee synovial cavity (F) or tibial growth plate 
(G). with There was rich staining of the musculature such within the intercostal muscles (C 
and D). There was further superficial staining in the kidney (E). 
 
3.5.4 -148kb_short founder D exhibited transgene activity in mature 
adulthood 
 
The activity of the β-galactosidase transgene product was assessed at mature 
adulthood (approximately six months) for -148kb_short D. Whole mount imaging 
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demonstrated striking staining co-localised with the vasculature across many 
tissues, as shown in Figure 3.45.  
 
 
Figure 3.45: X-gal stained tissue from founder D of the -148kb_short transgenic line 
at approximately six months of age. Potent β-galactosidase activity was observed within 
several tissues Transgene activity within the musculoskeletal system was most striking 
within the cranial sutures (A) but was also observed; albeit in a weak manner, within the 
caudal portion of the xiphoid process (E) and articular surfaces of the hip (H) and knee (I).. 
The most striking blue staining was confined to blood vessels such as across the surface 
of the ribs (C and D) heart (F), kidney (G) and foot (J).  
 
Further transgene activity was also recorded within musculoskeletal tissue, the 
most potent of which occurred in the cranial sutures (Figure 3.45 A). Very weak 
staining of the hyaline cartilage of the xiphoid process (Figure 3.45 E) and articular 
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cartilage of the femoral head (Figure 3.45 H) and femoral condyles (Figure 3.45 I) 
was also observed. This was visualised more effectively with histological sectioning 
of tissue (Figure 3.46).  
 
 
Figure 3.46: Representative images of histological sections of X-gal stained tissue 
from -148kb_short D in mature adulthood. Several tissues stained positively for β-
galactosidase activity at approximately six months of age. Striated staining was observed 
within the intercostal muscles (A). Sparse staining was observed within hyaline cartilage 
including the costal cartilage (A), and articular cartilage of the vertebral endplate (C), tibial 
plateau of the knee (D), and hind paw digits (F).The most prevalent staining occurred within 
the vasculature globally, this was well demonstrated within the tail vein (C), popliteal artery 
of the knee (arrow, D) and digital arteries of the hind paw (E).  
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Striated staining of the costal musculature observed in whole mount imaging 
(Figure 3.45 D) was also observed in histological sections (Figure 3.46 A). The 
staining of the kidney visualised in Figure 3.46 G was found to occur in a superficial 
manner within the cortex of the kidney (Figure 3.46 B).Staining occurred within 
chondrocytes of hyaline cartilage in a global; albeit weak, manner. There was no 
staining of osseous cells. The vascular localisation of staining was clearly observed 
within sections globally, with erythrocytes present within richly stained vessel 
structures, such as within the popliteal artery at the tibial plateau (Figure 3.46 D) 
and paw (Figure 3.46 F). There was sparse staining of chondrocytes within hyaline 
cartilage, such as within the costal cartilage (Figure 3.46 A) and the articular 
cartilage of the tibial plateau of the knee (Figure 3.46 D) and digits (Figure 3.46 F).  
 
3.6 Summary of enhancer driven reporter gene expression in vivo  
 
The compilation of information regarding the reporter gene expression patterns 
allows comparisons to be made between each of the enhancers to drive cell 
lineage-specific transgene expression. For example -102kb functioned highly 
specifically and consistently, within the vasculature whereas -148kb functioned 
most reproducibly within chondrocytes. A summary of in vivo reporter gene assays 
is outlined in Table 3.9. 
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Enhancer Timepoint Founder 
Tissue type 
Cardiovascular Musculoskeletal 
heart vasculature Cartilage Bone Skeletal muscle Hypertrophic Articular proliferative 
-4kb E15.5 
A No No No No No No No 
B No No No No No No No 
C No No No No No No No 
-102kb E15.5 
1 No Yes No No No No No 
2 No Yes No No No No No 
3 No Yes No No No No No 
4 No Yes No No No No No 
5 No Yes No No No No No 
6 No Yes No No No No No 
-137kb  E15.5 
1 No No No Yes No No No 
1 No No No Yes No No No 
3 No No No Yes No No No 
4 No No No Yes No No No 
5 No No No Yes No No No 
-148kb 
transient 
 
 
E11.5 
A No No n/a n/a n/a n/a n/a 
B No No n/a n/a n/a n/a n/a 
C No No n/a n/a n/a n/a n/a 
D No No n/a n/a n/a n/a n/a 
E No No n/a n/a n/a n/a n/a 
F No No n/a n/a n/a n/a n/a 
G No No n/a n/a n/a n/a n/a 
E15.5 
A No No Yes No No No No 
B No No Yes No No No No 
C No No No No Yes No No 
-148kb stable 
line 
E11.5 n/a Yes Yes n/a n/a n/a n/a n/a 
E12.5 n/a Yes Yes n/a n/a Yes n/a No 
E13.5 n/a Yes Yes Yes Yes Yes n/a No 
E15.5 - No No Yes Yes Yes No No 
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E17.5 - No No Yes Yes Yes No No 
Nine weeks - No No Yes Yes Yes No No 
Five months - No No Yes Yes Yes No No 
-148kb short 
E15.5 
A No Yes No No Yes No No 
B No No No No No No No 
C No No No No No Yes No 
D No No Yes No No No No 
E No No No No No No No 
Five months B Yes No No No No No No 
Six months C Yes No No No No No Yes D No Yes No Yes No No No 
-198kb E15.5 
A No No Yes Yes No No No 
B No No No No No No No 
C No No No No No No No 
-230kb 
 
 
E15.5 
A No No Yes No No Yes No 
B No No No No No No No 
C No No No No No No No 
D No No No No No No No 
P7 C No No No No No Yes Yes 
Six weeks C No No No No No Yes Yes 
Four 
months C 
No No No No No No No 
 
Table 3.9: Summary of reporter gene expression patterns driven by each of the enhancers of Ccn2. Highly reproducible expression within vascular 
endothelial cells and articular chondrocytes was observed for the -102kb and -137kb enhancers. The -148kb enhancer drove function within chondrocytes 
across several founders. Founder variants of the -148kb_short line also demonstrated chondrocyte function, this was shown in several of the founders, however 
this expression was not as consistent as expression driven by the whole enhancer. Strong transgene activity was only observed in one of the three E15.5 -
198kbHsp68LacZ embryos, limiting accuracy of transgene expression patterns driven by this enhancer.
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3.7 In vitro assay of Ccn2 enhancer function  
 
The capacity of putative enhancer regions to drive the expression of firefly 
luciferase reporter gene (luc2) was assayed in several cell types. Each enhancer 
region controlled the transcription of the reporter gene in conjunction with sequence 
corresponding to the Ccn2 promoter region. Renilla luciferase gene expression was 
recorded for each sample and used to normalise data. This minimised error due to 
discrepancies in cell number or transfection efficiency. Results were gathered from 
three independent experiments for each cell type, where each experimental 
condition was repeated with three biological replicates. The error bars in each 
graph represent standard deviation  
 
3.7.1 In vitro reporter gene expression within chondrocyte cell lines 
 
The HTB94 and TC28-i2 human chondrosarcoma derived immortalised cell lines 
were used as models for the in vitro assay of putative enhancer function within 
chondrocyte like cells. Given the precedent set from findings of in vivo reporter 
gene expression that the -137kb, -148kb and -198kb enhancers each functioned 
within chondrocyte cells (Chapter 3.2-3.6), it was expected that strong luciferase 
reporter gene would be observed in cells transfected with vectors containing these 
regions. However, this was not observed in TC28-i2 or HTB94 cells (Figures 3.47 
and 3.48 respectively).  
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Figure 3.47: Fold change in normalised expression of luciferase driven by enhancers 
relative to Ccn2 promoter in TC28-i2 cells, 24 hours after transfection. The largest 
change in luciferase production was observed for the -4kb and -255kb enhancers, however 
the average fold difference relative to the promoter was not significant due to variability in 
the data. There was a significant decrease in the amount of luciferase produced by cells 
transfected with the full -137kb enhancer relative to the promoter alone. Error bars represent 
standard deviation and * denotes significance p≤0.05 
 
In TC28i2 cells transfected with the enhancer containing luciferase expression 
vectors, the -4kb and -255kb enhancers facilitated the greatest fold change in 
luciferase expression relative to the promoter alone, however neither of these 
results was statistically significant. Surprisingly, the -148kb enhancer, which 
demonstrated strong chondrocyte related function in vivo did not drive reporter 
gene expression. The reduction in luciferase activity controlled by this element was 
not statistically significant. Interestingly, there was a difference between the 
luciferase activity driven by the -137kb short and -137kb full enhancer variants. The 
increase in fold change relative to pSLF01 was not statistically significant for the 
shorter version of the enhancer, however the decrease of approximately 20% in 
luciferase activity regulated by pSLF01_137kb compared to the control was 
statistically significant (p 0.008). This difference would have been due to the 
presence of TFBS within the full -137kb that were utilised by repressive factors that 
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prevented enhancer function and therefore increased luc2 expression. These 
results suggest that enhancer function did not have a significant impact on the 
transcriptional output of the luc2 compared to that driven by the promoter region 
alone in the period 24 hours after transfection.  
 
This experimental procedure was repeated in HTB94 chondrocytes. The trend of 
fold change in normalised luciferase expression relative to that controlled by the 
promoter alone (Figure 3.48) was similar to that observed for the TC28-i2 cells.  
Figure 3.48: Fold change in normalised expression of luciferase driven by enhancers 
relative to Ccn2 promoter in HTB-94 cells, 24 hours after transfection. The largest fold 
increase of approximately 3.5 times luciferase expression relative to the promoter alone 
occurred in cells treated with the -4kb enhancer, which was statistically significant P≤0.05. 
The small decrease in luciferase observed in cells treated with the -137kb full enhancer was 
also significantly significant. The results for -148kb, -198kb and -230kb were not statistically 
significant, with average similar to that of the promoter alone, suggesting negligible 
reproducible enhancer activity. Error bars represent standard deviation and * denotes 
significance p≤0.05 
 
The -4kb and -255kb enhancers were observed to drive transgene expression with 
the largest fold changes of approximately 3.5 and 2 times respectively greater 
luciferase expression relative to the promoter alone. The result for the -4kb 
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enhancer was significant with a P value of 0.023 whereas the result for the -255kb 
was not. This suggests that transcription factors within the HTB-94 cells interacted 
with cognate TFBS within the -4kb sequence facilitating enhancer function and an 
increase in the expression of luc2. The result for the -137kb full enhancer was also 
significant, with a decrease in luciferase of approximately 15%, this echoed the 
data from the TC28-i2 cells with the -137kb short enhancer seemingly driving a 
small increase in luciferase expression. Again, this could be due to the presence of 
repressive elements within the full -137kb enhancer that are not present in the short 
region. As in the TC28-i2 cells, the -148kb region did not drive an increase in the 
expression of luciferase, which was surprising given the strong chondrocyte-related 
function of the enhancer in vivo.  
 
3.7.2 In vitro enhancer expression in non-chondrocyte cells 
 
The capacity of the enhancers to drive luciferase expression within pre-osteoblast 
cells was examined using undifferentiated MC3T3-E1 cells. This cell line is 
originally derived from new-born mouse calvaria. The results obtained from this cell 
line (Figure 3.49) were similar to those obtained in the chondrocyte like cells 
(Figures 3.47 and 3.48). The -4kb enhancer facilitated a significant fold change with 
approximately 3.5 times more luciferase expression relative to the action of the 
Ccn2 promoter alone. The results for the -102kb, -137kb full, -148kb, -198kb and -
230kb enhancers all constituted significant changes in fold change relative to the 
promoter alone, which each facilitating approximately 50% decrease in luciferase 
expression. This result was surprising for the -230kb enhancer given that it 
functioned in osteoblastic cells in vivo (Figures 3.11 to 3.17). 
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Figure 3.49: Fold change in normalised luciferase expression relative to the activity 
of the Ccn2 promoter in MC3T3-E1 pre-osteoblast cells, 24 hours after transfection.  
A statistically significant increase in normalised relative luciferase expression was exhibited 
in cells transfected with the -4kb enhancer driving transgene expression. There were 
statistically significant (* denotes p≤0.05) decreases in normalised luciferase of 
approximately 50% in cells transfected with luc2 gene under control of the -102kb, -137kb 
full, -148kb, -198kb and -230kb enhancers relative to the promoter alone. Error bars 
represent standard deviation.  
 
Decrease in fold change in luciferase expression driven by the enhancers relative 
to the Ccn2 promoter was also observed within murine NIH3T3 fibroblastic cells 
(Figure 3.50). The greatest reduction in reporter expression compared to the 
pSLF01 control occurred in cells transfected with the -137kb full enhancer with 
decrease of approximately 80%. As in the other cell types, the shorter version of 
this sequence facilitated a greater level of gene expression, further suggesting the 
presence of additional repressive sequences within the full enhancer that prevent 
the activity of the promoter and enhancer regions. Both the -198kb and -230kb 
enhancers were capable of driving transgene activity in fibroblasts in vivo, yet the 
action of neither of these regions led to an increase in luciferase activity within the 
NHI3T3 cells.  
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Figure 3.50: Fold change in normalised luciferase expression relative to the activity 
of the Ccn2 promoter in NIH3T3 cells. There were significant decreases in normalised 
luciferase expression of at least 50% in cells transfected with the -102kb, -137kb short and 
full, -148kb, -198kb and -230kb enhancers, compared to pSLF01 promoter alone Error bars 
represent standard deviation and * denotes significance p≤0.05.   
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3.8 Identification of putative TFBS within Ccn2 enhancers 
 
Given the tissue specific patterns of reporter gene expression driven by transgenic 
mice harbouring the enhancer regions, further examination of the sequences of the 
enhancers was conducted in order to try and understand the cellular signalling 
mechanisms that mediate regulation of enhancer function. This was given 
precedence over the enhancers that functioned well in vitro due to time constraints, 
and so the -137kb, -148kb and -230kb regions were chosen for further scrutiny and 
the identification of TFBS.  
 
3.8.1 The -137kb enhancer contains a SOX9 consensus binding motif  
 
Putative TFBS within the sequence of the -137kb enhancer were identified using 
publicly available ChIP-Seq datasets and the TRAP tool.  The TRAP tool was used 
as it is publicly available and contains a comprehensive list of transcription factors 
and their predicted binding motifs. (Thomas-Chollier et al. 2011). Given the articular 
chondrocyte localisation of β-galactosidase expression in -137kbHsp68LacZ 
transgenic mice at E15.5, chondrocyte related genes were prioritised in the 
examination of TFBS.  
 
SOX9 was principally examined due to its role as its fundamental role in 
chondrocyte physiology, as outlined in Chapter 1. Three ChIP-Seq datasets 
concerning SOX9 TFBS in chondrocytes were used. Firstly SOX9 in P1 costal 
chondrocytes and E17.5 nasal chondrocytes (GSM1692996 and GSM1693007 
respectively; Ohba et al. (2015)). In addition to E12.5 limb chondrocytes 
(GSM1888973; Garside et al. (2015)). The peaks for SOX9 binding within -137kb 
lay within a sequence that is conserved to lizard (Figure 3.51). A 1275bp shorter 
region that contained the conserved sequence was chosen for further analysis (-
137kb short, Figure 3.51), with co-ordinates chr10:24,178,225-24,179,500. When 
this sequence was inputted into the TRAP tool, SOX9 matrix M00410 ranked with 
6th highest affinity for the sequence with probability of 0.00896 (Chapter 5.4). This 
motif has the consensus sequence NNNDAACAATRRNN.  
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Figure 3.51: Identification of SOX9 binding sequences within the -137kb enhancer region using ChIP-Seq datasets. Typical enhancer chromatin 
characteristics of histone modification and DNase I hypersensitivity peaked in the middle of the region (E). This also concurred with the most conserved region 
of the sequence which is approximately 250bp of sequence highly conserved to lizard (F). Peaks for SOX9 ChIP-Seq datasets for P1 rib chondrocytes 
(GSM1692996, B), E17.5 nasal chondrocytes (GSM1693007, C) and E12.5 limb chondrocytes (GSM1888973, D) converged within the most conserved region 
of the sequence. 137kb short region (A) was selected based on conservation and the fact that histone modifications fell within this area  
P1 rib 
E17.5 nasal chondrocyte  
E12.5 limb chondrocyte 
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Combination of the SOX9 ChIP-Seq TFBS and TRAP predicted motifs allowed the 
prediction of SOX9 consensus binding motif located 346bp to 359bp in the -137kb 
short sequence (red and bold typeface in sequence and highlighted yellow in matrix 
information, Figure 3.52).  
 
 
Figure 3.52: TRAP prediction of SOX9 binding motifs within the -137kb short region. 
The sequence for -137kb short was inputted into the TRAP tool, with red text highlighting 
four predicted SOX9 binding motifs based on the M00410 SOX9 consensus motif; 
NNNDAACAATRRNN. Sequence where all three SOX9 ChIP-Seq peaks from Figure 3.51 
overlap is highlighted with bold typeface. One of the predicted SOX9 binding motifs sat 
within the ChIP-Seq interaction region (highlighted yellow).  
 
Evolutionary conservation was then examined for the most conserved region of 
sequence within -137kb short; approximately 250bp that was conserved to lizard 
(Figure 3.51). DNA sequence was taken from the Multiz 30-way alignment tool in 
the UCSC Genome Browser for mouse, human, opossum, chicken and lizard and 
aligned using CLUSTALW (Figure 3.53). The strongest candidate for SOX9 binding 
motif, as aforementioned, was highly conserved between all organisms with the 
CAA motif that SOX9 interaction depends on replete in each organism. This motif 
and surrounding sequence was chosen to create an oligonucleotide probe for in 
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vitro validation of DNA sequence-SOX9 interaction (highlighted yellow, Figure 
3.53). 
 
 
Figure 3.53: ClustalW alignment of the most evolutionarily conserved segment of the 
-137kb region. The mouse, human, opossum, chicken and lizard DNA sequences were 
aligned using ClustalW. The SOX9 consensus motif identified in Figure 3.50 is highlighted 
in green, with conservation (*) of the key CAA nucleotides within the motif between all 
organisms. The EMSA probe sequence which was used for in vitro validation of SOX9 TFBS 
is highlighted in yellow.  
 
EMSA methodology was used to determine the capacity for the identified 
monomeric SOX9 consensus motif to interact with SOX9 protein. As previously 
mentioned a wild-type oligonucleotide probe was designed to span the identified 
SOX9 binding site with additional nucleotides to a length of 30nt (highlighted yellow 
Figure 3.53). Mutated oligonucleotide probes were also designed with substitution 
of A nucleotides for G in the SOX9 CAA recognition motif within the sequence. In 
these experiments, the wild-type oligonucleotide probe was bound by SOX9 protein 
(Figure 3.54).  
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Figure 3.54: EMSA determination of interaction between in vitro produced SOX9 
protein and consensus binding site within the -137kb enhancer DNA sequence. There 
was a shift in the signal produced by the probe in reactions containing the wild-type probe 
and SOX9 protein, representing DNA-protein interaction, with the migration of the probe 
signal being slowed by protein interaction. The intensity of this band was reduced with the 
use of wild-type competitor oligonucleotide, but not with a mutated competitor. There was 
no band present for interaction between the mutant probe and SOX9 protein.  
 
There was a reduction in the intensity of the band in lanes representing reactions 
in which the wild-type competitor was used. This band was lost in the absence of 
SOX9 protein. Moreover, this band was lost with abrogation of the clear CAA site 
in the mutated oligonucleotide. However, the mutation of the oligonucleotide probe 
did not remove a sub-optimal Sox9 binding site, which therefore did not prevent 
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SOX9-TFBS binding. These observations demonstrate the specificity of interaction 
between the wild-type oligonucleotide and SOX9 protein.  
 
3.8.2 The -148kb enhancer contains two SOX9 binding motifs 
 
Given the strong, chondrocyte based reporter gene expression driven by -148kb in 
vivo from E15.5 in the stable transgenic mouse line, the sequence of the enhancer 
was examined in an attempt to identify master chondrocyte regulator SOX9 TFBS. 
Using the TRAP tool, SOX9 was not predicted to bind within the enhancer (Chapter 
5.5). However, integration of ChIP-Seq datasets for SOX9 enabled visualisation of 
SOX9 TFBS in chondrocytes (Figure 3.55).  
 
Within the enhancer, one sequence contained peaks for interaction in both P1 rib 
chondrocytes and E17.5 nasal chondrocytes (Ohba et al. 2015) with conservation 
of sequence to platypus. Sequence conservation within this sub-region was 
examined using ClustalW (Figure 3.56).  
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Figure 3.55: Identification of SOX9 binding sequences within the -148kb enhancer region using ChIP-Seq datasets. ChIP-Seq peaks for SOX9 TFBS 
(A, Ohba et.al (2015)) occur in two loci across the enhancer, with peaks being present in both E17.5 nasal chondrocyte and P1 rib chondrocyte in the 5’ end of 
the enhancer, but only nasal chondrocytes for the 3’ peak. Probes were designed in the 5’ peak region that was not present in the -148kb_short transgenic 
mouse line. 
  
Sox9 
chondrocyte  
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Figure 3.56: ClustalW alignment of sequence within a ChIP-Seq SOX9 peak in the -
148kb sequence. There were three SOX9 motifs within the sequence and each are 
highlighted in green. The core motif of the first two motifs was evolutionarily conserved, 
however this was not true for the third motif. EMSA probes were designed to span the first 
two motifs, with sequences highlighted in yellow 
 
Two conserved SOX9 binding motifs were chosen for in vitro examination of DNA-
TF interaction in EMSA (sequences highlighted yellow, Figure 3.56). Both of these 
sequences lie within the sequence of the enhancer that was absent in the -
148kb_short transgenic mouse line. EMSA methodology demonstrated that both of 
these TFBS are bound by SOX9 (Figure 3.57). A band was present at a higher 
position in the gel relative to the unbound free oligonucleotide, representing 
impaired probe migration through the gel due to interaction with the SOX9 protein. 
The interaction between the probes and SOX9 was specific, as a 25x and 50x 
excess of competitor oligonucleotides reduced the signal of these shifted bands. 
The use of a mutant competitor sequence also reduced shifted band signal 
although this effect was not as strong as in the wild-type competitor lanes. This 
suggests that mutation of the sequence did not completely prevent competitor 
oligonucleotide DNA-protein interaction. Sub-optimal binding of Sox9 could 
therefore occur without complete ablation of CAA consensus motif.  
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Figure 3.57: EMSA examination of -148kb sequence- SOX9 interaction. Two probes 
were used containing SOX9 consensus motifs. A shift in signal was observed with 
incubation of each probe and SOX9 protein, corresponding to DNA-TF interaction. 
Moreover, this interaction was specific as the use of wild-type competitor oligonucleotide 
greatly reduced the intensity the shifted band compared to reactions containing water.  
 
3.8.3 The -230kb enhancer contains two SOX9 binding motifs 
 
The process of identifying SOX9 motifs was repeated for the -230kb enhancer 
region. Firstly, the aforementioned SOX9 ChIP-Seq dataset peaks were compiled 
within the whole -230kb enhancer (Figure 3.58).   
Sox9-probe 
interaction  
Free oligo  
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Figure 3.58: UCSC visualisation of SOX9 ChIP-Seq dataset TFBS within the -230kb enhancer region. Within the enhancer (A), there was a ChIP-Seq 
peak for Sox9 in one of the datasets (B-D). This peak lay within the region of the enhancer enriched for H3K4me1and H3K27ac in addition to DNase I 
hypersensitivity (E)). The most conserved fragment of sequence was shared between mouse and opossum (F). Peaks for SOX9 ChIP-Seq datasets only 
occurred in E12.5 limb chondrocytes (D), and not E17.5 nasal chondrocytes (B) or P1 rib chondrocytes (C) 
  
Sox9 
chondrocyte  
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This sequence was input into the TRAP and the M00410 SOX9 matrix was ranked 
with the 16th greatest affinity (Chapter 5.5). Within the sequence (Figure 3.58), none 
of the predicted binding sites (capitalised red typeface, Figure 3.59) for SOX9 sat 
within the peak for SOX9 binding within the GSM1888973 ChIP-Seq dataset (bold 
typeface, Figure 3.59) (Garside et al. 2015). An inverted repeat consensus Sox site 
was however manually identified within the ChIP-Seq dataset peak sequence, with 
a sequence of GACAAAGtacCTTTGTC (highlighted yellow, Figure 3.59). 
 
Figure 3.59: Visualisation of TRAP predicted SOX9 binding sites within the -230kb 
enhancer. None of the SOX9 M00410 motifs (red typeface) sat within the ChIP-Seq peak 
area (bold typeface). However an inverted repeat SOX9 motif was identified within this 
region (yellow highlight).  
 
The most conserved sub-region of -230kb is approximately 900bp that exhibits 
conservation to opossum in the Multiz tool. The sequences for mouse, human and 
opossum were aligned using ClustalW (Figure 3.60). One TRAP predicted 
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sequence fell within this sequence, but was not highly conserved between the 
species (red typeface, Figure 3.60). The core nucleotides of the inverted repeat 
motif GACAAAGtacCTTTGTC (blue, bold and underlined typeface Figure 3.60) 
identified in the ChIP dataset peak were conserved. 
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Figure 3.60: ClustalW alignment of the most conserved fragment of -230kb. 
Conservation of the sequence occurred to opossum. Bases that were identical between 
species when aligned are highlighted with asterisks. The TRAP predicted SOX9 motif (red 
box) was not evolutionarily conserved. The CAA and TTG bases of the putative SOX9 
inverted repeat site (blue box) were conserved.  
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An oligonucleotide sequence spanning this inverted repeat and flanking sequence 
to 30bp was created for in vitro validation of binding interaction between DNA and 
sequence (Figure 3.61). A mutant oligonucleotide probe was also designed with 
disruption of the ACAA and TTGT motifs within the sequence.  
 
 
Figure 3.61: Determination of interaction between Sox consensus sequence within -
230kb enhancer and SOX9 protein using EMSA. Bands represented shifted probe signal 
with SOX9 protein interaction were present in wells where reactions containing the wild-
type probe were run. These bands were much fainter with the mutant probe, suggesting 
that interaction had not completely ablated DNA-protein interaction.  
 
A band representing interaction between oligonucleotide sequence and SOX9 
protein was discernible in reactions containing the wild-type probe, this band was 
much fainter in the mutant oligonucleotide containing reactions (Figure 3.61). The 
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band for the WT probe (lane 2, Figure 3.61) is more pronounced than those 
representing reactions that contained wild-type competitor. This suggests that the 
competitor prevented interaction between the probe and protein in a specific 
manner. The single band, rather than the doublet band that was observed for the -
137kb and -148kb SOX9 suggests that SOX9 binds in monomeric form rather than 
dimeric form to interact with this -230kb TFBS (Oh et al. 2016).  
 
3.8.4 RUNX2 does not bind strongly within -148kb 
 
Two ChIP-Seq datasets pertaining to RUNX2 genomic interactions within MC3T3 
pre-osteoblast and day 15 MC3T3 differentiated osteoblasts from Meyer (et al. 
2014) (GSM1027478 and GSM1027496 respectively) were used in order to 
visualise potential interactions within enhancer regions. Peaks for these tracks 
within the UCSC Genome Browser lay within the -148kb enhancer region (Figure 
3.62). 
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Figure 3.62: Visualisation of ChIP-Seq peaks for RUNX2 interaction within the -148kb enhancer. RUNX2 interacts within the enhancer in differentiated 
(GSM102796) and non-differentiated (GSM1027478) MC3T3 cells (Meyer et al 2014) (A). A large peak of interaction lay within a region of sequence conserved 
to chicken (D). Enhancer associated chromatin traits (C) were split into two clusters  
  
Runx2 osteoblast  
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Upon examination of the full -148kb enhancer sequence in TRAP (Chapter 5.5) a 
RUNX1 (AML) rather than RUNX2 TFBS was predicted within the RUNX2 ChIP-
Seq peak for undifferentiated MC3T3 (Figure 3.62). There was no clear site for 
RUNX2 (OSF2) in TRAP predictions within this full sequence. RUNX2 binding sites 
were manually identified within the ChIP-Seq peak areas, with three TFBS probes 
for EMSA designed (Figures 3.63-65). 
 
 
Figure 3.63: Visualisation of RUNX2_1 binding site within -148kb. RUNX2 consensus 
site ACCACA (orange box) was highly conserved between species. This formed the basis 
of an EMSA probe. 
 
 
Figure 3.64: Visualisation of RUNX2_2 binding site within -148kb. Both of the ChIP-
Seq datasets used peak within this sequence (Meyer et al. 2014) RUNX consensus site is 
highlighted with an orange box.  
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Figure 3.65: Visualisation of RUNX2_3 site within the -148kb enhancer. Both of the 
RUNX2 ChIP-Seq datasets used (Meyer et al. 2014) contain peaks within the probe in close 
proximity to conserved RUNX2 motif (highlighted with orange box).  
 
The capacity for RUNX2 to bind each of these sequences was tested using EMSA. 
Binding conditions for DNA and protein were optimised using a control RUNX2 
TFBS that has previously been validated in EMSA (Lamour et al. 2007) (Chapter 
5.5) The band patterns for interaction between RUNX2 protein and probe for the 
RUNX probes designed herein did not match with the control but one of the bands 
for the RUNX2_3 probe was weaker with the use of a 25x and 50x excess of WT 
competitor, an effect that was reduced with use of a mutated competitor, suggesting 
specificity in interaction between probe and RUNX2 (Figure 3.66). In silico 
predictions of TFBS suggested the RUNX2_3 probe as most likely to be bound by 
Runx2. Unfortunately, a RUNX2 antibody was unavailable to conduct a supershift 
assay and further clarify DNA-protein interaction.  
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Figure 3.66: EMSA based investigation of interaction between RUNX2 consensus 
sequence within -148kb enhancer and RUNX2. An arrow highlights the band that was 
reduced for the RUNX2_3 probe with use of wild-type competitor, with both 25x and 50x 
excess, with reduced effect with the use of a mutant competitor.  
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3.9 CRISPR-Cas9 based manipulation of Ccn2 enhancer regions 
 
As detailed in Chapter 2.4, CRISPR-Cas9 technology has revolutionised the 
capacity to manipulate genomic sequences, both in vitro and in vivo. In the current 
project, CRISPR-Cas9 technology was employed with the intention of excising 
enhancer regions from the murine genome in vivo, thereby generating transgenic 
mice with knockout of the Ccn2 enhancers. 
 
3.9.1 In silico identification and in vitro validation of CRISPR target sites 
 
Guide RNA targeting loci in the vicinity of enhancer boundaries were identified 
using CHOP-CHOP tool (Labun et al. 2016; Montague et al. 2014); as outlined in 
Chapter 2, Materials and Methods 2.4.1. Guides were selected for the -137kb, -
148kb and -230kb enhancers in addition to a region of interest spanning both -
137kb and -148kb, as summarised in Table 3.10. (Guide sequence and off-
targeting information is listed in appendices, Table 5.2).  
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Table 3.10: Identification of suitable gRNA for the deletion of enhancers. Two guides were chosen for the deletion of each single enhancer, with one each 
for 5’ and 3’ for the dual -148kb/-137kb deletion. The location of the target protospacer sequence and predicted efficiency scores in accordance with the work 
of (Moreno-Mateos et al. 2015; Xu et al. 2015)were recorded for each guide.  
  
Enhancer  Boundary  Guide names Guide locus (mm10 genome) 
Predicted efficiency 
Xu et al 
(2015) 
Moreno-Maetos 
et al (2015) 
-137kb 
5’ 
-137kb_5’_1 chr10:24457863-24457882 0.48 0.64 
-137kb_5’_2 chr10:24457862-24457881 0.42 0.64 
3’ 
-137kb_3’_1 chr10:24460119-24460138 0.60 0.61 
-137kb_3’_2 chr10:24460306-24460325 0.57 0.57 
-148kb 
5’ 
-148kb_5’_1 chr10:24447029-24447048 0.45 0.60 
-148kb_5’_2 chr10:24447022-24447041 0.44 0.60 
3’ 
-148kb_3’_1 chr10:24449585-24449604 0.48 0.59 
-148kb_3’_2 chr10:24448996-24449015 0.52 0.56 
-148kb/-137kb 
5’ -148kb/-137kb_5’ chr10:24446390-24446409 0.70 0.66 
3’ -148kb/-137kb_3’ chr10:24461139-24461158 0.53 0.59 
-230kb 
5’ 
-230kb_5’_1 chr10:24364823-24364842 0.71 063 
-230kb_5’_2 chr10:24364563-24364582 0.58 0.61 
3’ 
-230kb_3’_1 chr10:24366271-24366290 0.42 0.63 
-230kb_3’_2 chr10:24366337-24366356 0.38 0.70 
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Where gRNA target sequences were identified within enhancer sequences; as 
oppose to flanking them, a rationale of compromise between gRNA efficiency and 
prediction of sequence function was made. This was based on the notion that 
sequences at the 5’ or 3’ extremities of the enhancer that are less conserved and 
would be unlikely to contain the lynchpin motifs that enhancer function depends on. 
Therefore, small fragments near the boundaries of enhancers left after CRISPR-
Cas9 excision would not constitute enhancer function.  
 
PCR products were designed to span target sites in order to assay cutting in vitro. 
Use of multiple primer pairs, including those used for the standard manipulation of 
enhancer sequences (Table 2.1) allowed assay of the gRNA to induce cutting in 
several substrates to be assessed. In vitro assay of enhancer cutting was carried 
out through incubation of target substrate PCR product, gRNA and recombinant 
SpCas9 before electrophoresis and visualisation of fragmentation. Initially, whole 
enhancer regions were used as substrate. This approach was later adapted with 
the use of smaller substrate for each enhancer boundary specifically rather than a 
whole enhancer region. Use of multiple primer pairs, including those used for the 
standard manipulation of enhancer sequences (Table 2.1) allowed assay of the 
gRNA to induce cutting in several substrates to be assessed. All combinations of 
primers used and resultant fragments generated through CRISPR-Cas9 genomic 
cleavage are listed in Appendices Chapter 5.3. The following results demonstrate 
that CRISPR-Cas9 cutting was more effective with the use of smaller substrates. 
This approach was therefore taken in the latter stages of the in vitro assays of 
CRISPR-Cas9 function. In addition, the concentration of reaction components was 
also optimised with the adoption of molar ratios of gRNA: Cas9 protein: substrate 
of 10:10:1 (as demonstrated in Appendices Chapter 5, Figure 5.18).  
 
3.9.1.1 Excision of the -137kb enhancer  
 
Two guide sequences were selected each for the 5’ and 3’ ends of the -137kb 
enhancer (Figure 3.65). The targets for the 5’ boundary both resided within the 
enhancer sequence, however conservation in this sub region was low suggesting 
that the sequence was not important in the function of the enhancer. Therefore, if 
the 5’ boundary and upstream sequence was retained upon CRISPR-Cas9 cutting, 
it would be highly unlikely that the enhancer function would be recapitulated. This 
ethos was also applied for 3’ guide number 1 which sat approximately 140bp 
upstream of the 3’ enhancer boundary.   
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Figure 3.67: UCSC Genome Browser visualisation of CRISPR guide sequences targeting the -137kb enhancer. PCR amplicon were designed to span 
cut sites for assessment of cutting (green blocks, A)Two guides with the highest ranking for cutting efficiency (red bars, B) were selected for both the 5’ and 3’ 
ends of the enhancer region (blue block, C). Both of the 5’ guide sequences sat approximately 200bp within the enhancer sequence. For the 3’ end, 3’_1 sat 
approximately 130bp upstream of the enhancer boundary, whereas 3’_2 sat approximately 60bp downstream of the enhancer. The 3’ guide for the -148kb/-
137kb dual cut, -148/137_3’ resides approximately 900bp downstream of the -137kb enhancer..  
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The capacity of each of these guides to induce DNA DSB in conjunction with the 
Cas9 was tested in vitro. This was firstly tested using a long substrate of 2864bp 
containing the full -137kb enhancer and additional 3’ sequence in order to 
incorporate 3’ gRNA target site, as demonstrated in Figure 3.68.  
 
Figure 3.68: In vitro assay of -137kb gRNA function using full enhancer as substrate. 
Red boxes highlight bands corresponding to cleavage fragments. The faint bands between 
100bp and 200bp represent gRNA, as demonstrated in the end 4 lanes which contained 
only gRNA. Substrate was cleaved through use of the -137kb 3’_1 guide RNA sequence 
only. Red marks in band indicate saturation with upper threshold of signal reached for 
transluminator system.  
 
The -137kb_3’_1 guide facilitated cutting of the substrate with fragmentation of the 
PCR substrate corresponding to the loss of the 3’ region. This occurred 
reproducibly in each reaction that contained this gRNA. Fragmentation in lanes 
corresponding to the activity of the other gRNA was not clear. An alternate 
approach with a shorter fragment was used to assess the capacity of the 5’ gRNA 
to mediate Cas9 activity (Figure 3.69). The 529bp substrate was cut by both of the 
guides (red boxes, Figure 3.69), with gel electrophoresis fragmentation patterns 
tallying with DNA cut approximately 200bp and 330bp. The presence of uncut 
substrate in both of the lanes containing gRNA indicates that cutting was not 100% 
efficient, although the band corresponding to uncut substrate was fainter than in 
the –gRNA control lane. The intensity of cut fragments was similar for both gRNA 
suggesting that gRNA-Cas9 interaction and cutting efficiency was similar for each 
gRNA.  
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Figure 3.69: In vitro assay of -137kb 5’ guides capacity to cut PCR amplicon spanning 
5’ enhancer boundary. Red boxes highlight bands corresponding to fragments produced 
from successful cleavage of the 529bp substrate. Both guides facilitated cleavage of the 
substrate DNA at the target site. Faint bands are also present at approximately 140bp 
corresponding to the guide RNA. 
 
 
3.9.1.2 Excision of the –148kb enhancer  
 
For the 148kb 5’ region, both guides sat within the enhancer sequence, 
approximately 160bp downstream of the boundary. For the 3’ guides, guide 1 sat 
downstream of the 3’ boundary, whereas guide 2 sat approximately 400bp 
upstream of the 3’ boundary in sequence with little interspecies conservation. The 
location of each guide with respect to the enhancer is illustrated in Figure 3.70.  
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Figure 3.70: UCSC Genome Browser visualisation of CRISPR guide sequences targeting the -148kb enhancer. Both of the 5’ guide sequence (red bars, 
B) lie within the enhancer (purple bar, C), approximately 160bp downstream of the 5’ boundary. For the 3’ guides, 3’_2 resides approximately 450bp upstream 
of the 3’ boundary within the boundary sequence whereas the 3’_1 guide sits approximately 150bp downstream of the enhancer. For each guide target within 
the enhancer, the sequence is not highly conserved between species, suggesting these regions are dispensable in enhancer function. The -148kb/-137kb dual 
cut 5’ guide is found approximately 500bp upstream of the enhancer region. PCR amplicon were designed for the -148kb/-137kb 5’ and -148kb_3’_1 guides 
(green bars, A). For the other guides, substrate of the whole enhancer was used for in vitro validation of CRISPR-Cas9 activity. 
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For the assay of gRNA activity, substrate of the basic enhancer region was carried 
out first (Figure 3.70). Albeit faint on the scanned gel image (rather than from digital 
image file), the fragment in the -148kb_5’_1 lane corresponds to the 5’ enhancer 
boundary to gRNA target site of approximately 160bp. This suggests that the gRNA 
is functional, but the efficiency of cutting is low. This fragmentation was repeated 
with the dual assay of -148_5’_1 and -148kb_3’_2, with fragmentation pattern 
showing that the 5’_1 guide alone facilitated substrate cleavage.  
 
Figure 3.71: Initial assay of -148kb 5’_1, 5’_2 and 3’_2 guides capacity to facilitate 
Cas9 cutting of substrate DNA. Bands representing cleavage product of the substrate 
were visible (within the red boxes) with the use of the -148kb 5’1 gRNA. The most 
substantial bands however represent guide RNA at approximately 120bp.  
 
This experiment was repeated with the use of the -148kb_3’_2 gRNA (Figure 3.72). 
Two substrates were used, firstly the standard -148kb enhancer region for 5’_1, 
5’2, 5’_1x 3’_2 and 5’_2x 3’_2 reactions, in addition to a substrate spanning from 
the 5’ enhancer boundary to 3’ of the 3’ cutting substrate reverse primer. 
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Figure 3.72: In vitro assay of capacity of -148kb guides to facilitate cleavage of -148kb 
enhancer containing substrate. Amplicon of the basic enhancer region was for each 
reaction aside from those containing -148kb_3’1 which used the enhancer forward primer 
and reverse primer for 3’C substrate. Use of both 3’ guides led to cleavage of substrate 
DNA with correct fragment sizes (highlighted with red boxes).  
 
Given that neither 5’ guide had generated discernible fragments in this experiment 
a further substrate was used spanning further upstream of the 5’ enhancer 
boundary (-148kb/-137kb 5’ cutting forward primer x reverse primer in the middle 
of the -148kb region). Both guides led to the cutting of the substrate, with 
fragmentation tallying with expected split of substrate into fragments of 
approximately 1270bp and 1700bp (Figure 3.73). Using this approach 
fragmentation of substrate corresponding to the action of each gRNA was 
produced.  
 
  
219 
 
Figure 3.73: In vitro assay of -148kb 5’ gRNA mediated cutting of substrate containing 
the -148kb enhancer. Substrate was amplified using the -148kb/-137kb 5’ cutting assay 
forward primer and reverse primer recognising sequence within the enhancer. 
 
3.9.1.3 Excision of the –230kb enhancer  
 
For the 5’ guides, _1 sat approximately 180bp within the enhancer sequence, 
whereas _2 was localised approximately 90bp upstream of the 5’ enhancer 
boundary. For the 3’ guides, both sequences sat at least 140bp downstream of the 
enhancer (Figure 3.74).  
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Figure 3.74: UCSC Genome Browser visualisation of CRISPR guide sequences within the -230kb enhancer. Aside from -230kb_5’_1, each target 
sequence gRNA (red bar, B) was found within sequence flanking the -230kb enhancer (lilac block, C) region. The target site for 5’_1 lay approximately 180bp 
downstream of the enhancer 5’ boundary, with a compromise made between predicted efficiency and sequence conservation. Primers were designed for in vitro 
validation, with amplicon spanning the -230kb_5’_2 target region and both 3’ target loci (green bars, A).  
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For the -230kb enhancer, multiple experiments were carried out in order to validate 
gRNA function. Initially, a 1950bp substrate spanning from the 5’ enhancer 
boundary to the 3’ end of the 3’ cutting substrate amplicon was used to test the 5’_1 
guide whereas substrate of the standard -230kb region was used to test the 5’_2 
and 3’_1 guides individually in addition to this gRNA in combination with one 
another (Figure 3.74).  
 
Figure 3.75: Initial assay of ability of -230kb 5’_1, 5’_2 and 3’_1 gRNA to induce 
cutting of DNA in vitro. The use of the 5’_1 and 5’_2 led to cleavage of substrate with 
fragments (denoted by red boxes) corresponding to target site DSB. The 3’_1 guide did not 
mediate cutting of the substrate.  
 
The capacity of the 5’2 guides to facilitate DNA cutting was further tested using a 
substrates designed to span each enhancer boundary. There was digestion of an 
amplicon spanning 869bp around the 5’_2 guide (Figure 3.76).  
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Figure 3.76: In vitro digestion of -230kb 5’ cutting assay substrate with -230kb_5’_2 
guide. PCR amplicon substrate was designed to span the -230kb_5’_2 target span. The 
fragment bands produced (asterisk) correspond to correct cleavage by Cas9 at the target 
site. The faint, smeared band above 100bp corresponds to gRNA.  
 
This process of using smaller amplicon designed to span the gRNA targeting site 
was repeated for the -230kb_3’ guides (Figure 3.77). The -230kb_3’_1 guide 
functioned in vitro (red boxes Figure 3.77), whereas the -230kb_3’_2 guide did not. 
 Moreover, the band for uncut 648bp substrate on the gel was much fainter than 
that in the –gRNA control, suggesting that Cas9-gRNA interaction functioned with 
high efficiency.  
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Figure 3.77: In vitro assay of -230kb 3’ guide function using substrate spanning the 
gRNA target site. The -230kb_3’_1 gRNA efficiently mediated cleavage of the substrate 
by Cas9, with pronounced bands corresponding to fragments generated by DSB (red 
boxes). Moreover, the band representing uncut substrate within this well was faint. The -
230kb_3’_2 guide did not facilitate DNA cleavage, with no fragmentation visible in the gel 
lane and band representing uncut substrate as in the –gRNA control. 
 
3.9.2 CRISPR mediated removal of enhancers in vivo 
 
Microinjection of mouse zygotes (as detailed in Chapter 2.5) was carried out in 
order to generate transgenic mice in which enhancer regions had been excised 
from the genome. Validated gRNA and recombinant Cas9 were injected into the 
cytoplasm of one-cell stage embryos (0.5dpc). The number of embryos harvested 
and injected, in addition to survival rate is recorded in Table 3.10. The number of 
mice born, and that survived to genotyping in addition to genotyping results are also 
recorded in Table 3.11. None of the mice born exhibited any discernible phenotype 
that could be associated with genomic manipulation. Three lines; Ccn2Δ148/137, 
Ccn2Δ148 and Ccn2Δ230 were generated. 
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Table 3.11: Record of microinjection of gRNA and Cas9 into mouse embryos, and subsequent survival of mice to genotyping stage, and number of 
mice genotyped as exhibiting deletion of the enhancer sequence.  
  
Line 
(enhancer) 
Guide RNA 
used 
Number of 
embryos 
isolated 
Number of 
embryos 
injected 
Number of 
embryos 
survived 
Number of 
pups born 
Number of 
mice 
genotyped 
Number of 
mice with 
deleted copy 
of enhancer 
Ccn2Δ148  
(-148kb) 
-148kb_5’_1 
and -
148kb_3’_1 
220 200 130 28 27 0 
Ccn2 Δ148/137 
(-148kb/  
-137kb dual) 
-148kb_5’_1, -
148/137_5, 
 -137kb_3’_1 
and -148/-
137_3’ 
270 250 150 50 46 0 
Ccn2Δ230  
(-230kb) 
-230kb_5’_2 
and -
230kb_3’_1 
100 80 56 28 27 0 
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Mice were genotyped through PCR of amplicon within the enhancer regions, in 
addition to spanning gRNA targeting sites (Chapter 5, Tables 5.4 to 5.7) Using this 
approach, successful CRISPR-Cas9 removal of the enhancer region would prevent 
amplification of region of interest in PCR. Product formation was assessed on 
agarose gels, with an internal control for every sample in order to rule out false 
positives for enhancer knockout. In the following gel images, where there is no band 
for internal control, PCR was repeated with lower concentration of DNA, DNA was 
re-precipitated or mouse was re-notched for sample. Therefore, there was an 
internal control reaction for every sample, albeit not on the same gel as amplicon 
of interest product. PCR conditions for each amplicon were optimised using 
genomic DNA isolated in the same manner as genotyping. However, multiple 
amplicon had to be tested for each line in order to ensure result accuracy.  
 
3.9.2.1 Genotyping of Ccn2Δ148/137  
 
The accuracy of genotyping PCR was a major issue in the genotyping for the 
simultaneous knockout of the -148kb and -137kb enhancers in the Ccn2Δ148/137 
line. A schematic of the PCR strategy used is illustrated in Figure 3.78.  
 
 
Figure 3.78: schematic of genotyping strategy for Ccn2Δ148/137. Standard cloning 
PCR primers are indicated for context with blue arrows. However, the CRISPR assay 
substrate primer pairs (green arrows) were used in attempts to generate amplicon (red bars) 
and therefore confirm whether the enhancers had been deleted.  
 
The problems that were faced are typified by the results of genotyping animals 9.1 
to 13.2 of the line (Figure 3.79). Both the -137kb 5’ and -148kb 3’ CRISPR cutting 
assay amplicon were used with optimised conditions. The -148kb 5’ amplicon was 
not produced in any reaction which indicated a failure in PCR rather than 100% 
efficiency of the CRISPR method; which is highly unlikely. For some of the samples, 
the -137kb 5’ product was absent, indicating a knockout. Where bands -137kb 5’ 
CRISPR cutting assay were faint, but the internal control band was comparable to 
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others, it would suggest heterozygosity. If the CRISPR-Cas9 system removed the 
sequence from one chromosome, a single copy of the target would still be present 
in the genome and would be amplified by PCR; albeit to a lesser extent than in a 
homozygote wild-type sample. 
 
 
Figure 3.79: Example of genotyping from Ccn2Δ148/137 line. Internal PCRs were 
carried out for every sample in order to ratify template suitability and reduce the possibility 
of false positives. Black arrows denote the expected band size of PCR amplicon. These 
reactions were repeated for samples 9.1 and 9.2 in order to ensure DNA integrity. The -
148kb 3’C amplicon was not produced in any sample suggesting issue with PCR 
experimental set up rather than CRISPR deletion.  
 
These samples were used as template in further PCR reactions with alternate 
amplicon. In these reactions, samples that were previously genotyped as potentially 
being heterozygous or homozygous for enhancer knockout were genotyped as still 
containing the region of interest (Figure 3.80).  
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Figure 3.80: Further genotyping of mice from the Ccn2Δ148/137 line. The -137kb 3’ 
CRISPR cutting substrate (529bp) was used as amplicon in gel half A, whereas the CRISPR 
substrate primers for -148kb 3’ (752bp) were used for gel half B. There was no product from 
sample 9.3 or 11.1 and 11.3 (red boxes) for either amplicon, suggesting CRISPR may have 
been successful.  
 
A total of eight different PCR conditions were tried in order to ascertain whether 
any mouse was negative for each amplicon. 9.1, 11.3 and 12.4 were all chosen as 
the most feasible heterozygotes for the dual deletion of -148kb/-137kb. 
Unfortunately, these mice were all male and so propagation of the line would 
require crossing with homozygous wild-type females. This was not a feasible option 
as resultant offspring would be heterozygous at best which could not be efficiently 
interrogated in the scope of this project in terms of time and budget and so 
propagation of other transgenic lines was prioritised.  
 
-137kb 
3’ C 
-148kb 
3’ C 
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3.9.2.2 Genotyping of Ccn2Δ148 transgenic line 
 
As with the Ccn2Δ148/137 line, problems with PCR hampered the accuracy of 
Ccn2Δ148 line genotyping. A schematic of the genotyping approach used for this 
transgenic mouse line is outlined in Figure 3.81 
 
Figure 3.81: Schematic representation of the genotyping of the excision of the -148kb 
enhancer in Ccn2Δ148 transgenic line. The positions of primers used for cloning of the 
region are highlighted with blue arrows. The green arrows indicate position of primers for 
CRISPR in vitro assay substrate amplicon and the purple arrows indicate primers that 
amplify from within the enhancer that were used for genotyping of the LacZ reporter 
transgenic line. Amplicon generated for genotyping are highlighted with red bars.  
 
Initial genotyping is illustrated in Figure 3.82.  
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Figure 3.82: Initial genotyping of the Ccn2Δ148 line. 2.4 was positive for internal control 
reaction, but negative for the amplicon of interest (red box), suggesting that this mouse 
harboured knockout of the enhancer.  
 
Genotyping PCR was repeated with several amplicon of interest where results were 
unclear from initial genotyping (as shown in Figure 3.83).  
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Figure 3.83: Representative gel image further genotyping of the Ccn2Δ148 line. 
Sample 1.3 which was previously negative for enhancer amplicon (Figure 3.79) contained 
both amplicon sequences. Bands that were faint and therefore suggesting heterozygosity 
for enhancer deletion were not concordant between PCR for samples, suggesting this 
difference was due to PCR conditions.  
 
Across a total of six genotyping PCR experiments, 2.4 and 3.2 were chosen as 
potential heterozygotes and bred to propagate the line, with the hope of producing 
homozygote knockouts. F1 mice were genotyped, as demonstrated in Figure 3.84.  
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Figure 3.84: Genotyping of F1 from Ccn2Δ148 line. Mice were genotyped for an 
amplicon spanning the middle of the enhancer (148-1) (A) in addition to internal control (B). 
There was a problem with the 10.2 template in the 148-1 reaction which is therefore a false 
positive for knockout. None of the mice were homozygous for deletion of the enhancer as 
shown by product formation for the 148-1 reaction. 
 
These mice were also genotyped from tissue after culling, with all samples 
producing PCR amplicon and therefore containing the -148kb enhancer. At this 
point, further propagation of the line was not temporally or fiscally feasible and so 
the line was discontinued.  
 
3.9.2.3 Genotyping of Ccn2Δ230 transgenic line 
 
The genotyping of Ccn2Δ230 mice was also problematic. A schematic of the 
approach used to PCR for amplicon within the enhancer region is shown in Figure 
3.85.  
Whole 
enhancer  
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Figure 3.85: schematic representation of strategy used to genotype for excision of 
the -230kb enhancer in Ccn2Δ230 transgenic line. Blue arrows depict the positioning of 
the primers used for cloning of the enhancer and green arrows depict the primers used to 
amplify substrate for in vitro CRISPR cutting assay. The red bars depict amplicon that 
were used for genotyping.  
 
Founder mice were initially genotyped using primers for the -230kb 5’ CRISPR 
cutting assay substrate (Figure 3.86). 
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Figure 3.86: Initial genotyping of the Ccn2Δ230 line. Internal control reaction was carried 
out for each sample, each of which had a strong band. Absence of CRISPR-specific PCR 
product in mice 1.2-2.1, 3.1, 4.1 and 8.1 (red boxes) suggested possible homozygous 
knockouts. The faint bands in lanes for 3.2, 4.2, 5.2 and 6.1 suggested potential 
heterozygosity for enhancer knockout.  
 
This process was repeated using the -230kb 3’ CRISPR cutting assay substrate as 
amplicon of interest (Figure 3.87).  
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Figure 3.87: Further genotyping of founders from the Ccn2Δ230 line. The -230kb 3’ 
CRISPR cutting assay substrate was used as amplicon (see Figure 3.72). PCR product was 
formed from each sample excluding 1.3 (red box). Weak bands were observed for 7.3 and 
8.1 suggesting heterozygosity for knockout of the enhancer.  
 
From four rounds of genotyping with different amplicon 1.3 and 8.1 were chosen as 
potential heterozygotes and bred to produce F1. Resultant offspring were 
genotyped for the presence of the whole -230kb enhancer, with the expectation 
that homozygote knockouts would be found with no PCR product on gel (Figure 
3.88).  
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Figure 3.88: Genotyping of F1 Ccn2Δ230 mice. The whole -230kb enhancer was used 
as amplicon of interest (1.5kb). PCR product was generated in each reaction, illustrating 
that the enhancer was present in every sample and no mouse was homozygous for deletion 
of the region.  
 
Given the strong bands obtained for PCR of the -230kb enhancer in F1 mice, work 
on this line was not continued as deletion of the enhancer had not occurred.  
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. Discussion 
 
4.1 Validation of putative enhancer function 
 
In this thesis, the role of cis-acting regulatory elements in regulation of the Ccn2 
gene was investigated. The data presented here demonstrate that novel enhancer 
regions located -102kb, -137kb, -148kb, -198kb and -230kb upstream of Ccn2 are 
each capable of driving reporter gene expression at E15.5 in transgenic mice (Frost 
et al. 2018) (summarised in Chapter 3.6). The -148kb enhancer drove potent 
chondrocyte based gene expression in both development and adulthood, with a 
truncated version of this region also displaying enhancer activity at E15.5 and in 
mature adulthood. Chondrocyte activity was also exhibited by the -137kb and -
198kb enhancers, in an articular chondrocyte specific, and more broad manner 
respectively. This contrasted the function of -230kb and -102kb enhancers which 
were capable of driving reporter gene expression in osseous tissue and the 
vasculature respectively. The range of cells and tissues in which β-galactosidase 
transgene activity was observed are a reflection of cell-type specific TF 
engagement with the enhancer sequences. These interactions therefore facilitated 
enhancer function which culminated in chromatin organisation that mediated 
transcriptional output from the LacZ reporter gene. Moreover, each of the tissues 
in which β-galactosidase activity was visualised have previously been reported to 
express Ccn2 endogenously (Friedrichsen et al. 2003, 2005; Ivkovic et al. 2003). 
Therefore, enhancer activity reflected regulation of Ccn2 transcription in a highly 
temporospatial specific manner. This echoes many other publications that have 
associated cis-regulatory elements with cognate genes using this methodology and 
ethos (Li et al. 2018; Nord 2015; Pennacchio et al. 2006). Furthermore, limb specific 
enhancers have been well established as fundamental regulators of skeletogenesis 
(Cotney et al. 2012; Infante et al. 2015; Kvon et al. 2016).  
 
4.1.1 Further in silico based evidence supporting enhancer function  
 
Further evidence to ratify the enhancer regions predicted in the current work has 
come from recently released ENCODE datasets in the mm10 Genome Browser 
Build. Upon LiftOver of the 300kb region of interest and putative enhancers 
identified in the mm9 Genome Browser build in the current study, the accuracy of 
enhancer predictions made in the current study can be further scrutinised. Firstly, 
the ‘ENCODE Enhancer-like regions mm10’ track set available as part of the 
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ENCODE Encyclopaedia version 3 at: http://zlab-
annotations.umassmed.edu/enhancers/. This allows the prediction of ‘enhancer-
like’ genomic regions at E11.5 and E14.5 in limb based on H3K27ac and DNase I 
sensitivity (yellow bars, Figure 4.1). Enhancer-like regions predicted at E11.5 limb 
in this data track concur with the -255kb, -137kb and -4kb enhancers identified in 
the current work. This ENCODE track also has prediction of enhancer-like regions 
at E14.5 overlapping with the -255kb, -230kb, -102kb and -4kb enhancers identified 
in the current work. Interestingly, the -198kb enhancer which drove transgene 
activity in three founder embryos at E15.5 in the current project, was not predicted 
to have enhancer-like activity at E14.5, which is unexpected given that based on 
the datasets used in the mm9 browser, the peaks for DNase I sensitivity and 
H3K27ac were comparable to that of -102kb which was given enhancer-like 
predicted function in the new ENCODE data set (Figure 3.1). At E14.5, peaks for 
H3K27ac and therefore active regulatory elements concur with the position of each 
putative enhancer described in the current project. Peaks for this modification were 
greater at E14.5 compared to E11.5, suggesting that at E11.5 enhancers may be 
poised, with greater chromatin accessibility and therefore enhancer activity as 
embryonic development proceeds (Rada-Iglesias et al. 2011).  
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Figure 4.1: UCSC Genome Browser graphic of ENCODE enhancer-like regions upstream of Ccn2 compared to positioning of enhancers described in 
the current study. This dataset plots DNase I hypersensitivity and H3K27ac at E11.5 (B) and E14.5 (C) in order to predict enhancer regions Yellow bars 
represent predicted enhancers, whereas red bars represent predicted promoter regions.. Overlay of this track with the putative enhancers of Ccn2 (A) allows 
further validation of enhancer predictions.  
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Enhancer predictions are also annotated in the recently available candidate 
Regulatory Element (cRE) resource from the ENCODE consortium. This track set 
is available through the Search Candidate cis-Regulatory Elements (SCREEN) 
interface within the ENCODE Encyclopaedia version 4 (available at: 
http://screen.encodeproject.org/) (The ENCODE Project Consortium 2011, 2012). 
This track set is based on data for H3K4me3 and H3K27ac presence in addition to 
DNase I hypersensitivity. Within limb tissue samples, each enhancer predicted in 
the current study is predicted to be a cRE. As with the enhancer-like track, 
regulatory function is acquired after E11.5 for the -230kb and -148kb regions. 
However, this contrasts the findings of enhancer function from the CTGF148 
transgenic mouse line utilised in the current study, in which chondrocyte based 
enhancer activity was observed at E12.5. This enhancer was also active in 
transgenic founders at E11.5. 
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Figure 4.2: cRE data set compilation in mm10 UCSC Genome Browser compared to enhancer positions examined in the current study. These samples 
encompass different time points from E10.5 to E14.5. Red blocks denote promoter predicted activity, yellow blocks for enhancer-like activity and green blocks 
for open chromatin hypersensitive to DNase I. The promoter region for Ccn2 (Ctgf) is prominently marked with red bars at each time-point. There is also a red 
promoter-associated block within the -148kb enhancer region  
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A major oversight in these two ENCODE enhancer prediction track sets is the lack 
of data concerning H3K4me1 and H3K27me3 modification in samples. H3K27me3 
would allow the distinction of repressive chromatin state, and therefore poised 
enhancers, or those that may be active in a different cellular context (Zhu et al. 
2013b). The use of H3K4me1 data would be a much more powerful tool in the 
prediction of the enhancer regions, as it would allow comparison of promoter and 
enhancer function, as carried out using datasets in the mm9 Genome Browser used 
in the current study. The lack of H3K4me1 data is puzzling given the strong 
consensus that this modification is important in enhancer prediction (Creyghton et 
al. 2010; Rada-Iglesias et al. 2011). H3K4me1 is much stronger than H3K4me3 at 
enhancers, with the latter modification being very weakly observed, if at all within 
enhancers (Heintzman et al. 2007). In addition, these ENCODE tracks suggest that 
-148kb is a promoter (red blocks Figures 4.1 and 4.2) based on H3K4me3. In the 
mm9 Genome Browser track set used in the current study, there is a negligible 
peak for H3K4me3 and substantial peak for H3K4me1, thereby suggesting 
enhancer function rather than promoter activity. Moreover, enhancers may be 
distinguished from promoter regions of the basis of the ratio of H3K4me1 to 
H3K4me3 (Calo and Wysocka 2013). The H3K4me3 peak at the true Ccn2 
promoter is much richer than in -148kb in each of the in silico resources, these 
factors therefore suggest that the -148kb region is an enhancer rather than a 
promoter. However, promoter function cannot be completely ruled out, in line with 
the findings of Mikhaylichenko et al. (2018) who found that enhancers may function 
as weak promoters.  
 
However, a further convoluting factor in the function of -148kb is that transcription 
is initiated from within the -148kb enhancer. The ‘Ensembl gene predictions’ track 
within the UCSC Genome Browser shows that a long intergenic non-coding RNA 
(lincRNA), ENSMUST00000134627 is transcribed from within -148kb (Hubbard et 
al. 2002) (highlighted blue box, Figure 4.3). As aforementioned in Chapter 1.3.3.5, 
enhancers may be transcribed to produce eRNA. ENSMUST00000134627 has not 
been characterised, but it is possible that it is the eRNA product of -148kb rather 
than a lincRNA (Kim et al. 2015). None of the other enhancers identified within the 
current study are co-localised with the location of lincRNA (Figure 4.3). Beyond the 
scope of the current project, future work examining the expression of this transcript 
would be pivotal in understanding -148kb. Most important would be ascertainment 
as to whether the transcript produced near this locus is eRNA, and if so, how does 
it function in the activity of the -148kb enhancer. This could occur through eRNA 
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interaction in chromatin looping or transcriptional elongation at Ccn2. Furthermore, 
assay of ENSMUST00000134627 and Ccn2 expression in various tissues and at 
different time points could enable refinement of the understanding of the specific 
temporospatial circumstances in which the enhancer functions. In vivo findings 
suggest that the enhancer functions most potently in chondrocytes (Chapter 3.4). 
This idea would be reaffirmed if the transcript was most abundant in chondrocyte 
cells and cartilaginous tissue. This therefore leads to the question as to whether 
ENSMUST00000134627 participates in enhancer activity, or its location is a 
coincidence with the lincRNA functioning in a completely different process 
unrelated to the enhancer? However, the fact that the -148kb full and short 
transgenic construct versions of the enhancer were able to drive reporter gene 
expression would suggest that ENSMUST00000134627 is not essential in its 
function. ENSMUST00000134627 is produced from approximately 600bp into the 
enhancer sequence through to approximately 3.2kb downstream of the 3’ enhancer 
boundary. Reporter gene constructs contained the enhancer alone spanning from 
5’ boundary to 3’ boundary of the enhancer sequence and therefore the full 
ENSMUST00000134627 transcript could not be transcribed. This would suggest 
that the RNA is not necessary in the function of the enhancer, as the enhancer 
sequence alone drove reporter gene expression. Moreover, the -148kb short 
transgenic line construct did not contain the start site for the 
ENSMUST00000134627 transcript. These findings highlight the need for further 
examination of the enhancer and the mechanism through which it increases 
transcriptional output. 
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Figure 4.3: UCSC Genome Browser graphic of transcripts occurring within region upstream of Ccn2. Transcripts from the ENSEMBL Gene Prediction 
Track (D) are produced bi-directionally from the promoter for the gene. The transcripts produced in a downstream to upstream direction are probably uaRNA 
that are a consequence of RNA pol II occupation at the promoter, with no protein coding potential. The only transcript produced near any enhancer is 
ENMUST00000134627 which is transcribed from within the -148kb enhancer (highlighted with blue box).  
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Predictions of enhancer function can also be bolstered by transcription factor-DNA 
interaction datasets. Moreover, Dogan et al. (2015) recommend that TF interaction 
with DNA sequence is a more reliable indicator of enhancer function than histone 
modification alone, with the suggestion that false predictions may be made using 
chromatin modification datasets only. The findings of Kwasnieski et al. (2014) 
support this with activity demonstrated in 26% of enhancers predicted using 
ENCODE dataset histone modifications, with the suggestion that TFBS are a more 
accurate tool in predicting enhancer activity. Of course, a major consideration in 
the use of ChIP-Seq datasets is the context in which the binding of protein to DNA 
was assessed i.e. the cell type or tissue assayed. This must be considered in 
drawing conclusions about the temporospatial context in which an enhancer 
functions and the cell signalling mechanisms that underpin this. For example, false 
negative relationship between an enhancer and TF may be observed regarding an 
enhancer that is only active during embryonic development yet a ChIP-Seq sample 
from adult tissue is used to look for TF-enhancer binding. Furthermore, a major 
attribute of enhancers is the plasticity in TF binding dependent on cellular context, 
with the change in chromatin state and transcription factor occupancy over time 
dictating refined gene transcription in a highly specific temporospatial manner 
(Creyghton et al. 2010; Spurrell et al. 2016).  
 
The assay of histone acetyltransferase p300 binding to DNA has been shown to be 
an effective tool in the identification of enhancer regions, with Visel et al. (2009) 
using ChIP-Seq of p300 to predict enhancer regions that were subsequently 
validated in vivo. Although not carried out during the prediction of enhancers for the 
current project, p300 can nonetheless provide further evidence for the enhancer 
function of the cis-acting regulatory regions described herein. Application of p300 
ChIP-Seq in mouse embryonic fibroblast cells (MEFs) dataset (GEO DataSet 
GSM2417166, Chronis et al. (2017)) to the intergenic region that was the focus of 
the current project serves as further validation of the enhancer regions described 
in, as demonstrated in Figure 4.4. There is a peak for p300 interaction within each 
of the putative Ccn2 enhancers. In addition, although peaks are spread throughout 
the 300kb region upstream of Ccn2, they are more concentrated in the vicinity of 
the enhancers identified herein.  
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Figure 4.4: ChIP-Seq validated binding of p300 within the intergenic region upstream of Ccn2. GEO DataSet GSM2417166 (Chronis et al. 2017) regarding 
ChIP-Seq validated interaction between p300 histone acetyltransferase and DNA in mouse embryonic fibroblasts cells, incorporated into the 300kb region 
upstream of Ccn2 (B and C) provides many peaks that illustrate interaction between p300 and the genomic sequence. Many of the peaks fall within enhancers 
of Ccn2 described in the current project (A). Peaks are aligned with enhancer associated chromatin characteristics (D) and evolutionary conservation of 
sequence (E) 
p300 MEF 
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The accuracy of in silico predictions is drawn into question with the -255kb putative 
enhancer. In the mm9 Genome Browser session used to predict enhancers (Figure 
3.1 and D), the region was highly conserved and the peaks for H3K4me1 and 
H3K27ac were substantially larger for -255kb compared to those of the other 
putative enhancers. There is also a peak for p300 within the region (Figure 4.4). In 
addition, this region is the only annotated to function at both E11.5 and E14.5 in the 
enhancer-like ENCODE track and is predicted to function from E12.5 in the cRE 
track (Figures 4.1 and 4.2 respectively). It would therefore be expected that this 
region would function as a strong enhancer in vivo, driving high levels of reporter 
gene expression in the transgenic model. This however was not the case, with no 
positive staining for β-galactosidase activity in any founder. This was also true for 
the -4kb putative enhancer. Although beyond the scope of the current project due 
to time and fiscal constraints, more experimental repeats of the creation of 
transgenic mice harbouring the enhancer driving reporter gene expression should 
be conducted before the -255kb and -4kb regions are ruled out as enhancers.  
 
4.1.2 -102kb functions as an enhancer in the vasculature 
 
The only previous attempt to examine enhancers within the region upstream of 
Ccn2 was made as part of the VISTA Enhancer Browser (Visel et al. 2007b). In this 
study, the only enhancer of Ccn2 that was posited concurred with a 1680bp 
fragment within the 2282bp -102kb enhancer described herein. The VISTA group 
examined this region at E11.5 in founder reporter transgenic mice and found it to 
be non-functional. In the current study, the -102kb enhancer functioned in a highly 
reproducible manner within the superficial vasculature at E15.5 (Chapter 3.2.2). 
This suggests that the enhancer is inactive at E11.5, and activated by E15.5, or 
that the full sequence of the enhancer is required for function. This latter idea is not 
likely as the most conserved part of the sequence, and region with histone 
modification peaks sits in the middle of the enhancer and were present in both 
transgenic constructs.  
 
The localisation of -102kb function tallies with previous studies that have 
demonstrated Ccn2 expression within the vasculature (Friedrichsen et al. 2003). 
Shimo et al. (1999) demonstrated that CCN2 functions in the proliferation, migration 
and adhesion of vascular endothelial cells. Hall-Glenn et al. (2012) used transgenic 
mice harbouring LacZ under control of the -4kb to TSS of Ccn2 (outlined in Chapter 
1.4). This group observed β-galactosidase activity throughout the vasculature at 
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E13.5. Moreover, this included the dermal microvasculature; akin to the pattern 
observed within the current study. A broader 160kb genomic fragment controlling 
GFP expression within the BAC system (described in Chapter 1.4) drove transgene 
expression within both vascular smooth muscle cells within large arterial vessels in 
addition to endothelial and mural cells of the microvasculature (Hall-Glenn et al. 
2012). An important finding from this work was that microvasculature of Ccn2 
embryos was aberrant with defective vessel maturation. Endogenous function of 
the -102kb enhancer therefore may act to reinforce microvasculature based 
expression of Ccn2 and subsequent vessel maturation. The findings of Hall-Glenn 
et al. (2012) were observed within the microvasculature of several tissues later in 
embryonic development than tested in the current study. It would therefore be 
useful to further examine -102kb activity at more time-points than E15.5, with the 
possibility that the enhancer continues to function as microvasculature vessels 
mature. 
 
Upon inputting the -102kb sequence into the TRAP database, several transcription 
factors with vascular or endothelial function are predicted to bind within the 
enhancer (Chapter 5.5). There are several consensus binding sites for MEF2, c-
MYC, ETS2, GATA and HIF2α within the -102kb enhancer. Each of these 
transcription factors is important in endothelial cell function and angiogenesis (De 
Val and Black 2009; Skuli et al. 2009; Wei et al. 2009). Beyond the scope of the 
current project, further work is required in order to validate the interaction between 
these TF and cognate sequence within -102kb. Nonetheless, the TRAP results do 
support the finding from the in vivo reporter gene assay that -102kb primarily 
functions in endothelial cells during angiogenesis and the development of the 
vasculature. Future work should validate this with EMSA experiments examining 
the capacity of transcription factors to bind to these sequences.  
 
4.1.3 -137kb enhancer functions in articular cartilage  
 
Highly reproducible transgene expression was also driven by the -137kb enhancer 
in vivo (Chapter 3.2.3). Chondrocytes were the only cell type in which transgene 
activity was observed at E15.5, with the enhancer only functioning within a specific 
sub-population of chondrocytes in proximity to articular joints. This occurred most 
notably within the elbow, knee, wrist and ankle. In addition, X-gal staining was 
reduced with distance from the joint surfaces (Chapter 3.2.3, Figures 3.6 and 3.7). 
There was no β-galactosidase activity within the stylopod articular chondrocytes of 
248 
the shoulder and hip. Interestingly, in silico prediction of enhancer function 
suggests that the -137kb enhancer is active at E11.5, with reduction in activity and 
open structure of chromatin by E14.5 (Figure 4.1). The temporal organisation of 
limb development with regard to proximal to distal advancement of differentiation, 
combined with these findings suggest that the enhancer functions in a highly 
temporospatial manner to drive the expression of Ccn2 during joint formation. In 
addition, the change in X-gal staining intensity with distance from the joint tallies 
with models of joint development where early joint cells are pushed into the 
endochondral epiphysis over time (Shwartz et al. 2016). Moreover, a limitation in 
the use of LacZ reporter genes is the half-life of the β-galactosidase protein, with 
the enzyme persisting in a cell after the enhancer regulating its expression has 
been, and is no longer active (Bi et al. 1999). Therefore, -137kb may have 
functioned more potently at an earlier time-point in the early interzone and articular 
chondrocytes of the shoulder and hip joints, but using the E15.5 time-point of the 
current study this activity would not be observed. Moreover, in ChIP-Seq datasets 
pertaining to active regulatory histone modification H3K27ac within the limb at 
E11.5 (Infante et al. 2015) (GSE64055), -137kb is the only enhancer that was 
validated in the current project to contain peaks for interaction and therefore the 
regulatory function associated histone modification at this time point (Figure 4.5).  
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Figure 4.5: UCSC Genome Browser visualisation of ChIP-Seq datasets for H3K27ac in E11.5 limb. Import of H3K27ac ChIP-Seq datasets of limb tissue 
at E11.5 (Infante et al. 2015) (A) enable refinement of the estimation of enhancer function earlier than the E15.5 time-point used in reporter gene assay in the 
current study (B) . Across three tissue samples there are peaks for H3K27ac and therefore active regulatory function in the -137kb enhancer and CCN2 promoter. 
The -148kb enhancer functioned in vivo at E11.5 but not strongly within limb tissue which may explain why there is no peak for H3K27ac in any sample (A). The 
greater number of peaks for H3K27ac at E14.5 (C) suggests the chromatin is remodelled to acquire regulatory function between E11.5 and E14.5  
H3k27ac 
E11.5 limb 
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Enhancer function specific to articular tissue has been demonstrated in previous 
studies, such as that of Chen et al. (2016) who describe cis-regulatory elements 
that drive expression of GDF5 within specific sub-populations of chondrocyte and 
joint cells. This study found discrepancy in enhancer function between proximal and 
distal joints, as observed in the current work. GDF5 could be a regulator of Ccn2 
expression within the articular joint through the function of the -137kb enhancer. 
Furthermore, the pattern of the β-galactosidase expression pattern driven by the 
enhancer is similar to GDF5-related LacZ expression that has been observed in 
several previous studies (Chen et al. 2016; Koyama et al. 2008; Shwartz et al. 
2016). Transcription factors that function downstream of GDF5 such as Smad1/5 
are not predicted to bind within the -137kb enhancer upon input of either the full 
enhancer or short region sequence into the TRAP tool (Chapter 5.5). The lack of 
enhancer function within the joint cavity tallies with the expression of SOX9 which 
is not found within developing joints after E14.5 (Soeda et al. 2010). Moreover, the 
SOX9 consensus binding site validated by EMSA in the current study could be 
utilised by SOX9 in regulating Ccn2 transcription during early articular joint 
formation. Therefore, as SOX9 expression is lost within this region as development 
proceeds, enhancer function would also decrease. Of course, SOX9 expression is 
retained throughout the endochondral anlage until the hypertrophic zone, and 
enhancer function was only found near to the articular zone, suggesting that further 
transcription factors are required in order to direct enhancer activity that is specific 
to articular chondrocytes within this narrow differentiation period. This highlights the 
complexity in the regulatory interactions that underpin joint formation and the need 
for further elucidation of -137kb activity within this process. Future work should seek 
to define how activity of the enhancer changes throughout joint development. 
Principle in this would be application of -137kbHsp68LacZ construct used herein to 
further developmental time-points such as E11.5 and E13.5 whereby the role of the 
enhancer within joint would be better characterised. 
 
The -137kbshortHsp68LacZ construct could also be examined in this process. Our 
attempt to create transgenic mice harbouring this construct was unsuccessful in 
this project. Repetition of this process with more founder animals would enable 
determination of how much of the putative sequence is required for the function of 
the enhancer. Another important facet of future study would be further examination 
of the TF that facilitate enhancer function, thereby allowing better understanding of 
the signalling mechanisms that dictate joint formation and the role of Ccn2 in this 
process.  
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4.1.4 The -148kb enhancer drives gene transcription within chondrocytes  
 
The most prevalent enhancer activity in vivo was driven by the -148kb enhancer 
(Chapter 3.3-3.5). In endochondral ossification, -148kb functioned in hypertrophic 
chondrocytes in each reporter transgenic founder at E15.5. The creation of the 
CTGF148 line enabled greater characterisation of ability of the enhancer to regulate 
gene transcription at several time points. The most potent β-galactosidase activity 
occurred within cartilaginous tissue during both embryonic development and 
adulthood (Chapter 3.4). This tallies with the need for CCN2 expression within 
cartilaginous tissue and the severe phenotype resulting from ablation of Ccn2 
expression in chondrocytes (Ivkovic et al. 2003). -148kb functioned strongly in 
hyaline cartilage on a global scale in elements such as the costal cartilage and 
articular cartilage from cartilage anlage in development through to established 
cartilage in mature adulthood. Transgene activity was also recorded in 
fibrocartilage, such as within the intervertebral disc. Whilst the whole endochondral 
growth plate is transgene positive at E15.5, the chondrocyte specific nature of 
enhancer function from this time-point onwards is indicated by the stratification of 
activity as ossification is advanced at E17.5, with loss of transgene activity in 
osseous cells and tissue. Indeed, as aforementioned, the transgene activity may 
reflect enhancer function at an earlier time-point due to β-galactosidase protein 
half-life. 
 
In embryonic development, the results of both Friedrichsen et al. (2003) and Ivkovic 
et al. (2003) demonstrate endogenous Ccn2 expression within cartilage globally, 
such as within the chondrocranium, ribs, vertebrae, limbs, and digits, matching the 
patterns observed for -148kb activation during embryonic development. Enhancer 
activity within the Meckel’s cartilage recapitulated the work of Shimo et al. (2004) 
who demonstrated endogenous expression of Ccn2 within this tissue during 
embryonic development. Much of the work concerning CCN2 within cartilage has 
not focused on characterising the expression profile of the gene and protein at 
several time-points, but more commonly ex vivo study of cartilage explants. 
However, CCN2 expression has been observed in adult articular cartilage, akin to 
the transgene in the current study (Kubota and Takigawa 2011).  
 
Transgene expression within adult articular cartilage was also demonstrated by a 
truncated version of the -148kb enhancer in the -148kb_short D transgenic line 
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variant. In this line variant and for founder A progeny, the enhancer also drove 
chondrocyte and perichondrium based transgene expression at E15.5, akin to the 
endogenous expression of Ccn2 (Ivkovic et al. 2003). These findings suggest that 
chondrocyte based transcription is directed from an element within this truncated 
region, but the full enhancer sequence is required for increased transcriptional 
output. Moreover, the variability of transgene expression in several tissues 
suggests that specificity in enhancer function directing expression in a 
temporospatial manner was reduced. A pertinent question is whether the enhancer 
sequence of approximately 1kb removed in the creation of -148kb_short would 
function in vivo if a lacZ reporter construct was created for this variant and tested 
in transgenic mice. This would allow further refinement of the understanding of the 
function of the sequences within the enhancer.  
 
4.1.5-198kb enhancer function  
 
The variety in reporter gene expression pattern and low number of founder embryos 
generated in the study of -198kb function hampered attempts to characterise the 
role of the enhancer, and tissue-type in which it functions most potently. If the 
expression pattern of founder A is true, with strong enhancer function within 
hypertrophic chondrocytes, it would suggest that the -198kb region would function 
as a further enhancer of Ccn2 transcription within chondrocytes. Whilst beyond the 
means of the current study, further repeats of -198kbHsp68LacZ assay at E15.5 
are required in order to validate this.  
 
4.1.6 The -230kb enhancer drives gene transcription within osseous tissue 
 
Transgene expression driven by the -230kb enhancer was observed within osseous 
tissue. There was however some variation in the time point that the enhancer was 
active within the two founder variant progeny. At E15.5 founder A gave rise to 
potent LacZ expression within periosteal tissue and within the primary ossification 
centres of long bones. The progeny of founder C did not exhibit transgene 
expression at E15.5, yet primary spongiosa osteoblasts were positive for β-
galactosidase activity at P7 and six weeks before repression in mature adulthood. 
The osteoblastic nature of expression suggests that TF involved in bone cell 
lineage commitment are predominant in the regulation of the function of -230kb, 
bestowing osteoblast specificity in enhancer activity and therefore Ccn2 
transcription. This would follow further studies that have demonstrated osteoblastic 
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expression of Ccn2 (Arnott et al. 2011). However, further validation of this is 
required through the in vivo assay of enhancer function in founder transgenic 
reporter mice such as with repetition of -230Hsp68LacZ line generation. Further 
important information would have also been gleaned through the assay of β-
galactosidase activity in Founder A in adult, however tissue samples were not 
available in order to allow this.  
 
4.1.7 In vitro validation of enhancer function 
 
Discrepancy between the modelling of enhancer activity and in vivo validation of 
function is highlighted by comparison of the results from in vitro and in vivo assay 
of enhancer capacity to drive reporter gene expression. This was exemplified by 
the fact that the -4kb and -255kb regions drove luciferase reporter gene expression 
in vitro yet neither demonstrated function in any in vivo assay that was carried out. 
This could however be due to sample size or function at a different time point.  
 
Moreover, the reporter gene expression induced by both of these regions in vitro 
was greater compared to that of the enhancers proven to function in vivo. 
Ultimately, the results of in vitro reporter gene assays described herein 
demonstrate that the enhancer regions can drive gene expression in tandem with 
the Ccn2 promoter region, but do not aid in understanding the regulatory 
interactions that facilitate enhancer function. Episomal DNA in reporter plasmids 
can acquire chromatin characteristics, and therefore be a better representative of 
the endogenous enhancer than plasmid DNA alone (Catarino and Stark 2018). 
However, the TF that dictate enhancer function may not be present in immortalised 
cell lines. For example, the HTB-94 chondrosarcoma line used herein has been 
shown to exhibit limited similarity in gene transcriptional profile with primary 
articular chondrocytes (Gebauer et al. 2005). Expression of Sox9 within TC28-i2 
cells have been used to demonstrate the effectiveness of this cell type in modelling 
chondrocyte function, yet primary chondrocytes are still posited as a better model 
(Finger et al. 2003). In the current study, use of the SOX9 TFBS containing -137kb 
and -230kb enhancer regions within TC28-i2 cells did not lead to marked changes 
in transcriptional output compared to the use of the Ccn2 promoter alone.  
 
Future attempts to study function of Ccn2 enhancers within a chondrocyte context 
in vitro should utilise primary chondrocytes or the ATDC5 cell line. Primary 
chondrocytes most accurately reflect in vivo chondrocyte behaviour. ATDC5 cells 
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can be stimulated to undergo chondrogenic differentiation and are well regarded as 
an in vitro model of endochondral ossification (Yao and Wang 2013). During 
differentiation, ATDC5 cells express TF and ECM proteins in a similar manner to 
chondrocytes in vivo (Akiyama et al. 2000; Chen et al. 2005). Enhancer activity 
could be assayed at several time points in ATDC5 differentiation in order examine 
if enhancer activity changes as the prevalence of cell lineage-specific transcription 
factors such as SOX9 and RUNX2 change. For example, it would be expected that 
activity of the -137kb and -148kb enhancers would decrease with change to 
osteoblastic cell prevalence, whereas the activity of -230kb would increase in this 
late stage of differentiation. Beyond the time-frame of the current project, further 
work should also focus on the effect of manipulating cell signalling pathways on 
enhancer activity. For example treatment with cytokines such as IL-1β, TGF-β or 
knockdown of protein expression using siRNA would enable further understanding 
of the key TF-DNA interactions and the context in which they occur in controlling 
enhancer activity.  
 
4.1.8 In vivo function most accurately reflects endogenous enhancer activity  
 
All of these findings highlight the fact that there are some limitations with the 
annotation of enhancer function using in silico and in vitro approaches; however, 
they are nevertheless useful in the preliminary stages of enhancer identification 
(Catarino and Stark 2018). Many predicted enhancers do not function in vivo 
(Pennacchio et al. 2006), thus in vivo assay of reporter expression driven by 
enhancers gives the most faithful recapitulation of endogenous enhancer activity. 
In vivo, the array of signalling mechanisms and transcription factors are 
endogenous and correspond to a specific cell type at a defined time-point. 
Moreover, the enhancer function within a cell type, tissue and whole organism can 
be assessed in one assay (Kvon 2015; Nord 2015). The complex signalling 
mechanisms that underpin the behaviour of a cell within its physiological tissue 
environment is lost in vitro, thereby limiting the ability to understand enhancer 
activity within immortalised cell lines.  
 
However, the in vivo system employed herein is still error prone in the assessment 
of enhancer function due to transgenic construct site of integration within the 
genome. The constructs were not directed to specific genomic loci during 
integration, and therefore landed within an uncontrolled and unknown portion of the 
genome (Nord 2015). Transgenic enhancer activity therefore does not reflect the 
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chromatin landscape in which the enhancer is found endogenously and the 
interactions that underlie chromatin topology in enhancer function (Catarino and 
Stark 2018). Moreover, regulatory elements from other genes could have a bearing 
on enhancer activity resulting in non-specific gene expression. This therefore 
highlights the need for many replicates of founder transgenic animals in order to 
ascertain reporter gene expression that is true to the function of the enhancer 
(Pennacchio et al. 2006). This is also emphasised by the fact that in the current 
study, some embryos and adult mice were genotyped as being positive for 
transgenic construct, yet no transgene function was observed, contrasting other 
founders bearing the same construct in which an enhancer was active.  
 
4.2 What regulates enhancer function in skeletogenesis? 
 
Given the complicated hierarchy of transcription factors that bind to any enhancer, 
it would be expected that several lineage-specific TF bind with co-activators in order 
to refine enhancer activity in a highly specific temporospatial manner. However, 
identification of TFBS within the enhancers does allow some refinement of the 
understanding of the signalling mechanisms that dictate and regulate enhancer 
function. Ultimately, future mutation of key TFBS within each enhancer and analysis 
of the impact on enhancer function will allow the identification of the lynchpin 
sequences that are fundamental in enhancer activity and therefore Ccn2 
transcription.  
 
4.2.1 SOX9 is capable of interacting with -137kb, -148kb and -230kb  
 
As stated earlier, ChIP-Seq is an important method in the study of enhancer 
regions. Aside from the identification of enhancer regions, this technique can also 
be used in the characterisation of enhancer regions and the regulatory mechanisms 
that control function. Ultimately, the work in the current project would have been 
greatly improved through the application of ChIP-Seq in order to further examine 
and validate SOX9 TFBS and their utilisation within chondrocytes. Nevertheless, 
publicly available ChIP-Seq datasets were useful in the identification of TF 
consensus binding sites that were subsequently examined using EMSA, and can 
be used to speculate as to which signalling mechanisms regulate enhancer 
function.  
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As mentioned in Chapter 1.1.2, He et al. (2016) hypothesise that synergistic AP-1 
–SOX9 interaction is important in driving chondrocyte hypertrophy. The data 
generated in this study regarding AP-1 family member Jun binding within the 
genome of P1 derived rib chondrocytes is publicly available as part of the GEO 
DataSets repository: GSM1891979 (He et al. 2016). This data complements 
previous work by this group examining SOX9 binding in the same samples 
(GSM1692996, (Ohba et al. 2015); as used in Chapter 3.6.1). These datasets can 
be compiled in the Ccn2 enhancer UCSC Genome Browser session in order to 
examine the co-localisation of SOX9 and AP-1 binding and the positioning of the 
SOX9 sites discovered herein. According to these ChIP-Seq datasets, SOX9 and 
AP-1 are predicted to bind in the -137kb and -148kb enhancers which functioned 
in chondrocytes, in addition to the -230kb enhancer which functioned within 
osseous tissue (Figures 4.6- 4.8). However, in the TRAP predicted TFBS, AP-1 is 
only predicted to bind within -137kb. This highlights discrepancy in computationally 
predicted TFBS and experimentally validated ChIP-Seq interaction sites; the latter 
of which is more biologically relevant and reliable (Visel et al. 2009a).  
 
In the -137kb enhancer, the SOX9 TFBS validated through EMSA (Figure 4.6, A) 
lies upstream of the AP1 site (Figure 4.6, B) and both of these sequences overlap 
with SOX9 ChIP-Seq sites (Figure 4.6, C). In the -148kb enhancer, ChIP-Seq peaks 
for AP-1 and SOX9 co-segregate into two clusters (Figure 4.7 C and D). Both of 
the EMSA validated SOX9 TFBS (Figure 4.7 B) lie in the 5’ cluster of sites that were 
not present in the -148kb_short transgenic mice which had a truncated stretch of 
the -148kb sequence (Figure 4.7 A). This could therefore account for the reduction 
in chondrocyte based transgene function within the -148kb_short line compared to 
transgenic mice created with the whole enhancer reporter construct. A clear and 
conserved SOX9 consensus site within the 3’ cluster of ChIP-Seq peaks was not 
clearly discernible in EMSA probe design, but should be investigated in future work.  
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Figure 4.6: UCSC Genome Browser visualisation of SOX9 and Jun ChIP-Seq validated binding within the -137kb enhancer region. EMSA validated 
SOX9 binding motif (A) lay within close proximity to ChIP-Seq peaks for Jun TFBS (B, GSM1891979) and SOX9 (C, ) (Garside et al. 2015; Ohba et al. 2015), 
and in close proximity to a Jun ChIP-Seq peak (B) (He et al. 2016). In line with findings of He et al. (2016), Jun may interact with SOX9 in order to drive the 
function of the enhancer in chondrocyte specific expression of Ccn2 
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258 
 
 
 
Figure 4.7: UCSC Genome Browser visualisation of SOX9 and Jun ChIP-Seq validated binding within the –148kb enhancer region. EMSA validated 
SOX9 binding motifs (B and C) lay upstream of the -148kb sequence used for the -148kb_short transgenic mouse line (A). ChIP-Seq peaks for chondrocytic 
SOX9 and Jun interaction were split within two clusters, as with other enhancer associated attributes and sequence conservation.(He et al. 2016; Ohba et al. 
2015) The EMSA validated SOX9 TFBS lay within both SOX9 and Jun peaks of interaction (D), supporting the study of He et al. (2016) with the notion that both 
of these TF direct chondrocyte transcription of Ccn2 through this enhancer element.  
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In accordance with the findings of He et al. (2016), the presence of both 
transcription binding sites would suggest that both AP-1 and SOX9 act 
synergistically in facilitating the activity of the enhancer and transcriptional output 
from Ccn2. Figures 4.6 and 4.7 therefore would suggest that Jun and SOX9 co-
localise within the -137kb and -148kb enhancers with concurrent function of both 
TF increasing the transcriptional output from Ccn2 via enhancer regions. These 
samples were isolated from postnatal tissue suggesting that the -137kb enhancer 
functions later than at the E15.5 time-point examined with the current in vivo 
reporter assay system. Further pertinent experiments would involve ratification of 
this theory through assay of enhancer function at P1 and comparison with E15.5. 
In addition, ChIP-Seq experiment using articular chondrocytes isolated from E15.5 
embryos would enable elucidation as to whether interaction with both AP-1/Jun and 
SOX9 combined boosts enhancer activity.  
 
The -230kb enhancer also contains sites for both AP-1 and SOX9 (Figure 4.8), but 
in vivo reporter assay suggests that this region is more active in osteoblastic cells 
than chondrocytes. On the basis of the findings of He et al. (2016) it would therefore 
be expected that the enhancer most probably interacts with one of the transcription 
factors, and that the other blocks the function of the enhancer within chondrocyte 
cells. Of course, this data doesn’t account for protein-protein interaction which may 
be the manner in which chondrocyte based enhancer activity is blocked.  
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Figure 4.8: UCSC Genome Browser visualisation of SOX9 and Jun ChIP-Seq validated binding within the –230kb enhancer region. EMSA validated 
SOX9 binding motif (A) lies within a SOX9 ChIP-Seq peak (C,(Garside et al. 2015)) but not within Jun ChIP-Seq peak. The lack of transgene activity in 
chondrocytes as a results of -230lkb function suggests that the TF may not bind cooperatively, and may antagonise one another in order to prevent chondrocyte 
based enhancer function, in line with the findings of He et al. (2016).  
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At E15.5, for founder A of the -230kbHsp68LacZ line, the enhancer was active 
within periosteal cells, and osteoblasts within long bone primary ossification centre. 
There was no transgene activity for E15.5 derived from founder C, but at P7 and 
six weeks of age the enhancer functioned within osseous tissue. CCN2 has been 
proven to function in both chondrocyte and osteoblastic cells (Arnott et al. 2011; 
Ivkovic et al. 2003). If AP-1 and SOX9 bind in tandem to cognate DNA motifs within 
-230kb to drive enhancer function in line with the findings of He et al. (2016), the 
enhancer may function in trans-differentiation of hypertrophic chondrocytes to 
osteoblasts, with promotion of osteoblastic behaviour. This theory could be tested 
using a Cre-recombinase approach. A transgenic mouse construct containing Cre 
under control of the enhancer region would lead to Cre expression in cells where 
the enhancer was active. Crossing this mouse line with a reporter transgenic line 
such ROSAmT/mG would enable tdTomato (mT) signal to be observed in cells where 
the enhancer was inactive. Where the enhancer was active and Cre was produced, 
in the presence of tamoxifen, cells in which the enhancer was active and resultant 
daughter cells would produce GFP (mG) signal. Therefore, for -230kb, if the 
enhancer was inactive at E13.5 in chondrocytes signal red mT would be abundant. 
By E15.5, if the enhancer was active in hypertrophic cells green mG signal would 
be observed. In osteoblastic cells derived from these chondrocytes, mG signal 
would also be produced at later time-points. This would therefore allow lineage 
tracing of enhancer activity. Moreover, the role of CCN2 in chondro-osseous 
lineage switching could also be explored; a concept which has not been elucidated. 
This lineage-tracing approach could be applied for any of the enhancers described 
herein, in order to ascertain the role of the enhancers in cell lineage fate 
commitment. This a highly relevant question given the importance of enhancer 
function in cellular programming (Bogdanović et al. 2012; Huang et al. 2016) 
 
A further consideration in the osteoblastic expression observed for the -230kb 
enhancer is the role of Wnt signalling. This pathway has been well documented as 
a repressor of activity (Kozhemyakina et al. 2015). Wnt signalling through β-catenin 
and SOX9 have been proven to antagonise the function of one another in skeletal 
development (Akiyama et al. 2004). Both SOX9 and TCF-LEF contain high mobility 
group box domains which mediate binding of the protein similar target consensus 
sequences DNA target resulting in DNA bending (Karsenty and Wagner 2002). The 
work of Huang et al. (2010) sets a precedent for antagonism between SOX9 and 
TCF-LEF/β-catenin in the regulation of Ccn2, in the vicinity of the promoter, as 
aforementioned in Chapter 1.4. Therefore, TCF-LEF/β-catenin may interact with 
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the -137kb and -230kb enhancers repressing SOX9 activity and chondrocyte based 
Ccn2 expression. This change could occur in late endochondral ossification with 
the switch from the dominance of cartilage to osseous tissue (Mackie et al. 2008). 
Within the EMSA probes designed for the putative SOX9 binding sites for -137kb 
and -230kb, TCF-LEF was also predicted to bind. Whilst beyond the scope of the 
current project, it would be pertinent to examine in further EMSA experiments 
whether TCF-LEF interacts with the enhancers through these sequences.  
 
4.2.2 Do other transcription factors regulate chondrocyte based -148kb 
function?  
 
Given the high levels of gene transcription driven by the -148kb enhancer within 
chondrocytes, it would be assumed that the master regulator of chondrocytes, Sox9 
would be the lynchpin TF in the function of this enhancer region. This regulation 
was not immediately clear with a lack of SOX9 consensus sites using the TRAP 
tool (Chapter 5.5). Nonetheless, SOX9 was proven to bind to sequences within this 
enhancer region. However, these EMSA validated TFBS (Chapter 3.8.2) lay within 
the 5’ sub-region of -148kb that was not used to create the -148kb_short 
Hsp68LacZ transgenic mice, yet chondrocyte expression, albeit weak, was still 
observed within founder variants of this line. This therefore piques interest as to 
whether SOX9 is the lynchpin transcription factor in -148kb chondrocyte function. 
Despite the strong consensus as to SOX9 being the master regulator of 
chondrocytes, its role as a pioneer factor in chondrocytes has recently been 
questioned. Liu et al. (2018) demonstrated that during chondrogenesis, SOX9 is 
not required for the removal of repressive epigenetic state and chromatin 
reprogramming; therefore SOX9 did not behave as a pioneer factor. This suggests 
that further transcription factors are required as pioneer factors in the 
commissioning of -148kb enhancer function in order to drive gene transcription 
during chondrogenesis.  
 
The results from EMSA analysis of RUNX2 TFBS within -148kb (Chapter 3.8.3) did 
not conclusively prove TF-enhancer sequence interaction. Of the three probes 
examined, -148kb RUNX2_3 is more likely to be bound by RUNX2 with the small 
shift in probe signal indicating that there may be weak interaction between the 
protein and DNA. In addition this interaction was reduced with the use of wild-type 
competitor oligonucleotide in a dose dependent manner. 
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The fact that the enhancer functioned in the articular cartilage of both CTGF148 
and -148kb_short mice suggests that a factor within the 1.5kb enhancer fragment 
mediates chondrocytic function. The markedly stronger transgene expression 
within articular cartilage of CTGF148 mice compared to -148kb short could have 
been due to chondroprotective SOX9 interaction in the 5’ sub-region of the 
enhancer that was not present in the short transgene construct (Henry et al. 2012). 
The β-galactosidase expression driven by -148kb was observed in articular 
cartilage that had physiological appearance rather than with osteoarthritic 
degradation or clefts, suggesting that -148kb is not regulated by RUNX2 within 
adult articular cartilage. RUNX2 in articular cartilage encourages hypertrophic 
phenotype and induction of the expression of catabolic genes such as MMP13, and 
therefore OA like changes in cartilage matrix (van der Kraan and van den Berg 
2012). Loss of enhancer function over time tallies with chondroprotective role for 
CCN2 with enhancer loss of activity and therefore CCN2 within articular cartilage 
with age. RUNX1 could also regulate the enhancer through interaction with 
consensus sequences that are redundant with those of Runx2. Furthermore, 
RUNX1 expression has been observed in non-OA articular cartilage, with a 
suggestion that this transcription factor is involved in superficial zone chondrocyte 
proliferation (LeBlanc et al. 2015). RUNX2 could regulate enhancer function within 
hypertrophic chondrocytes of the growth plate which also demonstrated in vivo 
transgene activity in adulthood. These findings highlights the issue of trying to 
predict TFBS based on ChIP-Seq data from other tissues, as with the use of 
RUNX2 ChIP-Seq in trying to predict RUNX2 sites within chondrocytes. ChIP-Seq 
interrogation of the interaction between enhancer sequences and RUNX1/2 in 
various populations of chondrocytes at numerous time-points would yield powerful 
information with regards to the capacity of Runx to regulate enhancer activity.  
 
ChIP-Seq data also suggests that DLX5 is capable of binding to sequences within 
-148kb during osteoblastic differentiation (GSE76185, Hojo et al. (2016)), as 
illustrated in Figure 4.9. DLX5 has been proven to be involved in the promotion of 
chondrocyte maturation and transition to chondrocyte hypertrophy in endochondral 
ossification (Ferrari and Kosher 2002; Zhu and Bendall 2009). Therefore, it is 
logical that the ChIP-Seq peaks contain TFBS that are utilised by DLX5 in 
mediating enhancer function in driving Ccn2 transcription in the promotion of 
chondrocyte hypertrophy. Further characterisation of DLX5 regulatory sequences 
in -148kb through EMSA is required in order to validate this idea.  
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Figure 4.9: UCSC Genome Browser visualisation of publicly available ChIP-Seq data for Dlx5 binding within -148kb. ChIP-Seq peaks for interaction 
between DLX5 (Hojo et al. 2016) and the -148kb enhancer in MC3T3-E1 pre-osteoblast cell line are grouped in two clusters, akin to those for SOX9 and Jun 
(Figure 4.7) and as was observed with enhancer associated chromatin characteristics in addition to sequence conservation which formed the rationale for the 
creation of the -148kb _short line (Chapter 3.5). This suggests DLX5 could bind within both the -148kb full and -148kb short sequences. 
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Upon examination of the -148kb sequence using the TRAP TFBS prediction tool 
(Chapter 5.5), several homeobox (HOX) transcription factors are highly ranked as 
interacting with the enhancer region. These paralogous genes are well established 
as regulators of skeletogenesis (De Laat and Duboule 2013). For example, removal 
of HOX10 and HOX11 gene groups each causes dysmorphism in vertebral, limb 
and synovial joint development (Koyama et al. 2010; Wellik and Capecchi 2003). 
Several HOX10 and HOX11 TFBS are predicted within -148kb, suggesting that 
these transcription factors may dictate enhancer function and therefore Ccn2 
expression in skeletogenesis. In addition HOX11 has been shown to regulate 
endochondral ossification from the perichondrium, thereby concurring with 
endogenous Ccn2 expression (Ivkovic et al. 2003; Papenbrock et al. 2000). 
 
Gross et al. (2012) demonstrated the role of HOX11 genes in chondrocyte 
differentiation, with knockout of HOXA11 and HOXD11 led to repression of 
columnar chondrocyte morphology, chondrocyte hypertrophy and the expression 
of Runx2. Application of this finding to the current work suggests that there may be 
interaction between HOX11 transcription factors and RUNX2 at the -148kb 
enhancer, mediating continued stringent control of Ccn2 transcription in the 
successive differentiation of chondrocytes along the endochondral growth plate. 
There could also be redundancy in the function of HOX genes in the regulation of -
148kb, which may in part account for the fact that several TFBS are predicted in 
the sequence. This would ensure enhancer function in the event of mutation of a 
TFBS and therefore lends credence to notion that the enhancer is important in 
driving Ccn2 expression during development and skeletogenesis. The prevalence 
of HOX genes and the sequential and tightly controlled activation in 
embryogenesis, as opposed to function within postnatal tissue, would suggest that 
these TFBS are not used to drive the postnatal function of the enhancer observed 
in CTGF148 and founder D of -148kb_short transgenic animals. Further in vitro 
validation of this idea through the use EMSA or ChIP-Seq is required.  
 
Interaction with additional limb related transcription factors could also refine 
enhancer function with chondrocyte specificity in function. PITX1 is a transcription 
factor involved in chondrogenesis and skeletal development (Lanctôt et al. 1999). 
As of yet, PITX1 has not been associated with the regulation of Ccn2 expression. 
However, using the TRAP tool, there are predicted TFBS for PITX1 in both full and 
short variants of the -148kb enhancer sequence. Beyond the scope of the current 
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project, PITX1 should be examined as a potential regulator of both -148kb 
enhancer and Ccn2.  
 
4.2.3 How stringent is enhancer grammar in function?  
 
Regardless of the identity of the transcription factors that bind to the enhancers of 
Ccn2, an important aspect of elucidating enhancer function will be characterisation 
of the hierarchical protein interactions that facilitate chromatin topological 
organisation and ultimately interaction between enhancer and Ccn2 promoter 
region.  
 
The fact that a shorter version of the -148kb enhancer containing the approximately 
1.5kb of sequence, rather than the full region of approximately 2.5kb, was able to 
drive gene transcription would suggest that the enhancer doesn’t follow the 
enhanceosome model of enhancer grammar. As outlined in Chapter 1.3.3, 
enhanceosome function relies on stringent interaction of transcription factors with 
an enhancer sequence in a highly ordered manner (Spitz and Furlong 2012). The 
loss of 1kb from the -148kb sequence did not impinge on the capacity of the region 
to drive transgene expression. The 5’ 1kb fragment of the enhancer therefore must 
contain TFBS which are dispensable, and may be redundant in enhancer function. 
Moreover, redundancy in TFBS positioning may favour a more robust billboard 
model-like function whereby the presence of the TFBS, rather than positioning 
within the sequence is required for enhancer function (Kulkarni and Arnosti 2003). 
The chondrocyte based transgene expression in founders bearing the -
148kb_short construct suggest that chondrocyte related TFBS are found within this 
shorter sequence. However, the variation in the tissues in which transgene activity 
was observed in -148kb_short would suggest that regulatory interactions 
constraining cell lineage-specific enhancer function were lost. Therefore, the fidelity 
of enhancer function is bestowed by the full sequence which reduces gene 
transcription within non-chondrocyte cell types, which could occur through 
repressive TF interaction at the enhancer. The expression within the -148kb_short 
transgenic animals was predominantly within mesenchymal tissues, suggesting 
that the factors that bind to this region in order to modulate its function are 
mesenchymal cell lineage related, but not cell-type specific. The enhancer could 
also follow a TF collective model of function whereby protein-protein interaction 
allows enhancer function rather than TF-DNA interaction (Harmston and Lenhard 
2013). Beyond the scope of the current work in terms of time and budget, further 
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characterisation of the TFBS within -148kb and their utilisation is required in order 
to understand the signalling mechanisms and interactions that control enhancer 
activity. This also applies for each of the enhancers described herein, in order to 
understand the grammar that underpins both enhancer DNA-TF interaction and 
resultant enhancer-promoter interaction.  
 
The stringency of enhancer grammar is also raised with the observation that in the 
CTGF148 -148kb full line, and -148kb_short transgenic mice, the cell lineages in 
which enhancer function was observed changed over time. This contradicts the 
consensus that enhancers function in lineage-specific regulation of gene 
expression (Heinz et al. 2015; Li et al. 2016). For the CTGF148 line, between E11.5 
and E13.5 expression within the vasculature and heart was observed before a 
switch to only chondrocyte based reporter gene expression in later embryonic 
development and adulthood. For the -148kb_short, expression in progeny of 
Founder C was observed in perichondrium/ primitive periosteal tissue at E15.5, yet 
at potently functioned within the musculature at approximately six months of age. 
The progeny of founder D did not exhibit vasculature localisation of transgene 
expression, which was potent by six months of age. This effect could be due to the 
site of integration where transgenic constructs landed in the genome, with influence 
from other regulatory sequences within the vicinity reducing the specificity of LacZ 
expression to enhancer activity. Further analysis of enhancer function in vivo is 
required to understand this.  
 
4.3 Further Ccn2 enhancer function 
 
4.3.1 Are there further enhancers of Ccn2? 
 
Reporter gene expression driven by the enhancer regions described herein does 
not constitute the replete expression profile of Ccn2. For example, the -230kb, -
198kb, -148kb, -137kb and -102kb enhancers did not drive expression in the 
gastrointestinal system, neuronal tissue, dentition and reproductive system 
(Friedrichsen et al. 2003, 2005). This therefore suggests that further cis-acting 
regulatory elements are required in the regulation of Ccn2 transcription. As of yet 
the only studies examining the region downstream of Ccn2 in vivo has been those 
of Hall-Glenn and Lyons (2011) and Hall-Glenn et al. (2012) who utilised the 
previously mentioned Tg(Ctgf-EGFP)FX156Gsat mouse line. Neither of these 
studies attempted to define enhancer elements within the 160kb of sequence used 
268 
in this BAC transgenic construct. The locus encompassing this can be examined in 
the UCSC Genome Browser in order to identify further putative enhancers of Ccn2 
expression (Figure 4.10). Using the same approach as used in the current project, 
within the UCSC Genome Browser, there are some potential regulatory elements 
further downstream of Cc2 however, there are no clear enhancer regions with 
similar peaks for H4K4me1 and H3K27ac comparable to the enhancers described 
in the current study.  
 
Figure 4.10: UCSC Genome Browser graphic of regulatory element-associated 
histone modification in several tissues types in the loci of interest the Tg (Ctgf-EGFP) 
FX156Gsat. Within the BAC construct (A, green bar), the most significant peaks across 
tissues occur in the promoter region for Ccn2. There are some small peaks for H3K4me1 
and H3K27ac in a cluster of loci (purple box) approximately 35kb downstream of CCN2 in 
several tissues, however this region could regulate the expression of Enpp1 rather than 
Ccn2.  
 
The lack of clearly discernible regulatory elements downstream of Ccn2 suggests 
that there are additional non-coding regulatory elements upstream of Ccn2. The 
current project was concerned primarily with skeletal; and especially chondrocyte, 
based enhancer function, it was therefore not feasible to examine each tissue type. 
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It is therefore plausible that further enhancers regulate the expression in Ccn2 in 
other tissue types. Using the approach of the current project, tracks concerning 
multiple tissues can be used in the identification of further Ccn2 enhancers located 
in the 300kb upstream intergenic region (Figures 4.11 and 4.12).  
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Figure 4.11: Use of the 
UCSC Genome Browser 
to predict enhancers of 
Ccn2 active in heart, 
kidney and liver tissue. 
Three further enhancers 
are discernible located -
278kb, -215kb -115kb and -
60kb upstream of Ccn2. 
There are peaks for 
sequence conservation 
and enhancer associated 
chromatin in heart, kidney 
and liver samples for the -
278kb and -215kb regions. 
The peaks for H3K4me1 
and H3K27ac occur most 
prominently in -115kb for 
heart samples, suggesting 
an enhancer that functions 
specifically within heart 
tissue at E14.5, and to a 
lesser extent at 8 weeks of 
age. Peaks for enhancer 
associated chromatin 
characteristics are also 
found within the enhancers 
examined herein.  
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Figure 4.12: Use of the 
UCSC Genome 
Browser to predict 
enhancers of Ccn2 
active in lung, small 
intestine, testis, 
thymus and brain 
tissues. In addition to 
the -278kb, and -115kb 
candidate enhancers 
identified in Figure 4.11, 
further enhancers are 
predicted at -204kb in 
small intestinal and 
testis tissues, and at -
60kb in testis tissue. The 
pre-existing putative 
enhancer regions also 
contain peaks for 
H3K4me1 and H3K27ac 
in several tissues. 
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Validation of the new putative -278kb, -220kb -215kb, -204kb, -115kb and -60kb 
enhancers using the transgenic approach utilised in the current study would be vital 
in understanding further temporospatial determinants of Ccn2 transcription. The 
peaks within a single enhancer across several tissues indicate that enhancer 
function is more likely to be cell lineage-specific rather than tissue specific, as there 
may be several cell types present in a tissue, yet the intracellular signalling 
mechanisms that underpin transcriptional regulation may be similar between the 
cell type of common lineage across several tissues, rather than the many cell types 
of one tissue. For example, the full -148kb enhancer region contains peaks for both 
H3K4me1 and H3K27ac; denoting active enhancer activity, within the heart at 
E14.5 and 8 weeks, small intestine and testis. This theory could be validated using 
a cell-specific rather than tissue based ChIP-Seq approach. Although, increased 
accessibility and activity -148kb chromatin in heart tissue could account for why 
reporter gene expression was observed in the heart in the CTGF148 line during 
embryonic development and in mice harbouring the shorter version of this enhancer 
in adulthood. Validation of the putative -220kb, -115kb and -60kb would be 
important in the context of the current project as they each contain peaks within 
limb based tissue, whilst overlooked thus far, they too could regulate chondrocyte 
based expression of Ccn2.  
 
4.3.2 Do enhancers of Ccn2 transcription function at further time-points, or 
in disease? 
 
Whilst beyond the capabilities of the current project, examination of activity of each 
enhancer at several time-points would enable greater understanding of the 
regulatory cues that govern enhancer function in the temporospatial regulation of 
Ccn2 transcription during development and adulthood. It would also be important 
to examine the capacity of the enhancers found here to function in adulthood. This 
was achieved for the CTGF148 line which demonstrated that the enhancer 
functioned in chondrocytes from embryonic chondrogenesis and postnatal articular 
cartilage. At five months of age, the -148kb enhancer still functioned in cartilaginous 
elements; albeit to a lesser extent, with reduced transgene activity compared to 
earlier time-points. This suggests that -148kb is required in the both the 
establishment and maintenance of Ccn2 expression within cartilage. The enhancer 
could carry on driving transgene expression at a later time point such as 12 months 
of age, which was not feasible to assay in the current study.  
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A pertinent question is whether the enhancer is used in solely a housekeeping-like 
fashion, or whether the output from this enhancer can be increased in a latent 
manner (Ostuni et al. 2013; Zabidi et al. 2015). This could be tested utilising the 
CTGF148 line and mechanical loading model of osteoarthritis (Poulet et al. 2011). 
This is relevant for the -137kb enhancer too, given the articular localisation of 
enhancer function. The knees of transgenic mice could be loaded in order to induce 
OA changes in the articular cartilage and synovial joint. Comparison of X-gal 
staining intensity between loaded and contralateral non-loaded knee joints would 
allow changes in enhancer activation to be observed. Given the controversial role 
of CCN2 in osteoarthritis, it would be interesting to examine whether enhancer 
activity was increased to boost the amount of CCN2 in a chondroprotective manner, 
or enhancer activity would be repressed to prevent the accumulation of CCN2 
within the joint and subsequent catabolic degradation of cartilage matrix. Therefore, 
the activation of the enhancer may change with the severity of the disease. TNF-α 
and TGF-β have both been implicated in osteoarthritis (Gabay et al. 2012; van der 
Kraan and van den Berg 2012), and both factors have previously been shown to 
antagonise the function of one another at the CCN2 promoter (Abraham et al. 
2000), this interaction could be repeated in the enhancer elements. In addition, 
TNF-α has been demonstrated to induce CCN2 expression in rheumatoid arthritis, 
leading to osteoclastogenesis (Nozawa et al. 2009). Further work in order to 
examine the TFBS and mechanism for osteoarthritis-linked signal transduction is 
required in order to ascertain the validity of this theory. Orthologous sequences of 
the Ccn2 enhancers could also be examined in patients with osteoarthritis. As 
outlined in Chapter 1.3, SNP within enhancers are increasingly being examined in 
disease association studies (Andersson et al. 2014). Capellini et al. (2017) found 
that an SNP in an enhancer for GDF5 causes reduced gene expression in the 
epiphyseal region of long bones, associated with OA susceptibility postulating that 
this increases susceptibility to osteoarthritis. This echoes the work of Reynard et 
al. (2016) who found that SNP within an intronic enhancer of cartilage related gene 
CHST11 cause changes in protein affinity for TFBS with decrease in enhancer 
activity and therefore target gene expression leading to OA susceptibility. This sets 
a precedent that SNP within the enhancers of CCN2 could lead to increased 
susceptibility to OA. Furthermore, predisposition to other diseases caused by 
changes in CCN2 expression such as fibrosis could be caused by SNP within the 
enhancers described herein. 
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The expression of CCN2 has previously been shown to be induced in proliferating 
periosteal cells in bone fracture repair (Nakata et al. 2002). This therefore leads to 
the question as to whether the -230kb enhancer is activated in a latent manner in 
order to drive osteoblast based CCN2 production in fracture healing. The function 
of further enhancers could also be latently induced in the maintenance of tissue 
homeostasis. For example, Kapoor et al. (2008) found activation of the promoter 
region in a skin wounding wounded model. This could occur in conjunction with 
latent enhancer activation that drives gene expression as part of a concerted 
response to increase ECM components and promote repair.  
 
4.4 Future direction  
 
In summary, the findings described herein give an insight into the role of novel cis-
acting regulatory elements in the region upstream of Ccn2. However, further work 
in required in order to fully comprehend the narrow temporospatial frames in which 
enhancers function to control the transcription of Ccn2, and the complicated 
molecular regulatory interactions that facilitate this process. Given that enhancers 
function within specific temporospatial windows, it is important to have a global 
approach in study of their function. This is more readily accomplished through the 
use of in vivo methodology.  
 
An important aspect of future should be study of the human CCN2 locus and 
validation of function between the murine enhancer regulatory sequences 
described herein and human regulatory elements. The congruity of predicted TAD 
boundaries between human and mouse shown in the 3DIV and Dixon et al. (2012) 
datasets would suggest that enhancers of CCN2 would be found in the equivalent 
positions to those described herein. Enhancer sequences were visualised in the 
human genome in the current project, but this was mostly carried out for 
contextualisation of TFBS. Therefore, future would should assay the ability of 
orthologous human CCN2 enhancer sequence to drive reporter gene expression, 
in addition to characterisation of loci through the wide array of in silico resources 
available such as SCREEN, the ROADMAP project and ChIP-Seq datasets from 
human samples. Use of the Genehancer dataset available as part of the 
‘Genecards’ website (https://www.genecards.org/) will also be a key aspect of this 
as it contains association data from interaction (Hi-C) and eRNA expression for 
predicted enhancers of CCN2, of which there are several entries. These regions 
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overlap with several of the murine enhancers described herein and are therefore 
fundamental in understanding CCN2 transcriptional regulation.  
 
A priority in future research into Ccn2 enhancers should be examination of the 
topological interactions that underpin the endogenous utilisation of enhancer 
regions in orchestrating the transcriptional regulation of Ccn2. This could be carried 
out using high-throughput chromatin conformation capture based assays, for 
example high resolution Hi-C in order to visualise interactions between enhancers 
and the promoter region, in addition to verification of TAD structure (Whalen et al. 
2016). In using samples from various cell and tissue types, the interactions within 
different cellular contexts would be visualised and compared. This would enable 
greater understanding of the temporospatial specificity in Ccn2 enhancer function 
and the mechanisms that dictate this key attribute.  
 
A critical aspect of future work in characterising the enhancer regions described 
herein will be the manipulation of the enhancer sequences in vivo through CRISPR-
Cas9 technology. Whilst unsuccessful in the application to make enhancer 
knockout transgenic mice in the current project, the results from this process will 
nevertheless inform and aid future work. Despite RNA-Cas9 injection into the 
cytoplasm being posited as the most efficient CRISPR-Cas9 system (Horii et al. 
2014), this was not effective under the condition used herein. The strategy 
employed in order to identify and design guide RNA was successful; as shown by 
the in vitro cleavage of target DNA substrate (Chapter 3.8). The lack of mutant mice 
highlight that the process required further optimisation at the microinjection stage. 
For example, although the recombinant Cas9 protein used had a nuclear 
localisation signal, injection of complexes directly into the pronucleus rather than 
cytoplasm would boost increase the amount of CRISPR-Cas9 complexes within the 
nucleus and therefore genomic targeting; albeit with higher rates of mortality. 
 
CRISPR-Cas9 has been well established in the study of enhancers and 
optimisation of the technique used in the current study would herald a turning point 
in the ability to assay the endogenous function of Ccn2 enhancers (Catarino and 
Stark 2018; Fulco et al. 2016; Lopes et al. 2016). Ideally, this work would also use 
CCN2 reporter mouse whereby endogenous expression of the gene would be 
replaced with that of a reporter such as GFP; which could be achieved through 
CRISPR-Cas9 genome editing. This would allow manipulation of enhancer function 
to be assayed through the production of GFP. This would also be the most effective 
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technique in maintaining the endogenous chromatin topology and environment that 
enhancer function depends on. Furthermore, this style of reporter gene assay 
would negate the issues site integration and construct copy number that could have 
hampered the accuracy of the current study. 
 
The first step using this approach would be deletion of enhancers, as was 
attempted herein. This would enable the importance of the function of each 
enhancer in physiological Ccn2 expression to be examined. For example, if the -
148kb enhancer is the lynchpin regulator of chondrocyte based Ccn2 expression, 
excision of this enhancer would be expected to lead to recapitulation of the 
profound chondrodysplasia phenotype exhibited by Ccn2-/- mice (Ivkovic et al. 
2003). Transgenic mice lines with deletion of each enhancer could be crossed in 
order to determine how robust the actions of cis-acting regulatory elements are in 
the regulation of Ccn2. This approach could also aid in determination of redundancy 
in enhancer function and whether any of the regions function as shadow enhancers, 
and their function is dispensable in the physiological expression of CCN2. 
Moreover, CRISPR-Cas9 has previously been used to demonstrate functional 
hierarchy of enhancers (Huang et al. 2016). If this were applied to the current 
project, would -148kb be found to be the most important enhancer of Ccn2?  
 
The robustness of enhancer function could also be tested in CRISPR-Cas9 based 
removal of sub-regions of enhancers. This reductionist approach would enable 
identification of the key sequences within the enhancers that are responsible for 
regulation and function. In addition, individual TFBS could be deleted or mutated 
using CRISPR-Cas9. Furthermore, enhancer grammar could also be examined 
using this approach. If the removal part of an enhancer repressed its activity, it 
would suggest the entire sequence of the enhancer was important in its function 
and therefore followed the enhanceosome model with strict and additive 
arrangement of TFBS and cognate TF.  
 
The putative TAD outlined in Chapter 4.4 and chromatin topology within this region 
could also be investigated using CRISPR-Cas9. The CTCF and cohesin sites at 
the predicted TAD boundary could be deleted, as has previously been 
demonstrated to perturb enhancer function (Guo et al. 2015). This could cause 
fidelity in Ccn2 enhancer-Ccn2 promoter interaction to be lost, and therefore the 
temporospatial specificity in Ccn2 transcription to be lost, resulting in aberrant 
patterns of gene activation or repression; which could have pathological 
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consequences (Lupiáñez et al. 2015). Moreover, elucidation of the physiological 
role of Ccn2 enhancers through genomic manipulation could in turn, aid the 
understanding and amelioration of the profound diseases caused by aberrant Ccn2 
expression such as osteoarthritis.  
 
4.5 Conclusions  
 
Enhancer function has been proven to critically regulate the transcription of several 
skeletogenesis related genes, especially during embryonic development. For 
example, Chen et al. (2016) found multiple enhancers of GDF5 expression that 
discretely specify gene transcription localisation, with elements driving expression 
in separate skeletal tissues. With the discovery of one of the largest distance 
enhancer-promoter interactions, Lettice et al. (2003) found that an enhancer 
located 1mb away from target gene SHH functions in limb patterning, and that 
mutations within this sequence are linked with polydactyly phenotype. This 
highlights the importance of the current findings with Ccn2 enhancers mediating 
differential transcription of Ccn2 in skeletogenesis, especially given the critical role 
of CCN2 in physiological chondrocyte behaviour during development and beyond.  
 
Chondrocyte based expression of Ccn2 can be driven by the -137kb, -148kb and -
198kb enhancers at E15.5. Within articular chondrocytes, where transgene 
expression was observed to be driven by all three enhancers, enhancer DNA-cell 
lineage-specific TF interaction, further activator protein-protein interaction and 
chromatin looping through CTCF and cohesin, could culminate in the enhancers 
being active and brought into close proximity with the promoter region for Ccn2. 
This would lead to increased transcriptional output from Ccn2 in articular 
chondrocytes specifically, as illustrated in Figure 4.13. The utilisation of enhancers 
could also occur sequentially with enhancer poising, in order to ensure robust 
expression of Ccn2 throughout skeletogenesis, in both chondrocyte and 
subsequently osteoblastic cells.  
 
The endogenous expression of Ccn2 therefore reflects composite activities of 
several enhancers, which are capable of functioning concurrently yet in highly 
specific cell and tissue types in order to confer temporospatial specificity in the 
transcription of Ccn2.  
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Figure 4.13: Schematic representation of the TAD of approximately 300kb that Ccn2 may reside in, and the TF-enhancer and protein interactions that 
determine -137kb, -148kb and -198kb activity within chondrocyte cells. Enhancers are active in a highly temporospatial manner, reflecting specific, open 
chromatin structure that enables interaction with pioneer and cell lineage-specific transcription factors. Further protein-protein interactions between TF and 
transcriptional coactivators and mediator protein complex, in addition to interaction between CTCF and cohesin with target sites facilitates chromatin looping 
that brings about interaction between the -137kb, -148kb, -198kb enhancers and Ccn2 promoter region in the nucleus of articular chondrocytes. This culminates 
in the assembly of the pre-initiation complex and protein machinery required for transcription at the TSS, therefore enhancing expression of Ccn2.   
279 
. Appendices 
 
5.1 Datasets assimilated into the UCSC Genome Browser  
 
Datasets available as part of the UCSC Genome Browser (Kent et al. 2002) were 
used in the first instance in order to identify putative enhancers of Ccn2 
predominantly within limb tissues.  
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The following GEO-DataSets were used to examine TF-DNA interaction and 
potential proteins that regulated enhancer function (Table 5.2).  
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5.2 Plasmid maps  
 
5.2.1 Hsp68LacZGW vector maps  
 
Figure 5.1: -4kbCTGFHsp68LacZGW plasmid map. The 1295bp -4kb enhancer (orange) 
drives the expression of LacZ reporter gene (blue) via an Hsp68 minimal promoter (red). 
The plasmid also contains sequences necessary for propagation and selection in E.coli. 
This plasmid was linearised using XhoI and NotI restriction enzymes. 
 
 
Figure 5.2: -102kbCTGFHsp68LacZGW plasmid map. The -102kb enhancer (2282bp) 
(yellow) regulates the transcription of LacZ reporter gene (blue) via an Hsp68 minimal 
promoter (red). The plasmid also contains sequences necessary for propagation and 
selection in E.coli. This plasmid was linearised using XhoI and NotI restriction sites 
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Figure 5.3: -137kbCTGFHsp68LacZGW plasmid map. The full -137kb enhancer region 
(2572bp) (pale blue) drives the expression of LacZ (dark blue) via an Hsp68 promoter (red). 
The plasmid also contains sequences necessary for propagation and selection in E.coli. 
This plasmid was linearised using XhoI and NotI restriction enzyme sites 
 
Figure 5.4: -148kbCTGFHsp68LacZGW plasmid map. The full -148kb enhancer region 
(purple) drives the expression of a LacZ reporter gene (blue) via an Hsp68 promoter. The 
plasmid also contains sequences necessary for propagation and selection in E.coli. XhoI 
and NotI restriction enzymes were used to linearise this plasmid. 
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Figure 5.5:-198kbCTGFHsp68LacZGW plasmid map. The -198kb enhancer sequence 
(2395bp) controls LacZ reporter gene expression via an Hsp68 minimal promoter region. 
The plasmid also contains sequences necessary for propagation and selection in E.coli. 
Plasmid linearisation was carried out using XhoI and NotI.  
 
Figure 5.6: -255kbCTGFHsp68LacZGW plasmid map. The -255kb enhancer region 
(2050bp) (pale blue) regulates the expression of LacZ reporter gene (dark blue) via an 
Hsp68 minimal promoter (red). The plasmid also contains sequences necessary for 
propagation and selection in E.coli. This plasmid was linearised using XhoI and NotI 
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5.2.2 Maps of LacZ plasmids without Gateway® 
 
  
Figure 5.7: -137kbshortCTGFHsp68LacZ plasmid map. The shorter form of the -137kb 
enhancer, with sequence spanning the most conserved region (1275bp) (bright blue) 
controls the expression of LacZ reporter gene (dark blue) via an Hsp68 minimal promoter 
region (red). The plasmid also contains sequences necessary for survival and propagation 
in E.coli. ApaI and NotI restriction enzymes were used to linearise this plasmid. 
 
 
Figure 5.8: -230kbCTGFHsp68LacZ plasmid map.  
 
The -230kb enhancer region (1423bp) (lilac) drives the expression of LacZ reporter gene 
(blue) via an Hsp68 minimal promoter (red). The plasmid also contains sequences required 
for propagation and survival in E.coli. This plasmid was linearised using ApaI and NotI 
restriction enzyme sites. 
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5.2.3 Maps of pSLF01 enhancer containing variant plasmids 
 
Figure 5.9: pSLF01 plasmid map. The promoter region spanning from -351bp to +17bp 
relative to CCN2 was cloned into the pGL4.10 vector. The CCN2 promoter region regulates 
the expression of firefly Luc2 luciferase reporter gene and was cloned into the MCS using 
XhoI and HindIII. The plasmid also contains sequences necessary for propagation in E.coli 
such as origin of replication and Ampicillin resistance gene for selection.  
 
 
Figure 5.10: pSLF01_-4kb plasmid map. The -4kb enhancer region (orange) was cloned 
into pSLF01 using KpnI and NheI sites and regulates the expression of Luc2 firefly 
luciferase reporter gene (green) in conjunction with the CCN2 promoter region (bright 
pink). This plasmid also contains sequences necessary for survival and selection within 
E.coli. This plasmid was linearised using the Acc65I and AflIII sites 
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Figure 5.11: pSLF01_-102kb plasmid map. The -102kb enhancer (yellow) was cloned into 
pSLF01 using KpnI and SacI sites. The enhancer regulates the expression of firefly 
luciferase luc2 expression (green) via the CCN2 promoter (pink). 
 
 
Figure 5.12: pSLF01_-137kb plasmid map.The full -137kb enhancer region (blue) was 
cloned into pSLF01 using KpnI and NheI. The enhancer controls expression of luc2 firefly 
luciferase reporter gene (green) via the CCN2 promoter region (pink). The plasmid also 
contains necessary sequences for propagation and selection in E.coli. 
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Figure 5.13: pSLF01_-137kb_S plasmid map. The short version of the -137kb enhancer, 
composed of the most evolutionarily conserved sequence regulates firefly luciferase luc2 
expression via the CCN2 promoter region. The plasmid also contains sequences necessary 
for propagation and selection in E.coli  
 
 
Figure 5.14: pSLF01_-148kb plasmid map. The -148kb enhancer (purple) drives the 
expression of firefly luciferase reporter gene (green) via the CCN2 promoter (pink). The 
enhancer was cloned into pSLF01 using KpnI and NheI sites. The plasmid also contains 
sequences necessary for propagation and selection in E.coli.  
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Figure 5.15: pSLF01_-198kb plasmid map. The -198kb enhancer (red) was cloned into 
pSLF01 using KpnI and NheI sites controls the expression of luc2 luciferase reporter gene 
(green) via the CCN2 promoter region (pink). The plasmid also contains sequences for 
propagation and selection in E.coli.  
 
 
 
Figure 5.16: pSLF01_-230kb plasmid map. The -230kb enhancer (lilac) was cloned into 
pSLF01 using KpnI and NheI sites. The enhancer drives the expression of firefly luciferase 
reporter gene (green) via the CCN2 promoter. The plasmid also contains sequences for 
propagation and selection in E.coli.  
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Figure 5.17: pSLF01_-255kb plasmid map. The -255kb enhancer region was cloned into 
pSLF01 using NheI and XhoI sites. This enhancer drives the expression of firefly luciferase 
(luc2, green) via the CCN2 promoter. This plasmid also requires sequences necessary for 
propagation and selection of plasmid in E.coli. 
 
5.3 CRISPR  
 
The following Tables and Figure supplement Chapters 2.4 and 3.9 regarding the 
CRISPR-Cas9 based manipulation of CCN2 enhancer sequences.  
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CRISPR in vitro digestion were optimised with comparison between Cas9 
manufacturer Toolgen’s recommended assay conditions and those recommended 
in previously published papers (Gong et al. 2018a; Kouranova et al. 2016) as 
represented in Figure 5.18.  
 
Figure 5.18: Optimisation of CRISPR gRNA-Cas9 complexing and cutting conditions. 
The -230kb 5’_2 guide RNA was used to cut -230kb 5’_C_Fx -230kb 3’_R PCR substrate. 
The use of 10:10:1 Cas9 protein: gRNA: substrate molar ratio led greater yield of fragments 
corresponding to the cutting of the fragment mediated by the gRNA and Cas9 of 300bp and 
800bp.  
 
5.4 Examination of transcription factor binding sites  
 
5.4.1 TRAP prediction of TFBS  
 
The following tables and figures concern the examination of transcription factor 
binding sites within the enhancers of CCN2 transcription and oligonucleotides used 
for EMSA. Transcription factors linked to the lineages in which the enhancer 
functioned in vivo are highlighted in each Table concerning prediction of TFBS.  
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Rank P value Matrix ID TF 
1 0.00302756026148676 M00191 ER 
2 0.00306086699554986 M00312 BEL1 
3 0.00813297102955457 M0050 E2F 
4 0.0087941028390065 M01232 SATB1 
5 0.00974567996503806 M00738 E2F4DP1 
6 0.0107435121100254 M01301 MEF2 
7 0.0130352706297904 M00102 CDP 
8 0.0132417173548243 M00740 E2F1DP1RB 
9 0.0133360645387725 M00423 FOXJ2 
10 0.0139115501333639 M01148 DMRT3 
11 0.014544328859379 M00340 ETS2 
12 0.0147656854963978 M00425 E2F 
13 0.0177211119941748 M00426 E2F 
14 0.0202980354370221 M00427 E2F 
15 0.021083873832637 M00088 IK3 
16 0.0215978097726057 M00941 MEF2 
17 0.0216922567354194 M00769 AML 
18 0.0221050523271429 M01150 DMRT5 
19 0.0228993941888092 M00406 MEF2 
20 0.0233318962508079 M00212 POLY_C 
21 0.0235126080211755 M00211 PADS_C 
22 0.0250718825354077 M00347 GATA1 
23 0.025211476876477 M00103 CLOX 
24 0.0257935119622424 M01163 ELK1 
25 0.025968099177357 M00078 EVI1 
26 0.0275298736081423 M00231 MEF2 
27 0.0276094436361739 M00278 LMO2COM 
28 0.0279624020302909 M00232 MEF2 
29 0.0286464424476612 M00216 TATA 
30 0.0305451939520733 M00420 MEISAHOXA9 
31 0.0309182548643682 M00410 SOX9 
32 0.0327715656653854 M00953 AR 
33 0.0328356796113028 M01145 CMYC 
34 0.0330845100556741 M01149 DMRT4 
35 0.0368864978222559 M00955 GR 
36 0.0381678754686549 M00085 ZID 
37 0.0384161235299434 M00493 STAT5A 
38 0.0386322024944555 M00006 MEF2 
39 0.0427793122565435 M01165 ELK1 
40 0.0428422793267728 M00214 ESF1 
41 0.0428592794653477 M00939 E2F1 
42 0.0431017031466299 M00918 E2F1 
43 0.0434606048155622 M00118 MYCMAX 
44 0.0470501352211926 M00481 AR 
45 0.0472826370499406 M00119 MAX 
46 0.0478701697973889 M00799 MYC 
47 0.0483058286405239 M00954 PR 
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48 0.0498649571840802 M01249 HIF2A 
Table 5.7: TRAP predicted TFBS within the -102kb enhancer region. The whole -102kb 
enhancer sequence was inputted into TRAP. The motifs with P≤0.05, therefore significant 
prediction of binding interaction are listed. 
 
Rank P value Matrix ID TF 
1 8.7785963709397e-07  M00750 HMGIY 
2 2.64434851466877e-05 M00493 STAT5A 
3  0.0020805236051108 M00515 PPARG 
4 0.00495926452064788 M01150 DMRT5 
5 0.00534351999516525 M01185 BCL6 
6 0.00617540437290076 M00026 RSRFC4 
7 0.00651611021625731 M00407 RSRFC4 
8 0.00675490046708382 M00231 MEF2 
9 0.0070591965752157 M01023 HSF1 
10 0.012547037893872 M00339 ETS1 
11 0.0133322201587713 M01224 P50RELAP65 
12 0.0140390771575355 M00215 SRF 
13 0.0157185149860948 M00771 ETS 
14 0.0162037091035698 M01112 RBPJK 
15 0.0172400333364215 M01125 OCT4 
16 0.0201924172322243 M00619 ALX4 
17 0.0233462958115297 M01123 NANOG 
18 0.0234274651574943 M00926 AP1 
19 0.0242734937246825 M00960 PR 
20 0.025129216568412 M01267 FRA1 
21 0.0251998539002951 M01244 HSF2 
22 0.0260325898804088 M01486 DLX7 
23 0.0282090302099872 M00212 POLY_C 
24 0.0307723028560771 M00097 PAX6 
25 0.0313132122814407 M01403 OTX3 
26 0.031335976692661 M00925 AP1 
27 0.0333899378425998 M00291 FREAC3 
28 0.0334661983420653 M00410 SOX9 
29 0.0387491217299648 M00025 ELK1 
30 0.0389501544033724 M01398 SIX6 
31 0.0399991472699811 M00340 ETS2 
32 0.0404773485433498 M00203 GATA 
33 0.0405726937449582 M00194 NRKB 
34 0.0412225909590964 M00057 COMP1 
35 0.0412861307458219 M00655 PEA3 
36 0.0416275341462234 M00955 GR 
37 0.0430102373517307 M01447 PITX2 
38 0.0431915302460939 M00232 MEF2 
39 0.049054271502528 M00512 PPARG 
Table 5.8: TRAP predicted TFBS within the -137kb full enhancer region. The motifs 
with P≤0.05, therefore significant prediction of binding interaction are listed. Chondrocyte 
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related AP-1 and SOX9 sites are highlighted (He et al. 2016). The SOX9 site was validated 
in Chapter 3.8.  
 
Rank P value Matrix ID TF 
1 0.000358596885802642 M00410 SOX9 
2 0.000855009838309551 M01244 HSF2 
3 0.000957658735226574 M01023 HSF1 
4 0.00185888133831547 M00926 AP1 
5 0.0054397045344674 M00960 PR 
6 0.00610235387308533 M01267 FRA1 
7 0.00622382607264738 M00034 P53 
8 0.00658560112764628 M00641 HSF 
9 0.00684369030265919 M00925 AP1 
10 0.00725263462741377 M00490 BACH2 
11 0.00815631694054531 M00109 CEBP 
12 0.00935695228765299 M00472 FOXO4 
13 0.00956357903590355 M00290 FREAC2 
14 0.00966698641278729 M01482 NKX32 
15 0.0104874553655619 M00495 BACH1 
16 0.0112953153885734 M00199 AP1 
17 0.0136948554436459 M00415 AREB6 
18 0.0137521449321824 M01308 SOX4 
19 0.0140105921176069 M00240 NKX25 
20 0.0167940732274563 M01652 P53 
21 0.0180978904688386 M00517 AP1 
22 0.0188141243060463 M00174 AP1 
23 0.0200938310247062 M00042 SOX5 
24 0.0204159410474702 M00222 HAND1E47 
25 0.0216246863781411 M00473 FOXO1 
26 0.0222214921582313 M01016 SOX17 
27 0.0224486592767784 M00115 TAXCREB 
28 0.0255214257136045 M00634 GCM 
29 0.0256942742283939 M00203 GATA 
30 0.0270908041483611 M01181 NKX32 
31 0.0291202082625213 M00485 NKX22 
32 0.0294492295458247 M00123 MYCMAX 
33 0.0302606921849399 M00277 LMO2COM 
34 0.031917955259521 M00456 FAC1 
35 0.0328628974514428 M00924 AP1 
36 0.0351896910724482 M01173 CREBP1 
37 0.0383817603164872 M01322 NKX26 
38 0.038679909306794 M00322 MYCMAX 
39 0.0389878096272638 M01216 FOXO1 
40 0.0403291461385736 M001168 SREBP 
41 0.0409182413443351 M00122 USF 
42 0.0443286590979773 M01655 P53 
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43 0.0458002547828497 M00734 CIZ 
44 0.0482655055441047 M001287 NEUROD 
Table 5.9: TRAP predicted TFBS within the -137kb short enhancer region. The motifs 
with P≤0.05, therefore significant prediction of binding interaction are listed. Chondrocyte 
related AP-1 and SOX9 sites are highlighted (He et al. 2016). The SOX9 site was validated 
in Chapter 3.8. This site is more highly ranked in the short region compared to the full -
137kb enhancer (Table 5.7). 
 
Rank P value Matrix ID TF 
1 000943188754867874 M00454 MERF2 
2 0.00183381239492753  M01437 HOXC12 
3 0.00323825844094916 M00810 SRF 
4 0.00453184161957132 M01378 HOXA11 
5 0.00472370704523217 M01361 HOXC10 
6 0.00523910985435194 M01329 HOXC11 
7 0.00639554054229985 M00922 SRF 
8 0.00667399893549392 M00185 SRF 
9 0.00705546212825858 M01416 HOXC9 
10 0.00841494917762742 M01434 HOXD11 
11 0.00985873671197013 M01257 SRF 
12 0.0114995205642501 M01250 ESF2 
13 0.0137421018625407 M00211 PADS 
14 0.01430627001459 M00201 CEBP 
15 0.0148914770437449 M01380 HOXD12 
16 0.0155780820350045 M00119 MAX 
17 0.015994224540852 M01480 OBOX5 
18 0.0161183698492418 M00377 PAX4 
19 0.0166895803422783 M01484 PITX1 
20 0.0179483754213986 M01304 SRF 
21 0.0179597399520495 M00156 RORA1 
22 0.0181604143543989 M01373 CCDX1 
23 0.0183319934880481 M01070 CMAF 
24 0.0186961531951948 M01342 CDP 
25 0.0203463168366016 M00956 AR 
26 0.0205324829795811 M01007 SRF 
27 0.0213053266786003 M00220 SREBP 
28 0.0224500806985822 M00960 PR 
29 0.0240728751486352 M01237 TRF1 
30 0.0242684442352505 M01352 NKX29 
31 0.0251487342734887 M00146 HSF1 
32 0.0256334046057471 M01410 IRX4 
33 0.0284275546905568 M00707 TFIIA 
34 0.0287491364218309 M00485 NKX22 
35 0.0291822167235998 M00063 IRF2 
36 0.0309273809623511 M00665 SP3 
37 0.0325679158276536 M01450 OBOX1 
38 0.0336506890360163 M00212 POLY_C 
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39 0.0339363305222814 M00964 PXR 
40 0.0364018210196211 M00737 E2F1DP2 
41 0.0366643626964319 M01425 HNF1B 
42 0.0367858452950779 M00769 AML 
43 0.0381344674203669 M01333 HDX 
44 0.0381454587578272  M00118 MYCMAX 
45 0.0409053325504842 M01145 OBOX6 
46 0.0418438276239931  M01485 IRX3 
47 0.0423281289920011 M00634 GCM 
48 0.0428884747755864 M01449 CDX2 
49 0.042993276455945 M00433 HMX1 
50 0.0443679646200701 M01234 IPF1 
51 0.0454411329036714 M00121 USF 
52 0.0482158700727762 M00511 ERR1 
53 0.0482402658836824 M00122 USF 
54 0.048729229807334 M00317 LDSPOLYA 
55 0.0493121821900077 M01132 SF1 
Table 5.10: TRAP predicted TF interaction in -148kb full enhancer region. The motifs 
with P≤0.05, therefore significant prediction of binding interaction are listed. Limb 
development and chondrocyte related AML (Runx) and Pitx1 sites are highlighted.  
 
Rank P value Matrix ID TF 
1 0.000318497155432085 M00454 MRF2 
2 0.0022769808648937 M01378 HOXA11 
3 0.0027583436115064 M01329 HOXC11 
4 0.00386853624917793 M00377 PAX4 
5 0.00405130836780143 M01361 HOXC10 
6 0.00579633622871956 M01480 OBOX5 
7 0.00640675923602274  M01484 PITX1 
8 0.00689435516525672 M01434 HOXD11 
9 0.0071940199193069 M00156 RORA1 
10 0.00812906053328555 M01410 IRX4 
11 0.00903209552745543 M01437 HOXC12 
12 0.00979235617060126 M00119 MAX 
13 0.0117509288018152 M00707 TFIIA 
14 0.0133039660299070 M01237 TRF1 
15 0.0135223699952858 M00220 SREBP1 
16 0.0148436235583799 M01380 HOXD12 
17 0.0157852061889879 M01450 OBOX1 
18 0.0169308672694924  M01485 IRX3 
19 0.0172761419977946 M00122 USF 
20 0.0177704288195416  M00511 ERR1 
21 0.0178232354864194 M01445 OBOX6 
22 0.0183828873800084 M01425 HNF1B 
23 0.0193618360738852 M00769 AML 
24 0.0202529067059094 M01107 RUSH1A 
25 0.0208602917945904 M01234 IPF1 
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26  0.0214022206096860 M01352 NKX29 
27 0.0216430949047122 M01132 SF1 
28 0.0219791865425958 M00118 MYCMAX 
29 0.0236553852740911 M01318 IRX3 
30 0.0241546706933410 M00737 E2FDP2 
31 0.0243549180447044  M00485 NKX22 
32 0.0243839503522254 M00317 LDSPOLYA 
33 0.0247704102343558 M00433 HMX1 
34 0.0262604038856323 M00729 CDX2 
35 0.026370823495063 M01260 STAT1 
36 0.0270284837732278 M00121 USF 
37 0.0284130303176033 M01359 DOBOX4 
38 0.0285756228465024 M00727 SF1 
39 0.0287935859021345 M01208 FLI1 
40 0.0294428196842479 M01416 HOXC9 
41 0.0298408439866519 M01472 IRX5 
42 0.0303766121074784 M01447 PITX2 
43  0.0303796835307774 M01366 OTX1 
44 0.0306595874562258 M01440 LHX8 
45 0.0316958532755759 M01145 CMYC 
46 0.0348629925580416 M00526 GCNF 
47 0.0362619955639563 M01589 ERR2 
48 0.0366209798677032 M00050 E2F 
49 0.0411667676097563 M01372 NKX22 
50 0.0412111179317466 M00236 ARNT 
51 0.0417435943199939 M00736 E2F1DP1 
52 0.0418790542314423  M00738 E2F4DP1 
53 0.0424206812509408 M00251 XBP1 
54 0.0429628852428795 M01364 OBOX2 
55 0.0432960549541755 M00360 PAX3 
56 0.0435482835189122 M00320 MTATA 
57 0.0445684889134201 M01373 CDX1 
58 0.0446181330245736 M01387 OTX2 
59 0.0446918911014534 M00097 PAX6 
60 0.0453088549703167  M00739 E2F4DP2 
61 0.0455486221951887 M01466 OBOX3 
62 0.0456525182510448 M00538 HTF 
63 0.0470503563320529 M00772 IRF 
64 0.0483384129519699  M00999 AIRE 
65 0.0492470107499716 M00740 E2F1DP1RB 
Table 5.11: TRAP predicted TF interaction within the -148kb_short region. The motifs 
with P≤0.05, therefore significant prediction of binding interaction are listed. Limb 
development and chondrocyte related AML (Runx) and Pitx1 sites are highlighted.  
 
Rank P value Matrix ID TF 
1 0.00268402186717798 M01069 GZF1 
2 0.00371987034413579 M00311 ATATA 
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3 0.00488290022015736 M00518 PPARA 
4 0.00609238102305076 M00769 AML 
5 0.00726266121975117 M00281 RFX1 
6 0.00806881579727858 M01204 SPIB 
7 0.0115342056261466 M00987 FOXP1 
8 0.0120209130450558 M00292 FREAC4 
9 0.013796166871901 M00103 CLOX 
10 0.0144290580263504 M00405 MEF2 
11 0.0144600536270681 M01661 HBP1 
12 0.0146755242327166 M01196 CTF1 
13 0.0153895788616608 M00767 FXR 
14 0.0155467523429637 M00007 ELK1 
15 0.0167352681071924 M01314 LHX61 
16 0.0177129084735395 M00410 SOX9 
17 0.0185612946398211 M00806 NF1 
18 0.0194385487872916 M00722 COREBINDINGFACTOR 
19 0.0201235204005591 M00731 OSF2 
20 0.0216010754782094  M01422 LHX61 
21 0.0226078060824153  M01431 BARX2 
22 0.0230415057961467 M00102 CDP 
23 0.0232133918913324 M00652 NRF1 
24 0.0236724872074090 M01255 IPF1 
25 0.0274242213582807 M00746 ELF1 
26 0.030077354971388 M00105 CDPCR3 
27 0.0315184760215368 M01216 FOXO1 
28 0.0316509279154596 M01456 HMBOX1 
29 0.0324925785430683 M00095 CDP 
30 0.0389404604084379  M01150 DMRT5 
31 0.0394546900307466 M01658 AML1 
32  0.0434740805610291 M00478 CDC5 
33 0.0436340785450632 M00211 PADS 
34 0.044538478156510  M01081 ZEC 
35 0.0446996657340436  M00236 ARNT 
36 0.0448052116164019  M01362 CART1 
37 0.0462422514780503 M01401 LBX2 
38 0.0463091762197797 M01367 LHX9 
39 0.0471099613571837 M00751 AML1 
40 0.0477574887770392 M00203 GATA 
41 0.0490929621456843 M00729 CDX2 
42 0.0496305441822428  M00476 FOXO4 
Table 5.12: TRAP predicted binding within the -230kb enhancer sequence. 
Chondrocyte related SOX9 and OSF2 (Runx2) are highlighted. The SOX9 site was 
validated in EMSA in Chapter 3.8 
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5.4.2 Optimisation of EMSA protein-probe binding conditions  
 
Transcription factor-EMSA probe binding conditions were optimised using various 
additives in the Li-Cor Odyssey® EMSA Buffer kit as outlined in Chapter 2.9.2. 
Reactions that generated the strongest bands were used for further experiments 
 
SOX9-probe interaction was optimised for the -137kb and -230kb wild-type probes 
as demonstrated in Figures 5.19 and 5.20.  
Figure 5.19: Optimisation of binding condition for EMSA of SOX9 binding in –137kb. 
Bands were present in each well where reaction with SOX9 protein was loaded, the intensity 
of bands was fainter in lanes where competitor oligos were added to reactions. KCl gave 
cleanest band and was chosen for subsequent EMSA exploring this protein-DNA interaction 
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Figure 5.20: Optimisation of binding condition for EMSA of SOX9 binding in -230kb 
SOX9 EMSA probe. As with the -137kb probe, KCl was chosen as binding reaction additive 
as a clear band was observed denoting SOX9-probe interaction.  
 
For the examination of Runx2 binding within -148kb, reaction conditions were 
optimised using a control probe that has previously been demonstrated to bind 
Runx2 (Lamour et al. 2007), as illustrated in Figure 5.21.  
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Figure 5.21: Optimisation of Runx2-EMSA probe interaction through the use of 
varying reaction additives. MgCl2 was chosen as reaction additive as the banding pattern 
in this reaction most closely resembled that from the work of Lamour et al. (2007) (black 
arrowhead).  
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5.5 Further in silico resources in the prediction of CCN2 localisation 
within a TAD  
 
The 3D- genome Interaction Viewer (3DIV) (Yang et al. 2018) was used to visualise 
interactive maps of chromatin interactions in the vicinity of human samples, as 
illustrated in Figures 5.22-23 which were lifted over into the mouse mm9 genome 
for predictions of the TAD in which CCN2 is localised. 
Figure 5.22: Screenshot of 3DIV IMR90 human fibroblast based chromatin 
interactions around CCN2 (CTGF). Predicted TAD is highlighted with a black box. This 
region was lifted over into the mouse genome for further comparisons of TAD organisation.  
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Figure 5.23: Screenshot of 3DIV h1-derived mesoderm human based chromatin 
interactions around CCN2 (CTGF). Predicted TAD is highlighted with a black box. This 
region was lifted over into the mouse genome for further comparisons of TAD organisation.  
 
 
ChIA-PET datasets available as part of the publicly available Yue Lab platform from 
http://promoter.bx.psu.edu/hi-c/chiapet.php (Wang et al. 2018) were also lifted over 
into the mm9 genome for TAD organisation These data included for CTCF binding 
within human K562 cell line (Figure 5.24).  
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Figure 5.24: screenshot of publicly ChIA-PET data pertaining to CTCF interaction in 
human immortalised cell line (Wang et al. 2018). Looping interactions between CTCF 
sites were visualised in the Yue Lab ChIA-PET resource available at: 
http://promoter.bx.psu.edu/hi-c/chiapet.php. These regions were lifted over into the mouse 
genome for TAD prediction.  
 
This resource also contains Hi-ChIP datasets for cohesin interaction within mESC 
which was also used in the prediction of TAD organisation (Figure 5.25).  
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Figure 5.25: screenshot of Hi-ChIP generated publicly available data concerning 
cohesin interaction in mESC. The TAD region in which CCN2 (CTGF) is predicted to sit 
is highlighted with a red box which stretches from close to the nearest 5’ neighbour of CCN2 
within the mouse genome, Moxd1 to downstream of CCN2, tallying with the localisation of 
the enhancers described in the current project.  
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